TW202334195A - Recombinant factor viii variants - Google Patents
Recombinant factor viii variantsInfo
- Publication number
- TW202334195A TW202334195A TW112100265A TW112100265A TW202334195A TW 202334195 A TW202334195 A TW 202334195A TW 112100265 A TW112100265 A TW 112100265A TW 112100265 A TW112100265 A TW 112100265A TW 202334195 A TW202334195 A TW 202334195A
- Authority
- TW
- Taiwan
- Prior art keywords
- amino acid
- factor viii
- seq
- viii polypeptide
- recombinant factor
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 572
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 629
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 618
- 229920001184 polypeptide Polymers 0.000 claims abstract description 614
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 576
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 575
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 256
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 256
- 239000002157 polynucleotide Substances 0.000 claims abstract description 256
- 230000000694 effects Effects 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 230000014509 gene expression Effects 0.000 claims abstract description 43
- 230000005847 immunogenicity Effects 0.000 claims abstract description 13
- 230000002829 reductive effect Effects 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 513
- 238000006467 substitution reaction Methods 0.000 claims description 336
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 164
- 210000004027 cell Anatomy 0.000 claims description 120
- 150000001413 amino acids Chemical class 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 53
- 239000012634 fragment Substances 0.000 claims description 49
- 125000000539 amino acid group Chemical group 0.000 claims description 44
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 43
- 208000009292 Hemophilia A Diseases 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 34
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 26
- 238000001415 gene therapy Methods 0.000 claims description 26
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 13
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 230000015271 coagulation Effects 0.000 claims description 11
- 238000005345 coagulation Methods 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 230000023555 blood coagulation Effects 0.000 claims description 9
- 210000005260 human cell Anatomy 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 229960004222 factor ix Drugs 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 238000010361 transduction Methods 0.000 claims description 4
- 230000026683 transduction Effects 0.000 claims description 4
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 3
- 108010076282 Factor IX Proteins 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000035602 clotting Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 237
- 108090000623 proteins and genes Proteins 0.000 description 84
- 229940024606 amino acid Drugs 0.000 description 78
- 102000004169 proteins and genes Human genes 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 52
- 102220560601 ATP-binding cassette sub-family C member 8_V63Q_mutation Human genes 0.000 description 36
- 201000010099 disease Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 108010076504 Protein Sorting Signals Proteins 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 30
- 238000012217 deletion Methods 0.000 description 27
- 230000037430 deletion Effects 0.000 description 27
- 102220608466 Suppressor of cytokine signaling 2_F59D_mutation Human genes 0.000 description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 21
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 19
- 108091026890 Coding region Proteins 0.000 description 17
- 102220537539 Transient receptor potential cation channel subfamily V member 4_K344E_mutation Human genes 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 16
- -1 aliphatic amino acid Chemical class 0.000 description 15
- 230000035772 mutation Effects 0.000 description 14
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 102220048309 rs138317624 Human genes 0.000 description 12
- 238000012384 transportation and delivery Methods 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 102220568789 Mediator of RNA polymerase II transcription subunit 27_V63G_mutation Human genes 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 102000057593 human F8 Human genes 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000004382 Amylase Substances 0.000 description 9
- 108010065511 Amylases Proteins 0.000 description 9
- 102000013142 Amylases Human genes 0.000 description 9
- 235000019418 amylase Nutrition 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 230000008488 polyadenylation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 229960000900 human factor viii Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 230000004952 protein activity Effects 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 241000746129 Aniara Species 0.000 description 5
- 240000006439 Aspergillus oryzae Species 0.000 description 5
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 5
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 102220562239 Disintegrin and metalloproteinase domain-containing protein 11_F16P_mutation Human genes 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 240000005379 Mecopus nidulans Species 0.000 description 4
- 241000005783 Monographella albescens Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000002641 enzyme replacement therapy Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102220470105 Amidophosphoribosyltransferase_Q37H_mutation Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100027612 Kallikrein-11 Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000079611 Mystacides niger Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102220473731 Ras-related protein Rab-5A_F57A_mutation Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102220467128 Runt-related transcription factor 1_L13Y_mutation Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102220608442 Suppressor of cytokine signaling 2_Y65A_mutation Human genes 0.000 description 3
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 3
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 3
- 101710152431 Trypsin-like protease Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 229940024171 alpha-amylase Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002342 ribonucleoside Substances 0.000 description 3
- 102220216788 rs1060501965 Human genes 0.000 description 3
- 102220232293 rs1085307293 Human genes 0.000 description 3
- 102220285454 rs1367937646 Human genes 0.000 description 3
- 102220003069 rs1800571 Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 2
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 2
- 108010037870 Anthranilate Synthase Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 241001513093 Aspergillus awamori Species 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 102220519361 Coatomer subunit alpha_C17S_mutation Human genes 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102220572775 Lamina-associated polypeptide 2, isoform alpha_F59Y_mutation Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028309 Muscle haemorrhage Diseases 0.000 description 2
- 102220570460 Myocardial zonula adherens protein_Q436G_mutation Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102220474362 Protein ZNRD2_T21M_mutation Human genes 0.000 description 2
- 241000235403 Rhizomucor miehei Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102220608485 Suppressor of cytokine signaling 2_F59L_mutation Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 102220353743 c.171C>A Human genes 0.000 description 2
- 102220352048 c.3311A>G Human genes 0.000 description 2
- 102220351742 c.4015G>T Human genes 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007820 coagulation assay Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 208000002085 hemarthrosis Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 102200068101 rs104894370 Human genes 0.000 description 2
- 102200009843 rs121434498 Human genes 0.000 description 2
- 102220286088 rs1553348889 Human genes 0.000 description 2
- 102220318612 rs1554096789 Human genes 0.000 description 2
- 102220285849 rs1555607683 Human genes 0.000 description 2
- 102220044832 rs587781608 Human genes 0.000 description 2
- 102220036045 rs62625271 Human genes 0.000 description 2
- 102200025917 rs72547556 Human genes 0.000 description 2
- 102220074442 rs730880032 Human genes 0.000 description 2
- 102200037603 rs878854026 Human genes 0.000 description 2
- 102220103142 rs878854929 Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000002477 vacuolizing effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid Chemical compound CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 208000033316 Acquired hemophilia A Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000259576 Atheta malleus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101710199851 Copy number protein Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical group 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000005561 Glufosinate Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101100295959 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) arcB gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 241001480714 Humicola insolens Species 0.000 description 1
- 102000006933 Hydroxymethyl and Formyl Transferases Human genes 0.000 description 1
- 108010072462 Hydroxymethyl and Formyl Transferases Proteins 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 101150068888 MET3 gene Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000878128 Malleus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000028221 Mild hemophilia A Diseases 0.000 description 1
- 208000033375 Moderate hemophilia A Diseases 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- SJDGTRIOQBZYSU-UHFFFAOYSA-N NP(O)(O)O Chemical compound NP(O)(O)O SJDGTRIOQBZYSU-UHFFFAOYSA-N 0.000 description 1
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101900354623 Saccharomyces cerevisiae Galactokinase Proteins 0.000 description 1
- 101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 1
- 208000026552 Severe hemophilia A Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000256247 Spodoptera exigua Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000223258 Thermomyces lanuginosus Species 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 102220614572 WD40 repeat-containing protein SMU1_F18R_mutation Human genes 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150008194 argB gene Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 102220427439 c.40C>A Human genes 0.000 description 1
- 102220363074 c.40C>G Human genes 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 101150039489 lysZ gene Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000002331 malleus Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 101150095344 niaD gene Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 101150054232 pyrG gene Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220236747 rs1135401787 Human genes 0.000 description 1
- 102200021966 rs121912936 Human genes 0.000 description 1
- 102220276854 rs1553628470 Human genes 0.000 description 1
- 102220220337 rs543748012 Human genes 0.000 description 1
- 102220058867 rs763596413 Human genes 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940036647 xyntha Drugs 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
相關申請案Related applications
本申請案根據35 U.S.C. § 119(e)主張2022年1月7日申請之美國臨時申請案第63/297,690號之權益,該申請案以全文引用之方式併入本文中。 序列表、表或電腦程式之引用 This application claims the benefit of U.S. Provisional Application No. 63/297,690, filed on January 7, 2022, under 35 U.S.C. § 119(e), which is incorporated herein by reference in its entirety. References to sequence listings, tables or computer programs
與此同時提交之序列表的檔案名稱為「CX7-224WO2_ST26.xml」,創建日期為2023年1月2日且大小為11.46百萬位元組,其為本說明書之一部分且以引用的方式併入本文中。 發明領域 The file name of the sequence listing submitted at the same time is "CX7-224WO2_ST26.xml", the creation date is January 2, 2023 and the size is 11.46 million bytes. It is a part of this specification and is incorporated by reference. into this article. Field of invention
本揭露內容提供重組因子VIII多肽變異體及其組成物。重組因子VIII多肽已經工程改造以具有改良之特性,諸如改良之表現、熱穩定性、血清穩定性、血漿穩定性、在鹼性條件下之穩定性、降低之免疫原性、改良之輔因子效能及改良之血液凝血。本揭露內容亦關於包含重組因子VIII多肽之組成物用於治療目的之用途。The present disclosure provides recombinant Factor VIII polypeptide variants and compositions thereof. Recombinant Factor VIII polypeptides have been engineered to have improved properties, such as improved performance, thermal stability, serum stability, plasma stability, stability under alkaline conditions, reduced immunogenicity, improved cofactor potency and improved blood coagulation. The present disclosure also relates to the use of compositions comprising recombinant Factor VIII polypeptides for therapeutic purposes.
發明背景Background of the invention
人類因子VIII (「FVIII」),亦稱為凝血因子VIII或抗血友病因子,係一種蛋白質輔因子,其充當血液凝血路徑之必需部分,該路徑響應於損傷而啟動一系列的酶,導致血液凝血。因子VIII作為輔因子直接支持因子IX,使其酶活性提高10 5倍(參見例如Mazurkiewicz-Pisarek等人,Acta Biochimica Polonica, 2016, 63.1:11-16)。A型血友病(Hemophilia A) (亦稱為血友病A型(haemophilia A))係因子VIII中之X連鎖遺傳缺乏症,其導致出血增加且缺乏血液結塊。存在三種一般公認形式之A型血友病。患有輕度A型血友病之患者在創傷或手術後出血過多,但在其他方面都很健康。患有中度A型血友病之患者亦在輕度創傷後遭受關節及肌肉出血。患有重度A型血友病之患者甚至在無創傷之情況下亦會遭受自發性關節及肌肉出血。所有患有A型血友病之患者需要治療,但患有重度形式之患者及一些患有中度形式之患者需要常規及頻繁輸注因子VIII以預防失血過多及死亡(參見例如Peters等人,Nature Reviews Drug Discovery, 2018, 17(7):493-508)。估計5,000位男性中有1位受此疾病影響,但女性中亦存在此疾病。治療一般為支持性的且不可治癒,因此仍需要安全且有效之治療。 Human factor VIII ("FVIII"), also known as coagulation factor VIII or antihemophilic factor, is a protein cofactor that serves as an essential part of the blood's clotting pathway, which activates a series of enzymes in response to injury, leading to Blood clotting. Factor VIII directly supports Factor IX as a cofactor, increasing its enzymatic activity 10 5 -fold (see, e.g., Mazurkiewicz-Pisarek et al., Acta Biochimica Polonica, 2016, 63.1:11-16). Hemophilia A (also known as haemophilia A) is an X-linked genetic deficiency in factor VIII that causes increased bleeding and a lack of blood clotting. There are three generally recognized forms of hemophilia A. People with mild hemophilia A bleed excessively after trauma or surgery but are otherwise healthy. People with moderate hemophilia A also experience joint and muscle bleeding after minor trauma. People with severe hemophilia A may suffer spontaneous joint and muscle bleeding even in the absence of trauma. All patients with hemophilia A require treatment, but those with severe forms and some with moderate forms require routine and frequent infusions of factor VIII to prevent excessive bleeding and death (see, e.g., Peters et al., Nature Reviews Drug Discovery, 2018, 17(7):493-508). The disease affects an estimated 1 in 5,000 men, but it also occurs in women. Treatment is generally supportive and not curative, so safe and effective treatments are still needed.
發明概要Summary of the invention
本揭露內容提供重組因子VIII多肽變異體及其組成物。重組因子VIII多肽變異體已經工程改造以具有改良之特性,包括增加之活性、熱穩定性、血清穩定性、血漿穩定性、降低之免疫原性及/或改良之血液凝血。本揭露內容亦關於重組因子VIII多肽用於治療目的之用途。The present disclosure provides recombinant Factor VIII polypeptide variants and compositions thereof. Recombinant Factor VIII polypeptide variants have been engineered to have improved properties, including increased activity, thermal stability, serum stability, plasma stability, reduced immunogenicity, and/or improved blood coagulation. The present disclosure also relates to the use of recombinant Factor VIII polypeptides for therapeutic purposes.
在一個態樣中,本揭露內容提供一種重組因子VIII多肽或其生物活性片段,其包含與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列的一或多個取代。In one aspect, the present disclosure provides a recombinant Factor VIII polypeptide, or a biologically active fragment thereof, comprising residue 20- corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 The reference sequence of 1457 or has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more An amino acid sequence of sequence identity, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072, or One or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 2之殘基20-1457的參考序列或與對應於SEQ ID NO: 2之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 2 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or a sequence corresponding to residues 20-1457 of SEQ ID NO: 2 One or more substitutions of the reference sequence of SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 or a reference sequence corresponding to SEQ ID NO: 252, The reference sequence of 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises One or more substitutions relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:13、14、15、16、17、18、19、20、21、24、37、56、57、58、59、61、63、64、65、85、96、104、110、119、127、132、158、160、164、167、168、171、175、178、186、187、205、210、211、212、215、225、246、257、260、265、281、292、294、301、303、304、306、308、310、311、312、318、320、321、325、328、332、334、335、344、346、347、349、351、353、354、355、356、358、359、362、370、387、388、390、392、393、397、407、428、429、433、435、436、481、487、488、489、491、498、499、503、514、527、533、534、535、536、538、543、550、551、555、558、569、580、581、584、610、611、612、613、614、615、616、617、618、619、620、621、622、643、646、650、665、667、676、680、681、682、683、684、686、693、696、698、700、706、707、708、712、716、724、726、729、731、732、734、735、736、737、738、739、740、744、746、747、748、749、750、751、752、753、754、755、756、757、759、770、773、775、785、786、787、790、791、792、793、794、795、797、798、799、800、801、802、805、806、807、808、809、810、811、812、815、816、817、818、819、821、822、824、825、826、828、830、831、836、837、838、839、840、841、844、866、873、879、892、896、897、903、907、914、916、917、918、919、921、922、923、924、926、929、938、939、945、948、951、968、999、1037、1040、1041、1042、1043、1049、1050、1051、1053、1054、1076、1078、1080、1084、1088、1089、1092、1093、1094、1095、1098、1099、1100、1101、1104、1108、1109、1113、1114、1116、1127、1129、1138、1145、1148、1151、1156、1158、1160、1186、1192、1193、1194、1205、1210、1218、1220、1221、1222、1224、1229、1245、1248、1250、1259、1264、1269、1270、1274、1281、1283、1292、1297、1339、1352、1373、1377、1378、1380、1389、1414、1422、1427、1428、1439、1440、1442或1452或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 37, 56, 57, 58, 59, 61, 63, 64, 65, 85, 96, 104, 110, 119, 127, 132, 158, 160, 164, 167, 168, 171, 175, 178, 186, 187, 205, 210, 211, 212, 215, 225, 246, 257, 260, 265, 281, 292, 294, 301, 303, 304, 306, 308, 310, 311, 312, 318, 320, 321, 325, 328, 332, 334, 335, 344, 346, 347, 349, 351, 353, 354, 355, 356, 358, 359, 362, 370, 387, 388, 390, 392, 393, 397, 407, 428, 429, 433, 435, 436, 481, 487, 488, 489, 491, 498, 499, 503, 514, 527, 533, 534, 535, 536, 538, 543, 550, 551, 555, 558, 569, 580, 581, 584, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 643, 646, 650, 665, 667, 676, 680, 681, 682, 683, 684, 686, 693, 696, 698, 700, 706, 707, 708, 712, 716, 724, 726, 729, 731, 732, 734, 735, 736, 737, 738, 739, 740, 744, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 759, 770, 773, 775, 785, 786, 787, 790, 791, 792, 793, 794, 795, 797, 798, 799, 800, 801, 802, 805, 806, 807, 808, 809, 810, 811, 812, 815, 816, 817, 818, 819, 821, 822, 824, 825, 826, 828, 830, 831, 836, 837, 838, 839, 840, 841, 844, 866, 873, 879, 892, 896, 897, 903, 907, 914, 916, 917, 918, 919, 921, 922, 923, 924, 926, 929, 938, 939, 945, 948, 951, 968, 999, 1037, 1040, 1041, 1042, 1043, 1049, 1050, 1051, 1053, 1054, 1076, 1078, 1080, 1084, 1088, 1089, 1092, 1093, 1094, 1095, 1098, 1099, 1100, 1101, 1104, 1108, 1109, 1113, 1114, 1116, 1127, 1129, 1138, 1145, 1148, 1151, 1156, 1158, 1160, 118 6. 1192, 1193, 1194, 1205, 1210, 1218, 1220, 1221, 1222, 1224, 1229, 1245, 1248, 1250, 1259, 1264, 1269, 1270, 1274, 1281, 1283, 1292, 1297, 1339, 135 2. 1373, 1377, 1378, 1380, 1389, 1414, 1422, 1427, 1428, 1439, 1440, 1442 or 1452 or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2 .
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基13G/Y、14G/M/V、15G/S、16A/D/G/P/V、17S/V、18L/R、19G、20L、21M、24V、37H、56E/P、57A/L/S/T/V、58K、59D/G/L/M/Q/R/S/V/W、61Q/S、63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、64D/G、65A、85Q、96I/L/R/V/W、104S、110H、119G/V、127V、132P/R、158G、160E/T、164E、167G/H/R、168G/R、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、175A/G/H、178C/M/Q/V/W、186A、187C/G、205R、210P、211G/K/P/Q/R、212A/F/G/K/L/M/N/P/R/S/V/Y、215E/P/S、225R、246D、257I、260E/K/T、265R/S/W、281A/S、292D、294G、301K/M、303G/T、304A/E/G、306A/D/G/P/S/T、308P、310G/V、311E/G、312L、318C/G/K/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、321Y、325Y、328G/Q/S、332A/F/G/H/N/P/Q/R/T/V/W/Y、334G、335E/P、344A/E/L、346R/V、347N、349G、351S、353S、354R、355C、356L/N、358K/S、359E/G、362E/G/N/P/T/V/W、370A、387A/G/I/L/Q/R/S/T/V/W、388A/P、390A/E/G/L/M/P/S/T/V、392A、393A/F/G/H/M/Q/R/W/Y、397G/N、407V、428F、429L/S、433A/G、435Q、436D/G、481V、487N、488G、489E/F/Q/R、491E、498A、499C/L、503S、514L、527A、533R/V/Y、534F/I/L/M、535C/G/N、536A/G/K/L/M/P/R/W、538V、543G/L/P/W、550G、551W、555E/G/R/T、558A/E/G/L/P/Q/R/S/T/V/W、569T、580S/Y、581K/V、584A、610H/K/L/R/S/T、611D/E、612G/S/T、613S、614A/F/H/I/N/T、615D/N、616D/E/G/Q/W、617D/E/G/N、618C/E/G/P/Y、619E、620N/P、621K/M/R/T/W、622D、643N、646I、650M、665G、667I、676Q、680L/R、681A/C/E/F/G/L/N/R/Q/S/T/W、682R、683W、684G/K、686W、693T、696E、698D/S/W/Y、700A/E/Q/T/V、706A/G/M/Y、707H、708A/K/T/V、712G/L/M/Q/S/T/Y、716K/L/W、724I、726A/L、729T、731I/L/R、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、734I/R/S、735D/S/V、736F/G、737F/G/K/L/M/N/S/V、738A/D/E/F/H/K/N/P/R/S/T、739G/P/R、740G、744A/R、746P、747D、748F/G/K/N/S/V、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S/V、753D、754W、755G/L/P/Q/S/Y、756G/P/R/T、757A/G/K/T、759S、770W、773H、775E/G/K/N/P/S/V、785V、786C/D/L、787W、790A/G/I/M/P/W、791M/T、792H/W/Y、793G、794R、795C/N/S/T、797C/G/P/Q/T/W/Y、798C/R/T、799A/E/G/M/P/Q/R/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、801A/G/I/R、802S/V、805C/G/H/K/L/M/P/Q/R/S/V/W、806E/G/R/S、807C/L/P/R、808K/S、809A/C/G/I/K/L/N/Q/R/S/T/V/W、810V、811F、812G/I/V、815I、816V/W、817A/D、818A/E/G/P/S/V/W、819V、821Q、822S/T、824W、825L、826G、828K、830M/V、831W、836G/R/V/W、837G、838G/T、839A/G/K/P、840G、841W、844H、866A、873L/Q/T、879Q、892T、896L/V、897G/K/R、903E、907D、914V、916C/E/I/K/L/M/Q/T、917G、918M/S、919G、921R/W、922W、923M、924I/M/P/Q/W、926T/V、929A/Q/V、938R/V、939E/S、945K、948S、951V、968A/P、999R、1037H/M/N/P、1040E、1041G/H/N、1042A/E/T、1043E/R、1049G/W、1050E/P/Q/S/T、1051E/H/K/R/S/W、1053A/R、1054C、1076G/S、1078S、1080G/V、1084L/N、1088G/S、1089F/S、1092G、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1094S、1095G、1098G、1099G、1100I/S、1101G、1104C/E、1108M/S/V/W、1109G、1113F、1114A/M、1116A/G/I/L/R、1127L/V、1129P、1138Q、1145R、1148A/C/E/L/M/N/Q/R/S、1151S、1156D/G/N/R、1158N、1160R、1186E、1192D、1193A/E/G/I/L、1194P、1205L、1210M/T/V/W、1218A/G/L/M/P、1220D/E/L/T、1221G/S/T/V、1222F、1224P、1229D、1245R、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1250A/P/S/T、1259T、1264L/R/W、1269F、1270V、1274N/V、1281H/K/P/Q/R/S、1283E/H/L/S/T、1292Y、1297A、1339C、1352E、1373S、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1378A/C/D/E、1380A/G/W、1389W、1414A/C/D/E/G/H/N/P/T/W、1422I、1427Y、1428G、1439A/E/H/L/S/T、1440A/C/E/G/S/T、1442T或1452L或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or amino acid residue 13G/Y, 14G/M/V, 15G/S, 16A/D/G/P/V, 17S /V, 18L/R, 19G, 20L, 21M, 24V, 37H, 56E/P, 57A/L/S/T/V, 58K, 59D/G/L/M/Q/R/S/V/W , 61Q/S, 63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y, 64D/G, 65A, 85Q, 96I/L/R /V/W, 104S, 110H, 119G/V, 127V, 132P/R, 158G, 160E/T, 164E, 167G/H/R, 168G/R, 171A/D/E/F/H/K/N /M/P/Q/R/S/T/V/W/Y, 175A/G/H, 178C/M/Q/V/W, 186A, 187C/G, 205R, 210P, 211G/K/P /Q/R, 212A/F/G/K/L/M/N/P/R/S/V/Y, 215E/P/S, 225R, 246D, 257I, 260E/K/T, 265R/S /W, 281A/S, 292D, 294G, 301K/M, 303G/T, 304A/E/G, 306A/D/G/P/S/T, 308P, 310G/V, 311E/G, 312L, 318C /G/K/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V, 321Y, 325Y, 328G/Q/S, 332A/F/G/H /N/P/Q/R/T/V/W/Y, 334G, 335E/P, 344A/E/L, 346R/V, 347N, 349G, 351S, 353S, 354R, 355C, 356L/N, 358K /S, 359E/G, 362E/G/N/P/T/V/W, 370A, 387A/G/I/L/Q/R/S/T/V/W, 388A/P, 390A/E /G/L/M/P/S/T/V, 392A, 393A/F/G/H/M/Q/R/W/Y, 397G/N, 407V, 428F, 429L/S, 433A/G , 435Q, 436D/G, 481V, 487N, 488G, 489E/F/Q/R, 491E, 498A, 499C/L, 503S, 514L, 527A, 533R/V/Y, 534F/I/L/M, 535C /G/N, 536A/G/K/L/M/P/R/W, 538V, 543G/L/P/W, 550G, 551W, 555E/G/R/T, 558A/E/G/L /P/Q/R/S/T/V/W, 569T, 580S/Y, 581K/V, 584A, 610H/K/L/R/S/T, 611D/E, 612G/S/T, 613S , 614A/F/H/I/N/T, 615D/N, 616D/E/G/Q/W, 617D/E/G/N, 618C/E/G/P/Y, 619E, 620N/P , 621K/M/R/T/W, 622D, 643N, 646I, 650M, 665G, 667I, 676Q, 680L/R, 681A/C/E/F/G/L/N/R/Q/S/T /W, 682R, 683W, 684G/K, 686W, 693T, 696E, 698D/S/W/Y, 700A/E/Q/T/V, 706A/G/M/Y, 707H, 708A/K/T /V, 712G/L/M/Q/S/T/Y, 716K/L/W, 724I, 726A/L, 729T, 731I/L/R, 732C/D/E/G/L/R/W /K/M/Q/S/T/V/Y, 734I/R/S, 735D/S/V, 736F/G, 737F/G/K/L/M/N/S/V, 738A/D /E/F/H/K/N/P/R/S/T, 739G/P/R, 740G, 744A/R, 746P, 747D, 748F/G/K/N/S/V, 749A/C /D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T /V/W, 751A/D/E/Y, 752D/E/F/G/L/M/Q/R/S/V, 753D, 754W, 755G/L/P/Q/S/Y, 756G /P/R/T, 757A/G/K/T, 759S, 770W, 773H, 775E/G/K/N/P/S/V, 785V, 786C/D/L, 787W, 790A/G/I /M/P/W, 791M/T, 792H/W/Y, 793G, 794R, 795C/N/S/T, 797C/G/P/Q/T/W/Y, 798C/R/T, 799A /E/G/M/P/Q/R/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 801A/G/I/R , 802S/V, 805C/G/H/K/L/M/P/Q/R/S/V/W, 806E/G/R/S, 807C/L/P/R, 808K/S, 809A /C/G/I/K/L/N/Q/R/S/T/V/W, 810V, 811F, 812G/I/V, 815I, 816V/W, 817A/D, 818A/E/G /P/S/V/W, 819V, 821Q, 822S/T, 824W, 825L, 826G, 828K, 830M/V, 831W, 836G/R/V/W, 837G, 838G/T, 839A/G/K /P, 840G, 841W, 844H, 866A, 873L/Q/T, 879Q, 892T, 896L/V, 897G/K/R, 903E, 907D, 914V, 916C/E/I/K/L/M/Q /T, 917G, 918M/S, 919G, 921R/W, 922W, 923M, 924I/M/P/Q/W, 926T/V, 929A/Q/V, 938R/V, 939E/S, 945K, 948S , 951V, 968A/P, 999R, 1037H/M/N/P, 1040E, 1041G/H/N, 1042A/E/T, 1043E/R, 1049G/W, 1050E/P/Q/S/T, 1051E /H/K/R/S/W, 1053A/R, 1054C, 1076G/S, 1078S, 1080G/V, 1084L/N, 1088G/S, 1089F/S, 1092G, 1093A/E/G/M/N /P/Q/R/S/T/V/W/Y, 1094S, 1095G, 1098G, 1099G, 1100I/S, 1101G, 1104C/E, 1108M/S/V/W, 1109G, 1113F, 1114A/M , 1116A/G/I/L/R, 1127L/V, 1129P, 1138Q, 1145R, 1148A/C/E/L/M/N/Q/R/S, 1151S, 1156D/G/N/R, 1158N , 1160R, 1186E, 1192D, 1193A/E/G/I/L, 1194P, 1205L, 1210M/T/V/W, 1218A/G/L/M/P, 1220D/E/L/T, 1221G/S /T/V, 1222F, 1224P, 1229D, 1245R, 1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y, 1250A/P /S/T, 1259T, 1264L/R/W, 1269F, 1270V, 1274N/V, 1281H/K/P/Q/R/S, 1283E/H/L/S/T, 1292Y, 1297A, 1339C, 1352E , 1373S, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1378A/C/D/E, 1380A/G/W, 1389W, 1414A/C /D/E/G/H/N/P/T/W, 1422I, 1427Y, 1428G, 1439A/E/H/L/S/T, 1440A/C/E/G/S/T, 1442T or 1452L or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:63、171、212、260、306、317、320、332、387、390、393、534、558、681、732、738、749、750、775、1148、1248、1377或1439或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 63, 171, 212, 260, 306, 317, 320, 332, 387, 390, 393, 534, 558, 681, 732, 738, 749, 750, 775, 1148, 1248, 1377 or 1439 or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、212A/F/G/L/K/M/N/P/R/S/V/Y、260E/K/T、306A/D/G/P/S/T、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、332A/F/G/H/N/P/Q/R/T/V/W/Y、387A/G/I/L/Q/R/S/T/V/W、390A/E/G/L/M/P/S/T/V、393A/F/G/H/M/Q/R/W/Y、499C/L、534I/F/L/M、558A/E/G/L/P/Q/R/S/T/V/W、681A/C/E/F/G/L/N/R/Q/S/T/W、700A/E/Q/T/V、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、738A/D/E/F/H/K/N/P/R/S/T/Y、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、752D/E/F/G/L/M/Q/R/S/V、775E/G/K/N/P/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、805C/G/H/K/L/M/P/Q/R/S/V/W、809A/C/G/I/K/L/N/Q/R/S/T/V/W、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1148A/C/E/L/M/N/Q/R/S、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1414A/C/D/E/G/H/N/P/T/W或1439A/E/H/L/S/T或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or amino acid residue 63C/E/F/G/H/I/K/L/M/N/Q/R/S /T/W/Y, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y, 212A/F/G/L/K/M /N/P/R/S/V/Y, 260E/K/T, 306A/D/G/P/S/T, 318C/G/K/L/M/Q/R/T/V, 320G /I/L/P/Q/R/S/T/V, 332A/F/G/H/N/P/Q/R/T/V/W/Y, 387A/G/I/L/Q /R/S/T/V/W, 390A/E/G/L/M/P/S/T/V, 393A/F/G/H/M/Q/R/W/Y, 499C/L , 534I/F/L/M, 558A/E/G/L/P/Q/R/S/T/V/W, 681A/C/E/F/G/L/N/R/Q/S /T/W, 700A/E/Q/T/V, 732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y, 738A/D/E/F /H/K/N/P/R/S/T/Y, 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A /D/G/K/M/N/P/Q/R/S/T/V/W, 752D/E/F/G/L/M/Q/R/S/V, 775E/G/K /N/P/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 805C/G/H/K/L/M/P/Q /R/S/V/W, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 1093A/E/G/M/N/P/Q/R /S/T/V/W/Y, 1148A/C/E/L/M/N/Q/R/S, 1248A/C/D/E/F/G/H/I/K/M/P /Q/R/S/T/W/Y, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1414A/C/D/E/G /H/N/P/T/W or 1439A/E/H/L/S/T or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1148、85/708/1148、798、706、171、335、63、344、428、879、59、429、205、1264、797、1248、873、792、708、57、96、362、1292、346、433、65、795、684/798、353、332、1259、356、436、1245、1145、716、56、773、734、358、729、665、359、61、1250、726、37/96/171/429/708/799/1148、171/429/732/1148、96/171、171/919/1151、171/792/797/799/1148、171/569/1148、96/171/429/792/797/799、171/429/708/1422、171/429、321/362/732/797/799、171/1100、708/1148/1186、429/724/732/1148、171/362/795/797/799、171/429/732、96/171/643/797/799、171/792/797/799、503、171/732、1148/1193、96/171/362/429/732/795/797、334、732、351、1377、999、306、349、257、646、435或58,其中該等位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1148, 85/708/1148, 798, 706, 171, 335, 63, 344 ,428,879,59,429,205,1264,797,1248,873,792,708,57,96,362,1292,346,433,65,795,684/798,353,332,1259,356 ,436,1245,1145,716,56,773,734,358,729,665,359,61,1250,726,37/96/171/429/708/799/1148,171/429/732/1148 ,96/171, 171/919/1151, 171/792/797/799/1148, 171/569/1148, 96/171/429/792/797/799, 171/429/708/1422, 171/429 ,321/362/732/797/799, 171/1100, 708/1148/1186, 429/724/732/1148, 171/362/795/797/799, 171/429/732, 96/171/643 /797/799, 171/792/797/799, 503, 171/732, 1148/1193, 96/171/362/429/732/795/797, 334, 732, 351, 1377, 999, 306, 349 , 257, 646, 435 or 58, wherein these positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個 表4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代或取代集,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1, 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 A substitution or set of substitutions as set forth in , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 or a reference sequence corresponding to SEQ ID NO: 252, The reference sequence of 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity of the amino acid sequence.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO. 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的參考序列或與對應於SEQ ID NO. 4-2346及2350-2870中之偶數編號SEQ ID NO.之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列。In some embodiments, a recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NO. 4-2346 and 2360-2870 or corresponding to SEQ ID NO. The reference sequences of the even-numbered SEQ ID NO. in 4-2346 and 2350-2870 have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, Amino acid sequences with 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 or a reference sequence corresponding to SEQ ID NO: 252, The reference sequence of 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises Relative to this reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 or relative to SEQ ID NO: 252, 504, 706, 840, 1200, One or more substitutions of 1514 or 2072 of the reference sequence.
在前述一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列位置處的取代:13、14、15、16、17、18、19、20、21、24、37、56、57、58、59、61、63、64、65、85、96、104、110、119、127、132、158、160、164、167、168、171、175、178、186、187、205、210、211、212、215、225、246、257、260、265、281、292、294、301、303、304、306、308、310、311、312、318、320、321、325、328、332、334、335、344、346、347、349、351、353、354、355、356、358、359、362、370、387、388、390、392、393、397、407、428、429、433、435、436、481、487、488、489、491、498、499、503、514、527、533、534、535、536、538、543、550、551、555、558、569、580、581、584、610、611、612、613、614、615、616、617、618、619、620、621、622、643、646、650、665、667、676、680、681、682、683、684、686、693、696、698、700、706、707、708、712、716、724、726、729、731、732、734、735、736、737、738、739、740、744、746、747、748、749、750、751、752、753、754、755、756、757、759、770、773、775、785、786、787、790、791、792、793、794、795、797、798、799、800、801、802、805、806、807、808、809、810、811、812、815、816、817、818、819、821、822、824、825、826、828、830、831、836、837、838、839、840、841、844、866、873、879、892、896、897、903、907、914、916、917、918、919、921、922、923、924、926、929、938、939、945、948、951、968、999、1037、1040、1041、1042、1043、1049、1050、1051、1053、1054、1076、1078、1080、1084、1088、1089、1092、1093、1094、1095、1098、1099、1100、1101、1104、1108、1109、1113、1114、1116、1127、1129、1138、1145、1148、1151、1156、1158、1160、1186、1192、1193、1194、1205、1210、1218、1220、1221、1222、1224、1229、1245、1248、1250、1259、1264、1269、1270、1274、1281、1283、1292、1297、1339、1352、1373、1377、1378、1380、1389、1414、1422、1427、1428、1439、1440、1442或1452或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some of the foregoing embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following positions: 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 37, 56, 57, 58, 59, 61, 63, 64, 65, 85, 96, 104, 110, 119, 127, 132, 158, 160, 164, 167, 168, 171, 175, 178, 186, 187, 205, 210, 211, 212, 215, 225, 246, 257, 260, 265, 281, 292, 294, 301, 303, 304, 306, 308, 310, 311, 312, 318, 320, 321, 325, 328, 332, 334, 335, 344, 346, 347, 349, 351, 353, 354, 355, 356, 358, 359, 362, 370, 387, 388, 390, 392, 393, 397, 407, 428, 429, 433, 435, 436, 481, 487, 488, 489, 491, 498, 499, 503, 514, 527, 533, 534, 535, 536, 538, 543, 550, 551, 555, 558, 569, 580, 581, 584, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 643, 646, 650, 665, 667, 676, 680, 681, 682, 683, 684, 686, 693, 696, 698, 700, 706, 707, 708, 712, 716, 724, 726, 729, 731, 732, 734, 735, 736, 737, 738, 739, 740, 744, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 759, 770, 773, 775, 785, 786, 787, 790, 791, 792, 793, 794, 795, 797, 798, 799, 800, 801, 802, 805, 806, 807, 808, 809, 810, 811, 812, 815, 816, 817, 818, 819, 821, 822, 824, 825, 826, 828, 830, 831, 836, 837, 838, 839, 840, 841, 844, 866, 873, 879, 892, 896, 897, 903, 907, 914, 916, 917, 918, 919, 921, 922, 923, 924, 926, 929, 938, 939, 945, 948, 951, 968, 999, 1037, 1040, 1041, 1042, 1043, 1049, 1050, 1051, 1053, 1054, 1076, 1078, 1080, 1084, 1088, 1089, 1092, 1093, 1094, 1095, 1098, 1099, 1100, 1101, 1104, 1108, 1109, 1113, 1114, 1116, 1127, 1129, 1138, 1145, 1148, 1151, 1156, 1158, 1160, 1186, 119 2. 1193,1194,1205,1210,1218,1220,1221,1222,1224,1229,1245,1248,1250,1259,1264,1269,1270,1274,1281,1283,1292,1297,1339,1352,137 3. 1377, 1378, 1380, 1389, 1414, 1422, 1427, 1428, 1439, 1440, 1442 or 1452 or a combination thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706, 840 , 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基13G/Y、14G/M/V、15G/S、16A/D/G/P/V、17S/V、18L/R、19G、20L、21M、24V、37H、56E/P、57A/L/S/T/V、58K、59D/G/L/M/Q/R/S/V/W、61Q/S、63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、64D/G、65A、85Q、96I/L/R/V/W、104S、110H、119G/V、127V、132P/R、158G、160E/T、164E、167G/H/R、168G/R、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、175A/G/H、178C/M/Q/V/W、186A、187C/G、205R、210P、211G/K/P/Q/R、212A/F/G/L/K/M/N/P/R/S/V/Y、215E/P/S、225R、246D、257I、260E/K/T、265R/S/W、281A/S、292D、294G、301K/M、303G/T、304A/E/G、306A/D/G/P/S/T、308P、310G/V、311E/G、312L、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、321Y、325Y、328G/Q/S、332A/F/G/H/N/P/Q/R/T/V/W/Y、334G、335E/P、344A/E/L、346R/V、347N、349G、351S、353S、354R、355C、356L/N、358K/S、359E/G、362E/G/N/P/T/V/W、370A、387A/G/I/L/Q/R/S/T/V/W、388A/P、390A/E/G/L/M/P/S/T/V、392A、393A/F/G/H/M/Q/R/W/Y、397G/N、407V、428F、429L/S、433A/G、435Q、436D/G、481V、487N、488G、489E/F/Q/R、491E、498A、499C/L、503S、514L、527A、533R/V/Y、534I/F/L/M、535C/G/N、536A/G/K/L/M/P/R/W、538V、543G/L/P/W、550G、551W、555E/G/R/T、558A/E/G/L/P/Q/R/S/T/V/W、569T、580S/Y、581K/V、584A、610H/K/L/R/S/T、611D/E、612G/S/T、613S、614A/F/H/I/N/T、615D/N、616D/E/G/Q/W、617D/E/G/N、618C/E/G/P/Y、619E、620N/P、621K/M/R/T/W、622D、643N、646I、650M、665G、667I、676Q、680L/R、681A/C/E/F/G/L/N/R/Q/S/T/W、682R、683W、684G/K、686W、693T、696E、698D/S/W/Y、700A/E/Q/T/V、706A/G/M/Y、707H、708A/K/T/V、712G/L/M/Q/S/T/Y、716K/L/W、724I、726A/L、729T、731I/L/R、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、734I/R/S、735D/S/V、736F/G、737F/G/K/L/M/N/S/V、738A/D/E/F/H/K/N/P/R/S/T/Y、739G/P/R、740G、744A/R、746P、747D、748F/G/K/N/S/V、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S/V、753D、754W、755G/L/P/Q/S/Y、756G/P/R/T、757A/G/K/T、759S、770W、773H、775E/G/K/N/P/S/V、785V、786C/D/L、787W、790A/G/I/M/P/W、791M/T、792H/W/Y、793G、794R、795C/N/S/T、797C/G/P/Q/T/W/Y、798C/R/T、799A/E/G/M/P/Q/R/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、801A/G/I/R、802S/V、805C/G/H/K/L/M/P/Q/R/S/V/W、806E/G/R/S、807C/L/P/R、808K/S、809A/C/G/I/K/L/N/Q/R/S/T/V/W、810V、811F、812G/I/V、815I、816V/W、817A/D、818A/E/G/P/S/V/W、819V、821Q、822S/T、824W、825L、826G、828K、830M/V、831W、836G/R/V/W、837G、838G/T、839A/G/K/P、840G、841W、844H、866A、873L/Q/T、879Q、892T、896L/V、897G/K/R、903E、907D、914V、916C/E/I/K/L/M/Q/T、917G、918M/S、919G、921R/W、922W、923M、924I/M/P/Q/W、926T/V、929A/Q/V、938R/V、939E/S、945K、948S、951V、968A/P、999R、1037H/M/N/P、1040E、1041G/H/N、1042A/E/T、1043E/R、1049G/W、1050E/P/Q/S/T、1051E/H/K/R/S/W、1053A/R、1054C、1076G/S、1078S、1080G/V、1084L/N、1088G/S、1089F/S、1092G、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1094S、1095G、1098G、1099G、1100I/S、1101G、1104C/E、1108M/S/V/W、1109G、1113F、1114A/M、1116A/G/I/L/R、1127L/V、1129P、1138Q、1145R、1148A/C/E/L/M/N/Q/R/S、1151S、1156D/G/N/R、1158N、1160R、1186E、1192D、1193A/E/G/I/L、1194P、1205L、1210M/T/V/W、1218A/G/L/M/P、1220D/E/L/T、1221G/S/T/V、1222F、1224P、1229D、1245R、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1250A/P/S/T、1259T、1264L/R/W、1269F、1270V、1274N/V、1281H/K/P/Q/R/S、1283E/H/L/S/T、1292Y、1297A、1339C、1352E、1373S、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1378A/C/D/E、1380A/G/W、1389W、1414A/C/D/E/G/H/N/P/T/W、1422I、1427Y、1428G、1439A/E/H/L/S/T、1440A/C/E/G/S/T、1442T或1452L或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or amino acid residue 13G/Y, 14G/M/V, 15G/S, 16A/D/G/P/V, 17S /V, 18L/R, 19G, 20L, 21M, 24V, 37H, 56E/P, 57A/L/S/T/V, 58K, 59D/G/L/M/Q/R/S/V/W , 61Q/S, 63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y, 64D/G, 65A, 85Q, 96I/L/R /V/W, 104S, 110H, 119G/V, 127V, 132P/R, 158G, 160E/T, 164E, 167G/H/R, 168G/R, 171A/D/E/F/H/K/N /M/P/Q/R/S/T/V/W/Y, 175A/G/H, 178C/M/Q/V/W, 186A, 187C/G, 205R, 210P, 211G/K/P /Q/R, 212A/F/G/L/K/M/N/P/R/S/V/Y, 215E/P/S, 225R, 246D, 257I, 260E/K/T, 265R/S /W, 281A/S, 292D, 294G, 301K/M, 303G/T, 304A/E/G, 306A/D/G/P/S/T, 308P, 310G/V, 311E/G, 312L, 318C /G/K/L/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V, 321Y, 325Y, 328G/Q/S, 332A/F/G /H/N/P/Q/R/T/V/W/Y, 334G, 335E/P, 344A/E/L, 346R/V, 347N, 349G, 351S, 353S, 354R, 355C, 356L/N , 358K/S, 359E/G, 362E/G/N/P/T/V/W, 370A, 387A/G/I/L/Q/R/S/T/V/W, 388A/P, 390A /E/G/L/M/P/S/T/V, 392A, 393A/F/G/H/M/Q/R/W/Y, 397G/N, 407V, 428F, 429L/S, 433A /G, 435Q, 436D/G, 481V, 487N, 488G, 489E/F/Q/R, 491E, 498A, 499C/L, 503S, 514L, 527A, 533R/V/Y, 534I/F/L/M , 535C/G/N, 536A/G/K/L/M/P/R/W, 538V, 543G/L/P/W, 550G, 551W, 555E/G/R/T, 558A/E/G /L/P/Q/R/S/T/V/W, 569T, 580S/Y, 581K/V, 584A, 610H/K/L/R/S/T, 611D/E, 612G/S/T , 613S, 614A/F/H/I/N/T, 615D/N, 616D/E/G/Q/W, 617D/E/G/N, 618C/E/G/P/Y, 619E, 620N /P, 621K/M/R/T/W, 622D, 643N, 646I, 650M, 665G, 667I, 676Q, 680L/R, 681A/C/E/F/G/L/N/R/Q/S /T/W, 682R, 683W, 684G/K, 686W, 693T, 696E, 698D/S/W/Y, 700A/E/Q/T/V, 706A/G/M/Y, 707H, 708A/K /T/V, 712G/L/M/Q/S/T/Y, 716K/L/W, 724I, 726A/L, 729T, 731I/L/R, 732C/D/E/G/L/R /W/K/M/Q/S/T/V/Y, 734I/R/S, 735D/S/V, 736F/G, 737F/G/K/L/M/N/S/V, 738A /D/E/F/H/K/N/P/R/S/T/Y, 739G/P/R, 740G, 744A/R, 746P, 747D, 748F/G/K/N/S/V , 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A/D/G/K/M/N/P/Q/R /S/T/V/W, 751A/D/E/Y, 752D/E/F/G/L/M/Q/R/S/V, 753D, 754W, 755G/L/P/Q/S /Y, 756G/P/R/T, 757A/G/K/T, 759S, 770W, 773H, 775E/G/K/N/P/S/V, 785V, 786C/D/L, 787W, 790A /G/I/M/P/W, 791M/T, 792H/W/Y, 793G, 794R, 795C/N/S/T, 797C/G/P/Q/T/W/Y, 798C/R /T, 799A/E/G/M/P/Q/R/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 801A/G /I/R, 802S/V, 805C/G/H/K/L/M/P/Q/R/S/V/W, 806E/G/R/S, 807C/L/P/R, 808K /S, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 810V, 811F, 812G/I/V, 815I, 816V/W, 817A/D, 818A /E/G/P/S/V/W, 819V, 821Q, 822S/T, 824W, 825L, 826G, 828K, 830M/V, 831W, 836G/R/V/W, 837G, 838G/T, 839A /G/K/P, 840G, 841W, 844H, 866A, 873L/Q/T, 879Q, 892T, 896L/V, 897G/K/R, 903E, 907D, 914V, 916C/E/I/K/L /M/Q/T, 917G, 918M/S, 919G, 921R/W, 922W, 923M, 924I/M/P/Q/W, 926T/V, 929A/Q/V, 938R/V, 939E/S , 945K, 948S, 951V, 968A/P, 999R, 1037H/M/N/P, 1040E, 1041G/H/N, 1042A/E/T, 1043E/R, 1049G/W, 1050E/P/Q/S /T, 1051E/H/K/R/S/W, 1053A/R, 1054C, 1076G/S, 1078S, 1080G/V, 1084L/N, 1088G/S, 1089F/S, 1092G, 1093A/E/G /M/N/P/Q/R/S/T/V/W/Y, 1094S, 1095G, 1098G, 1099G, 1100I/S, 1101G, 1104C/E, 1108M/S/V/W, 1109G, 1113F , 1114A/M, 1116A/G/I/L/R, 1127L/V, 1129P, 1138Q, 1145R, 1148A/C/E/L/M/N/Q/R/S, 1151S, 1156D/G/N /R, 1158N, 1160R, 1186E, 1192D, 1193A/E/G/I/L, 1194P, 1205L, 1210M/T/V/W, 1218A/G/L/M/P, 1220D/E/L/T , 1221G/S/T/V, 1222F, 1224P, 1229D, 1245R, 1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y , 1250A/P/S/T, 1259T, 1264L/R/W, 1269F, 1270V, 1274N/V, 1281H/K/P/Q/R/S, 1283E/H/L/S/T, 1292Y, 1297A , 1339C, 1352E, 1373S, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1378A/C/D/E, 1380A/G/W, 1389W , 1414A/C/D/E/G/H/N/P/T/W, 1422I, 1427Y, 1428G, 1439A/E/H/L/S/T, 1440A/C/E/G/S/T , 1442T or 1452L or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:63、171、212、260、306、317、320、332、387、390、393、534、558、681、732、738、749、750、775、1148、1248、1377或1439或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 63, 171, 212, 260, 306, 317, 320, 332, 387, 390, 393, 534, 558, 681, 732, 738, 749, 750, 775, 1148, 1248, 1377 or 1439 or a combination thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706, 840 , 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、212A/F/G/L/K/M/N/P/R/S/V/Y、260E/K/T、306A/D/G/P/S/T、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、332A/F/G/H/N/P/Q/R/T/V/W/Y、387A/G/I/L/Q/R/S/T/V/W、390A/E/G/L/M/P/S/T/V、393A/F/G/H/M/Q/R/W/Y、499C/L、534I/F/L/M、558A/E/G/L/P/Q/R/S/T/V/W、681A/C/E/F/G/L/N/R/Q/S/T/W、700A/E/Q/T/V、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、738A/D/E/F/H/K/N/P/R/S/T/Y、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、752D/E/F/G/L/M/Q/R/S/V、775E/G/K/N/P/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、805C/G/H/K/L/M/P/Q/R/S/V/W、809A/C/G/I/K/L/N/Q/R/S/T/V/W、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1148A/C/E/L/M/N/Q/R/S、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1414A/C/D/E/G/H/N/P/T/W或1439A/E/H/L/S/T或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or amino acid residue 63C/E/F/G/H/I/K/L/M/N/Q/R/S /T/W/Y, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y, 212A/F/G/L/K/M /N/P/R/S/V/Y, 260E/K/T, 306A/D/G/P/S/T, 318C/G/K/L/M/Q/R/T/V, 320G /I/L/P/Q/R/S/T/V, 332A/F/G/H/N/P/Q/R/T/V/W/Y, 387A/G/I/L/Q /R/S/T/V/W, 390A/E/G/L/M/P/S/T/V, 393A/F/G/H/M/Q/R/W/Y, 499C/L , 534I/F/L/M, 558A/E/G/L/P/Q/R/S/T/V/W, 681A/C/E/F/G/L/N/R/Q/S /T/W, 700A/E/Q/T/V, 732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y, 738A/D/E/F /H/K/N/P/R/S/T/Y, 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A /D/G/K/M/N/P/Q/R/S/T/V/W, 752D/E/F/G/L/M/Q/R/S/V, 775E/G/K /N/P/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 805C/G/H/K/L/M/P/Q /R/S/V/W, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 1093A/E/G/M/N/P/Q/R /S/T/V/W/Y, 1148A/C/E/L/M/N/Q/R/S, 1248A/C/D/E/F/G/H/I/K/M/P /Q/R/S/T/W/Y, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1414A/C/D/E/G /H/N/P/T/W or 1439A/E/H/L/S/T or a combination thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252之殘基20-1457的參考序列或與對應於SEQ ID NO: 252之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 252之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 252之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 252 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 One or more substitutions of the reference sequence of SEQ ID NO: 252.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1380、388、1043、610、1274、1220、1442、1193、621、1054、755、1041、748、1049、1221、1051、612、1037、616、387、489、750、1224、618、1050、1053、896、897、749、260、481、613、756、63、265、752、1218、1378、614、1440、1439、1205、1222、1389、1269、390、397/1218、757、1373、346、63/1248、349、306/355/1422、1422、306/346/708、1148、171/346/1248、63/797/799/1248/1422、171/799、362、1248、171/306/346/999/1248、171/1148、734/799/1248/1422、63/732、63/171/306/346/732、171、171/1422、63/362/732/799/1248、999/1148/1422、346/349、306/349、63/171/1148/1151、306、344/349/354/1250、1250、63/306/344/349/354/503/1248、59/63/332/349/503/706/708、63/306/344/349/354/706/1248、59/63、332/706/708/1248/1250、503、59/63/349/354、59/349/708、59/306/344/1248、344/1248/1250、708、63/344/349、59、63/344/349/354、706、59/306/770、63/347/354/1248或354/503,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1380, 388, 1043, 610, 1274, 1220, 1442, 1193, 621, 1054 ,755,1041,748,1049,1221,1051,612,1037,616,387,489,750,1224,618,1050,1053,896,897,749,260,481,613,756,63,265 ,752,1218,1378,614,1440,1439,1205,1222,1389,1269,390,397/1218,757,1373,346,63/1248,349,306/355/1422,1422,306/346 /708、1148、171/346/1248、63/797/799/1248/1422、171/799、362、1248、171/306/346/999/1248、171/1148、734/799/1248/1422 , 63/732, 63/171/306/346/732, 171, 171/1422, 63/362/732/799/1248, 999/1148/1422, 346/349, 306/349, 63/171/1148 /1151, 306, 344/349/354/1250, 1250, 63/306/344/349/354/503/1248, 59/63/332/349/503/706/708, 63/306/344/349 /354/706/1248, 59/63, 332/706/708/1248/1250, 503, 59/63/349/354, 59/349/708, 59/306/344/1248, 344/1248/1250 , 708, 63/344/349, 59, 63/344/349/354, 706, 59/306/770, 63/347/354/1248 or 354/503, where the amino acid positions are relative to the corresponding The reference sequence at SEQ ID NO: 252.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 504之殘基20-1457的參考序列或與對應於SEQ ID NO: 504之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 504之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 504之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 504 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 One or more substitutions of the reference sequence of SEQ ID NO: 504.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:750、1051、260、756、1193、332、897、387、1037、306/749、1270、489、487、488、903、171/1248/1440、260/1148/1378、171/260/387/750/1248、171/260、171/260/387/750/1051/1148、171、750/1051/1148、171/260/756、171/1248、171/1148、59、1440、332/750/1248、756/1248、1248、171/387/1248/1440、750/1440、59/171/750、171/1193/1248、750/1148/1193/1440、1148、171/387/1051、748、306、306/387/390/749/1220、390、306/390/1037、306/612/749、387/390/749、63/390/503/749、1220、63/306、749、306/390/749/1037、306/749/1220、306/387/390/612/749/1037或328,其中該等胺基酸位置係相對於對應於SEQ ID NO: 504之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 750, 1051, 260, 756, 1193, 332, 897, 387, 1037, 306 /749, 1270, 489, 487, 488, 903, 171/1248/1440, 260/1148/1378, 171/260/387/750/1248, 171/260, 171/260/387/750/1051/1148 ,171,750/1051/1148,171/260/756,171/1248,171/1148,59,1440,332/750/1248,756/1248,1248,171/387/1248/1440,750/1440 ,59/171/750,171/1193/1248,750/1148/1193/1440,1148,171/387/1051,748,306,306/387/390/749/1220,390,306/390/1037 ,306/612/749, 387/390/749, 63/390/503/749, 1220, 63/306, 749, 306/390/749/1037, 306/749/1220, 306/387/390/612 /749/1037 or 328, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 504.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 706之殘基20-1457的參考序列或與對應於SEQ ID NO: 706之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 706之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 706之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 706 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 One or more substitutions of the reference sequence of SEQ ID NO: 706.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1051、1221、1218、387、749/1218、332、897、696、816、824、826、393、825、698、332/387/390/1148、328/387/749、749、306/328/332/390/1051/1193/1218、63/306/332/1051/1148、63/306/332/387/1051、387/390/1051、186/306/328/332/390/749/1051/1148/1193、387/390/756/1051、306/390/1051、306/332/390/749、306/387/390/1148、306/328/332/387/390/749/1051/1148/1193、332/387/390/749/1148、387/390/749、306/387/749/1051/1148、387/749、306/945/1051/1193/1221、306/390/749/1051、63/306/332/390、306/387/390/749/1148/1193/1221、306/332/387/390/749/1218、63/306/332/390/1051/1148/1193/1218、924、755、752、751、923、797、754、793、753、922、896、938、775、732、810、747、393/407、819、787、802、811、392或397,其中該等胺基酸位置係相對於對應於SEQ ID NO: 706之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1051, 1221, 1218, 387, 749/1218, 332, 897, 696, 816 ,824,826,393,825,698,332/387/390/1148,328/387/749,749,306/328/332/390/1051/1193/1218,63/306/332/1051/1148 , 63/306/332/387/1051, 387/390/1051, 186/306/328/332/390/749/1051/1148/1193, 387/390/756/1051, 306/390/1051, 306 /332/390/749, 306/387/390/1148, 306/328/332/387/390/749/1051/1148/1193, 332/387/390/749/1148, 387/390/749, 306 /387/749/1051/1148、387/749、306/945/1051/1193/1221、306/390/749/1051、63/306/332/390、306/387/390/749/1148/1193 /1221, 306/332/387/390/749/1218, 63/306/332/390/1051/1148/1193/1218, 924, 755, 752, 751, 923, 797, 754, 793, 753, 922 , 896, 938, 775, 732, 810, 747, 393/407, 819, 787, 802, 811, 392 or 397, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 706 .
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 840之殘基20-1457的參考序列或與對應於SEQ ID NO: 840之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 840之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 840之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 840 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 One or more substitutions of the reference sequence of SEQ ID NO: 840.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:620、491、1229、615、1283、822、328、212、818、555/684、828、550、830、839、13、14、17、836、1210、1281、64、682、318、20、21、325、533、19、817、831、225、1156、393/747、753、393/732/751、63/797、622、617、907、1040、611、488、1192、1194、619、16、802、211、555、536、527、841、320、837、558、914、312、681、838、15、1427、18、683、24、534、840、1160、551、393、393/747/752/811/819/923/1148、393/751/775、63/393/732/775/1148、393/732/1148、775/1148、393/752/753/775/793/797、393/923、393/923/1148、393/747/751、393/747/753/775/1148、752/923/1051、63/775、63/393/752/775/793/1051/1053、752/753/775/793/819、63/1051、63/747/752/753/775/811/819/923/1051、393/752/787、751、63/1148、63/747/752/753/819/923/1148、1148、747/752/753/793/811、63、797/1148、751/752/753/1051、63/732/1051、752/797/815/923/1051/1148或747/753,其中該等胺基酸位置係相對於對應於SEQ ID NO: 840之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 620, 491, 1229, 615, 1283, 822, 328, 212, 818, 555 /684, 828, 550, 830, 839, 13, 14, 17, 836, 1210, 1281, 64, 682, 318, 20, 21, 325, 533, 19, 817, 831, 225, 1156, 393/747 ,753,393/732/751,63/797,622,617,907,1040,611,488,1192,1194,619,16,802,211,555,536,527,841,320,837,558 ,914,312,681,838,15,1427,18,683,24,534,840,1160,551,393,393/747/752/811/819/923/1148,393/751/775,63 /393/732/775/1148, 393/732/1148, 775/1148, 393/752/753/775/793/797, 393/923, 393/923/1148, 393/747/751, 393/747 /753/775/1148、752/923/1051、63/775、63/393/752/775/793/1051/1053、752/753/775/793/819、63/1051、63/747/752 /753/775/811/819/923/1051, 393/752/787, 751, 63/1148, 63/747/752/753/819/923/1148, 1148, 747/752/753/793/811 , 63, 797/1148, 751/752/753/1051, 63/732/1051, 752/797/815/923/1051/1148 or 747/753, wherein the amino acid positions are relative to those corresponding to SEQ. The reference sequence of ID NO: 840.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 1200之殘基20-1457的參考序列或與對應於SEQ ID NO: 1200之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 1200之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 1200之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 or at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 1200 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 One or more substitutions of the reference sequence of SEQ ID NO: 1200.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:681、622、617、558、536、211、320、839、797、533、751、303、951、164、818、807、799、735、794、926、755、921、801、1094、968、929、924、698、168、581、916、1428、805、1114、311、737、693、809、757、1099、676、740、791、211/536/622/681、536/558、211/536/555/617/732、211/681/732、211/536/555、555、211/536、211/212、211/536/617/681/732、211/536/558/617/681、555/732、536/555/558/617/732、536/617/681/732、536/555、536/622/681、732、212/320/533/617/681、211/312/533/534/617/619/681/839、212、211/212/320/619/681/839、797/839、212/312/320/533/534/617/681、558/619/681、320/558/681、212/320/534/619/681/797/839、320/558/619/732/839、211/212/312/534/558/619/681/732/839、320/534/558/619/732/797、558/617/619/681、211/534/558/611/681、211/320/617/619/681、558/617/681/797、320/534/619/732、211/619/681、211/212/534/558/619/732/839、212/320/619/681/797/839、212/320/611/839、320/558/619/681、312/533/617/681/797/839、558/611/681、312、211/320/558/619/681/732/797/839、320/558/732/797、533/558/611/619/716/732/839、312/681、320/534/619/681、211/320/533/536/619、558/617/681/839、212/320/534/558/681、533/534/681/839、212/534/619/681、617/619/681、211/212/320/558/617/681、212/534/558/681/797、212/320/534、211/312/619、212/312/619/839、210/212/320/558/681、212/312/534/681/797/839、211/320/558/839、294、759、538或1109,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1200之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at the following amino acid positions: 681, 622, 617, 558, 536, 211, 320, 839, 797, 533 ,751,303,951,164,818,807,799,735,794,926,755,921,801,1094,968,929,924,698,168,581,916,1428,805,1114,311 ,737,693,809,757,1099,676,740,791,211/536/622/681,536/558,211/536/555/617/732,211/681/732,211/536/555 ,555,211/536,211/212,211/536/617/681/732,211/536/558/617/681,555/732,536/555/558/617/732,536/617/681 /732, 536/555, 536/622/681, 732, 212/320/533/617/681, 211/312/533/534/617/619/681/839, 212, 211/212/320/619 /681/839、797/839、212/312/320/533/534/617/681、558/619/681、320/558/681、212/320/534/619/681/797/839、320 /558/619/732/839, 211/212/312/534/558/619/681/732/839, 320/534/558/619/732/797, 558/617/619/681, 211/534 /558/611/681、211/320/617/619/681、558/617/681/797、320/534/619/732、211/619/681、211/212/534/558/619/732 /839、212/320/619/681/797/839、212/320/611/839、320/558/619/681、312/533/617/681/797/839、558/611/681、312 ,211/320/558/619/681/732/797/839, 320/558/732/797, 533/558/611/619/716/732/839, 312/681, 320/534/619/681 ,211/320/533/536/619, 558/617/681/839, 212/320/534/558/681, 533/534/681/839, 212/534/619/681, 617/619/681 ,211/212/320/558/617/681, 212/534/558/681/797, 212/320/534, 211/312/619, 212/312/619/839, 210/212/320/558 /681, 212/312/534/681/797/839, 211/320/558/839, 294, 759, 538 or 1109, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 1200 Reference sequence.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 1514之殘基20-1457的參考序列或與對應於SEQ ID NO: 1514之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 1514之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 1514之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 1514 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 One or more substitutions of the reference sequence of SEQ ID NO: 1514.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1042、1041、1051、1283、1281、916、187、215、178、1050、1210、104、615、610、536、618、621、614、110、301、1078、812、786、127、175、1093、1088、650、535、806、738、700、132、1076、1084、498、756、1108、746、160、543、310、584、918、1452、790、292、800、167、892、304、1116、752、281、917、712、1080、806/1352、1095、744、1098、948、119、785、1113、667、158、580、707、731、1100、1089、1092、939、1104、736、1297、1127、686、1129、1138、786/821、680、1101、808、739、308、536/555/619/732/799/805、555/619/801、555/619/799、619/799/801/805、536/555/619/732/799、799/805、801、246/619/799/801、536/555/619、619/839、619/799/805、536/801/805、555/619/799/805、619/801/805、555/619、536/619/801、801/805、536/619/799/805、555/619/732/799/801/805、749、616、611、370/614、1156、1158、555/681/737/799、536/619/809/1109、536/555/619/737/799/809/839/916/921、916/1109、536/619/681/799/916/1109、555/619/681/807/1109、555/619/681/737/799、619/681/799/916/1109、619/681、555/921、619/681/916、555/619/681/799、555、732、619/799、619、681、555/916、839或799,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1514之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1042, 1041, 1051, 1283, 1281, 916, 187, 215, 178, 1050 ,1210,104,615,610,536,618,621,614,110,301,1078,812,786,127,175,1093,1088,650,535,806,738,700,132,1076,1084 ,498,756,1108,746,160,543,310,584,918,1452,790,292,800,167,892,304,1116,752,281,917,712,1080,806/1352,1095 ,744,1098,948,119,785,1113,667,158,580,707,731,1100,1089,1092,939,1104,736,1297,1127,686,1129,1138,786/821,680 ,1101,808,739,308,536/555/619/732/799/805,555/619/801,555/619/799,619/799/801/805,536/555/619/732/799 ,799/805,801,246/619/799/801,536/555/619,619/839,619/799/805,536/801/805,555/619/799/805,619/801/805 ,555/619,536/619/801,801/805,536/619/799/805,555/619/732/799/801/805,749,616,611,370/614,1156,1158,555 /681/737/799, 536/619/809/1109, 536/555/619/737/799/809/839/916/921, 916/1109, 536/619/681/799/916/1109, 555 /619/681/807/1109, 555/619/681/737/799, 619/681/799/916/1109, 619/681, 555/921, 619/681/916, 555/619/681/799 , 555, 732, 619/799, 619, 681, 555/916, 839 or 799, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1514.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2072之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 or at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 2072 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 One or more substitutions of the reference sequence of SEQ ID NO: 2072.
在一些實施例中,重組因子VIII多肽包含具有至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:167、167/738/1076/1093、167/738/752/800/805/808/809/1116、167/800/809/1076、167/318、167/318/800/805/808/809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167、167/738/1076/1093、167/738/752/800/805/808/809/1116、167/800/809/1076、167/318、167/318/800/805/808/809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167/318/700/1076、167/318/700/738/739/1076、167/681/738/800/808/809、167/178/700/752/1093、167/700、167/700/738/739/1093、167/700/738/752/1093、167/700/738/752/805/808/809/1093/1116、808/809、1076、738、738/808/809、738/1076、738/739、738/739/809、738/739/809/1093/1116、738/739/1093、738/739/752/1093、738/739/799/800/1093、738/739/1116、738/800、738/1093、738/752、738/752/1093、738/752/799、738/799/809/1093、738/799/1093、739、739/800/809、800、800/805/809、809、809/1093、809/1093/1116、809/1116、318、318/1076、318/1076/1116、318/739/805/808/809/1076、318/499/700/738/809、318/1093、318/752/1093、318/1116、318/543/739、318/543/681/752/1116、318/543/1093、318/700/738/1093/1414、681、681/738、681/738/739/1093、681/738/739/752/799/800/809/1116/1339、681/738/739/1116、681/738/800、681/800/805/809、681/809/1093、681/752/1093、681/752/1093、681/700、681/700/738/739/1093/1116、681/700/809、681/700/1093、681/700/752/808/809/1093/1116、681/700/752/1093、681/700/844、681/700/805/809、1093、1093/1116、752、752/1076、752/800/809、752/800/1093、752/809、752/866、752/1093、752/1116、178/318/739/752/809/1076/1116、178/318/800/809、178/318/681/800/808/809/1076、178/681、178/681/738/1116、178/752/809、178/700/800/805/808/809、178/805/809/866、1116、543、543/738/739/809、543/738/809/1093、543/739/1093、543/800/1093/1116、543/809/1093、543/809/1093/1116、543/681/738/739/752/809/1093、543/681/738/739/752/1093、543/681/739/752/800/805/809/1093、543/681/700/738/739/800/1093/1116、543/681/700/738/739/805/808/809、543/681/700/752、543/681/700/752/809/1093、543/1093、543/700、543/700/738/739/752/800/1093/1116、543/700/809、543/700/1093、543/700/752、543/700/752/800/1093、543/700/752/809/1116、543/700/752/1093、700、700/738/739/800/1093、700/738/739/799/1093、700/738/800/1093、700/738/1116、700/809、700/809/1093、700/1093、700/1093/1116、700/752、700/752/808/809/1093/1116、700/752/809/1093、700/752/799/1116、700/752/805/809/1093、700/799/800、700/1116、700/805/808/809/1076、514/543/681/805/808/809、805/808/809或805/809/1116,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2072之該參考序列。In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence having at least one substitution or set of substitutions at the following amino acid positions: 167, 167/738/1076/1093, 167/738/752/800/ 805/808/809/1116, 167/800/809/1076, 167/318, 167/318/800/805/808/809, 167/318/681, 167/318/681/700/805/808/ 809/1076/1116, 167/318/700, 167, 167/738/1076/1093, 167/738/752/800/805/808/809/1116, 167/800/809/1076, 167/318, 167/318/800/805/808/809, 167/318/681, 167/318/681/700/805/808/809/1076/1116, 167/318/700, 167/318/700/1076, 167/318/700/738/739/1076, 167/681/738/800/808/809, 167/178/700/752/1093, 167/700, 167/700/738/739/1093, 167/ 700/738/752/1093, 167/700/738/752/805/808/809/1093/1116, 808/809, 1076, 738, 738/808/809, 738/1076, 738/739, 738/ 739/809, 738/739/809/1093/1116, 738/739/1093, 738/739/752/1093, 738/739/799/800/1093, 738/739/1116, 738/800, 738/ 1093, 738/752, 738/752/1093, 738/752/799, 738/799/809/1093, 738/799/1093, 739, 739/800/809, 800, 800/805/809, 809, 809/1093, 809/1093/1116, 809/1116, 318, 318/1076, 318/1076/1116, 318/739/805/808/809/1076, 318/499/700/738/809, 318/ 1093, 318/752/1093, 318/1116, 318/543/739, 318/543/681/752/1116, 318/543/1093, 318/700/738/1093/1414, 681, 681/738, 681/738/739/1093, 681/738/739/752/799/800/809/1116/1339, 681/738/739/1116, 681/738/800, 681/800/805/809, 681/ 809/1093, 681/752/1093, 681/752/1093, 681/700, 681/700/738/739/1093/1116, 681/700/809, 681/700/1093, 681/700/752/ 808/809/1093/1116, 681/700/752/1093, 681/700/844, 681/700/805/809, 1093, 1093/1116, 752, 752/1076, 752/800/809, 752/ 800/1093, 752/809, 752/866, 752/1093, 752/1116, 178/318/739/752/809/1076/1116, 178/318/800/809, 178/318/681/800/ 808/809/1076, 178/681, 178/681/738/1116, 178/752/809, 178/700/800/805/808/809, 178/805/809/866, 1116, 543, 543/ 738/739/809, 543/738/809/1093, 543/739/1093, 543/800/1093/1116, 543/809/1093, 543/809/1093/1116, 543/681/738/739/ 752/809/1093, 543/681/738/739/752/1093, 543/681/739/752/800/805/809/1093, 543/681/700/738/739/800/1093/1116, 543/681/700/738/739/805/808/809, 543/681/700/752, 543/681/700/752/809/1093, 543/1093, 543/700, 543/700/738/ 739/752/800/1093/1116, 543/700/809, 543/700/1093, 543/700/752, 543/700/752/800/1093, 543/700/752/809/1116, 543/ 700/752/1093, 700, 700/738/739/800/1093, 700/738/739/799/1093, 700/738/800/1093, 700/738/1116, 700/809, 700/809/ 1093, 700/1093, 700/1093/1116, 700/752, 700/752/808/809/1093/1116, 700/752/809/1093, 700/752/799/1116, 700/752/805/ 809/1093, 700/799/800, 700/1116, 700/805/808/809/1076, 514/543/681/805/808/809, 805/808/809 or 805/809/1116, which Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2072.
在一些實施例中,重組因子VIII多肽包含具有至少一個 表4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, a recombinant Factor VIII polypeptide comprises at least one of the polypeptides set forth in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1, 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 A substituted amino acid sequence, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含具有至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之變異體的取代或取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, a recombinant Factor VIII polypeptide comprises at least one of the polypeptides set forth in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1, 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 An amino acid sequence of a variant substitution or set of substitutions, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含胺基酸序列,該胺基酸序列包含 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之偶數編號SEQ ID NO.的序列的殘基20-1457,或包含 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之偶數編號SEQ ID NO.的序列。 In some embodiments, the recombinant Factor VIII polypeptide comprises an amino acid sequence comprising Table 4.1 , 4.2 , 5.1 , 5.2, 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , residues 20-1457 of the even-numbered SEQ ID NO. sequences set forth in Tables 11.1 and 15.1 , or include Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2, 8.1 , 8.2 , 9.1 , 9.2 , The even-numbered SEQ ID NO. sequences set forth in 10.1 , 10.2 , 11.1 and 15.1 .
在一些實施例中,重組因子VIII多肽包含胺基酸序列,該胺基酸序列包含SEQ ID NO: 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457,或包含SEQ ID NO: 4-2346及2350-2870中之偶數編號SEQ ID NO.。在一些實施例中,重組因子VIII多肽之胺基酸序列任擇地包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代。在一些實施例中,重組因子VIII多肽之胺基酸序列任擇地包括1、2、3、4或5個胺基酸取代。In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NOs: 4-2346 and 2360-2870, or comprising SEQ ID NO: Even-numbered SEQ ID NO. among 4-2346 and 2350-2870. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 amino acid substitutions. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide optionally includes 1, 2, 3, 4, or 5 amino acid substitutions.
在一些實施例中,重組因子VIII多肽包含胺基酸序列,該胺基酸序列包含SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457,或包含SEQ ID NO: 252、504、706、840、1200、1514或2072。在一些實施例中,重組因子VIII多肽之胺基酸序列任擇地包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代。在一些實施例中,重組因子VIII多肽之胺基酸序列任擇地包括1、2、3、4或5個胺基酸取代。In some embodiments, the recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072, or comprising SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 amino acid substitutions. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide optionally includes 1, 2, 3, 4, or 5 amino acid substitutions.
在本文之實施例中,重組因子VIII多肽具有凝血活性。在一些實施例中,重組因子VIII多肽呈現出與參考因子VIII多肽相比改良之特性。在一些實施例中,參考因子VIII多肽具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列。在一些實施例中,參考因子VIII多肽具有對應於SEQ ID NO: 2之殘基20-1457之序列或對應於SEQ ID NO: 2之序列。In the embodiments herein, the recombinant Factor VIII polypeptide has coagulation activity. In some embodiments, a recombinant Factor VIII polypeptide exhibits improved properties compared to a reference Factor VIII polypeptide. In some embodiments, the reference Factor VIII polypeptide has a sequence corresponding to residues 20-1457 of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 or corresponding to SEQ ID NO: 2, 252 , 504, 706, 840, 1200, 1514 or 2072 sequence. In some embodiments, the reference Factor VIII polypeptide has a sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or a sequence corresponding to SEQ ID NO: 2.
在一些實施例中,與具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽相比,本文所描述之重組因子VIII多肽展現至少一種選自下列之改良特性:i)增加之活性/效能;ii)增加之凝血活性/效能;iii)增加之血漿或血清穩定性;iv)增加之熱穩定性;v)降低之免疫原性;vi)增加之來自經表現載體轉染之細胞的表現及/或分泌;vii)增加之來自經基因療法載體(例如AAV、mRNA或脂質奈米顆粒)轉導之細胞的轉導及/或分泌,或i)、ii)、iii)、iv)、v)、vi)及vii)中之任一者之組合。在一些實施例中,參考因子VIII多肽具有對應於SEQ ID NO: 2之殘基20-1457之序列或具有對應於SEQ ID NO: 2之序列。In some embodiments, with a sequence having residues 20-1457 corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 or having a sequence corresponding to SEQ ID NO: 2, 252, 504 , 706, 840, 1200, 1514 or 2072, the recombinant Factor VIII polypeptides described herein exhibit at least one improved property selected from: i) increased activity/potency; ii) increased Coagulation activity/potency; iii) increased plasma or serum stability; iv) increased thermal stability; v) reduced immunogenicity; vi) increased expression and/or secretion from cells transfected with the expression vector; vii) Increased transduction and/or secretion from cells transduced with gene therapy vectors (e.g. AAV, mRNA or lipid nanoparticles), or i), ii), iii), iv), v), vi) and a combination of any of vii). In some embodiments, the reference Factor VIII polypeptide has a sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or has a sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽包含「去免疫性」重組因子VIII多肽,諸如提供於 表 12-1至 12-8及 15-2中。 In some embodiments, recombinant Factor VIII polypeptides comprise "deimmunized" recombinant Factor VIII polypeptides, such as provided in Tables 12-1 to 12-8 and 15-2 .
在一些其他實施例中,重組因子VIII經純化。在另一態樣中,本揭露內容亦提供本文所揭示之重組因子VIII多肽之功能性或生物活性片段。In some other embodiments, recombinant Factor VIII is purified. In another aspect, the present disclosure also provides functional or biologically active fragments of the recombinant Factor VIII polypeptides disclosed herein.
在另一態樣中,本揭露內容進一步提供一種編碼至少一種本文所描述之重組因子VIII多肽或其生物活性片段的重組聚核苷酸。在一些實施例中,聚核苷酸為DNA、RNA或mRNA。In another aspect, the present disclosure further provides a recombinant polynucleotide encoding at least one recombinant Factor VIII polypeptide described herein, or a biologically active fragment thereof. In some embodiments, the polynucleotide is DNA, RNA, or mRNA.
在一些實施例中,重組聚核苷酸包含與對應於SEQ ID NO: 1-2345及2359-2869中之奇數編號SEQ ID NO.之核苷酸殘基58-4371的參考聚核苷酸序列或與對應於SEQ ID NO: 1-2345及2349-2869中之奇數編號SEQ ID NO.之參考聚核苷酸序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的聚核苷酸序列,其中該重組聚核苷酸編碼重組因子VIII多肽。In some embodiments, the recombinant polynucleotide comprises a reference polynucleotide sequence corresponding to nucleotide residues 58-4371 of odd-numbered SEQ ID NO. in SEQ ID NOs: 1-2345 and 2359-2869 Or have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more A sequence identical polynucleotide sequence, wherein the recombinant polynucleotide encodes a recombinant Factor VIII polypeptide.
在一些實施例中,重組聚核苷酸包含經密碼子最佳化以在宿主細胞中表現之聚核苷酸序列。在一些實施例中,重組聚核苷酸包含經密碼子最佳化以在哺乳動物細胞、尤其人類細胞中表現之聚核苷酸序列。In some embodiments, recombinant polynucleotides comprise polynucleotide sequences that are codon-optimized for expression in a host cell. In some embodiments, recombinant polynucleotides comprise polynucleotide sequences that are codon-optimized for expression in mammalian cells, particularly human cells.
在一些實施例中,重組聚核苷酸包含聚核苷酸序列,該聚核苷酸序列包含SEQ ID NO: 1-2345及2359-2869中之奇數編號SEQ ID NO.的核苷酸殘基58-4371,或包含SEQ ID NO: 1-2345及2349-2869中之奇數編號SEQ ID NO.。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence comprising the odd-numbered nucleotide residues of SEQ ID NO. in SEQ ID NOs: 1-2345 and 2359-2869 58-4371, or odd-numbered SEQ ID NO. including SEQ ID NOs: 1-2345 and 2349-2869.
在一些實施例中,重組聚核苷酸包含聚核苷酸序列,該聚核苷酸序列包含SEQ ID NO: 1、251、503、705、839、1199、1513或2071之核苷酸殘基58-4371,或包含SEQ ID NO: 1、251、503、705、839、1199、1513或2071。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence comprising the nucleotide residues of SEQ ID NO: 1, 251, 503, 705, 839, 1199, 1513, or 2071 58-4371, or contains SEQ ID NO: 1, 251, 503, 705, 839, 1199, 1513 or 2071.
在另一態樣中,本揭露內容提供包含編碼如本文所描述之重組因子VIII多肽之重組聚核苷酸的表現載體。在一些實施例中,重組聚核苷酸可操作地連接至一或多個控制序列。在一些實施例中,控制序列包含啟動子。在一些其他實施例中,啟動子為異源啟動子。In another aspect, the present disclosure provides expression vectors comprising recombinant polynucleotides encoding recombinant Factor VIII polypeptides as described herein. In some embodiments, a recombinant polynucleotide is operably linked to one or more control sequences. In some embodiments, the control sequence includes a promoter. In some other embodiments, the promoter is a heterologous promoter.
在另一態樣中,本揭露內容提供一種宿主細胞,其包含編碼重組因子VIII多肽之重組聚核苷酸。在一些實施例中,宿主細胞為真核細胞或原核細胞。在一些實施例中,宿主細胞為哺乳動物細胞,尤其為人類細胞,諸如經培養之人類細胞。在一些實施例中,宿主細胞為人類幹細胞。In another aspect, the present disclosure provides a host cell comprising a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide. In some embodiments, the host cell is a eukaryotic cell or a prokaryotic cell. In some embodiments, the host cell is a mammalian cell, particularly a human cell, such as a cultured human cell. In some embodiments, the host cells are human stem cells.
在另一態樣中,本揭露內容提供產生本文所描述之重組因子VIII多肽之方法,其包含在使得重組因子VIII多肽產生之條件下培養包含編碼重組因子VIII多肽之重組聚核苷酸的宿主細胞。在一些實施例中,該方法進一步包含回收諸如來自培養基或細胞的經表現之重組因子VIII多肽的步驟。在一些實施例中,該方法進一步包含純化經表現之重組因子VIII多肽的步驟。In another aspect, the present disclosure provides a method of producing a recombinant Factor VIII polypeptide described herein, comprising culturing a host comprising a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide under conditions such that the recombinant Factor VIII polypeptide is produced. cells. In some embodiments, the method further comprises the step of recovering the expressed recombinant Factor VIII polypeptide, such as from the culture medium or cells. In some embodiments, the method further comprises the step of purifying the expressed recombinant Factor VIII polypeptide.
在另一態樣中,本揭露內容提供包含至少一種本文所描述之重組因子VIII多肽之組成物。在一些實施例中,重組因子VIII多肽以醫藥組成物形式提供。在一些實施例中,醫藥組成物包含重組因子VIII多肽及醫藥學上可接受之載劑及/或賦形劑。在一些實施例中,醫藥組成物適用於非經腸注射或輸注,尤其適用於向人類個體投予。In another aspect, the present disclosure provides compositions comprising at least one recombinant Factor VIII polypeptide described herein. In some embodiments, recombinant Factor VIII polypeptides are provided in the form of pharmaceutical compositions. In some embodiments, a pharmaceutical composition includes a recombinant Factor VIII polypeptide and a pharmaceutically acceptable carrier and/or excipient. In some embodiments, the pharmaceutical composition is suitable for parenteral injection or infusion, particularly for administration to a human subject.
在一些實施例中,醫藥組成物包含至少一種編碼重組因子VIII多肽之重組聚核苷酸,尤其用於基因療法。在一些實施例中,用於基因療法之組成物包含編碼本文所描述之重組因子VIII多肽中之至少一者的重組聚核苷酸。在一些實施例中,基因療法組成物包含病毒載體,該病毒載體包含編碼本文所描述之重組因子VIII多肽之重組聚核苷酸。In some embodiments, pharmaceutical compositions comprise at least one recombinant polynucleotide encoding a recombinant Factor VIII polypeptide, particularly for use in gene therapy. In some embodiments, compositions for gene therapy comprise a recombinant polynucleotide encoding at least one of the recombinant Factor VIII polypeptides described herein. In some embodiments, a gene therapy composition comprises a viral vector comprising a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide described herein.
在一些實施例中,基因療法組成物包含編碼至少一種本文中所描述之重組因子VIII多肽的重組聚核苷酸,其中該聚核苷酸調配於脂質體、陽離子聚合物中,或藉由樹枝狀聚合物調配或連接至細胞穿透肽。在一些實施例中,提供基因療法組成物之重組聚核苷酸作為用於在哺乳動物細胞中表現之表現載體。In some embodiments, gene therapy compositions comprise a recombinant polynucleotide encoding at least one recombinant Factor VIII polypeptide described herein, wherein the polynucleotide is formulated in a liposome, a cationic polymer, or via a dendron polymers formulated or linked to cell-penetrating peptides. In some embodiments, recombinant polynucleotides of gene therapy compositions are provided as expression vectors for expression in mammalian cells.
在另一態樣中,重組因子VIII多肽及編碼重組因子VIII多肽之相應重組聚核苷酸適用於治療由因子VIII缺乏症表徵之病狀或疾病的治療應用。在一些實施例中,用於治療及/或預防個體之因子VIII缺乏症之症狀的方法包含向患有因子VIII缺乏症之個體投予有效量之重組因子VIII多肽或包含重組因子VIII多肽之醫藥組成物。在一些實施例中,用於治療及/或預防個體之因子VIII缺乏症之症狀的方法包含向患有因子VIII缺乏症之個體提供包含編碼本文所描述之重組因子VIII多肽之重組聚核苷酸的基因療法組成物。In another aspect, recombinant Factor VIII polypeptides and corresponding recombinant polynucleotides encoding recombinant Factor VIII polypeptides are suitable for therapeutic use in treating a condition or disease characterized by Factor VIII deficiency. In some embodiments, methods for treating and/or preventing symptoms of Factor VIII deficiency in an individual comprise administering to an individual suffering from Factor VIII deficiency an effective amount of a recombinant Factor VIII polypeptide or a medicament comprising a recombinant Factor VIII polypeptide. composition. In some embodiments, methods for treating and/or preventing symptoms of Factor VIII deficiency in an individual comprise providing to an individual suffering from Factor VIII deficiency a recombinant polynucleotide comprising a recombinant Factor VIII polypeptide described herein. Gene therapy compositions.
在另一態樣中,本揭露內容亦提供重組因子VIII多肽或其醫藥或包含編碼重組因子VIII多肽之重組聚核苷酸的基因療法組成物用於治療個體之因子VIII缺乏症的用途。在一些實施例中,重組因子VIII多肽或包含編碼重組因子VIII多肽之重組聚核苷酸的基因療法組成物之用途係用於製備供治療個體之因子VIII缺乏症用之藥物。在一些實施例中,該方法或用途係用於治療個體之A型血友病。In another aspect, the present disclosure also provides the use of a recombinant Factor VIII polypeptide, or a medicament thereof, or a gene therapy composition comprising a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide, for treating Factor VIII deficiency in an individual. In some embodiments, use of a recombinant Factor VIII polypeptide or a gene therapy composition comprising a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide is for the preparation of a medicament for treating Factor VIII deficiency in an individual. In some embodiments, the method or use is for treating hemophilia A in an individual.
較佳實施例之詳細說明Detailed description of preferred embodiments
本揭露內容係關於重組因子VIII多肽(FVIII)變異體及其組成物。重組因子VIII多肽變異體經工程改造以展現改良之特性,諸如改良之活性,包括血液凝血活性、改良之輔因子效能、改良之表現、增加之熱穩定性、增加之血清穩定性、增加之血漿穩定性及/或降低之免疫原性。本揭露內容亦提供包含重組因子VIII多肽變異體或編碼該等重組因子VIII多肽變異體之聚核苷酸的組成物用於治療目的之用途。The present disclosure relates to recombinant Factor VIII polypeptide (FVIII) variants and compositions thereof. Recombinant Factor VIII polypeptide variants are engineered to exhibit improved properties, such as improved activity, including blood coagulation activity, improved cofactor potency, improved performance, increased thermal stability, increased serum stability, increased plasma stability and/or reduced immunogenicity. The present disclosure also provides for the use of compositions comprising recombinant Factor VIII polypeptide variants or polynucleotides encoding such recombinant Factor VIII polypeptide variants for therapeutic purposes.
應理解,前述包括附圖在內之大體說明及以下詳細說明皆僅為例示性及說明性的且不限制本揭露內容。 縮寫及定義 It should be understood that the foregoing general description, including the accompanying drawings, and the following detailed description are illustrative and explanatory only and do not limit the disclosure. Abbreviations and definitions
除非另外定義,否則本文所用之所有技術及科學術語一般皆具有與一般熟習本發明所屬技術者通常所理解相同之含義。一般而言,本文所使用之命名法以及下文所描述之細胞培養實驗步驟、分子遺傳學、微生物學、生物化學、有機化學、分析化學及核酸化學為此項技術中熟知且通常採用之命名法、細胞培養實驗步驟、分子遺傳學、微生物學、生物化學、有機化學、分析化學及核酸化學。此類技術為熟知的且描述於熟習此項技術者熟知的諸多教材以及參考文獻著作中。化學合成及化學分析係使用標準技術或其變型。Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein and in the cell culture protocols, molecular genetics, microbiology, biochemistry, organic chemistry, analytical chemistry, and nucleic acid chemistry described below are those well known and commonly used in the art. , cell culture experimental procedures, molecular genetics, microbiology, biochemistry, organic chemistry, analytical chemistry and nucleic acid chemistry. Such techniques are well known and described in numerous textbooks and reference works familiar to those skilled in the art. Chemical synthesis and chemical analysis are performed using standard techniques or variations thereof.
儘管與本文所描述類似或等效的任何適合方法及材料可用於本發明的實施,但本文描述一些方法及材料。應瞭解,本發明不限於所描述特定方法、方案及試劑,原因在於此等方法、方案及試劑可根據熟習此項技術者使用其的背景而變化。因此,下文緊接著定義之術語係藉由參考整個申請案而加以更充分的描述。Although any suitable methods and materials similar or equivalent to those described herein can be used in the practice of the invention, some methods and materials are described herein. It is to be understood that this invention is not limited to the particular methods, protocols and reagents described, as such methods, protocols and reagents may vary depending on the context in which they are used by those skilled in the art. Accordingly, the terms defined immediately below are more fully described by reference to the entire application.
此外,除非上下文另外清楚地指示,否則如本文所使用之單數「一(a)」、「一(an)」以及「該(the)」包括多個提及物。Furthermore, as used herein, the singular "a", "an" and "the" include plural referents unless the context clearly dictates otherwise.
數值範圍包括界定該範圍之數字。因此,本文所揭露之每個數值範圍均意欲涵蓋落入此類較寬數值範圍內之每個較窄數值範圍,如同此類較窄數值範圍在本文中全部被明確地書寫一般。亦希望本文所揭露之每個最大(或最小)數值限制包括每個較低(或較高)數值限制,如同此類較低(或較高)數值限制在本文中被明確地書寫一般。Numerical ranges include the numbers defining the range. Therefore, every numerical range disclosed herein is intended to include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. It is also intended that every maximum (or minimum) numerical limitation disclosed herein include every lower (or higher) numerical limitation, as if such lower (or higher) numerical limitations were expressly written herein.
術語「約」意謂特定值之可接受誤差。在一些情況下,「約」意謂在既定值範圍之0.05%、0.5%、1.0%或2.0%內。在一些情況下,「約」意謂在既定值之1、2、3或4個標準差內。The term "about" means an acceptable error for a particular value. In some cases, "about" means within 0.05%, 0.5%, 1.0% or 2.0% of a stated value range. In some cases, "about" means within 1, 2, 3 or 4 standard deviations of a given value.
如本文所用,術語「包含」及其同源詞係在其包括性意義上(亦即,等效於術語「包括」及其對應同源詞)使用。As used herein, the term "comprising" and its cognates are used in its inclusive sense (i.e., equivalent to the term "includes" and its corresponding cognates).
亦應理解,在各種實施例之描述使用術語「包含」之情況下,所屬領域中熟習此項技術者將理解在一些特定情況中,可使用措辭「基本上由……組成」或「由……組成」替代地描述實施例。It should also be understood that where the term "comprising" is used in the description of various embodiments, those skilled in the art will understand that in some specific cases, the phrase "consisting essentially of" or "consisting of" may be used. Composition" alternatively describes embodiments.
另外,本文所提供之標題不限制本發明之各種態樣或實施例,該等態樣或實施例可參考整個申請案實施。因此,下文緊接著定義之術語係藉由參考整個申請案而加以更充分的定義。儘管如此,但為了促進瞭解本發明,下文中定義多個術語。Additionally, the headings provided herein do not limit the various aspects or embodiments of the invention, which may be practiced with reference to the entire application. Accordingly, the terms defined immediately below are more fully defined by reference to the entire application. Nonetheless, in order to facilitate an understanding of the present invention, a number of terms are defined below.
「ATCC」係指其生物庫集合包括基因以及菌株之美國菌種中心(American Type Culture Collection)。"ATCC" refers to the American Type Culture Collection whose biobank collection includes genes and strains.
「NCBI」係指國家生物資訊中心(National Center for Biological Information)以及其中所提供之序列資料庫。"NCBI" refers to the National Center for Biological Information and the sequence database provided therein.
「蛋白質」、「多肽」及「肽」在本文中可互換使用,以表示藉由醯胺鍵共價連接之至少二種胺基酸之聚合物,不論長度或轉譯後修飾(例如糖基化或磷酸化)。"Protein", "polypeptide" and "peptide" are used interchangeably herein to mean a polymer of at least two amino acids covalently linked by amide bonds, regardless of length or post-translational modification (e.g. glycosylation) or phosphorylation).
「成熟蛋白質」或「成熟多肽」係指最終經處理之生物蛋白質或多肽或產物。"Mature protein" or "mature polypeptide" refers to the final processed biological protein or polypeptide or product.
「原蛋白」、「原多肽」或「原肽」係指藉由轉譯後修飾處理以形成生物活性蛋白質、多肽或肽的前驅蛋白、多肽或肽。在一些實施例中,轉譯後修飾為形成蛋白質、多肽或肽之裂解反應。"Proprotein", "propolypeptide" or "propeptide" refers to a precursor protein, polypeptide or peptide that is processed by post-translational modification to form a biologically active protein, polypeptide or peptide. In some embodiments, the post-translational modification is a cleavage reaction to form a protein, polypeptide or peptide.
「前原蛋白」、「前原多肽」或「前原肽」係指前驅蛋白、多肽或肽,其包括信號序列或信號肽,且可藉由轉譯後修飾,尤其裂解反應處理,產生原蛋白、原多肽或原肽。一般而言,裂解反應移除信號序列或信號肽以產生前蛋白、前多肽或前肽。"Preproprotein", "prepropolypeptide" or "prepropeptide" refers to a precursor protein, polypeptide or peptide, which includes a signal sequence or signal peptide and can be processed by post-translational modification, especially cleavage reaction, to produce a preprotein, prepropolypeptide or propeptide. Generally, cleavage reactions remove a signal sequence or signal peptide to produce a proprotein, propolypeptide or propeptide.
在蛋白質或多肽之情況下,「全長」係指未經處理以改變整個蛋白質或多肽之胺基酸序列的蛋白質或多肽。舉例而言,全長蛋白質為編碼於相應mRNA中的整個蛋白質。In the context of a protein or polypeptide, "full-length" refers to a protein or polypeptide that has not been processed to alter the amino acid sequence of the entire protein or polypeptide. For example, a full-length protein is the entire protein encoded in the corresponding mRNA.
「胺基酸」在本文中用其通常已知之三字母符號或由IUPAC-IUB生物化學命名法委員會所推薦之單字母符號來提及。用於基因編碼之胺基酸之縮寫為習知的且如下:丙胺酸(Ala或A)、精胺酸(Arg或R)、天冬醯胺(Asn或N)、天冬胺酸(Asp或D)、半胱胺酸(Cys或C)、麩胺酸(Glu或E)、麩醯胺酸(Gln或Q)、甘胺酸(Gly或G)、組胺酸(His或H)、異白胺酸(Ile或I)、白胺酸(Leu或K)、離胺酸(Lys或K)、甲硫胺酸(Met或M)、苯丙胺酸(Phe或F)、脯胺酸(Pro或P)、絲胺酸(Ser或S)、蘇胺酸(Thr或T)、色胺酸(Trp或W)、酪胺酸(Tyr或Y)及纈胺酸(Val或V)。當使用三字母縮寫時,除非前面特定地存在「L」或「D」或自使用該縮寫之上下文明顯可見,否則胺基酸可在α-碳(C α)周圍呈L組態或D組態。舉例而言,鑒於在不指定α-碳周圍之組態之情況下「Ala」指示丙胺酸,「D-Ala」及「L-Ala」分別表示D-丙胺酸及L-丙胺酸。當多肽序列呈現為一串單字母縮寫或三字母縮寫(或其混合形式)時,根據常用慣例,序列在胺基(N)至羧基(C)方向呈現。 "Amino acids" are referred to herein by their commonly known three-letter symbols or by their single-letter symbols recommended by the IUPAC-IUB Committee on Biochemical Nomenclature. The abbreviations for amino acids encoded by genes are conventional and are as follows: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamic acid (Glu or E), glutamic acid (Gln or Q), glycine (Gly or G), histamine (His or H) , isoleucine (Ile or I), leucine (Leu or K), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y) and valine (Val or V) . When a three-letter abbreviation is used, the amino acid may be in the L configuration or the D configuration around the alpha carbon (C α ) unless specifically preceded by an "L" or "D" or is obvious from the context in which the abbreviation is used. state. For example, whereas "Ala" indicates alanine without specifying the configuration around the alpha-carbon, "D-Ala" and "L-Ala" indicate D-alanine and L-alanine, respectively. When a polypeptide sequence is presented as a sequence of one-letter or three-letter abbreviations (or a mixture thereof), the sequence is presented in the amine (N) to carboxyl (C) direction according to common convention.
「聚核苷酸」在本文中用以表示包含至少二個核苷酸之聚合物,其中核苷酸為去氧核糖核苷酸或核糖核苷酸或去氧核糖核苷酸及核糖核苷酸之混合物。在一些實施例中,用於基因編碼核苷之縮寫為習知的且如下:腺苷(A);鳥苷(G);胞苷(C);胸苷(T);及尿苷(U)。除非特定地敍述,否則縮寫核苷可為核糖核苷或2'-去氧核糖核苷。在個別基礎上或在聚合基礎上,核苷可被規定為核糖核苷或2'-去氧核糖核苷。當核酸序列呈現為一串單字母縮寫時,根據常用慣例,序列在5'至3'方向呈現,且磷酸不被指示。術語「DNA」係指去氧核糖核酸。術語「RNA」係指核糖核酸。"Polynucleotide" is used herein to mean a polymer containing at least two nucleotides, where the nucleotides are deoxyribonucleotides or ribonucleotides or both deoxyribonucleotides and ribonucleosides A mixture of acids. In some embodiments, abbreviations for gene-encoded nucleosides are conventional and are as follows: adenosine (A); guanosine (G); cytidine (C); thymidine (T); and uridine (U ). Unless stated specifically, the abbreviation nucleoside may be ribonucleoside or 2'-deoxyribonucleoside. Nucleosides may be designated as ribonucleosides or 2'-deoxyribonucleosides, either on an individual basis or on a collective basis. When a nucleic acid sequence is presented as a string of single-letter abbreviations, according to common convention, the sequence is presented in the 5' to 3' direction, and the phosphates are not indicated. The term "DNA" refers to deoxyribonucleic acid. The term "RNA" refers to ribonucleic acid.
術語「經工程改造之」、「重組」、「非天然存在之」以及「變異體」在關於細胞、聚核苷酸或多肽使用時係指已以不另外存在於自然界中之方式經修飾或與其具有一致性、但由合成物質產生或衍生及/或藉由操縱使用重組技術產生或衍生的物質或對應於該物質的天然或自然形式的物質。The terms "engineered," "recombinant," "non-naturally occurring," and "variant" when used with respect to cells, polynucleotides, or polypeptides mean that have been modified or modified in a manner that would not otherwise occur in nature. A substance consistent therewith but produced or derived from a synthetic substance and/or produced or derived by manipulation using recombinant techniques or a substance corresponding to a natural or natural form of that substance.
「野生型」以及「天然存在之」係指在自然界中發現之形式。舉例而言,野生型多肽或聚核苷酸序列為存在於生物體中的序列,該序列可自自然界中的來源分離出來且尚未藉由人類操控有意修飾。“Wild type” and “naturally occurring” refer to the form found in nature. For example, a wild-type polypeptide or polynucleotide sequence is a sequence present in an organism that can be isolated from a source in nature and that has not been intentionally modified by human manipulation.
「編碼序列」係指編碼蛋白質或多肽之胺基酸序列的核酸(例如基因)的一部分。"Coding sequence" refers to a portion of a nucleic acid (eg, a gene) encoding the amino acid sequence of a protein or polypeptide.
「序列一致性百分比(%)」在本文中用於指聚核苷酸以及多肽中之比較結果,且藉由比較比較窗上之二個經最佳比對序列來測定,其中相較於參考序列而言,比較窗中之聚核苷酸或多肽序列之部分可包含添加或缺失(亦即間隙)以用於二個序列的最佳比對。該百分比可如下計算:測定二個序列中存在相同核酸鹼基或胺基酸殘基之位置的數目以產生匹配位置數,將該匹配位置數除以比較窗中之總位置數且將結果乘以100以產生序列一致性百分比。或者,該百分比可如下計算:測定二個序列中存在相同核酸鹼基或胺基酸殘基之位置的數目或核酸鹼基或胺基酸殘基與空位對準之位置的數目以產生匹配位置數,將該匹配位置數除以比較窗中之總位置數且將結果乘以100,以產生序列一致性百分比。熟習此項技術者瞭解,存在可用於比對二個序列之許多已建立算法。用於比較之最佳序列比對可例如藉由Smith及Waterman之局部同源性演算法(Smith及Waterman, Adv. Appl. Math., 1981, 2:482)、藉由Needleman及Wunsch之同源性比對演算法(Needleman及Wunsch, J. Mol. Biol., 1970, 48:443)、藉由Pearson及Lipman之類似性搜尋方法(Pearson及Lipman, Proc. Natl. Acad. Sci. USA, 1988, 85:2444)、藉由此等演算法之電腦化實施方式(例如GCG Wisconsin套裝軟體中之GAP、BESTFIT、FASTA以及TFASTA)或藉由如此項技術中已知之視覺檢查來進行。適用於測定序列一致性及序列類似性百分比之演算法之實例包括但不限於Altschul等人所描述之BLAST以及BLAST 2.0演算法(分別參見Altschul等人,J. Mol. Biol., 1990, 215: 403-410;以及Altschul等人,1977, Nucleic Acids Res., 1977, 3389-3402)。用於進行BLAST分析之軟體可經由國家生物技術資訊中心(National Center for Biotechnology Information)網站公開獲得。此算法包括藉由識別查詢序列中之長度W之短字來首先識別高評分序列對(HSP),該等短字在與資料庫序列中相同長度之字比對時匹配或滿足某些正值臨限值分數T。T稱為鄰域字分數臨限值(參見Altschul等人,同上)。此等初始鄰域字成功結果充當用於起始搜尋之種子以尋找含有其之較長HSP。字匹配接著沿各序列在二個方向上延伸,只要累積對準分數增加即可。對於核苷酸序列,累積分數係使用參數M (一對匹配殘基之獎勵分數;始終> 0)以及N (錯配殘基之懲罰分數;始終< 0)來計算。對於胺基酸序列,使用計分矩陣計算累積分數。當以下情況時,字命中者沿各方向之延伸中斷:累積比對分值自其達成之最大值降低數量X;累積分值由於一或多個負分殘基比對之累加而變成零或以下;或達至任一序列之末端。BLAST演算法參數W、T及X確定比對之靈敏度及速度。BLASTN程式(對於核苷酸序列)使用以下作為預設值:11之字長(W),10之期望值(E),M = 5,N = -4以及二股之比較結果。對於胺基酸序列而言,BLASTP程式係使用字長(W) 3、期望值(E) 10及BLOSUM62評分矩陣(參見Henikoff及Henikoff, Proc. Natl. Acad. Sci. USA, 1989, 89:10915)作為預設參數。序列比對及序列一致性%之例示性測定可採用GCG Wisconsin套裝軟體(Accelrys, Madison WI)中之BESTFIT或GAP程式,該等程式使用所提供之預設參數。"Percent sequence identity (%)" is used herein to refer to comparison results in polynucleotides and polypeptides, and is determined by comparing two optimally aligned sequences over a comparison window, where compared to a reference For sequences, the portion of the polynucleotide or polypeptide sequence in the comparison window may contain additions or deletions (i.e., gaps) for optimal alignment of the two sequences. This percentage can be calculated by determining the number of positions in the two sequences where the same nucleic acid base or amino acid residue exists to produce the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window and multiplying the result Take 100 to generate percent sequence identity. Alternatively, the percentage can be calculated by determining the number of positions in the two sequences where the same nucleic acid base or amino acid residue exists or the number of positions where the nucleic acid base or amino acid residue aligns with a gap to produce a matching position. Number, divide the number of matching positions by the total number of positions in the comparison window and multiply the result by 100 to generate percent sequence identity. Those skilled in the art appreciate that there are many established algorithms that can be used to align two sequences. The optimal sequence alignment for comparison can be, for example, by Smith and Waterman's local homology algorithm (Smith and Waterman, Adv. Appl. Math., 1981, 2:482), by Needleman and Wunsch's homology Similarity comparison algorithm (Needleman and Wunsch, J. Mol. Biol., 1970, 48:443), similarity search method by Pearson and Lipman (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 1988 , 85:2444), by computerized implementations of such algorithms (such as GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin software suite) or by visual inspection as is known in the art. Examples of algorithms suitable for determining percent sequence identity and sequence similarity include, but are not limited to, the BLAST and BLAST 2.0 algorithms described by Altschul et al. (see, respectively, Altschul et al., J. Mol. Biol., 1990, 215: 403-410; and Altschul et al., 1977, Nucleic Acids Res., 1977, 3389-3402). Software used to perform BLAST analyzes is publicly available through the National Center for Biotechnology Information website. This algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or satisfy some positive value when aligned with words of the same length in the database sequence. The threshold score T. T is called the neighborhood word score threshold (see Altschul et al., supra). These initial neighborhood word success results serve as seeds for initial searches to find longer HSPs containing them. Word matches are then extended in both directions along each sequence as long as the cumulative alignment score increases. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for a mismatched residue; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. The extension of word hits in all directions is interrupted when: the cumulative alignment score decreases by the amount below; or to the end of any sequence. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the comparison. The BLASTN program (for nucleotide sequences) uses the following as default values: word length (W) of 11, expectation (E) of 10, M = 5, N = -4 and the result of the two-strand comparison. For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA, 1989, 89:10915) as default parameters. Exemplary determinations of sequence alignment and % sequence identity can be performed using the BESTFIT or GAP programs in the GCG Wisconsin software suite (Accelrys, Madison WI) using the default parameters provided.
「參考序列」係指用作序列比較之基礎之經界定序列。參考序列可為較大序列(例如全長基因或多肽序列的區段)之子集。一般而言,參考序列具有至少20個核苷酸或胺基酸殘基的長度,至少25個殘基的長度,至少50個殘基的長度,至少100個殘基的長度,或核酸或多肽之全長。由於二個聚核苷酸或多肽可各自(1)包含在二個序列之間相似的序列(亦即,完整序列之一部分)且(2)可進一步包含在二個序列之間相異之序列,因此二個(或更多個)聚核苷酸或多肽之間的序列比較典型地藉由在「比較窗」上比較二個聚核苷酸或多肽的序列以識別且比較序列相似的局部區域來執行。在一些實施例中,「參考序列」可基於一級胺基酸序列,其中參考序列為在一級序列中可具有一或多個變化之序列。「比較窗」係指至少約20個鄰接核苷酸位置或胺基酸殘基的概念性區段,其中可將一種序列與至少20個鄰接核苷酸或胺基酸的參考序列進行比較且其中該序列在比較窗中的部分可包含為了達成二個序列的最佳對準而存在的20%或更少添加或缺失(亦即,空位) (相較於參考序列(其不包含添加或缺失))。比較窗可長於20個鄰接殘基,且任擇地包括30、40、50、100個或更長窗。"Reference sequence" means a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of a larger sequence, such as a segment of a full-length gene or polypeptide sequence. Generally, a reference sequence has a length of at least 20 nucleotides or amino acid residues, a length of at least 25 residues, a length of at least 50 residues, a length of at least 100 residues, or a nucleic acid or polypeptide its full length. Since two polynucleotides or polypeptides may each (1) comprise a sequence that is similar between the two sequences (i.e., a portion of the complete sequence) and (2) may further comprise a sequence that is divergent between the two sequences Therefore, sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing the sequences of the two polynucleotides or polypeptides over a "comparison window" to identify and compare local areas of sequence similarity. area to execute. In some embodiments, a "reference sequence" may be based on a primary amino acid sequence, where the reference sequence is a sequence that may have one or more changes in the primary sequence. "Comparison window" means a conceptual segment of at least about 20 contiguous nucleotide positions or amino acid residues within which a sequence can be compared to a reference sequence of at least 20 contiguous nucleotide or amino acid residues and The portion of the sequence in the comparison window may contain 20% or less of the additions or deletions (i.e., gaps) present for optimal alignment of the two sequences compared to the reference sequence (which contains no additions or deletions). missing)). Comparison windows can be longer than 20 contiguous residues, and optionally include windows of 30, 40, 50, 100, or longer.
「對應於」、「參照」或「相對於」當在既定胺基酸或聚核苷酸序列之編號的上下文中使用時,係指當既定胺基酸或聚核苷酸序列與參考序列進行比較時,所指定之參考序列的殘基編號。換言之,既定聚合物之殘基編號或殘基位置係相對於參考序列指定,而非根據既定胺基酸或聚核苷酸序列內的殘基之實際編號位置來指定。舉例而言,既定胺基酸序列,諸如重組因子VIII多肽之胺基酸序列,可藉由引入空位以使二個序列之間的殘基匹配最佳化來與參考序列比對。在此等情況下,儘管存在空位,但既定胺基酸或聚核苷酸序列中之殘基編號係相對於已與其對準的參考序列來達成。"Corresponds to", "references" or "relative to" when used in the context of the numbering of a given amino acid or polynucleotide sequence means when the given amino acid or polynucleotide sequence is compared with a reference sequence When comparing, the residue number of the reference sequence specified. In other words, residue numbers or residue positions for a given polymer are assigned relative to a reference sequence rather than based on the actual numbered positions of the residues within a given amino acid or polynucleotide sequence. For example, a given amino acid sequence, such as that of a recombinant Factor VIII polypeptide, can be aligned to a reference sequence by introducing gaps to optimize the residue match between the two sequences. In these cases, notwithstanding the presence of gaps, the numbering of residues in a given amino acid or polynucleotide sequence is achieved relative to a reference sequence to which it is aligned.
「突變」係指核酸序列之改變。在一些實施例中,突變導致編碼多肽序列之變化(亦即相較於無突變之原始序列)。在一些實施例中,突變包含取代,使得產生不同胺基酸。在一些替代實施例中,突變包含添加,使得胺基酸添加(例如插入)至原始多肽序列。在一些其他實施例中,突變包含缺失,使得自原始多肽序列缺失胺基酸。任何數目之突變可存在於既定序列中。"Mutation" refers to a change in a nucleic acid sequence. In some embodiments, mutations result in a change in the sequence encoding the polypeptide (i.e., compared to the original sequence without the mutation). In some embodiments, mutations comprise substitutions such that different amino acids are produced. In some alternative embodiments, mutations comprise additions such that an amino acid is added (eg, inserted) to the original polypeptide sequence. In some other embodiments, mutations comprise deletions such that an amino acid is deleted from the original polypeptide sequence. Any number of mutations can be present in a given sequence.
「胺基酸差異」或「殘基差異」係指多肽序列之位置處之胺基酸殘基相對於參考序列中對應位置處之胺基酸殘基而言的差異。胺基酸有差異之位置在本文中一般稱為「Xn」,其中n係指參考序列中之對應位置,基於該對應位置,出現殘基差異。舉例而言,「相較於SEQ ID NO: 2的位置X59之殘基差異」係指對應於SEQ ID NO: 2之位置59之多肽位置之胺基酸殘基差異。因此,若SEQ ID NO: 2之參考多肽在位置59具有苯丙胺酸,則「相較於SEQ ID NO: 2的位置X59之殘基差異」為除苯丙胺酸之外在對應於SEQ ID NO: 2之位置59之多肽位置處之任何的殘基之胺基酸取代。在本文中之一些情況下,一位置處之特定胺基酸殘基差異指示為「XnY」,其中「Xn」規定如上文所描述之對應位置,且「Y」為在經工程改造之多肽中發現之胺基酸(亦即與參考多肽中之殘基不同之殘基)之單字母識別符。在一些情況下(例如如 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1以及 15.1中所示),本揭露內容亦提供由習知記號「AnB」表示之特定胺基酸差異,其中A為參考序列中之殘基之單字母識別符,「n」為參考序列中之殘基位置數,且B為經工程改造之多肽之序列中的殘基取代的單字母識別符。在一些實施例中,例如取代之胺基酸差異由無參考序列中之殘基之識別符的縮寫「nB」表示。在一些實施例中,片語「胺基酸殘基nB」指示經工程改造之多肽中存在胺基殘基,其在參考多肽之情況下可為或可不為取代。 "Amino acid difference" or "residue difference" refers to the difference in an amino acid residue at a position in a polypeptide sequence relative to an amino acid residue at a corresponding position in a reference sequence. The positions where amino acids differ are generally referred to herein as "Xn", where n refers to the corresponding position in the reference sequence based on which the residue difference occurs. For example, "residue difference compared to position X59 of SEQ ID NO: 2" refers to the amino acid residue difference at the polypeptide position corresponding to position 59 of SEQ ID NO: 2. Therefore, if the reference polypeptide of SEQ ID NO: 2 has phenylalanine at position 59, then the "residue difference compared to position X59 of SEQ ID NO: 2" corresponds to SEQ ID NO: 2 except for phenylalanine. Amino acid substitution of any residue at position 59 of the polypeptide. In some instances herein, a specific amino acid residue difference at a position is designated "XnY", where "Xn" specifies the corresponding position as described above, and "Y" is in the engineered polypeptide The one-letter identifier of the amino acid found (ie, the residue that is different from the residue in the reference polypeptide). In some cases (for example, as shown in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2, 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 ), this disclosure is also provided by A specific amino acid difference represented by the conventional notation "AnB", where A is the one-letter identifier of the residue in the reference sequence, "n" is the number of residue positions in the reference sequence, and B is the engineered polypeptide A single-letter identifier for a residue substitution in the sequence. In some embodiments, amino acid differences such as substitutions are represented by the abbreviation "nB" without the identifier of the residue in the reference sequence. In some embodiments, the phrase "amino acid residue nB" indicates the presence of an amine residue in the engineered polypeptide, which may or may not be substituted in the case of the reference polypeptide.
在一些情況下,相對於參考序列,本揭露內容之多肽可包括一或多個胺基酸殘基差異,其由相對於參考序列存在殘基差異之指定位置之清單指示,如下文所描述。在一些實施例中,在可在多肽之特定殘基位置使用多於一個胺基酸時,可使用的各種胺基酸殘基藉由「/」分離(例如X61Q/X61S或X61Q/S或61Q/S)。In some cases, a polypeptide of the present disclosure may include one or more amino acid residue differences relative to a reference sequence, as indicated by a list of designated positions at which residue differences exist relative to the reference sequence, as described below. In some embodiments, when more than one amino acid can be used at a specific residue position in a polypeptide, the various amino acid residues that can be used are separated by a "/" (e.g., X61Q/X61S or X61Q/S or 61Q /S).
「胺基酸取代集」及「取代集」係指多肽序列內之一組胺基酸取代。在一些實施例中,取代集包含2、3、4、5、6、7、8、9、10、11、12、13、14、15或更多個胺基酸取代。在一些實施例中,取代集係指實例中之表中之任一者中所列之變異體多肽中的任一者中所存在之胺基酸取代集。在取代集中,個別取代藉由分號(「;」;例如Q96R;L171P或縮寫為96R;171P)或斜線(「/」;例如Q96R/L171P或縮寫為96R/171P)分開。在一些實施例中,「取代」包含胺基酸之缺失,且可由「-」符號表示。"Amino acid substitution set" and "substitution set" refer to a group of amino acid substitutions within a polypeptide sequence. In some embodiments, a set of substitutions includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more amino acid substitutions. In some embodiments, the set of substitutions refers to the set of amino acid substitutions present in any of the variant polypeptides listed in any of the tables in the Examples. Within a substitution set, individual substitutions are separated by a semicolon (";"; such as Q96R;L171P or abbreviated 96R;171P) or a slash ("/"; such as Q96R/L171P or abbreviated 96R/171P). In some embodiments, "substitution" includes deletion of an amino acid and may be represented by a "-" symbol.
「守恆胺基酸取代」係指用具有類似側鏈之不同殘基進行之殘基取代,且因此通常涉及用相同或類似經界定類別之胺基酸內之胺基酸進行的多肽中的胺基酸取代。為了舉例而非限制,相應地,具有脂族側鏈之胺基酸可經另一脂族胺基酸(例如丙胺酸、纈胺酸、白胺酸以及異白胺酸)取代;具有羥基側鏈之胺基酸經具有羥基側鏈之另一胺基酸(例如絲胺酸以及蘇胺酸)取代;具有芳族側鏈之胺基酸經具有芳族側鏈之另一胺基酸(例如苯丙胺酸、酪胺酸、色胺酸以及組胺酸)取代;具有鹼性側鏈之胺基酸經具有鹼性側鏈之另一胺基酸(例如離胺酸以及精胺酸)取代;具有酸性側鏈之胺基酸經具有酸性側鏈之另一胺基酸(例如天冬胺酸或麩胺酸)取代;及/或疏水性或親水性胺基酸經另一疏水性或親水性胺基酸置換。"Conserved amino acid substitution" refers to residue substitution with different residues having similar side chains, and thus generally involves amines in a polypeptide with amino acids within the same or similar defined classes of amino acids. Acid substitution. By way of example and not limitation, accordingly, an amino acid having an aliphatic side chain may be substituted by another aliphatic amino acid (such as alanine, valine, leucine, and isoleucine); having a hydroxyl side chain The amino acid of the chain is replaced by another amino acid with a hydroxyl side chain (such as serine and threonine); the amino acid with an aromatic side chain is replaced by another amino acid with an aromatic side chain (such as serine and threonine). For example, phenylalanine, tyrosine, tryptophan, and histidine) are substituted; an amino acid with a basic side chain is substituted by another amino acid with a basic side chain (such as lysine and arginine) ;An amino acid with an acidic side chain is replaced by another amino acid with an acidic side chain (such as aspartic acid or glutamic acid); and/or a hydrophobic or hydrophilic amino acid is replaced by another hydrophobic or Hydrophilic amino acid replacement.
「非守恆取代」係指用具有顯著地不同之側鏈特性之胺基酸進行之多肽中的胺基酸取代。非守恆取代可使用已定義群組之間而非已定義群組內的胺基酸且影響(a)肽骨架在取代區域中之結構(例如脯胺酸取代甘胺酸)、(b)電荷或疏水性,或(c)側鏈容積。為了舉例而非限制,例示性非守恆取代可為酸性胺基酸經鹼性或脂族胺基酸取代;芳族胺基酸經小胺基酸取代;以及親水性胺基酸經疏水性胺基酸取代。"Nonconservative substitution" refers to an amino acid substitution in a polypeptide with an amino acid having significantly different side chain properties. Non-conservative substitutions can use amino acids between defined groups rather than within defined groups and affect (a) the structure of the peptide backbone in the substitution region (such as proline replacing glycine), (b) charge or hydrophobicity, or (c) side chain volume. By way of example and not limitation, exemplary non-conservative substitutions may be substitution of acidic amino acids with basic or aliphatic amino acids; substitution of aromatic amino acids with small amino acids; and substitution of hydrophilic amino acids with hydrophobic amines. Acid substitution.
「缺失」係指藉由自參考多肽移除一或多個胺基酸進行之對多肽之修飾。缺失可包含移除1或多個胺基酸、2個或更多個胺基酸、5個或更多個胺基酸、10個或更多個胺基酸、15個或更多個胺基酸或20個或更多個胺基酸,至多構成參考多肽之胺基酸總數之10%或至多構成參考多肽之胺基酸總數之20%,同時保留活性及/或保留經工程改造之多肽的經改善特性。缺失可針對多肽之內部部分及/或末端部分。在各種實施例中,缺失可包含連續區段或可為非連續的。"Deletion" refers to a modification of a polypeptide by removing one or more amino acids from a reference polypeptide. Deletions may include removal of 1 or more amino acids, 2 or more amino acids, 5 or more amino acids, 10 or more amino acids, 15 or more amines amino acids or 20 or more amino acids, up to 10% of the total amino acids constituting the reference polypeptide or up to 20% of the total amino acids constituting the reference polypeptide, while retaining activity and/or retaining the engineered Improved properties of polypeptides. Deletions may be directed to internal and/or terminal portions of the polypeptide. In various embodiments, deletions may comprise contiguous segments or may be non-contiguous.
「插入」係指藉由自參考多肽添加一或多個胺基酸進行之對多肽之修飾。插入可發生於多肽之內部部分,或發生於羧基或胺基端。如本文所用之插入包括如此項技術中已知之融合蛋白。插入可為鄰接的胺基酸區段或藉由天然存在之多肽中的一或多個胺基酸間隔開。"Insertion" refers to a modification of a polypeptide by the addition of one or more amino acids from a reference polypeptide. Insertion can occur within the internal portion of the polypeptide, or at the carboxyl or amine terminus. Inserts as used herein include fusion proteins as known in the art. Insertions may be contiguous stretches of amino acids or separated by one or more amino acids in a naturally occurring polypeptide.
本文中可互換使用之「功能性片段」或「生物活性片段」係指一種多肽,其具有胺基端及/或羧基端缺失及/或內部缺失,但其中剩餘胺基酸序列與其所比較之序列(例如本揭露內容之全長重組因子VIII)中之對應位置一致且保留全長多肽之實質上全部活性。在一些實施例中,「功能性片段」或「生物活性片段」涵蓋藉由天然生物過程處理成多肽之重組因子VIII,諸如裂解成形成二聚體及活化三聚體之多肽片段。"Functional fragment" or "biologically active fragment" as used interchangeably herein refers to a polypeptide that has amino-terminal and/or carboxyl-terminal deletions and/or internal deletions, but the remaining amino acid sequence is compared with that of the The corresponding positions in the sequence (eg, the full-length recombinant Factor VIII of the present disclosure) are identical and retain substantially all the activities of the full-length polypeptide. In some embodiments, "functional fragments" or "biologically active fragments" encompass recombinant Factor VIII that is processed into polypeptides by natural biological processes, such as cleavage into polypeptide fragments that form dimers and activated trimers.
「經分離多肽」係指與天然地伴隨其之其他污染物實質上分離之多肽(例如蛋白質、脂質以及聚核苷酸)。該術語涵蓋已自其天然存在之環境或表現系統(例如宿主細胞或活體外合成)移除或純化的多肽。重組因子VIII多肽可存在於細胞內,存在於細胞介質中,或以諸如裂解物或經分離製備物之各種形式製備。因而,在一些實施例中,重組因子VIII多肽可為經分離多肽。"Isolated polypeptide" refers to a polypeptide (such as proteins, lipids, and polynucleotides) that is substantially separated from other contaminants that naturally accompany it. The term encompasses polypeptides that have been removed or purified from their naturally occurring environment or expression system (eg, host cells or in vitro synthesis). Recombinant Factor VIII polypeptides may be present intracellularly, in the cell medium, or prepared in various forms such as lysates or isolated preparations. Thus, in some embodiments, a recombinant Factor VIII polypeptide may be an isolated polypeptide.
「實質上純多肽」係指其中多肽物種為所存在之主導物種(亦即基於莫耳濃度或重量計,其比組成物中之任何其他個別巨分子物種更豐富)之組成物,且在按莫耳或重量%計目標物種包含至少約50%所存在之巨分子物種時一般為實質上經純化組成物。一般而言,以組成物中所存在之莫耳或重量%計,實質上純因子VIII組成物包含約60%或更多、約70%或更多、約80%或更多、約90%或更多、約95%或更多及約98%或更多的所有巨分子物種。在一些實施例中,目標物種經純化至基本均質性(亦即,組成物中之污染物物種無法藉由習知偵測方法偵測到),其中組成物主要由單一巨分子物種組成。溶劑物種、小分子(< 500道爾頓)以及元素離子物種不被視為巨分子物種。在一些實施例中,經分離重組因子VIII多肽為實質上純多肽組成物。"Substantially pure polypeptide" means a composition in which the polypeptide species is the dominant species present (i.e., it is more abundant on a molar concentration or weight basis than any other individual macromolecular species in the composition) and is A substantially purified composition is generally one in which the target species contains at least about 50% of the macromolecular species present on a molar or weight % basis. Generally speaking, substantially pure Factor VIII compositions comprise about 60% or more, about 70% or more, about 80% or more, about 90%, based on moles or weight % present in the composition. or more, about 95% or more, and about 98% or more of all macromolecular species. In some embodiments, the target species is purified to substantial homogeneity (i.e., contaminant species in the composition cannot be detected by conventional detection methods), wherein the composition consists primarily of a single macromolecular species. Solvent species, small molecules (<500 daltons), and elemental ionic species are not considered macromolecular species. In some embodiments, the isolated recombinant Factor VIII polypeptide is a substantially pure polypeptide composition.
「經改良之蛋白質特性」係指相比於參考FVIII多肽及/或野生型因子VIII多肽或另一重組因子VIII多肽展現出任何蛋白質特性改良的重組因子VIII多肽。改良之特性包括(但不限於)諸如以下特性:增加之基因表現、增加之蛋白質產生、增加之熱活性、增加之熱穩定性、增加之各種pH位準下之活性、增加之穩定性、增加之輔因子效能、增加之比活性、增加之對受質及/或產物抑制之抗性、增加之化學穩定性、改良之溶劑穩定性、增加之對酸性、中性或鹼性pH之耐受性、增加之蛋白水解活性耐受性(亦即降低之對蛋白水解之敏感性)、降低之聚集、增加之溶解性、降低之免疫原性增、增加之產生多肽的細胞的分泌,等等。"Improved protein properties" refers to a recombinant Factor VIII polypeptide that exhibits any improvement in protein properties compared to a reference FVIII polypeptide and/or a wild-type Factor VIII polypeptide or another recombinant Factor VIII polypeptide. Improved properties include (but are not limited to) properties such as: increased gene expression, increased protein production, increased thermal activity, increased thermal stability, increased activity at various pH levels, increased stability, increased Cofactor potency, increased specific activity, increased resistance to substrate and/or product inhibition, increased chemical stability, improved solvent stability, increased tolerance to acidic, neutral or alkaline pH properties, increased resistance to proteolytic activity (i.e., decreased susceptibility to proteolysis), decreased aggregation, increased solubility, decreased immunogenicity, increased secretion of polypeptide-producing cells, etc. .
「增加之活性」、「增加之輔因子效能」或「增強之活性」係指與參考因子VIII多肽相比,重組因子VIII多肽之改良特性,其可由比活性(例如產物產生/時間/重量蛋白質與因子IX (FIX)之組合)增加或受質轉化至產物的百分比(例如在指定時段使用指定量之因子VIII多肽與FIX組合,受質轉化為產物之百分比)增加表示。例示性用於測定蛋白質活性之方法係在實例中提供。與蛋白質活性相關之任何特性均可受影響。蛋白質活性之改良可為相對應野生型蛋白質或親代蛋白質或多肽之蛋白質活性的約1.1倍至比天然存在之因子VIII或衍生的因子VIII多肽之另一重組因子VIII (例如,B區域缺失之因子VIII)高多達2倍、5倍、10倍、20倍、25倍、50倍、75倍、100倍、150倍、200倍或更高的活性。"Increased activity", "increased cofactor potency" or "enhanced activity" refers to the improved properties of a recombinant Factor VIII polypeptide compared to a reference Factor VIII polypeptide, which can be measured by specific activity (e.g. product production/time/weight protein It is expressed as an increase in the percentage of substrate converted to product (e.g., the percentage of substrate converted to product using a specified amount of a Factor VIII polypeptide in combination with FIX over a specified period of time). Exemplary methods for determining protein activity are provided in the Examples. Any property related to protein activity can be affected. The improvement in protein activity may range from about 1.1-fold over the protein activity corresponding to the wild-type protein or the parent protein or polypeptide to another recombinant Factor VIII over naturally occurring Factor VIII or a derived Factor VIII polypeptide (e.g., one in which the B region is deleted) Factor VIII) up to 2-fold, 5-fold, 10-fold, 20-fold, 25-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold or higher activity.
相比於參考因子VIII或另一重組因子VIII多肽,「增加之鹼性pH之耐受性」意謂根據本發明之重組因子VIII將具有增加之穩定性(例如,在特定時段(1小時,至多24小時)暴露於鹼性pH之後在>pH 7下的較高保留活性)。"Increased tolerance to alkaline pH" means that a recombinant Factor VIII according to the invention will have increased stability (e.g., over a specific period of time (1 hour)) compared to a reference Factor VIII or another recombinant Factor VIII polypeptide. up to 24 hours) higher retained activity at >pH 7) after exposure to alkaline pH).
如本文所用,「生理pH」意謂一般在個體(例如人類)血液中發現之pH範圍。在一些實施例中,「生理pH」為約pH 7至約7.4。As used herein, "physiological pH" means the pH range typically found in the blood of an individual (eg, a human). In some embodiments, "physiological pH" is about pH 7 to about 7.4.
「鹼性pH」(例如參考鹼性pH值條件之改良穩定性或鹼性pH值之增加的耐受性使用)意謂pH範圍>pH 7,例如約7至11。"Alkaline pH" (eg used with reference to improved stability of alkaline pH conditions or increased tolerance of alkaline pH) means a pH range >pH 7, eg about 7 to 11.
「酸性pH」(例如,參考酸性pH條件之改良穩定性或酸性pH之增加的耐受性使用)意謂pH 7> pH範圍,例如約1.5至4.5。"Acidic pH" (eg, used with reference to improved stability of acidic pH conditions or increased tolerance of acidic pH) means a pH 7>pH range, eg, about 1.5 to 4.5.
如本文所用的「去免疫性」係指蛋白質序列操作以產生預測不為同野生型或參考蛋白質一般具有免疫原性的變異體。在一些實施例中,經預測之去免疫係完全的,因為預測變異體蛋白質在投予變異體蛋白質之患者中不刺激免疫反應。此反應可藉由各種方法量測,該等方法包括(但不限於):抗藥物抗體之存在或豐度、中和抗體之存在或豐度、過敏性反應之存在、主要組織相容複合體II (MHC-II)蛋白質上之肽呈現或投予蛋白質後細胞介素釋放之發生率或強度。在一些實施例中,變異體蛋白的免疫原性比野生型或參考蛋白質少。在一些實施例中,去免疫涉及對藉由人類白血球抗原(HLA)受體識別之蛋白質(例如抗原決定基)之子序列的修飾。在一些實施例中,此等抗原決定基藉由改變其胺基酸序列以產生去免疫性變異體蛋白來移除,其中此類子序列不再由HLA受體識別。在一些其他實施例中,此等抗原決定基保持與HLA受體之結合親和力,但不呈現。在一些實施例中,去免疫性蛋白質在人類免疫反應之生化及細胞生物預測因子(包括樹突狀細胞T細胞活化分析或(HLA)肽結合分析)中展示較低位準之反應。在一些實施例中,藉由改變此等抗原決定基之胺基酸序列以產生去免疫性變異體蛋白來移除此等抗原決定基,其中抗原決定基不再由T細胞受體識別。在其他實施例中,去免疫性蛋白質在其相應T細胞中誘導失能,活化T調節細胞,或引起純系缺失識別B細胞。在一些實施例中,總免疫原性分數(TIS)反映變異體之總體經預測免疫原性(亦即較高分數指示較高經預測免疫原性位準)。"Deimmunization" as used herein refers to manipulation of protein sequence to produce variants that are not predicted to be generally immunogenic as wild-type or reference proteins. In some embodiments, predicted deimmunization is complete because the variant protein is predicted to not stimulate an immune response in the patient to whom the variant protein is administered. This response can be measured by a variety of methods, including (but not limited to): the presence or abundance of anti-drug antibodies, the presence or abundance of neutralizing antibodies, the presence of allergic reactions, major histocompatibility complex II (MHC-II) The incidence or intensity of interleukin release following presentation of a peptide on a protein or administration of a protein. In some embodiments, the variant protein is less immunogenic than the wild-type or reference protein. In some embodiments, deimmunization involves modification of subsequences of proteins (eg, epitopes) recognized by human leukocyte antigen (HLA) receptors. In some embodiments, these epitopes are removed by altering their amino acid sequences to produce deimmunized variant proteins, in which such subsequences are no longer recognized by HLA receptors. In some other embodiments, these epitopes retain binding affinity for HLA receptors but do not exhibit it. In some embodiments, the deimmunized protein exhibits lower levels of response in biochemical and cellular biological predictors of human immune response, including dendritic cell T cell activation assays or (HLA) peptide binding assays. In some embodiments, these epitopes are removed by altering their amino acid sequence to produce deimmunized variant proteins, wherein the epitopes are no longer recognized by T cell receptors. In other embodiments, the deimmunized protein induces anergy in its corresponding T cell, activates T regulatory cells, or causes a pure-line deletion of recognizing B cells. In some embodiments, the total immunogenicity score (TIS) reflects the overall predicted immunogenicity of a variant (ie, a higher score indicates a higher predicted immunogenicity level).
在核酸雜交中,「雜交嚴格度」與諸如洗滌條件之雜交條件有關。一般而言,雜交反應在較低嚴格度條件下進行,隨後在小較高嚴格度下進行洗滌變化(參見例如Sambrook等人,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001)。術語「中度嚴格雜交」係指准許目標DNA結合與目標DNA具有約60%一致性、較佳約75%一致性、約85%一致性、與目標聚核苷酸具有大於約90%一致性之互補核酸的條件。例示性中度嚴格條件為等效於以下之條件:在42℃下在50%甲醯胺、5 ×鄧哈特氏溶液(Denhart's solution)、5 × SSPE、0.2% SDS中之雜交,之後為在42℃下在0.2 × SSPE、0.2% SDS中之洗滌。「高嚴格度雜交」一般指如在溶液條件下針對經界定聚核苷酸序列所測定離熱熔融溫度 T m 約10℃或更少之條件。在一些實施例中,高嚴格度條件係指准許在65℃下在0.018 M NaCl中形成穩定雜交體之僅彼等核酸序列雜交的條件(亦即如本文所考慮,若雜交體在65℃下在0.018 M NaCl中不穩定,則其將在高嚴格度條件下不穩定)。高嚴格度條件可如下提供:例如在等效於以下的條件下雜交:在42℃下,50%甲醯胺、5×鄧哈特氏溶液、5×SSPE、0.2% SDS,隨後在65℃下、在0.1×SSPE以及0.1% SDS中洗滌。另一種高嚴格度條件為在等效於以下的條件下雜交:在65℃下,在含有0.1% (w:v) SDS之5X SSC中雜交,且在65℃下、在含有0.1% SDS之0.1x SSC中洗滌。其他高嚴格度雜交條件以及中度嚴格條件描述於本文所引用之參考文獻中。 In nucleic acid hybridization, "hybridization stringency" is related to hybridization conditions such as wash conditions. Generally, hybridization reactions are performed at lower stringency conditions, followed by wash changes at slightly higher stringency conditions (see, eg, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001). The term "moderately stringent hybridization" refers to permitting target DNA binding with about 60% identity to the target DNA, preferably about 75% identity, about 85% identity, and greater than about 90% identity to the target polynucleotide. conditions for complementary nucleic acids. Exemplary moderately stringent conditions are equivalent to the following: hybridization in 50% formamide, 5×Denhart's solution, 5×SSPE, 0.2% SDS at 42°C, followed by Wash in 0.2 × SSPE, 0.2% SDS at 42°C. "High stringency hybridization" generally refers to conditions that are about 10°C or less from the thermal melting temperature T m as determined for a defined polynucleotide sequence under solution conditions. In some embodiments, high stringency conditions refer to conditions that permit hybridization of only those nucleic acid sequences to form stable hybrids in 0.018 M NaCl at 65°C (i.e., as contemplated herein, if the hybrids are is unstable in 0.018 M NaCl, it will not be stable under high stringency conditions). High stringency conditions can be provided as follows: for example, hybridize under conditions equivalent to: 50% formamide, 5× Dunhart's solution, 5× SSPE, 0.2% SDS at 42°C, followed by 65°C Next, wash in 0.1×SSPE and 0.1% SDS. Another high stringency condition is to hybridize under conditions equivalent to: hybridization in 5X SSC containing 0.1% (w:v) SDS at 65°C and hybridization in 5X SSC containing 0.1% SDS at 65°C. Wash in 0.1x SSC. Other high stringency hybridization conditions as well as moderate stringency conditions are described in the references cited herein.
「經密碼子最佳化」係指編碼蛋白質之聚核苷酸之密碼子變化,該等變化使得經編碼蛋白質在感興趣之生物及/或細胞中更有效地表現。儘管遺傳密碼的簡倂性使得大部分胺基酸由若干密碼子表示,稱為「同義詞」或「同義」密碼子,但已熟知特定生物體的密碼子使用並非隨機的且偏向於特定密碼子三聯體。關於既定基因、具有共同功能或祖性起源之基因、相對於低複本數蛋白質而言之經高度表現之蛋白質以及生物基因體之聚合蛋白編碼區,此密碼子使用偏好可為較高的。在一些實施例中,編碼因子VIII多肽之聚核苷酸可經密碼子最佳化以自選擇用於表現、解釋GC含量、隱蔽剪接位點、轉錄終止信號、可影響RNA穩定性之模體及核酸二級結構以及任何其他感興趣之因子之宿主生物體及/或細胞類型最佳產生。"Codon-optimized" refers to codon changes in a polynucleotide encoding a protein that result in more efficient expression of the encoded protein in the organism and/or cell of interest. Although the simplicity of the genetic code means that most amino acids are represented by a few codons, called "synonymous" or "synonymous" codons, it is known that the codon usage of a given organism is not random and is biased toward specific codons triplet. This codon usage preference may be higher for established genes, genes with a common function or ancestral origin, highly expressed proteins relative to low copy number proteins, and polymeric protein coding regions of biological genomes. In some embodiments, polynucleotides encoding Factor VIII polypeptides can be codon-optimized to self-select for expression, interpretation of GC content, cryptic splice sites, transcription termination signals, and motifs that can affect RNA stability. and nucleic acid secondary structure as well as any other factors of interest that are optimally produced by the host organism and/or cell type.
「控制序列」在本文中指包括本申請案之聚核苷酸及/或多肽之表現所需或對其有利的所有組分。對於編碼多肽之核酸序列,各控制序列可為原生的或外來的。該等控制序列包括但不限於前導序列、聚腺苷酸化序列、原肽序列、啟動子序列、信號肽序列、起始序列以及轉錄終止子。控制序列至少包括啟動子以及轉錄及轉譯中止信號。"Control sequences" as used herein are meant to include all components necessary for or advantageous for the performance of the polynucleotides and/or polypeptides of the present application. For nucleic acid sequences encoding polypeptides, each control sequence may be native or foreign. Such control sequences include, but are not limited to, leader sequences, polyadenylation sequences, propeptide sequences, promoter sequences, signal peptide sequences, initiation sequences, and transcription terminators. Control sequences include at least a promoter and transcription and translation termination signals.
「可操作地連接」在本文中定義為其中控制序列適當地置放於相對於感興趣之聚核苷酸之位置處(亦即在函數關係中)以使得控制序列導引或調節感興趣之聚核苷酸及/或多肽之表現的組態。"Operably linked" is defined herein as one in which the control sequence is suitably positioned relative to the polynucleotide of interest (ie, in a functional relationship) such that the control sequence directs or modulates the polynucleotide of interest. The configuration of expression of polynucleotides and/or polypeptides.
「啟動子序列」係指由宿主細胞辨識以用於感興趣之聚核苷酸之表現的核酸序列,諸如編碼序列。啟動子序列含有介導感興趣之聚核苷酸表現的轉錄控制序列。啟動子可為在所選宿主細胞中顯示轉錄活性的任何核酸序列,包括突變型啟動子、截斷的啟動子及雜交啟動子,且可獲自編碼細胞外或細胞內多肽的基因,該等基因為宿主細胞同源或異源的。"Promoter sequence" refers to a nucleic acid sequence, such as a coding sequence, recognized by a host cell for expression of a polynucleotide of interest. The promoter sequence contains transcriptional control sequences that mediate the expression of the polynucleotide of interest. A promoter can be any nucleic acid sequence that exhibits transcriptional activity in the host cell of choice, including mutant promoters, truncated promoters, and hybrid promoters, and can be obtained from genes encoding extracellular or intracellular polypeptides. Homologous or heterologous to the host cell.
「異源」或「重組」係指來源於不同來源且在自然界中不相關之二個或更多個核酸或蛋白質序列(例如啟動子序列、信號肽、終止子序列等)之間的關係。"Heterologous" or "recombinant" refers to the relationship between two or more nucleic acid or protein sequences (such as promoter sequences, signal peptides, terminator sequences, etc.) that are derived from different sources and are not related in nature.
「適合反應條件」係指反應溶液中之彼等條件(例如,蛋白質負載、溫度、pH、緩衝液、共溶劑等之範圍),在該等條件下,本揭露內容之因子VIII多肽能夠充當因子IX之輔因子以將受質轉化為所需產物化合物。例示性「適合反應條件」提供於本申請案中且於實例中說明。"Suitable reaction conditions" refer to those conditions in a reaction solution (e.g., ranges of protein loading, temperature, pH, buffers, co-solvents, etc.) under which Factor VIII polypeptides of the present disclosure are able to function as factors The cofactor of IX is used to convert the substrate into the desired product compound. Exemplary "suitable reaction conditions" are provided in this application and illustrated in the Examples.
「蛋白質負載量」係指在反應開始時反應混合物中之組分之濃度或量。「受質」在涉及因子VIII之反應過程之情形下係指因子VIII-因子IX多肽複合物所作用之化合物或分子。"Protein loading" refers to the concentration or amount of a component in the reaction mixture at the beginning of the reaction. "Substance", in the context of a reaction process involving Factor VIII, refers to the compound or molecule on which the Factor VIII-Factor IX polypeptide complex acts.
「產物」在酶轉化過程之情形下係指由因子VIII-因子IX多肽複合物對受質之作用產生之化合物或分子。"Product" in the context of an enzymatic conversion process means a compound or molecule resulting from the action of the Factor VIII-Factor IX polypeptide complex on the substrate.
如本文所使用之「培養」係指在任何合適條件下(例如使用液體、凝膠或固體培養基)生長微生物、哺乳動物或其他合適細胞之群體。"Culture" as used herein refers to the growth of a population of microorganisms, mammalian or other suitable cells under any suitable conditions (eg, using liquid, gel, or solid media).
「載體」係指用於將聚核苷酸序列引入細胞中之聚核苷酸構築體。在一些實施例中,載體係具有可操作地連接至適合控制序列之所感興趣之聚核苷酸的表現載體,該控制序列能夠影響在所感興趣之聚核苷酸序列中所編碼之多肽的適合宿主中表現。在一些實施例中,「表現載體」具有可操作地連接至聚核苷酸序列(例如轉殖基因)以驅動宿主細胞中之表現的啟動子序列,且在一些實施例中,亦包含轉錄終止子序列。"Vector" refers to a polynucleotide construct used to introduce a polynucleotide sequence into a cell. In some embodiments, the vector system has an expression vector for a polynucleotide of interest operably linked to a control sequence suitable for affecting the expression of a polypeptide encoded in the polynucleotide sequence of interest. Performance in the host. In some embodiments, an "expression vector" has a promoter sequence operably linked to a polynucleotide sequence (e.g., a transgene) to drive expression in a host cell, and in some embodiments, also includes transcription termination subsequence.
如本文所使用之「基因療法載體」係指適用於將聚核苷酸序列遞送至細胞之媒劑或載劑。在一些實施例中,載體囊封基因(例如治療性基因)或聚核苷酸序列以用於遞送至細胞或組織,該等載體包括但不限於腺病毒(AV)載體、腺相關病毒(AAV)載體、慢病毒(LV)載體以及非病毒載體,諸如脂質體。預期本發明不限於任何特定基因療法載體,此係因為適用於既定環境之任何媒劑均在本文中可用。基因療法載體可經設計以將基因遞送至特定物種或宿主,或可具更一般適用性。"Gene therapy vector" as used herein refers to a vehicle or vehicle suitable for delivering a polynucleotide sequence to a cell. In some embodiments, vectors encapsulate genes (eg, therapeutic genes) or polynucleotide sequences for delivery to cells or tissues, including, but not limited to, adenovirus (AV) vectors, adeno-associated virus (AAV) ) vectors, lentiviral (LV) vectors, and non-viral vectors such as liposomes. It is contemplated that the present invention is not limited to any particular gene therapy vector, as any vehicle suitable for a given setting may be used herein. Gene therapy vectors may be designed to deliver genes to a specific species or host, or may have more general applicability.
如本文所用之「表現」包括參與多肽產生之任何步驟,包括(但不限於)轉錄、轉錄後修飾、轉譯以及轉譯後修飾。在一些實施例中,該術語亦涵蓋細胞分泌多肽。"Performance" as used herein includes any step involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses cell-secreted polypeptides.
如本文所使用之「產生」係指由細胞進行之蛋白質及/或其他化合物產生。希望該術語涵蓋參與多肽產生之任何步驟,包括(但不限於)轉錄、轉錄後修飾、轉譯以及轉譯後修飾。在一些實施例中,該術語亦涵蓋細胞分泌多肽。"Production" as used herein refers to the production of proteins and/or other compounds by cells. The term is intended to encompass any step involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses cell-secreted polypeptides.
「宿主細胞」及「宿主菌株」係指包含本文所提供之聚核苷酸(例如編碼重組因子VIII變異體之聚核苷酸)的表現載體的適合宿主。在一些實施例中,宿主細胞為已使用如此項技術中已知之重組DNA技術構築之載體轉型或轉染的原核細胞或真核細胞。"Host cell" and "host strain" refer to a suitable host for an expression vector containing a polynucleotide provided herein (eg, a polynucleotide encoding a recombinant Factor VIII variant). In some embodiments, the host cell is a prokaryotic or eukaryotic cell that has been transformed or transfected using vectors constructed using recombinant DNA techniques as known in the art.
如本文所用之「類似物」意謂與參考多肽具有超過70%序列一致性、但小於100%序列一致性(例如超過75%、78%、80%、83%、85%、88%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%序列一致性)的多肽。在一些實施例中,「類似物」意謂含有一或多個包括但不限於高精胺酸、鳥胺酸及正纈胺酸之非天然存在之胺基酸殘基以及天然存在之胺基酸的多肽。在一些實施例中,類似物亦包括一或多個D-胺基酸殘基以及介於二個或更多個胺基酸殘基之間的非肽鍵聯。"Analog" as used herein means having more than 70% sequence identity, but less than 100% sequence identity with a reference polypeptide (e.g., more than 75%, 78%, 80%, 83%, 85%, 88%, 90%). %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity). In some embodiments, "analog" means containing one or more non-naturally occurring amino acid residues including, but not limited to, homoarginine, ornithine, and norvaline as well as naturally occurring amine groups. acid peptides. In some embodiments, analogs also include one or more D-amino acid residues and non-peptide linkages between two or more amino acid residues.
如本文所用之「治療性」係指向展示疾病或症狀或病理學之病徵或症狀之個體投予的具有有益或合乎需要之醫學效應的化合物或組成物。"Therapeutic" as used herein refers to a compound or composition that has a beneficial or desirable medical effect that is administered to an individual exhibiting signs or symptoms of a disease or pathology.
如本文所用之「醫藥組成物」指適用於哺乳動物個體(例如人類)中之醫藥用途的組成物,其包含醫藥學上有效量之重組因子VIII多肽及可接受之載劑及/或賦形劑。"Pharmaceutical composition" as used herein refers to a composition suitable for medical use in a mammalian subject (eg, a human), which includes a pharmaceutically effective amount of a recombinant Factor VIII polypeptide and an acceptable carrier and/or excipient. agent.
「組成物」及「調配物」涵蓋包含至少一個本揭露內容之重組因子VIII的產物,其意欲用於任何合適用途(例如醫藥組成物等)。"Compositions" and "formulations" encompass products containing at least one recombinant Factor VIII of the present disclosure intended for any suitable use (eg, pharmaceutical compositions, etc.).
「基因療法」係指將一或多個基因、多去氧核糖核苷酸或聚核苷酸序列與基因療法載體一起遞送至細胞或組織以修飾彼等細胞或組織來治療或預防疾病。基因療法可包括用基因之健康複本置換引起疾病之突變基因;不活化或「基因剔除」,其為不恰當地起作用之突變基因;或提供足以治療及/或預防疾病或病狀之基因的功能複本。在一些實施例中,基因療法係用於治療患者之疾病。"Gene therapy" refers to the delivery of one or more genes, polydeoxyribonucleotides or polynucleotide sequences together with a gene therapy vector to cells or tissues to modify those cells or tissues to treat or prevent disease. Gene therapy may include replacing a disease-causing mutated gene with a healthy copy of the gene; inactivating or "knocking out" a mutated gene that functions inappropriately; or providing a gene sufficient to treat and/or prevent a disease or condition. Functional replica. In some embodiments, gene therapy is used to treat a disease in a patient.
「mRNA療法」係指將mRNA聚核糖核苷酸遞送至細胞或組織以修飾彼等細胞或組織來治療或預防疾病。在一些實施例中,用於遞送至細胞或組織之mRNA聚核苷酸例如但不限於在脂質體中經調配。在一些實施例中,mRNA療法係用於治療患者之疾病。"mRNA therapy" refers to the delivery of mRNA polyribonucleotides to cells or tissues to modify those cells or tissues to treat or prevent disease. In some embodiments, mRNA polynucleotides for delivery to cells or tissues are formulated, for example, but not limited to, in liposomes. In some embodiments, mRNA therapy is used to treat a disease in a patient.
「細胞療法」係指將已經外源性修飾之活細胞遞送至患者以提供遺失基因來治療或預防疾病。隨後,將經修飾細胞再引入身體中。"Cell therapy" refers to the delivery of exogenously modified living cells to patients to provide missing genes to treat or prevent disease. The modified cells are then reintroduced into the body.
「有效量」意謂足以產生所需結果之量。一般熟習此項技術者可藉由使用常規實驗來測定有效量。"Effective amount" means an amount sufficient to produce the desired result. One skilled in the art can determine the effective amount by using routine experimentation.
「經分離」以及「經純化」用於指自與其天然地締合之至少一種其他組分移除之分子(例如經分離核酸、多肽等)或其他組分。術語「純化」不要求絕對純度,相反,希望其為相對定義。"Isolated" and "purified" are used to refer to a molecule (eg, isolated nucleic acid, polypeptide, etc.) or other component that has been removed from at least one other component with which it is naturally associated. The term "purified" does not require absolute purity, but rather is intended to be a relative definition.
「個體」涵蓋哺乳動物,諸如人類、非人類靈長類動物、家畜、伴侶動物及實驗室動物(例如嚙齒動物及兔類動物)。希望該術語涵蓋雌性以及雄性。"Individual" includes mammals, such as humans, non-human primates, livestock, companion animals, and laboratory animals (such as rodents and lagomorphs). Hopefully the term covers females as well as males.
「患者」意謂經評定用於疾病、治療疾病或正經歷疾病之任何個體。在一些實施例中,患者為人類患者。"Patient" means any individual assessed for, treatment for, or experiencing a disease. In some embodiments, the patient is a human patient.
「嬰兒」係指在出生之後第一個月至約一(1)歲之時段內之兒童。如本文所用,術語「新生兒」係指自出生至生命第28天之時段內之兒童。術語「早產嬰兒」係指在妊娠第二十整週之後、但在足月之前出生、出生時體重一般為約500至約2499公克之嬰兒。「極低出生體重嬰兒」為出生時體重低於1500 g之嬰兒。"Infant" means a child from the first month after birth to approximately one (1) year old. As used herein, the term "newborn" refers to a child from birth to the 28th day of life. The term "premature infant" refers to an infant born after the twentieth full week of pregnancy but before full term, with a birth weight generally ranging from about 500 to about 2499 grams. "Extremely low birth weight infants" are infants whose birth weight is less than 1500 g.
「兒童」係指尚未達到同意治療或研究程序之法定年齡的個人。在一些實施例中,該術語係指介於出生時間與青春期之間的個人。"Child" means an individual who has not reached the legal age to consent to treatment or research procedures. In some embodiments, the term refers to an individual between the time of birth and puberty.
「成人」係指已達到相關司法管轄權規定之法定年齡(例如在美國為18歲)的個人。在一些實施例中,該術語係指充分生長的任何成熟生物體。在一些實施例中,術語「青少年」係指低於18歲、但已達到性成熟的個人。"Adult" means an individual who has reached the age of majority in the relevant jurisdiction (for example, 18 years of age in the United States). In some embodiments, the term refers to any fully grown, mature organism. In some embodiments, the term "adolescent" refers to an individual under the age of 18 who has reached sexual maturity.
(例如投予(Administration)」及「投予(administering)」組成物意謂向個體(例如向罹患因子VIII缺乏症,諸如A型血友病之影響的個人)提供本發明之組成物。(e.g., administering) and "administering" a composition means providing a composition of the invention to an individual (e.g., to an individual affected by a factor VIII deficiency, such as hemophilia A).
「醫藥學上可接受之」意謂可投予至個體而不造成任何非所需生物效應或以有害方式與其中所含有、且具有所需生物活性之組分中之任一者相互作用的物質。"Pharmaceutically acceptable" means one that can be administered to an individual without causing any undesirable biological effects or interacting in a harmful manner with any of the components contained therein that have the desired biological activity. material.
「賦形劑」係指除活性醫藥成分以外的任何醫藥學上可接受之添加劑、載劑、稀釋劑、佐劑或其他成分(API;例如本揭露內容之重組因子VIII多肽)。賦形劑典型地出於調配及/或投予目的而包括在內。"Excipient" refers to any pharmaceutically acceptable additive, carrier, diluent, adjuvant or other ingredient other than the active pharmaceutical ingredient (API; such as the recombinant Factor VIII polypeptide of the present disclosure). Excipients are typically included for purposes of formulation and/or administration.
「載劑」在關於醫藥組成物使用時意謂標準醫藥載劑、緩衝劑以及賦形劑(諸如穩定劑、防腐劑以及佐劑)中之任一者。"Carrier" when used in connection with a pharmaceutical composition means any of standard pharmaceutical carriers, buffers and excipients such as stabilizers, preservatives and adjuvants.
當用於參考疾病/病況之症狀時,「治療有效量」表示可改善、減弱或消除疾病/病狀之一或多個症狀或預防或延遲症狀發作的化合物(例如,重組因子VIII多肽)之量及/或濃度。當參考疾病或病狀使用時,「治療有效量」係指改善、減弱或消除疾病/病況之組成物(例如重組因子VIII多肽)的量及/或濃度。在一些實施例中,該術語的使用係指研究人員、醫師、獸醫或其他臨床醫師所尋求之引發組織、系統或動物個體之生物學(例如醫學)反應的組成物之量。When used with reference to symptoms of a disease/condition, "therapeutically effective amount" means an amount of a compound (e.g., a recombinant Factor VIII polypeptide) that ameliorates, attenuates, or eliminates one or more symptoms of the disease/condition or prevents or delays the onset of symptoms. quantity and/or concentration. When used with reference to a disease or condition, a "therapeutically effective amount" refers to an amount and/or concentration of a composition (e.g., a recombinant Factor VIII polypeptide) that ameliorates, attenuates, or eliminates the disease/condition. In some embodiments, the term is used to refer to an amount of a composition sought by a researcher, physician, veterinarian, or other clinician to elicit a biological (eg, medical) response in a tissue, system, or individual animal.
如本文所用,疾病、病症或症候群之「治療(treating)」或「治療(treatment)」包括(i)預防該疾病、病症或症候群在個體中發生,亦即,使可能暴露於或易患該疾病、病症或症候群但尚未經歷或顯示該疾病、病症或症候群之症狀的動物不發展該疾病、病症或症候群之臨床症狀;(ii)抑制該疾病、病症或症候群,亦即,遏制其發展;及(iii)緩解該疾病、病症或症候群,亦即,使該疾病、病症或症候群消退。如此,術語「治療(treating)」、「治療(treat)」及「治療(treatment)」涵蓋預防性(例如防治性)治療以及緩解性治療。如此項技術中已知,可能需要對全身遞送相對於局部遞送、年齡、體重、一般健康狀況、性別、飲食、投予時間、藥物相互相用及病狀嚴重程度進行調節,且該等調節可由一般熟習此項技術者確定。 重組因子 VIII 多肽 As used herein, "treating" or "treatment" of a disease, condition, or syndrome includes (i) preventing the occurrence of the disease, condition, or syndrome in an individual, that is, rendering the disease, condition, or syndrome susceptible to the disease, condition, or syndrome in an individual; Animals that have a disease, disease or syndrome but have not yet experienced or shown symptoms of the disease, disease or syndrome do not develop clinical signs of the disease, disease or syndrome; (ii) inhibit the disease, disease or syndrome, that is, arrest its progression; and (iii) alleviate the disease, condition or syndrome, that is, cause the disease, condition or syndrome to subside. As such, the terms "treating", "treat" and "treatment" encompass preventive (eg preventive) treatment as well as palliative treatment. As is known in the art, adjustments to systemic delivery versus local delivery, age, weight, general health, sex, diet, timing of administration, drug interactions, and severity of condition may need to be made, and such adjustments may be made by Generally, it is determined by those who are familiar with this technology. Recombinant factor VIII polypeptide
如上文所論述,血液凝血因子VIII (FVIII)為活化凝血因子IX (例如FIXa)之輔因子,其在其蛋白分解活化形式中與FIXa相互作用以形成結合至且活化因子X (FX)之緊密非共價複合物。A型血友病為由缺失或缺陷FVIII蛋白所致之因子VIII缺乏症。A型血友病患者之治療可包括用VIII因子蛋白質之製劑進行酶替代療法。標準酶替代療法使用重組表現形式之野生型人類因子VIII或B區域缺失形式之人類因子VIII (例如,XYNTHA ®抗血友病因子(重組);Wyeth Pharmaceuticals LLC)。已知靜脈內投予之FVIII在血流中循環且恢復血液凝血功能。然而,此等藥物並未完全減輕患者症狀,因為在創傷之後或在手術之前需要額外劑量。另外,蛋白質相對不穩定且在數天內自血流清除。因此,問題仍為可用酶替代治療。另外,患者可發展免疫反應(靶向所投予藥物之IgG及IgE抗體),且遭受重度過敏性(allergic/anaphylactic)反應、重度輸注反應及甚至死亡。 As discussed above, blood coagulation factor VIII (FVIII) is a cofactor of activated coagulation factor IX (eg, FIXa), which in its proteolytically activated form interacts with FIXa to form a tight binding to and activated factor X (FX) Non-covalent complexes. Hemophilia A is a factor VIII deficiency caused by missing or defective FVIII protein. Treatment for patients with hemophilia A may include enzyme replacement therapy with preparations of the factor VIII protein. Standard enzyme replacement therapy uses a recombinant expression of wild-type human Factor VIII or a B-region deleted form of human Factor VIII (e.g., XYNTHA® Antihemophilic Factor (recombinant); Wyeth Pharmaceuticals LLC). Intravenously administered FVIII is known to circulate in the bloodstream and restore blood coagulation function. However, these drugs do not completely alleviate patient symptoms because additional doses are required after trauma or before surgery. Additionally, the protein is relatively unstable and cleared from the bloodstream within days. Therefore, the question remains as to available enzyme replacement therapy. Additionally, patients can develop immune responses (IgG and IgE antibodies targeting the administered drugs) and suffer severe allergic/anaphylactic reactions, severe infusion reactions, and even death.
本文揭示之重組因子VIII多肽或其生物活性片段意欲提供與目前可獲得之治療相比更穩定且有效的適用於治療A型血友病之蛋白質,但具有減少之副作用及改善之結果。在一些實施例中,重組因子VIII多肽之特徵在於血液中之穩定性增加(pH 7.4),該等酶在引入血流中及其中酶在療法期間具有活性。重組因子VIII多肽亦在其他特性中展示改良之凝血功能,且在一些實施例中,展示降低之預測免疫原性(去免疫)。The recombinant Factor VIII polypeptides or bioactive fragments thereof disclosed herein are intended to provide proteins suitable for the treatment of hemophilia A that are more stable and effective than currently available treatments, but with reduced side effects and improved outcomes. In some embodiments, recombinant Factor VIII polypeptides are characterized by increased stability in the blood (pH 7.4) where the enzymes are introduced into the bloodstream and where the enzymes are active during therapy. Recombinant Factor VIII polypeptides also exhibit, among other properties, improved coagulation function and, in some embodiments, reduced predicted immunogenicity (deimmunization).
本揭露內容之重組因子VIII多肽衍生自具有B區域缺失之重組因子VIII (SEQ ID NO: 2;參見例如美國專利公開案第2017/0360900號),其中B區域缺失之因子VIII係以天然存在之因子VIII胺基酸序列為主。簡言之,出於解釋而非限制之目的,因子VIII多肽由多肽內之五個區域構成:信號肽、A1區域、A2區域、B區域及輕鏈區域。其中B區域之缺失由SEQ ID NO: 2表示的重組因子VIII具有與野生型人類因子VIII一致之信號肽A1、A2及輕鏈區域,但其B區域已減少至十四個殘基。在一些實施例中,在本揭露內容中,當參考B區域缺失之因子VIII或參考因子VIII多肽序列中之胺基酸殘基中之胺基酸差異提及特定因子VIII變異體時,應理解,在等效位置中經修飾之另一因子VIII多肽之變異體(如自各別胺基酸序列之間的任擇地選用之胺基酸序列比對確定)涵蓋於本文中。The recombinant Factor VIII polypeptides of the present disclosure are derived from recombinant Factor VIII with a deletion of the B region (SEQ ID NO: 2; see, eg, U.S. Patent Publication No. 2017/0360900), where the factor VIII with a deletion of the B region is naturally occurring. Factor VIII amino acid sequence is dominant. Briefly, for purposes of explanation and not limitation, a Factor VIII polypeptide consists of five regions within the polypeptide: the signal peptide, the A1 region, the A2 region, the B region, and the light chain region. The recombinant Factor VIII in which the deletion of the B region is represented by SEQ ID NO: 2 has the same signal peptides A1, A2 and light chain regions as wild-type human Factor VIII, but its B region has been reduced to fourteen residues. In some embodiments, in the present disclosure, when a particular Factor VIII variant is referred to with reference to a Factor VIII deleted in the B region or to an amino acid difference in an amino acid residue in a Factor VIII polypeptide sequence, it will be understood that Variants of another Factor VIII polypeptide modified in equivalent positions (as determined from an optionally selected amino acid sequence alignment between respective amino acid sequences) are encompassed herein.
此外,本揭露內容亦提供本文所揭示之重組因子VIII多肽變異體之生物活性片段。應理解,因子VIII在生物學上處理成多肽片段。舉例而言而非限制,具有B區域缺失之因子VIII可藉由移除信號序列(例如,胺基酸殘基1至19)來處理,得到經處理因子VIII (例如,約20-1457之胺基酸殘基)。因子VIII可隨後經處理以產生編碼二聚人類因子VIII (或其變異體)之多肽,在SEQ ID NO: 2之殘基760至773之間發生一或多個裂解且該多肽不含對應於SEQ ID NO: 2之胺基酸760至773的一些或全部胺基酸序列。因子VIII可經進一步處理以產生編碼三聚人類因子VIII (或其變異體)之多肽,額外裂解發生在SEQ ID NO: 2之殘基391及392之間且該多肽不含對應於SEQ ID NO: 2之胺基酸760至773的一些或全部胺基酸序列。重組因子VIII多肽變異體可或可不與具有天然存在之序列之B區域之缺失因子VIII相同處理。In addition, the present disclosure also provides biologically active fragments of the recombinant Factor VIII polypeptide variants disclosed herein. It is understood that Factor VIII is biologically processed into polypeptide fragments. By way of example, and not limitation, Factor VIII with a B region deletion can be processed by removing the signal sequence (e.g., amino acid residues 1 to 19), resulting in processed Factor VIII (e.g., about 20-1457 amines) amino acid residues). Factor VIII can subsequently be processed to produce a polypeptide encoding dimeric human Factor VIII (or a variant thereof) that undergoes one or more cleavages between residues 760 to 773 of SEQ ID NO: 2 and that does not contain a polypeptide corresponding to Some or all of the amino acid sequences of amino acids 760 to 773 of SEQ ID NO: 2. Factor VIII can be further processed to produce a polypeptide encoding trimeric human Factor VIII (or a variant thereof) with additional cleavage occurring between residues 391 and 392 of SEQ ID NO: 2 and which does not contain the polypeptide corresponding to SEQ ID NO : Some or all of the amino acid sequences of amino acids 760 to 773 of 2. Recombinant Factor VIII polypeptide variants may or may not be treated identically to a deleted Factor VIII having a naturally occurring sequence of the B region.
因此,本文中所提及之重組因子VIII多肽之「生物活性」或「功能活性」片段意欲包括在哺乳動物細胞或患者中表現時,或在向患者投予重組因子VIII多肽後藉由天然生物處理形成之多肽,無論該等「生物活性」或「功能活性」片段為與具有天然存在之序列的B區域之缺失因子VIII相似的處理產物,或為與具有天然存在之序列的B區域之缺失因子VIII不同的處理結果的片段。Therefore, references herein to "biologically active" or "functionally active" fragments of a recombinant Factor VIII polypeptide are intended to include expression by natural organisms when expressed in mammalian cells or patients, or after administration of a recombinant Factor VIII polypeptide to a patient. Polypeptides formed by processing, whether such "biologically active" or "functionally active" fragments are the product of processing similar to the deletion of Factor VIII with a naturally occurring sequence of the B region, or a deletion of the B region with a naturally occurring sequence Fragments of different processing results for Factor VIII.
在一個態樣中,本揭露內容提供一種重組因子VIII多肽或其生物活性片段,其包含與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於該參考序列的一或多個取代。In one aspect, the present disclosure provides a recombinant Factor VIII polypeptide, or a biologically active fragment thereof, comprising residue 20- corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 The reference sequence of 1457 or has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more A sequence-identical amino acid sequence, wherein the amino acid sequence contains one or more substitutions relative to the reference sequence.
在一些實施例中,重組因子VIII多肽或其生物活性片段包含與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide or biologically active fragment thereof comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 or corresponding to The reference sequence of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity of amino acids Sequence, wherein the amino acid sequence comprises the reference sequence relative to residues 20-1457 corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 or relative to residues 20-1457 corresponding to SEQ ID NO. : One or more substitutions of 2, 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽或其生物活性片段包含與對應於SEQ ID NO: 2之殘基20-1457的參考序列或與對應於SEQ ID NO: 2之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide, or biologically active fragment thereof, comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or is at least 70% identical to a reference sequence corresponding to SEQ ID NO: 2. 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% , an amino acid sequence with 96%, 97%, 98% or 99% or more sequence identity, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 Or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽或其生物活性片段包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, a recombinant Factor VIII polypeptide or biologically active fragment thereof comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 or corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072. The reference sequence of ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, an amino acid sequence with 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity, wherein the amino acid sequence comprises one or more substitutions relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽或其生物活性片段包含與對應於SEQ ID NO. 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的參考序列或與對應於SEQ ID NO. 4-2346及2350-2870中之偶數編號SEQ ID NO.之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide or biologically active fragment thereof comprises a reference sequence corresponding to residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NO. 4-2346 and 2360-2870 or corresponding to The reference sequences of the even-numbered SEQ ID NO. in SEQ ID NO. 4-2346 and 2350-2870 have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity of amino acids Sequence, wherein the amino acid sequence comprises one or more substitutions relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:13、14、15、16、17、18、19、20、21、24、37、56、57、58、59、61、63、64、65、85、96、104、110、119、127、132、158、160、164、167、168、171、175、178、186、187、205、210、211、212、215、225、246、257、260、265、281、292、294、301、303、304、306、308、310、311、312、318、320、321、325、328、332、334、335、344、346、347、349、351、353、354、355、356、358、359、362、370、387、388、390、392、393、397、407、428、429、433、435、436、481、487、488、489、491、498、499、503、514、527、533、534、535、536、538、543、550、551、555、558、569、580、581、584、610、611、612、613、614、615、616、617、618、619、620、621、622、643、646、650、665、667、676、680、681、682、683、684、686、693、696、698、700、706、707、708、712、716、724、726、729、731、732、734、735、736、737、738、739、740、744、746、747、748、749、750、751、752、753、754、755、756、757、759、770、773、775、785、786、787、790、791、792、793、794、795、797、798、799、800、801、802、805、806、807、808、809、810、811、812、815、816、817、818、819、821、822、824、825、826、828、830、831、836、837、838、839、840、841、844、866、873、879、892、896、897、903、907、914、916、917、918、919、921、922、923、924、926、929、938、939、945、948、951、968、999、1037、1040、1041、1042、1043、1049、1050、1051、1053、1054、1076、1078、1080、1084、1088、1089、1092、1093、1094、1095、1098、1099、1100、1101、1104、1108、1109、1113、1114、1116、1127、1129、1138、1145、1148、1151、1156、1158、1160、1186、1192、1193、1194、1205、1210、1218、1220、1221、1222、1224、1229、1245、1248、1250、1259、1264、1269、1270、1274、1281、1283、1292、1297、1339、1352、1373、1377、1378、1380、1389、1414、1422、1427、1428、1439、1440、1442或1452或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 37, 56, 57, 58, 59, 61, 63, 64, 65, 85, 96, 104, 110, 119, 127, 132, 158, 160, 164, 167, 168, 171, 175, 178, 186, 187, 205, 210, 211, 212, 215, 225, 246, 257, 260, 265, 281, 292, 294, 301, 303, 304, 306, 308, 310, 311, 312, 318, 320, 321, 325, 328, 332, 334, 335, 344, 346, 347, 349, 351, 353, 354, 355, 356, 358, 359, 362, 370, 387, 388, 390, 392, 393, 397, 407, 428, 429, 433, 435, 436, 481, 487, 488, 489, 491, 498, 499, 503, 514, 527, 533, 534, 535, 536, 538, 543, 550, 551, 555, 558, 569, 580, 581, 584, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 643, 646, 650, 665, 667, 676, 680, 681, 682, 683, 684, 686, 693, 696, 698, 700, 706, 707, 708, 712, 716, 724, 726, 729, 731, 732, 734, 735, 736, 737, 738, 739, 740, 744, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 759, 770, 773, 775, 785, 786, 787, 790, 791, 792, 793, 794, 795, 797, 798, 799, 800, 801, 802, 805, 806, 807, 808, 809, 810, 811, 812, 815, 816, 817, 818, 819, 821, 822, 824, 825, 826, 828, 830, 831, 836, 837, 838, 839, 840, 841, 844, 866, 873, 879, 892, 896, 897, 903, 907, 914, 916, 917, 918, 919, 921, 922, 923, 924, 926, 929, 938, 939, 945, 948, 951, 968, 999, 1037, 1040, 1041, 1042, 1043, 1049, 1050, 1051, 1053, 1054, 1076, 1078, 1080, 1084, 1088, 1089, 1092, 1093, 1094, 1095, 1098, 1099, 1100, 1101, 1104, 1108, 1109, 1113, 1114, 1116, 1127, 1129, 1138, 1145, 1148, 1151, 1156, 1158, 1160, 118 6. 1192, 1193, 1194, 1205, 1210, 1218, 1220, 1221, 1222, 1224, 1229, 1245, 1248, 1250, 1259, 1264, 1269, 1270, 1274, 1281, 1283, 1292, 1297, 1339, 135 2. 1373, 1377, 1378, 1380, 1389, 1414, 1422, 1427, 1428, 1439, 1440, 1442 or 1452 or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2 .
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基13G/Y、14G/M/V、15G/S、16A/D/G/P/V、17S/V、18L/R、19G、20L、21M、24V、37H、56E/P、57A/L/S/T/V、58K、59D/G/L/M/Q/R/S/V/W、61Q/S、63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、64D/G、65A、85Q、96I/L/R/V/W、104S、110H、119G/V、127V、132P/R、158G、160E/T、164E、167G/H/R、168G/R、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、175A/G/H、178C/M/Q/V/W、186A、187C/G、205R、210P、211G/K/P/Q/R、212A/F/G/K/L/M/N/P/R/S/V/Y、215E/P/S、225R、246D、257I、260E/K/T、265R/S/W、281A/S、292D、294G、301K/M、303G/T、304A/E/G、306A/D/G/P/S/T、308P、310G/V、311E/G、312L、318C/G/K/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、321Y、325Y、328G/Q/S、332A/F/G/H/N/P/Q/R/T/V/W/Y、334G、335E/P、344A/E/L、346R/V、347N、349G、351S、353S、354R、355C、356L/N、358K/S、359E/G、362E/G/N/P/T/V/W、370A、387A/G/I/L/Q/R/S/T/V/W、388A/P、390A/E/G/L/M/P/S/T/V、392A、393A/F/G/H/M/Q/R/W/Y、397G/N、407V、428F、429L/S、433A/G、435Q、436D/G、481V、487N、488G、489E/F/Q/R、491E、498A、499C/L、503S、514L、527A、533R/V/Y、534F/I/L/M、535C/G/N、536A/G/K/L/M/P/R/W、538V、543G/L/P/W、550G、551W、555E/G/R/T、558A/E/G/L/P/Q/R/S/T/V/W、569T、580S/Y、581K/V、584A、610H/K/L/R/S/T、611D/E、612G/S/T、613S、614A/F/H/I/N/T、615D/N、616D/E/G/Q/W、617D/E/G/N、618C/E/G/P/Y、619E、620N/P、621K/M/R/T/W、622D、643N、646I、650M、665G、667I、676Q、680L/R、681A/C/E/F/G/L/N/R/Q/S/T/W、682R、683W、684G/K、686W、693T、696E、698D/S/W/Y、700A/E/Q/T/V、706A/G/M/Y、707H、708A/K/T/V、712G/L/M/Q/S/T/Y、716K/L/W、724I、726A/L、729T、731I/L/R、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、734I/R/S、735D/S/V、736F/G、737F/G/K/L/M/N/S/V、738A/D/E/F/H/K/N/P/R/S/T、739G/P/R、740G、744A/R、746P、747D、748F/G/K/N/S/V、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S/V、753D、754W、755G/L/P/Q/S/Y、756G/P/R/T、757A/G/K/T、759S、770W、773H、775E/G/K/N/P/S/V、785V、786C/D/L、787W、790A/G/I/M/P/W、791M/T、792H/W/Y、793G、794R、795C/N/S/T、797C/G/P/Q/T/W/Y、798C/R/T、799A/E/G/M/P/Q/R/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、801A/G/I/R、802S/V、805C/G/H/K/L/M/P/Q/R/S/V/W、806E/G/R/S、807C/L/P/R、808K/S、809A/C/G/I/K/L/N/Q/R/S/T/V/W、810V、811F、812G/I/V、815I、816V/W、817A/D、818A/E/G/P/S/V/W、819V、821Q、822S/T、824W、825L、826G、828K、830M/V、831W、836G/R/V/W、837G、838G/T、839A/G/K/P、840G、841W、844H、866A、873L/Q/T、879Q、892T、896L/V、897G/K/R、903E、907D、914V、916C/E/I/K/L/M/Q/T、917G、918M/S、919G、921R/W、922W、923M、924I/M/P/Q/W、926T/V、929A/Q/V、938R/V、939E/S、945K、948S、951V、968A/P、999R、1037H/M/N/P、1040E、1041G/H/N、1042A/E/T、1043E/R、1049G/W、1050E/P/Q/S/T、1051E/H/K/R/S/W、1053A/R、1054C、1076G/S、1078S、1080G/V、1084L/N、1088G/S、1089F/S、1092G、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1094S、1095G、1098G、1099G、1100I/S、1101G、1104C/E、1108M/S/V/W、1109G、1113F、1114A/M、1116A/G/I/L/R、1127L/V、1129P、1138Q、1145R、1148A/C/E/L/M/N/Q/R/S、1151S、1156D/G/N/R、1158N、1160R、1186E、1192D、1193A/E/G/I/L、1194P、1205L、1210M/T/V/W、1218A/G/L/M/P、1220D/E/L/T、1221G/S/T/V、1222F、1224P、1229D、1245R、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1250A/P/S/T、1259T、1264L/R/W、1269F、1270V、1274N/V、1281H/K/P/Q/R/S、1283E/H/L/S/T、1292Y、1297A、1339C、1352E、1373S、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1378A/C/D/E、1380A/G/W、1389W、1414A/C/D/E/G/H/N/P/T/W、1422I、1427Y、1428G、1439A/E/H/L/S/T、1440A/C/E/G/S/T、1442T或1452L或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or amino acid residue 13G/Y, 14G/M/V, 15G/S, 16A/D/G/P/V, 17S /V, 18L/R, 19G, 20L, 21M, 24V, 37H, 56E/P, 57A/L/S/T/V, 58K, 59D/G/L/M/Q/R/S/V/W , 61Q/S, 63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y, 64D/G, 65A, 85Q, 96I/L/R /V/W, 104S, 110H, 119G/V, 127V, 132P/R, 158G, 160E/T, 164E, 167G/H/R, 168G/R, 171A/D/E/F/H/K/N /M/P/Q/R/S/T/V/W/Y, 175A/G/H, 178C/M/Q/V/W, 186A, 187C/G, 205R, 210P, 211G/K/P /Q/R, 212A/F/G/K/L/M/N/P/R/S/V/Y, 215E/P/S, 225R, 246D, 257I, 260E/K/T, 265R/S /W, 281A/S, 292D, 294G, 301K/M, 303G/T, 304A/E/G, 306A/D/G/P/S/T, 308P, 310G/V, 311E/G, 312L, 318C /G/K/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V, 321Y, 325Y, 328G/Q/S, 332A/F/G/H /N/P/Q/R/T/V/W/Y, 334G, 335E/P, 344A/E/L, 346R/V, 347N, 349G, 351S, 353S, 354R, 355C, 356L/N, 358K /S, 359E/G, 362E/G/N/P/T/V/W, 370A, 387A/G/I/L/Q/R/S/T/V/W, 388A/P, 390A/E /G/L/M/P/S/T/V, 392A, 393A/F/G/H/M/Q/R/W/Y, 397G/N, 407V, 428F, 429L/S, 433A/G , 435Q, 436D/G, 481V, 487N, 488G, 489E/F/Q/R, 491E, 498A, 499C/L, 503S, 514L, 527A, 533R/V/Y, 534F/I/L/M, 535C /G/N, 536A/G/K/L/M/P/R/W, 538V, 543G/L/P/W, 550G, 551W, 555E/G/R/T, 558A/E/G/L /P/Q/R/S/T/V/W, 569T, 580S/Y, 581K/V, 584A, 610H/K/L/R/S/T, 611D/E, 612G/S/T, 613S , 614A/F/H/I/N/T, 615D/N, 616D/E/G/Q/W, 617D/E/G/N, 618C/E/G/P/Y, 619E, 620N/P , 621K/M/R/T/W, 622D, 643N, 646I, 650M, 665G, 667I, 676Q, 680L/R, 681A/C/E/F/G/L/N/R/Q/S/T /W, 682R, 683W, 684G/K, 686W, 693T, 696E, 698D/S/W/Y, 700A/E/Q/T/V, 706A/G/M/Y, 707H, 708A/K/T /V, 712G/L/M/Q/S/T/Y, 716K/L/W, 724I, 726A/L, 729T, 731I/L/R, 732C/D/E/G/L/R/W /K/M/Q/S/T/V/Y, 734I/R/S, 735D/S/V, 736F/G, 737F/G/K/L/M/N/S/V, 738A/D /E/F/H/K/N/P/R/S/T, 739G/P/R, 740G, 744A/R, 746P, 747D, 748F/G/K/N/S/V, 749A/C /D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T /V/W, 751A/D/E/Y, 752D/E/F/G/L/M/Q/R/S/V, 753D, 754W, 755G/L/P/Q/S/Y, 756G /P/R/T, 757A/G/K/T, 759S, 770W, 773H, 775E/G/K/N/P/S/V, 785V, 786C/D/L, 787W, 790A/G/I /M/P/W, 791M/T, 792H/W/Y, 793G, 794R, 795C/N/S/T, 797C/G/P/Q/T/W/Y, 798C/R/T, 799A /E/G/M/P/Q/R/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 801A/G/I/R , 802S/V, 805C/G/H/K/L/M/P/Q/R/S/V/W, 806E/G/R/S, 807C/L/P/R, 808K/S, 809A /C/G/I/K/L/N/Q/R/S/T/V/W, 810V, 811F, 812G/I/V, 815I, 816V/W, 817A/D, 818A/E/G /P/S/V/W, 819V, 821Q, 822S/T, 824W, 825L, 826G, 828K, 830M/V, 831W, 836G/R/V/W, 837G, 838G/T, 839A/G/K /P, 840G, 841W, 844H, 866A, 873L/Q/T, 879Q, 892T, 896L/V, 897G/K/R, 903E, 907D, 914V, 916C/E/I/K/L/M/Q /T, 917G, 918M/S, 919G, 921R/W, 922W, 923M, 924I/M/P/Q/W, 926T/V, 929A/Q/V, 938R/V, 939E/S, 945K, 948S , 951V, 968A/P, 999R, 1037H/M/N/P, 1040E, 1041G/H/N, 1042A/E/T, 1043E/R, 1049G/W, 1050E/P/Q/S/T, 1051E /H/K/R/S/W, 1053A/R, 1054C, 1076G/S, 1078S, 1080G/V, 1084L/N, 1088G/S, 1089F/S, 1092G, 1093A/E/G/M/N /P/Q/R/S/T/V/W/Y, 1094S, 1095G, 1098G, 1099G, 1100I/S, 1101G, 1104C/E, 1108M/S/V/W, 1109G, 1113F, 1114A/M , 1116A/G/I/L/R, 1127L/V, 1129P, 1138Q, 1145R, 1148A/C/E/L/M/N/Q/R/S, 1151S, 1156D/G/N/R, 1158N , 1160R, 1186E, 1192D, 1193A/E/G/I/L, 1194P, 1205L, 1210M/T/V/W, 1218A/G/L/M/P, 1220D/E/L/T, 1221G/S /T/V, 1222F, 1224P, 1229D, 1245R, 1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y, 1250A/P /S/T, 1259T, 1264L/R/W, 1269F, 1270V, 1274N/V, 1281H/K/P/Q/R/S, 1283E/H/L/S/T, 1292Y, 1297A, 1339C, 1352E , 1373S, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1378A/C/D/E, 1380A/G/W, 1389W, 1414A/C /D/E/G/H/N/P/T/W, 1422I, 1427Y, 1428G, 1439A/E/H/L/S/T, 1440A/C/E/G/S/T, 1442T or 1452L or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代L13G/Y、L14G/M/V、R15G/S、F16A/D/G/P/V、C17S/V、F18L/R、S19G、A20L、T21M、Y24V、Q37H、S56E/P、F57A/L/S/T/V、P58K、F59D/G/L/M/Q/R/S/V/W、T61Q/S、V63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、V64D/G、Y65A、P85Q、Q96I/L/R/V/W、V104S、M110H、A119G/V、A127V、E132P/R、Q158G、L160E/T、G164E、A167G/H/R、S168G/R、L171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、Y175A/G/H、L178C/M/Q/V/W、D186A、L187C/G、K205R、T210P、L211G/K/P/Q/R、H212A/F/G/L/K/M/N/P/R/S/V/Y、I215E/P/S、K225R、A246D、V257I、S260E/K/T、T265R/S/W、T281A/S、G292D、T294G、R301K/M、A303G/T、S304A/E/G、E306A/D/G/P/S/T、S308P、I310G/V、T311E/G、F312L、L318C/G/K/M/Q/R/T/V、M320G/I/L/P/Q/R/S/T/V、D321Y、F325Y、F328G/Q/S、S332A/F/G/H/N/P/Q/R/T/V/W/Y、H334G、Q335E/P、K344A/E/L、D346R/V、S347N、P349G、E351S、Q353S、L354R、R355C、M356L/N、N358K/S、N359E/G、A362E/G/N/P/T/V/W、T370A、F387A/G/I/L/Q/R/S/T/V/W、I388A/P、I390A/E/G/L/M/P/S/T/V、S392A、V393A/F/G/H/M/Q/R/W/Y、H397G/N、A407V、S428F、Q429L/S、N433A/G、P435Q、Q436D/G、L481V、Q487N、A488G、S489E/F/Q/R、P491E、G498A、I499C/L、R503S、V514L、I527A、T533R/V/Y、V534I/F/L/M、T535C/G/N、V536A/G/K/L/M/P/R/W、D538V、S543G/L/P/W、R550G、Y551W、F555E/G/R/T、M558A/E/G/L/P/Q/R/S/T/V/W、P569T、Q580S/Y、R581K/V、Q584A、I610H/K/L/R/S/T、Q611D/E、R612G/S/T、F613S、L614A/F/H/I/N/T、P615D/N、N616D/E/G/Q/W、P617D/E/G/N、A618C/E/G/P/Y、G619E、V620N/P、Q621K/M/R/T/W、L622D、S643N、L646I、L650M、T665G、F667I、T676Q、K680L/R、M681A/C/E/F/G/L/N/R/Q/S/T/W、V682R、Y683W、E684G/K、T686W、S693T、T696E、F698D/S/W/Y、S700A/E/Q/T/V、L706A/G/M/Y、W707H、I708A/K/T/V、H712G/L/M/Q/S/T/Y、F716K/L/W、L724I、K726A/L、S729T、D731I/L/R、K732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、T734I/R/S、G735D/S/V、D736F/G、Y737F/G/K/L/M/N/S/V、Y738A/D/E/F/H/K/N/P/R/S/T、E739G/P/R、D740G、D744A/R、A746P、A747D、Y748F/G/K/N/S/V、L749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、L750A/D/G/K/M/N/P/Q/R/S/T/V/W、A751A/D/E/Y、K752D/E/F/G/L/M/Q/R/S/V、N753D、N754W、A755G/L/P/Q/S/Y、I756G/P/R/T、E757A/G/K/T、R759S、R770W、R773H、I775E/G/K/N/P/S/V、E785V、E786C/D/L、I787W、D790A/G/I/M/P/W、D791M/T、T792H/W/Y、I793G、S794R、Y795C/N/S/T、M797C/G/P/Q/T/W/Y、K798C/R/T、K799A/E/G/M/P/Q/R/S/V、E800C/G/I/L/M/N/P/Q/R/T/V/W/Y、D801A/G/I/R、F802S/V、Y805C/G/H/K/L/M/P/Q/R/S/V/W、D806E/G/R/S、E807C/L/P/R、D808K/S、E809A/C/G/I/K/L/N/Q/R/S/T/V/W、N810V、Q811F、S812G/I/V、S815I、F816V/W、Q817A/D、K818A/E/G/P/S/V/W、K819V、R821Q、H822S/T、F824W、I825L、A826G、V828K、R830M/V、L831W、M836G/R/V/W、S837G、S838G/T、S839A/G/K/P、P840G、H841W、R844H、G866A、Y873L/Q/T、E879Q、V892T、I896L/V、M897G/K/R、Q903E、P907D、L914V、S916C/E/I/K/L/M/Q/T、Y917G、E918M/S、E919G、Q921R/W、R922W、Q923M、G924I/M/P/Q/W、E926T/V、K929A/Q/V、K938R/V、T939E/S、Q945K、M948S、T951V、L968A/P、Q999R、F1037H/M/N/P、N1040E、Y1041G/H/N、R1042A/E/T、F1043E/R、Y1049G/W、I1050E/P/Q/S/T、M1051E/H/K/R/S/W、T1053A/R、L1054C、E1076G/S、I1078S、S1080G/V、S1084L/N、F1088G/S、T1089F/S、K1092G、K1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、E1094S、E1095G、M1098G、A1099G、L1100I/S、Y1101G、Y1104C/E、F1108M/S/V/W、E1109G、M1113F、L1114A/M、S1116A/G/I/L/R、I1127L/V、E1129P、L1138Q、K1145R、T1148A/C/E/L/M/N/Q/R/S、G1151S、H1156D/G/N/R、R1158N、F1160R、A1186E、P1192D、F1193A/E/G/I/L、S1194P、I1205L、K1210M/T/V/W、F1218A/G/L/M/P、S1220D/E/L/T、L1221G/S/T/V、Y1222F、S1224P、M1229D、T1245R、L1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、V1250A/P/S/T、G1259T、I1264L/R/W、I1269F、I1270V、I1274N/V、Y1281H/K/P/Q/R/S、I1283E/H/L/S/T、M1292Y、N1297A、G1339C、K1352E、V1373S、L1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、T1378A/C/D/E、M1380A/G/W、S1389W、S1414A/C/D/E/G/H/N/P/T/W、L1422I、L1427Y、T1428G、V1439A/E/H/L/S/T、H1440A/C/E/G/S/T、I1442T或E1452L或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution L13G/Y, L14G/M/V, R15G/S, F16A/D/G/P/V, C17S/V, F18L/R , S19G, A20L, T21M, Y24V, Q37H, S56E/P, F57A/L/S/T/V, P58K, F59D/G/L/M/Q/R/S/V/W, T61Q/S, V63C /E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y, V64D/G, Y65A, P85Q, Q96I/L/R/V/W, V104S , M110H, A119G/V, A127V, E132P/R, Q158G, L160E/T, G164E, A167G/H/R, S168G/R, L171A/D/E/F/H/K/N/M/P/Q /R/S/T/V/W/Y, Y175A/G/H, L178C/M/Q/V/W, D186A, L187C/G, K205R, T210P, L211G/K/P/Q/R, H212A /F/G/L/K/M/N/P/R/S/V/Y, I215E/P/S, K225R, A246D, V257I, S260E/K/T, T265R/S/W, T281A/S , G292D, T294G, R301K/M, A303G/T, S304A/E/G, E306A/D/G/P/S/T, S308P, I310G/V, T311E/G, F312L, L318C/G/K/M /Q/R/T/V, M320G/I/L/P/Q/R/S/T/V, D321Y, F325Y, F328G/Q/S, S332A/F/G/H/N/P/Q /R/T/V/W/Y, H334G, Q335E/P, K344A/E/L, D346R/V, S347N, P349G, E351S, Q353S, L354R, R355C, M356L/N, N358K/S, N359E/G , A362E/G/N/P/T/V/W, T370A, F387A/G/I/L/Q/R/S/T/V/W, I388A/P, I390A/E/G/L/M /P/S/T/V, S392A, V393A/F/G/H/M/Q/R/W/Y, H397G/N, A407V, S428F, Q429L/S, N433A/G, P435Q, Q436D/G , L481V, Q487N, A488G, S489E/F/Q/R, P491E, G498A, I499C/L, R503S, V514L, I527A, T533R/V/Y, V534I/F/L/M, T535C/G/N, V536A /G/K/L/M/P/R/W, D538V, S543G/L/P/W, R550G, Y551W, F555E/G/R/T, M558A/E/G/L/P/Q/R /S/T/V/W, P569T, Q580S/Y, R581K/V, Q584A, I610H/K/L/R/S/T, Q611D/E, R612G/S/T, F613S, L614A/F/H /I/N/T, P615D/N, N616D/E/G/Q/W, P617D/E/G/N, A618C/E/G/P/Y, G619E, V620N/P, Q621K/M/R /T/W, L622D, S643N, L646I, L650M, T665G, F667I, T676Q, K680L/R, M681A/C/E/F/G/L/N/R/Q/S/T/W, V682R, Y683W , E684G/K, T686W, S693T, T696E, F698D/S/W/Y, S700A/E/Q/T/V, L706A/G/M/Y, W707H, I708A/K/T/V, H712G/L /M/Q/S/T/Y, F716K/L/W, L724I, K726A/L, S729T, D731I/L/R, K732C/D/E/G/L/R/W/K/M/Q /S/T/V/Y, T734I/R/S, G735D/S/V, D736F/G, Y737F/G/K/L/M/N/S/V, Y738A/D/E/F/H /K/N/P/R/S/T, E739G/P/R, D740G, D744A/R, A746P, A747D, Y748F/G/K/N/S/V, L749A/C/D/F/G /I/K/L/M/P/Q/R/S/T/V/Y, L750A/D/G/K/M/N/P/Q/R/S/T/V/W, A751A /D/E/Y, K752D/E/F/G/L/M/Q/R/S/V, N753D, N754W, A755G/L/P/Q/S/Y, I756G/P/R/T , E757A/G/K/T, R759S, R770W, R773H, I775E/G/K/N/P/S/V, E785V, E786C/D/L, I787W, D790A/G/I/M/P/W , D791M/T, T792H/W/Y, I793G, S794R, Y795C/N/S/T, M797C/G/P/Q/T/W/Y, K798C/R/T, K799A/E/G/M /P/Q/R/S/V, E800C/G/I/L/M/N/P/Q/R/T/V/W/Y, D801A/G/I/R, F802S/V, Y805C /G/H/K/L/M/P/Q/R/S/V/W, D806E/G/R/S, E807C/L/P/R, D808K/S, E809A/C/G/I /K/L/N/Q/R/S/T/V/W, N810V, Q811F, S812G/I/V, S815I, F816V/W, Q817A/D, K818A/E/G/P/S/V /W, K819V, R821Q, H822S/T, F824W, I825L, A826G, V828K, R830M/V, L831W, M836G/R/V/W, S837G, S838G/T, S839A/G/K/P, P840G, H841W , R844H, G866A, Y873L/Q/T, E879Q, V892T, I896L/V, M897G/K/R, Q903E, P907D, L914V, S916C/E/I/K/L/M/Q/T, Y917G, E918M /S, E919G, Q921R/W, R922W, Q923M, G924I/M/P/Q/W, E926T/V, K929A/Q/V, K938R/V, T939E/S, Q945K, M948S, T951V, L968A/P , Q999R, F1037H/M/N/P, N1040E, Y1041G/H/N, R1042A/E/T, F1043E/R, Y1049G/W, I1050E/P/Q/S/T, M1051E/H/K/R /S/W, T1053A/R, L1054C, E1076G/S, I1078S, S1080G/V, S1084L/N, F1088G/S, T1089F/S, K1092G, K1093A/E/G/M/N/P/Q/R /S/T/V/W/Y, E1094S, E1095G, M1098G, A1099G, L1100I/S, Y1101G, Y1104C/E, F1108M/S/V/W, E1109G, M1113F, L1114A/M, S1116A/G/I /L/R, I1127L/V, E1129P, L1138Q, K1145R, T1148A/C/E/L/M/N/Q/R/S, G1151S, H1156D/G/N/R, R1158N, F1160R, A1186E, P1192D , F1193A/E/G/I/L, S1194P, I1205L, K1210M/T/V/W, F1218A/G/L/M/P, S1220D/E/L/T, L1221G/S/T/V, Y1222F , S1224P, M1229D, T1245R, L1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y, V1250A/P/S/T, G1259T , I1264L/R/W, I1269F, I1270V, I1274N/V, Y1281H/K/P/Q/R/S, I1283E/H/L/S/T, M1292Y, N1297A, G1339C, K1352E, V1373S, L1377A/C /D/E/G/H/I/M/P/R/S/V/T/Y, T1378A/C/D/E, M1380A/G/W, S1389W, S1414A/C/D/E/G /H/N/P/T/W, L1422I, L1427Y, T1428G, V1439A/E/H/L/S/T, H1440A/C/E/G/S/T, I1442T or E1452L, or a combination thereof, where the Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:63、171、212、260、306、317、320、332、387、390、393、534、558、681、732、738、749、750、775、1148、1248、1377或1439或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 63, 171, 212, 260, 306, 317, 320, 332, 387, 390, 393, 534, 558, 681, 732, 738, 749, 750, 775, 1148, 1248, 1377 or 1439 or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、212A/F/G/L/K/M/N/P/R/S/V/Y、260E/K/T、306A/D/G/P/S/T、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、332A/F/G/H/N/P/Q/R/T/V/W/Y、387A/G/I/L/Q/R/S/T/V/W、390A/E/G/L/M/P/S/T/V、393A/F/G/H/M/Q/R/W/Y、499C/L、534I/F/L/M、558A/E/G/L/P/Q/R/S/T/V/W、681A/C/E/F/G/L/N/R/Q/S/T/W、700A/E/Q/T/V、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、738A/D/E/F/H/K/N/P/R/S/T/Y、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、752D/E/F/G/L/M/Q/R/S/V、775E/G/K/N/P/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、805C/G/H/K/L/M/P/Q/R/S/V/W、809A/C/G/I/K/L/N/Q/R/S/T/V/W、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1148A/C/E/L/M/N/Q/R/S、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1414A/C/D/E/G/H/N/P/T/W或1439A/E/H/L/S/T或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or amino acid residue 63C/E/F/G/H/I/K/L/M/N/Q/R/S /T/W/Y, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y, 212A/F/G/L/K/M /N/P/R/S/V/Y, 260E/K/T, 306A/D/G/P/S/T, 318C/G/K/L/M/Q/R/T/V, 320G /I/L/P/Q/R/S/T/V, 332A/F/G/H/N/P/Q/R/T/V/W/Y, 387A/G/I/L/Q /R/S/T/V/W, 390A/E/G/L/M/P/S/T/V, 393A/F/G/H/M/Q/R/W/Y, 499C/L , 534I/F/L/M, 558A/E/G/L/P/Q/R/S/T/V/W, 681A/C/E/F/G/L/N/R/Q/S /T/W, 700A/E/Q/T/V, 732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y, 738A/D/E/F /H/K/N/P/R/S/T/Y, 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A /D/G/K/M/N/P/Q/R/S/T/V/W, 752D/E/F/G/L/M/Q/R/S/V, 775E/G/K /N/P/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 805C/G/H/K/L/M/P/Q /R/S/V/W, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 1093A/E/G/M/N/P/Q/R /S/T/V/W/Y, 1148A/C/E/L/M/N/Q/R/S, 1248A/C/D/E/F/G/H/I/K/M/P /Q/R/S/T/W/Y, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1414A/C/D/E/G /H/N/P/T/W or 1439A/E/H/L/S/T or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基63Q、171P、212A、260T、306G、317G、320R、332P、387I、390A、393G、534I、558W、681G、732W、7338E、749F、750D、775G、1148N、1248D、1377D或1439E或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or amino acid residue 63Q, 171P, 212A, 260T, 306G, 317G, 320R, 332P, 387I, 390A, 393G, 534I, 558W , 681G, 732W, 7338E, 749F, 750D, 775G, 1148N, 1248D, 1377D or 1439E or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代V63Q、L171P、H212A、S260T、E306G、L317G、M320R、S332P、F387I、I390A、V393G、V534I、M558W、M681G、K732W、Y738E、L749F、L750D、I775G、T1148N、L1248D、L1377D或V1439E或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution V63Q, L171P, H212A, S260T, E306G, L317G, M320R, S332P, F387I, I390A, V393G, V534I, M558W, M681G, K732W, Y738E , L749F, L750D, I775G, T1148N, L1248D, L1377D or V1439E or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置1377處的取代。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代1377D。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at position 1377. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution 1377D.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置1439或1377/1439處的取代或取代集。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集1439E或1377D/1439E。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at position 1439 or 1377/1439. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 1439E or 1377D/1439E.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置171、260、387、750、1248或171/260/387/750/1248處的取代或取代集。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集171P、260T、387I、750D、1248D或171P/260T/387I/750D/1248D。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at positions 171, 260, 387, 750, 1248, or 171/260/387/750/1248. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 171P, 260T, 387I, 750D, 1248D, or 171P/260T/387I/750D/1248D.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置306、332、390、749或306/332/390/749處的取代或取代集。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集306G、332P、390A、749F或306G/332P/390A/749F。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at positions 306, 332, 390, 749, or 306/332/390/749. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 306G, 332P, 390A, 749F, or 306G/332P/390A/749F.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置63、393、732、775、1148或63/393/732/775/1148處的取代或取代集。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集63Q、393G、732W、775G、1148N或63Q/393G/732W/775G/1148N。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at positions 63, 393, 732, 775, 1148, or 63/393/732/775/1148. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 63Q, 393G, 732W, 775G, 1148N, or 63Q/393G/732W/775G/1148N.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置212、320、534、558、681,或212/320/534/558/681處的取代或取代集。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集212A、320R、534I、558W、681G,或212A/320R/534I/558W/681G。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at positions 212, 320, 534, 558, 681, or 212/320/534/558/681. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 212A, 320R, 534I, 558W, 681G, or 212A/320R/534I/558W/681G.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在位置317、738或317/738處的取代或取代集。在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集317G、738E或317G/738E。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at positions 317, 738, or 317/738. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions 317G, 738E, or 317G/738E.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1148、85/708/1148、798、706、171、335、63、344、428、879、59、429、205、1264、797、1248、873、792、708、57、96、362、1292、346、433、65、795、684/798、353、332、1259、356、436、1245、1145、716、56、773、734、358、729、665、359、61、1250、726、37/96/171/429/708/799/1148、171/429/732/1148、96/171、171/919/1151、171/792/797/799/1148、171/569/1148、96/171/429/792/797/799、171/429/708/1422、171/429、321/362/732/797/799、171/1100、708/1148/1186、429/724/732/1148、171/362/795/797/799、171/429/732、96/171/643/797/799、171/792/797/799、503、171/732、1148/1193、96/171/362/429/732/795/797、334、732、351、1377、999、306、349、257、646、435或58,其中該等位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1148, 85/708/1148, 798, 706, 171, 335, 63, 344 ,428,879,59,429,205,1264,797,1248,873,792,708,57,96,362,1292,346,433,65,795,684/798,353,332,1259,356 ,436,1245,1145,716,56,773,734,358,729,665,359,61,1250,726,37/96/171/429/708/799/1148,171/429/732/1148 ,96/171, 171/919/1151, 171/792/797/799/1148, 171/569/1148, 96/171/429/792/797/799, 171/429/708/1422, 171/429 ,321/362/732/797/799, 171/1100, 708/1148/1186, 429/724/732/1148, 171/362/795/797/799, 171/429/732, 96/171/643 /797/799, 171/792/797/799, 503, 171/732, 1148/1193, 96/171/362/429/732/795/797, 334, 732, 351, 1377, 999, 306, 349 , 257, 646, 435 or 58, wherein these positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集1148N、85Q/708T/1148N、798T、706G、706A、171Q、335E、63R、344A、428F、879Q、59L、429S、205R、1264W、797P、1248S、1264R、873T、792Y、708K、344L、57V、96L、362W、63G、873L、1292Y、1148Q、346V、797G、706Y、1248R、433A、65A、59W、873Q、795C、684K/798R、57L、353S、332Q、708A、1259T、63M、356L、1248G、1248P、436G、57A、59S、1245R、59R、96W、797Y、1145R、436D、716L、56E、773H、734I、358S、335P、59Q、729T、716K、665G、362T、57T、359G、61S、1250A、362V、359E、716W、332W、708V、63H、797C、61Q、356N、1250S、798C、433G、795N、96I、56P、63N、792W、1264L、1250P、332P、59V、726L、37H/96R/171P/429L/708T/799R/1148N、171P、171P/429L/732R/1148N、96R/171P、171P/919G/1151S、171P/792Y/797Q/799R/1148N、171P/569T/1148N、96R/171P/429L/792Y/797T/799R、171P/429L/708T/1422I、171P/429L、321Y/362P/732E/797T/799R、171P/1100I、708T/1148N/1186E、429L/724I/732E/1148N、171P/362E/795T/797Q/799M、171P/429L/732E、96R/171P/643N/797T/799R、171P/792Y/797T/799M、503S、171P/732E、1148N/1193L、96R/171P/362E/429L/732R/795T/797Q、726A、59M、734R、362N、334G、732G、63Q、351S、1377D、795S、358K、999R、1250T、306G、349G、1377G、332F、1377E、257I、646I、346R、435Q、96V、1377R、1377S、59G、171M、792H、1248D、306S、706M、171H、1377A、1377V、734S、1148R、57S、59D、344E、362G或58K,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 1148N, 85Q/708T/1148N, 798T, 706G, 706A, 171Q, 335E, 63R, 344A, 428F, 879Q, 59L, 429S, 205R, 1264W, 797P, 1248S, 1264R, 873T, 792Y, 708K, 344L, 57V, 96L, 362W, 63G, 873L, 1292Y, 1148Q, 346V, 797G, 706Y, 1248R, 433A, 65A, 59W, 87 3Q. 795C、684K/798R、57L、353S、332Q、708A、1259T、63M、356L、1248G、1248P、436G、57A、59S、1245R、59R、96W、797Y、1145R、436D、716L、56E、773H、734I、 358S, 335P, 59Q, 729T, 716K, 665G, 362T, 57T, 359G, 61S, 1250A, 362V, 359E, 716W, 332W, 708V, 63H, 797C, 61Q, 356N, 1250S, 798C, 433G, 795N, 96I, 56P, 63N, 792W, 1264L, 1250P, 332P, 59V, 726L, 37H/96R/171P/429L/708T/799R/1148N, 171P, 171P/429L/732R/1148N, 96R/171P, 171P/919G/1151S , 171P/792Y/797Q/799R/1148N, 171P/569T/1148N, 96R/171P/429L/792Y/797T/799R, 171P/429L/708T/1422I, 171P/429L, 321Y/362P/732E/797T/7 99R、 171P/1100I, 708T/1148N/1186E, 429L/724I/732E/1148N, 171P/362E/795T/797Q/799M, 171P/429L/732E, 96R/171P/643N/797T/799R, 171P/792Y/ 797T/ 799M, 503S, 171P/732E, 1148N/1193L, 96R/171P/362E/429L/732R/795T/797Q, 726A, 59M, 734R, 362N, 334G, 732G, 63Q, 351S, 1377D, 795S, 358K, 999 R. 1250T, 306G, 349G, 1377G, 332F, 1377E, 257I, 646I, 346R, 435Q, 96V, 1377R, 1377S, 59G, 171M, 792H, 1248D, 306S, 706M, 171H, 1377A, 1377V, 734S, 11 48R, 57S, 59D, 344E, 362G or 58K, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集T1148N、P85Q/I708T/T1148N、K798T、L706G、L706A、L171Q、Q335E、V63R、K344A、S428F、E879Q、F59L、Q429S、K205R、I1264W、M797P、L1248S、I1264R、Y873T、T792Y、I708K、K344L、F57V、Q96L、A362W、V63G、Y873L、M1292Y、T1148Q、D346V、M797G、L706Y、L1248R、N433A、Y65A、F59W、Y873Q、V795C、E684K/K798R、F57L、Q353S、S332Q、I708A、G1259T、V63M、M356L、L1248G、L1248P、Q436G、F57A、F59S、T1245R、F59R、Q96W、M797Y、K1145R、Q436D、F716L、S56E、R773H、T734I、N358S、Q335P、F59Q、S729T、F716K、T665G、A362T、F57T、N359G、T61S、V1250A、A362V、N359E、F716W、S332W、I708V、V63H、M797C、T61Q、M356N、V1250S、K798C、N433G、V795N、Q96I、S56P、V63N、T792W、I1264L、V1250P、S332P、F59V、K726L、Q37H/Q96R/L171P/Q429L/I708T/K799R/T1148N、L171P、L171P/Q429L/K732R/T1148N、Q96R/L171P、L171P/E919G/G1151S、L171P/T792Y/M797Q/K799R/T1148N、L171P/P569T/T1148N、Q96R/L171P/Q429L/T792Y/M797T/K799R、L171P/Q429L/I708T/L1422I、L171P/Q429L、D321Y/A362P/K732E/M797T/K799R、L171P/L1100I、I708T/T1148N/A1186E、Q429L/L724I/K732E/T1148N、L171P/A362E/V795T/M797Q/K799M、L171P/Q429L/K732E、Q96R/L171P/S643N/M797T/K799R、L171P/T792Y/M797T/K799M、R503S、L171P/K732E、T1148N/F1193L、Q96R/L171P/A362E/Q429L/K732R/V795T/M797Q、K726A、F59M、T734R、A362N、H334G、K732G、V63Q、E351S、L1377D、V795S、N358K、Q999R、V1250T、E306G、P349G、L1377G、S332F、L1377E、V257I、L646I、D346R、P435Q、Q96V、L1377R、L1377S、F59G、L171M、T792H、L1248D、E306S、L706M、L171H、L1377A、L1377V、T734S、T1148R、F57S、F59D、K344E、A362G或P58K,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set T1148N, P85Q/I708T/T1148N, K798T, L706G, L706A, L171Q, Q335E, V63R, K344A, S428F, E879Q, F59L, Q429S, K205R, I1264W, M797P, L1248S, I1264R, Y873T, T792Y, I708K, K344L, F57V, Q96L, A362W, V63G, Y873L, M1292Y, T1148Q, D346V, M797G, L706Y, L1 248R, N433A, Y65A, F59W, Y873Q, V795C, E684K/K798R, F57L, Q353S, S332Q, I708A, G1259T, V63M, M356L, L1248G, L1248P, Q436G, F57A, F59S, T1245R, F59R, Q96W, M797Y, K1145R, Q436D , F716L, S56E, R773H, T734I, N358S, Q335P, F59Q, S729T, F716K, T665G, A362T, F57T, N359G, T61S, V1250A, A362V, N359E, F716W, S332W, I708V, V63H, M797C, T61Q, M356N, V1250S, K 798C, N433G, V795N, Q96I, S56P, V63N, T792W, I1264L, V1250P, S332P, F59V, K726L, Q37H/Q96R/L171P/Q429L/I708T/K799R/T1148N, L171P, L171P/Q429L/K732R/T1148N, Q96R/ L171P, L171P/E919G/G1151S, L171P/T792Y/M797Q/K799R/T1148N, L171P/P569T/T1148N, Q96R/L171P/Q429L/T792Y/M797T/K799R, L171P/Q429L/I708T/L1422I, L171P/Q429L, D3 21Y/A362P/K732E/M797T/K799R、 L171P/L1100I, I708T/T1148N/A1186E, Q429L/L724I/K732E/T1148N, L171P/A362E/V795T/M797Q/K799M, L171P/Q429L/K732E, Q96R/L171P/S643N/M 797T/K799R, L171P/T792Y/M797T/ K799M, R503S, L171P/K732E, T1148N/F1193L, Q96R/L171P/A362E/Q429L/K732R/V795T/M797Q, K726A, F59M, T734R, A362N, H334G, K732G, V63Q, E351S , L1377D, V795S, N358K, Q999R, V1250T, E306G, P349G, L1377G, S332F, L1377E, V257I, L646I, D346R, P435Q, Q96V, L1377R, L1377S, F59G, L171M, T792H, L1248D, E306S, L706M, L171H, L1377A, L1377V, T734S, T1148R, F57S, F59D, K344E, A362G or P58K, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1377/1380、388/1377、1043/1377、610/1377、1274/1377、1220/1377、1377/1442、1193/1377、621/1377、1054/1377、755/1377、1041/1377、748/1377、1049/1377、1221/1377、1051/1377、612/1377、1037/1377、616/1377、387/1377、489/1377、750/1377、1224/1377、618/1377、1050/1377、1053/1377、896/1377、897/1377、749/1377、260/1377、481/1377、613/1377、756/1377、63/1377、265/1377、752/1377、1218/1377、1377/1378、614/1377、1378/1377、1440/1377、1377/1440、1377/1439、1205/1377、1222/1377、1377/1389、1269/1377、390/1377、397/1218/1377、757/1377、1373/1377、346/1377、63/1248/1377、349/1377、306/355/1377/1422、1377/1422、306/346/708/1377、1148/1377、171/346/1248/1377、63/797/799/1248/1377/1422、171/799/1377、362/1377、1248/1377、171/306/346/999/1248/1377、171/1148/1377、734/799/1248/1377/1422、63/732/1377、63/171/306/346/732/1377、171/1377、171/1377/1422、63/362/732/799/1248/1377、999/1148/1377/1422、346/349/1377、306/349/1377、63/171/1148/1377/1151、306/1377、344/349/354/1250/1377、1250/1377、63/306/344/349/354/503/1248/1377、59/63/332/349/503/706/708/1377、63/306/344/349/354/706/1248/1377、59/63/1377、332/706/708/1248/1250/1377、503/1377、59/63/349/354/1377、59/349/708/1377、59/306/344/1248/1377、344/1248/1250/1377、708/1377、63/344/349/1377、59/1377、63/344/349/354/1377、706/1377、59/306/770/1377、63/347/354/1248/1377或354/503/1377,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at the following amino acid positions: 1377/1380, 388/1377, 1043/1377, 610/1377, 1274/1377 ,1220/1377,1377/1442,1193/1377,621/1377,1054/1377,755/1377,1041/1377,748/1377,1049/1377,1221/1377,1051/1377,612/1377,1037 /1377, 616/1377, 387/1377, 489/1377, 750/1377, 1224/1377, 618/1377, 1050/1377, 1053/1377, 896/1377, 897/1377, 749/1377, 260/1377 ,481/1377, 613/1377, 756/1377, 63/1377, 265/1377, 752/1377, 1218/1377, 1377/1378, 614/1377, 1378/1377, 1440/1377, 1377/1440, 1377 /1439、1205/1377、1222/1377、1377/1389、1269/1377、390/1377、397/1218/1377、757/1377、1373/1377、346/1377、63/1248/1377、349/1377 ,306/355/1377/1422, 1377/1422, 306/346/708/1377, 1148/1377, 171/346/1248/1377, 63/797/799/1248/1377/1422, 171/799/1377 ,362/1377, 1248/1377, 171/306/346/999/1248/1377, 171/1148/1377, 734/799/1248/1377/1422, 63/732/1377, 63/171/306/346 /732/1377、171/1377、171/1377/1422、63/362/732/799/1248/1377、999/1148/1377/1422、346/349/1377、306/349/1377、63/171 /1148/1377/1151、306/1377、344/349/354/1250/1377、1250/1377、63/306/344/349/354/503/1248/1377、59/63/332/349/503 /706/708/1377, 63/306/344/349/354/706/1248/1377, 59/63/1377, 332/706/708/1248/1250/1377, 503/1377, 59/63/349 /354/1377、59/349/708/1377、59/306/344/1248/1377、344/1248/1250/1377、708/1377、63/344/349/1377、59/1377、63/344 /349/354/1377, 706/1377, 59/306/770/1377, 63/347/354/1248/1377 or 354/503/1377, wherein the amino acid positions are relative to those corresponding to SEQ ID NO. : 2 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集1377D/1380W、388A/1377D、1043E/1377D、1043R/1377D、610R/1377D、1274N/1377D、1220T/1377D、1377D/1442T、1193L/1377D、621T/1377D、1054C/1377D、755Q/1377D、1041G/1377D、748S/1377D、1049G/1377D、1221V/1377D、1051E/1377D、612G/1377D、1037H/1377D、616E/1377D、1041H/1377D、387S/1377D、489R/1377D、621M/1377D、489Q/1377D、750G/1377D、1224P/1377D、618C/1377D、616G/1377D、612T/1377D、1050Q/1377D、1053A/1377D、616W/1377D、896V/1377D、489F/1377D、1050P/1377D、897G/1377D、749T/1377D、1274V/1377D、1220L/1377D、260E/1377D、481V/1377D、613S/1377D、387G/1377D、621R/1377D、756R/1377D、63R/1377D、265S/1377D、1221T/1377D、1377D/1380G、752G/1377D、748K/1377D、755L/1377D、1218A/1377D、748N/1377D、1377D/1378E、614I/1377D、749F/1377D、387V/1377D、750T/1377D、1193G/1377D、749V/1377D、1378A/1377D、750V/1377D、387T/1377D、387Q/1377D、750A/1377D、1037N/1377D、1377D/1440A、1051S/1377D、1221G/1377D、1377D/1378D、1377D/1440S、387R/1377D、1193A/1377D、387I/1377D、1218M/1377D、265W/1377D、1377D/1440E、1377D/1439L、1377D/1440T、612S/1377D、1049W/1377D、1221S/1377D、1220D/1377D、749G/1377D、749S/1377D、1218G/1377D、1205L/1377D、1222F/1377D、1193E/1377D、1050S/1377D、1377D/1389W、1377D/1439E、260T/1377D、1037P/1377D、1051K/1377D、1269F/1377D、265R/1377D、1051R/1377D、1218L/1377D、897R/1377D、388P/1377D、748G/1377D、756P/1377D、748F/1377D、390A/1377D、610L/1377D、755G/1377D、749R/1377D、748V/1377D、1377D/1380A、1377D/1440C、397N/F1218M/1377D、1037M/1377D、1218P/1377D、757K/1377D、1373S/1377D、1377D/1440G、1193I/1377D、1377D/1439T、750D/1377D、390G/1377D、756G/1377D、1220E/1377D、1377D/1378C、618G/1377D、346R/1377D、63Q/1248D/1377D、349G/1377D、306G/355C/1377D/1422I、1377D/1422I、306G/346R/708T/1377D、1148N/1377D、171P/346R/1248D/1377D、63Q/797T/799R/1248D/1377D/1422I、171P/799R/1377D、362P/1377D、1248D/1377D、63Q/1377D、171P/306G/346R/999R/1248D/1377D、171P/1148N/1377D、734S/799R/1248D/1377D/1422I、63Q/732E/1377D、63Q/171P/306G/346R/732G/1377D、171P/1377D、171P/1377D/1422I、63Q/362P/732G/799R/1248D/1377D、999R/1148N/1377D/1422I、346R/349G/1377D、306G/349G/1377D、63Q/171P/1148N/1377D/1151S、306G/1377D、344E/349G/354R/1250T/1377D、63G/1377D、1250T/1377D、63R/306G/344E/349G/354R/503S/1248R/1377D、59D/63S/332P/349G/503S/706M/708K/1377D、63S/306G/344A/349G/354R/706M/1248R/1377D、1248R/1377D、59D/63G/1377D、332P/706M/708K/1248R/1250T/1377D、503S/1377D、59D/63R/349G/354R/1377D、59D/349G/708K/1377D、59D/306G/344E/1248R/1377D、344E/1248R/1250T/1377D、708K/1377D、63R/344E/349G/1377D、59D/1377D、63S/344A/349G/354R/1377D、706M/1377D、59D/306G/770W/1377D、63G/347N/354R/1248R/1377D或354R/503S/1377D,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 1377D/1380W, 388A/1377D, 1043E/1377D, 1043R/1377D, 610R/1377D, 1274N/1377D, 1220T/1377D, 1377D/1442T, 1193L/1377D, 621T/1377D, 1054C/1377D, 755Q/1377D, 1041G/1377D, 748S/1377D, 1049G/1377D, 1221V/1377D, 1051E/1377D, 612G/1 377D、1037H/1377D、616E/ 1377D, 1041H/1377D, 387S/1377D, 489R/1377D, 621M/1377D, 489Q/1377D, 750G/1377D, 1224P/1377D, 618C/1377D, 616G/1377D, 612T/1377D, 1050Q /1377D、1053A/1377D、 616W/1377D, 896V/1377D, 489F/1377D, 1050P/1377D, 897G/1377D, 749T/1377D, 1274V/1377D, 1220L/1377D, 260E/1377D, 481V/1377D, 613S/1377D ,387G/1377D,621R/ 1377D, 756R/1377D, 63R/1377D, 265S/1377D, 1221T/1377D, 1377D/1380G, 752G/1377D, 748K/1377D, 755L/1377D, 1218A/1377D, 748N/1377D, 1377D /1378E、614I/1377D、 749F/1377D, 387V/1377D, 750T/1377D, 1193G/1377D, 749V/1377D, 1378A/1377D, 750V/1377D, 387T/1377D, 387Q/1377D, 750A/1377D, 1037N/1377D ,1377D/1440A,1051S/ 1377D, 1221G/1377D, 1377D/1378D, 1377D/1440S, 387R/1377D, 1193A/1377D, 387I/1377D, 1218M/1377D, 265W/1377D, 1377D/1440E, 1377D/1439L, 1377D/1440T, 612S/1377D, 1049W/1377D, 1221S/1377D, 1220D/1377D, 749G/1377D, 749S/1377D, 1218G/1377D, 1205L/1377D, 1222F/1377D, 1193E/1377D, 1050S/1377D, 1377D /1389W、1377D/1439E、260T/ 74 8F/1377D, 390A/1377D, 13 73S/1377D, 1377D/1440G, 1193I/1377D, 1377D/1439T, 750D/1377D, 390G/1377D, 756G/1377D, 1220E/1377D, 1377D/1378C, 618G/1377D, 346R/1377D, 63Q/1248D/1377D, 349G /1377D、306G/355C/ 1377D/1422I, 1377D/1422I, 306G/346R/708T/1377D, 1148N/1377D, 171P/346R/1248D/1377D, 63Q/797T/799R/1248D/1377D/1422I, 171P/799R/13 77D、362P/1377D、 1248D/1377D, 63Q/1377D, 171P/306G/346R/999R/1248D/1377D, 171P/1148N/1377D, 734S/799R/1248D/1377D/1422I, 63Q/732E/1377D, 63Q/171P/ 306G/346R/ 732G/1377D, 171P/1377D, 171P/1377D/1422I, 63Q/362P/732G/799R/1248D/1377D, 999R/1148N/1377D/1422I, 346R/349G/1377D, 306G/349G/1377 D. 63Q/171P/ 1148N/1377D/1151S, 306G/1377D, 344E/349G/354R/1250T/1377D, 63G/1377D, 1250T/1377D, 63R/306G/344E/349G/354R/503S/1248R/1377D, 59D/ 63S/332P/ 349G/503S/706M/708K/1377D, 63S/306G/344A/349G/354R/706M/1248R/1377D, 1248R/1377D, 59D/63G/1377D, 332P/706M/708K/1248R/1250T/137 7D、503S/ 1377D, 59D/63R/349G/354R/1377D, 59D/349G/708K/1377D, 59D/306G/344E/1248R/1377D, 344E/1248R/1250T/1377D, 708K/1377D, 63R/344E/349G /1377D、 59D/1377D, 63S/344A/349G/354R/1377D, 706M/1377D, 59D/306G/770W/1377D, 63G/347N/354R/1248R/1377D or 354R/503S/1377D, wherein the amino acid position is Relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:750/1377/1439、1051/1377/1439、260/1377/1439、756/1377/1439、1193/1377/1439、332/1377/1439、897/1377/1439、387/1377/1439、1037/1377/1439、306/749/1377/1439、1270/1377/1439、489/1377/1439、487/1377/1439、488/1377/1439、903/1377/1439、171/1248/ 1377/1439/1440、260/1148/1377/1378/1439、171/260/387/750/1248/1377/1439、171/260/1377/1439、171/260/387/750/1051/1148/1377/1439、171/1377/1439、750/1051/1148/1377/1439、171/260/756/1377/1439、171/1248/1377/1439、171/1148/1377/1439、59/1377/1439、1377/1439/1440、332/750/1248/1377/1439、756/1248/1377/1439、1248/1377/1439、171/387/1248/1377/1440/1439、750/1377/1439/1440、59/171/750/1377/1439、171/1193/1248/1377/1439、750/1148/1193/1377/1439/1440、1148/1377/1439、171/387/1051/1377/1439、748/1377/1439、306/1377/1439、306/387/390/749/1220/1377/1439、390/1377/1439、306/390/1037/1377/1439、306/612/749/1377/1439、387/390/749/1377/1439、63/390/503/749/1377/1439、1220/1377/1439、63/306/1377/1439、749/1377/1439、306/390/749/1037/1377/1439、306/749/1220/1377/1439、306/387/390/612/749/1037/1377/1439或328/1377/1439,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 750/1377/1439, 1051/1377/1439, 260/1377/1439, 756 /1377/1439、1193/1377/1439、332/1377/1439、897/1377/1439、387/1377/1439、1037/1377/1439、306/749/1377/1439、1270/1377/1439、489 /1377/1439, 487/1377/1439, 488/1377/1439, 903/1377/1439, 171/1248/ 1377/1439/1440, 260/1148/1377/1378/1439, 171/260/387/750 /1248/1377/1439, 171/260/1377/1439, 171/260/387/750/1051/1148/1377/1439, 171/1377/1439, 750/1051/1148/1377/1439, 171/260 /756/1377/1439、171/1248/1377/1439、171/1148/1377/1439、59/1377/1439、1377/1439/1440、332/750/1248/1377/1439、756/1248/1377 /1439、1248/1377/1439、171/387/1248/1377/1440/1439、750/1377/1439/1440、59/171/750/1377/1439、171/1193/1248/1377/1439、750 /1148/1193/1377/1439/1440、1148/1377/1439、171/387/1051/1377/1439、748/1377/1439、306/1377/1439、306/387/390/749/1220/1377 /1439、390/1377/1439、306/390/1037/1377/1439、306/612/749/1377/1439、387/390/749/1377/1439、63/390/503/749/1377/1439 ,1220/1377/1439, 63/306/1377/1439, 749/1377/1439, 306/390/749/1037/1377/1439, 306/749/1220/1377/1439, 306/387/390/612 /749/1037/1377/1439 or 328/1377/1439, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集750D/1377D/1439E、1051K/1377D/1439E、1051S/1377D/1439E、260T/1377D/1439E、756P/1377D/1439E、1193A/1377D/1439E、332P/1377D/1439E、897R/1377D/1439E、387Q/1377D/1439E、1037N/1377D/1439E、387R/1377D/1439E、306G/749F/1377D/1439E、1270V/1377D/1439E、489E/1377D/1439E、487N/1377D/1439E、488G/1377D/1439E、903E/1377D/1439E、171P/1248D/ 1377D/1439E/1440T、260T/1148N/1377D/1378D/1439E、171P/260T/387I/750D/1248D/1377D/1439E、171P/260T/1377D/1439E、171P/260T/387I/750D/1051S/1148N/1377D/1439E、171P/1377D/1439E、750D/1051S/1148N/1377D/1439E、171P/260T/756P/1377D/1439E、171P/1248D/1377D/1439E、171P/1148N/1377D/1439E、387I/1377D/1439E、59D/1377D/1439E、1377D/1439E/1440S、332P/750D/1248D/1377D/1439E、756P/1248D/1377D/1439E、1248D/1377D/1439E、171P/387I/1248D/1377D/1440S/1439E、750D/1377D/1439E/1440S、59D/171P/750D/1377D/1439E、171P/1193A/1248D/1377D/1439E、750D/1148N/1193A/1377D/1439E/1440S、1148N/1377D/1439E、171P/387I/1051K/1377D/1439E、748G/1377D/1439E、306G/1377D/1439E、306G/387R/390A/749F/1220D/1377D/1439E、390A/1377D/1439E、306G/390A/1037N/1377D/1439E、306G/612S/749F/1377D/1439E、387V/390A/749F/1377D/1439E、63S/390A/503S/749F/1377D/1439E、387R/390A/749R/1377D/1439E、1220D/1377D/1439E、63S/306G/1377D/1439E、749F/1377D/1439E、306G/390A/749F/1037N/1377D/1439E、387V/1377D/1439E、306G/749F/1220D/1377D/1439E、306G/387V/390A/612S/749F/1037N/1377D/1439E或328S/1377D/1439E,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 750D/1377D/1439E, 1051K/1377D/1439E, 1051S/1377D/1439E, 260T/1377D/1439E, 756P/1377D/ 1439E, 1193A/1377D/1439E, 332P/1377D/1439E, 897R/1377D/1439E, 387Q/1377D/1439E, 1037N/1377D/1439E, 387R/1377D/1439E, 306G/749F/137 7D/1439E, 1270V/1377D/ 1439E, 489E/1377D/1439E, 487N/1377D/1439E, 488G/1377D/1439E, 903E/1377D/1439E, 171P/1248D/ 1377D/1439E/1440T, 260T/1148N/1377D/13 78D/1439E、171P/260T/ 387I/750D/1248D/1377D/1439E, 171P/260T/1377D/1439E, 171P/260T/387I/750D/1051S/1148N/1377D/1439E, 171P/1377D/1439E, 750D/1051S/1 148N/1377D/1439E、 171P/260T/756P/1377D/1439E, 171P/1248D/1377D/1439E, 171P/1148N/1377D/1439E, 387I/1377D/1439E, 59D/1377D/1439E, 1377D/1439E/1440S ,332P/750D/1248D/ 1377D/1439E, 756P/1248D/1377D/1439E, 1248D/1377D/1439E, 171P/387I/1248D/1377D/1440S/1439E, 750D/1377D/1439E/1440S, 59D/171P/750D /1377D/1439E、171P/ 3 06G/1377D/1439E, 306G/ 387R/390A/749F/1220D/1377D/1439E, 390A/1377D/1439E, 306G/390A/1037N/1377D/1439E, 306G/612S/749F/1377D/1439E, 387V/390A/749F/137 7D/1439E, 63S/ 390A/503S/749F/1377D/1439E, 387R/390A/749R/1377D/1439E, 1220D/1377D/1439E, 63S/306G/1377D/1439E, 749F/1377D/1439E, 306G/390A/749 F/1037N/1377D/ 1439E, 387V/1377D/1439E, 306G/749F/1220D/1377D/1439E, 306G/387V/390A/612S/749F/1037N/1377D/1439E or 328S/1377D/1439E, wherein the amino acid positions are relative to This reference sequence corresponds to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:171/260/387/750/1051/1248/1377/1439、171/260/387/750/1221/1248/1377/1439、171/260/387/750/1218/1248/1377/1439、171/260/387/750/1248/1377/1439、171/260/387/749/750/1218/1248/1377/1439、171/260/332/387/750/1248/1377/1439、171/260/387/750/897/1248/1377/1439、171/260/387/696/750/1248/1377/1439、171/260/387/750/816/1248/1377/1439、171/260/387/750/824/1248/1377/1439、171/260/387/750/826/1248/1377/1439、171/260/387/393/750/1248/1377/1439、171/260/387/750/825/1248/1377/1439、171/260/387/698/750/1248/1377/1439、171/260/332/387/390/750/1148/1248/1377/1439、171/260/328/387/749/750/1248/1377/1439、171/260/387/749/750/1248/1377/1439、171/260/306/328/332/387/390/750/1051/1193/1218/1248/1377/1439、63/171/260/306/332/387/750/1051/1148/1248/1377/1439、63/171/260/306/332/387/750/1051/1248/1377/1439、171/260/387/390/750/1051/1248/1377/1439、171/186/260/306/328/332/387/390/749/750/1051/1148/1193/1248/1377/1439、171/260/387/390/750/756/1051/1248/1377/1439、171/260/306/387/390//750/1051/1248/1377/1439、171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/387/390/750/1148/1248/1377/1439、171/260/306/328/332/387/390/749/750/1051/1148/1193/1248/1377/1439、171/260/332/387/390/749/750/1148/1248/1377/1439、171/260/387/390/749/750/1248/1377/1439、171/260/306/387/749/750/1051/1148/1248/1377/1439、171/260/306/387/750/945/1051/1193/1221/1248/1377/1439、171/260/306/387/390/749/750/1051/1248/1377/1439、63/171/260/306/332/387/390/750/1248/1377/1439、171/260/306/387/390/749/750/1148/1193/1221/1248/1377/1439、171/260/306/332/387//390/749/750/1218/1248/1377/1439、63/171/260/306/332/387/390/750/1051/1148/1193/1218/1248/1377/1439、171/260/387/750/924/1248/1377/1439、171/260/387/750/755/1248/1377/1439、171/260/387/750/752/1248/1377/1439、171/260/387/750/751/1248/1377/1439、171/260/387/750/923/1248/1377/1439、171/260/387/750/797/1248/1377/1439、171/260/387/750/754/1248/1377/1439、171/260/387/750/793/1248/1377/1439、171/260/387/750/753/1248/1377/1439、171/260/387/750/922/1248/1377/1439、171/260/387/750/896/1248/1377/1439、171/260/387/750/938/1248/1377/1439、171/260/387/750/775/1248/1377/1439、171/260/387/750/732/1248/1377/1439、171/260/387/750/810/1248/1377/1439、171/260/387/750/747/1248/1377/1439、171/260/387/393/407/750/1248/1377/1439、171/260/387/750/819/1248/1377/1439、171/260/387/750/787/1248/1377/1439、171/260/387/750/802/1248/1377/1439、171/260/387/732/750/1248/1377/1439、171/260/387/750/811/1248/1377/1439、171/260/387/392/750/1248/1377/1439或171/260/387/397/750/1248/1377/1439,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 171/260/387/750/1051/1248/1377/1439, 171/260 /387/750/1221/1248/1377/1439, 171/260/387/750/1218/1248/1377/1439, 171/260/387/750/1248/1377/1439, 171/260/387/749 /750/1218/1248/1377/1439, 171/260/332/387/750/1248/1377/1439, 171/260/387/750/897/1248/1377/1439, 171/260/387/696 /750/1248/1377/1439, 171/260/387/750/816/1248/1377/1439, 171/260/387/750/824/1248/1377/1439, 171/260/387/750/826 /1248/1377/1439、171/260/387/393/750/1248/1377/1439、171/260/387/750/825/1248/1377/1439、171/260/387/698/750/1248 /1377/1439、171/260/332/387/390/750/1148/1248/1377/1439、171/260/328/387/749/750/1248/1377/1439、171/260/387/749 /750/1248/1377/1439, 171/260/306/328/332/387/390/750/1051/1193/1218/1248/1377/1439, 63/171/260/306/332/387/750 /1051/1148/1248/1377/1439, 63/171/260/306/332/387/750/1051/1248/1377/1439, 171/260/387/390/750/1051/1248/1377/1439 ,171/186/260/306/328/332/387/390/749/750/1051/1148/1193/1248/1377/1439, 171/260/387/390/750/756/1051/1248/1377 /1439、171/260/306/387/390//750/1051/1248/1377/1439、171/260/306/332/387/390/749/750/1248/1377/1439、171/260/ 306/387/390/750/1148/1248/1377/1439, 171/260/306/328/332/387/390/749/750/1051/1148/1193/1248/1377/1439, 171/260/ 332/387/390/749/750/1148/1248/1377/1439, 171/260/387/390/749/750/1248/1377/1439, 171/260/306/387/749/750/1051/ 1148/1248/1377/1439, 171/260/306/387/750/945/1051/1193/1221/1248/1377/1439, 171/260/306/387/390/749/750/1051/1248/ 1377/1439, 63/171/260/306/332/387/390/750/1248/1377/1439, 171/260/306/387/390/749/750/1148/1193/1221/1248/1377/ 1439、171/260/306/332/387//390/749/750/1218/1248/1377/1439、63/171/260/306/332/387/390/750/1051/1148/1193/1218 /1248/1377/1439、171/260/387/750/924/1248/1377/1439、171/260/387/750/755/1248/1377/1439、171/260/387/750/752/1248 /1377/1439、171/260/387/750/751/1248/1377/1439、171/260/387/750/923/1248/1377/1439、171/260/387/750/797/1248/1377 /1439、171/260/387/750/754/1248/1377/1439、171/260/387/750/793/1248/1377/1439、171/260/387/750/753/1248/1377/1439 ,171/260/387/750/922/1248/1377/1439, 171/260/387/750/896/1248/1377/1439, 171/260/387/750/938/1248/1377/1439, 171 /260/387/750/775/1248/1377/1439, 171/260/387/750/732/1248/1377/1439, 171/260/387/750/810/1248/1377/1439, 171/260 /387/750/747/1248/1377/1439, 171/260/387/393/407/750/1248/1377/1439, 171/260/387/750/819/1248/1377/1439, 171/260 /387/750/787/1248/1377/1439, 171/260/387/750/802/1248/1377/1439, 171/260/387/732/750/1248/1377/1439, 171/260/387 /750/811/1248/1377/1439, 171/260/387/392/750/1248/1377/1439 or 171/260/387/397/750/1248/1377/1439, where the amino acid positions Relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集171P/260T/387I/750D/1051K/1248D/1377D/1439E、171P/260T/387I/750D/1221G/1248D/1377D/1439E、171P/260T/387I/750D/1218G/1248D/1377D/1439E、171P/260T/387R/750D/1248D/1377D/1439E、171P/260T/387I/750D/1051R/1248D/1377D/1439E、171P/260T/387I/749F/750D/1218G/1248D/1377D/1439E、171P/260T/387T/750D/1248D/1377D/1439E、171P/260T/332P/387I/750D/1248D/1377D/1439E、171P/260T/387I/750D/897K/1248D/1377D/1439E、171P/260T/387I/696E/750D/1248D/1377D/1439E、171P/260T/387I/750D/816W/1248D/1377D/1439E、171P/260T/387I/750D/824W/1248D/1377D/1439E、171P/260T/387I/750D/826G/1248D/1377D/1439E、171P/260T/387I/393W/750D/1248D/1377D/1439E、171P/260T/387I/750D/825L/1248D/1377D/1439E、171P/260T/387I/750D/897R/1248D/1377D/1439E、171P/260T/387I/750D/816V/1248D/1377D/1439E、171P/260T/387I/698W/750D/1248D/1377D/1439E、171P/260T/387I/393Q/750D/1248D/1377D/1439E、171P/260T/332P/387R/390A/750D/1148N/1248D/1377D/1439E、171P/260T/328S/387R/749F/750D/1248D/1377D/1439E、171P/260T/387I/749F/750D/1248D/1377D/1439E、171P/260T/306G/328S/332P/387I/390A/750D/1051R/1193A/1218G/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/750D/1051R/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387T/750D/1051K/1248D/1377D/1439E、171P/260T/387T/390A/750D/1051R/1248D/1377D/1439E、171P/186A/260T/306G/328S/332P/387I/390A/749F/750D/1051K/1148N/1193A/1248D/1377D/1439E、171P/260T/387T/390A/750D/756P/1051R/1248D/1377D/1439E、171P/260T/306G/387I/390A//750D/1051R/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/387R/390A/750D/1148N/1248D/1377D/1439E、171P/260T/306G/328S/332P/387T/390A/749F/750D/1051R/1148N/1193A/1248D/1377D/1439E、171P/260T/332P/387R/390A/749F/750D/1148N/1248D/1377D/1439E、171P/260T/387R/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/387T/749F/750D/1051K/1148N/1248D/1377D/1439E、171P/260T/387R/749F/750D/1248D/1377D/1439E、171P/260T/306G/387I/750D/945K/1051R/1193A/1221G/1248D/1377D/1439E、171P/260T/306G/387I/390A/749F/750D/1051K/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/750D/1248D/1377D/1439E、171P/260T/306G/387T/390A/749F/750D/1148N/1193A/1221G/1248D/1377D/1439E、171P/260T/306G/332P/387R/390A/749F/750D/1218M/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/750D/1051R/1148N/1193A/1218G/1248D/1377D/1439E、171P/260T/387I/750D/924I/1248D/1377D/1439E、171P/260T/387I/750D/755S/1248D/1377D/1439E、171P/260T/387I/750D/752F/1248D/1377D/1439E、171P/260T/387I/750D/S751Y/1248D/1377D/1439E、171P/260T/387I/750D/923M/1248D/1377D/1439E、171P/260T/387I/750D/797Y/1248D/1377D/1439E、171P/260T/387I/750D/754W/1248D/1377D/1439E、171P/260T/387I/750D/793G/1248D/1377D/1439E、171P/260T/387I/750D/753D/1248D/1377D/1439E、171P/260T/387I/750D/922W/1248D/1377D/1439E、171P/260T/387I/750D/896L/1248D/1377D/1439E、171P/260T/387I/750D/938R/1248D/1377D/1439E、171P/260T/387I/750D/775G/1248D/1377D/1439E、171P/260T/387I/750D/751E/1248D/1377D/1439E、171P/260T/387I/750D/732W/1248D/1377D/1439E、171P/260T/387I/750D/752G/1248D/1377D/1439E、171P/260T/387I/750D/810V/1248D/1377D/1439E、171P/260T/387I/750D/938V/1248D/1377D/1439E、171P/260T/387I/750D/747D/1248D/1377D/1439E、171P/260T/387I/750D/755G/1248D/1377D/1439E、171P/260T/387I/393G/407V/750D/1248D/1377D/1439E、171P/260T/387I/750D/797W/1248D/1377D/1439E、171P/260T/387I/750D/819V/1248D/1377D/1439E、171P/260T/387I/393G/750D/1248D/1377D/1439E、171P/260T/387I/750D/787W/1248D/1377D/1439E、171P/260T/387I/393R/750D/1248D/1377D/1439E、171P/260T/387I/750D/802V/1248D/1377D/1439E、171P/260T/387I/750D/775E/1248D/1377D/1439E、171P/260T/387I/750D/924P/1248D/1377D/1439E、171P/260T/387I/732G/750D/1248D/1377D/1439E、171P/260T/387I/750D/811F/1248D/1377D/1439E、171P/260T/387I/750D/802S/1248D/1377D/1439E、171P/260T/387I/750D/752L/1248D/1377D/1439E、171P/260T/387I/392A/750D/1248D/1377D/1439E或171P/260T/387I/397G/750D/1248D/1377D/1439E,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 171P/260T/387I/750D/1051K/1248D/1377D/1439E, 171P/260T/387I/750D/1221G/1248D/ 1377D/1439E, 171P/260T/387I/750D/1218G/1248D/1377D/1439E, 171P/260T/387R/750D/1248D/1377D/1439E, 171P/260T/387I/750D/1051R/124 8D/1377D/1439E、 171P/260T/387I/749F/750D/1218G/1248D/1377D/1439E, 171P/260T/387T/750D/1248D/1377D/1439E, 171P/260T/332P/387I/750D/1248D/1377D /1439E、171P/ 260T/387I/750D/897K/1248D/1377D/1439E, 171P/260T/387I/696E/750D/1248D/1377D/1439E, 171P/260T/387I/750D/816W/1248D/1377D/1439E ,171P/260T/ 387I/750D/824W/1248D/1377D/1439E, 171P/260T/387I/750D/826G/1248D/1377D/1439E, 171P/260T/387I/393W/750D/1248D/1377D/1439E, 171P /260T/387I/ 171P/260T /387I/698W/ 171 P/260T/328S/ 387R/749F/750D/1248D/1377D/1439E, 171P/260T/387I/749F/750D/1248D/1377D/1439E, 171P/260T/306G/328S/332P/387I/390A/750D/1051R/1 193A/1218G/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/750D/1051R/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387T/750D/1051K/1 248D/1377D/ 1439E、171P/260T/387T/390A/750D/1051R/1248D/1377D/1439E、171P/186A/260T/306G/328S/332P/387I/390A/749F/750D/1051K/1148N/1193A/ 1248D/1377D/ 1439E, 171P/260T/387T/390A/750D/756P/1051R/1248D/1377D/1439E, 171P/260T/306G/387I/390A//750D/1051R/1248D/1377D/1439E, 171P/260 T/306G/332P /387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/387R/390A/750D/1148N/1248D/1377D/1439E, 171P/260T/306G/328S/332P/387T/3 90A/749F /750D/1051R/1148N/1193A/1248D/1377D/1439E, 171P/260T/332P/387R/390A/749F/750D/1148N/1248D/1377D/1439E, 171P/260T/387R/390A/749 F/750D/1248D /1377D/1439E、171P/260T/306G/387T/749F/750D/1051K/1148N/1248D/1377D/1439E、171P/260T/387R/749F/750D/1248D/1377D/1439E、171P/260 T/306G/387I /750D/945K/1051R/1193A/1221G/1248D/1377D/1439E, 171P/260T/306G/387I/390A/749F/750D/1051K/1248D/1377D/1439E, 63Q/171P/260T/306G /332P/387I /390A/750D/1248D/1377D/1439E, 171P/260T/306G/387T/390A/749F/750D/1148N/1193A/1221G/1248D/1377D/1439E, 171P/260T/306G/332P/387R /390A/749F /750D/1218M/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/750D/1051R/1148N/1193A/1218G/1248D/1377D/1439E, 171P/260T/387 I/750D/924I /1248D/1377D/1439E、171P/260T/387I/750D/755S/1248D/1377D/1439E、171P/260T/387I/750D/752F/1248D/1377D/1439E、171P/260T/387I/750D /S751Y/1248D /1377D/1439E、171P/260T/387I/750D/923M/1248D/1377D/1439E、171P/260T/387I/750D/797Y/1248D/1377D/1439E、171P/260T/387I/750D/754W/ 1248D/1377D /1439E、171P/260T/387I/750D/793G/1248D/1377D/1439E、171P/260T/387I/750D/753D/1248D/1377D/1439E、171P/260T/387I/750D/922W/1248D/ 1377D/1439E , 171P/260T/387I/750D/896L/1248D/1377D/1439E, 171P/260T/387I/750D/938R/1248D/1377D/1439E, 171P/260T/387I/750D/775G/1248D/1377D /1439E、171P /260T/387I/750D/751E/1248D/1377D/1439E、171P/260T/387I/750D/732W/1248D/1377D/1439E、171P/260T/387I/750D/752G/1248D/1377D/1439E ,171P/260T /387I/750D/810V/1248D/1377D/1439E、171P/260T/387I/750D/938V/1248D/1377D/1439E、171P/260T/387I/750D/747D/1248D/1377D/1439E、171P /260T/387I /750D/755G/1248D/1377D/1439E、171P/260T/387I/393G/407V/750D/1248D/1377D/1439E、171P/260T/387I/750D/797W/1248D/1377D/1439E、171P /260T/387I /750D/819V/1248D/1377D/1439E、171P/260T/387I/393G/750D/1248D/1377D/1439E、171P/260T/387I/750D/787W/1248D/1377D/1439E、171P/260T /387I/393R /750D/1248D/1377D/1439E、171P/260T/387I/750D/802V/1248D/1377D/1439E、171P/260T/387I/750D/775E/1248D/1377D/1439E、171P/260T/387I /750D/924P /1248D/1377D/1439E、171P/260T/387I/732G/750D/1248D/1377D/1439E、171P/260T/387I/750D/811F/1248D/1377D/1439E、171P/260T/387I/750D /802S/1248D /1377D/1439E, 171P/260T/387I/750D/752L/1248D/1377D/1439E, 171P/260T/387I/392A/750D/1248D/1377D/1439E or 171P/260T/387I/397G/750D/ 1248D/1377D /1439E, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:171/260/306/332/387/390/620/749/750/1248/1377/1439、171/260/306/332/387/390/491/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1229/1248/1377/1439、171/260/306/332/387/390/615/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1248/1283/1377/1439、171/260/306/332/387/390/749/750/822/1248/1377/1439、171/260/306/328/332/387/390/749/750/1248/1377/1439、171/212/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/818/1248/1377/1439、171/260/306/332/387/390/555/684/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/828/1248/1377/1439、171/260/306/332/387/390/550/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/830/1248/1377/1439、171/260/306/332/387/390/749/750/839/1248/1377/1439、13/171/260/306/332/387/390/749/750/1248/1377/1439、14/171/260/306/332/387/390/749/750/1248/1377/1439、17/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/836/1248/1377/1439、171/260/306/332/387/390/749/750/1210/1248/1377/1439、171/260/306/332/387/390/749/750/1248/1281/1377/1439、64/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/682/749/750/1248/1377/1439、171/260/306/318/332/387/390/749/750/1248/1377/1439、20/171/260/306/332/387/390/749/750/1248/1377/1439、21/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/325/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/533/749/750/1248/1377/1439、19/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/817/1248/1377/1439、171/260/306/332/387/390/749/750/831/1248/1377/1439、171/225/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1156/1248/1377/1439、171/260/306/332/387/390/393/747/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/753/1248/1377/1439、171/260/306/332/387/390/393/732/749/750/751/1248/1377/1439、63/171/260/306/332/387/390/749/750/797/1248/1377/1439、171/260/306/332/387/390/622/749/750/1248/1377/1439、171/260/306/332/387/390/617/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/907/1248/1377/1439、171/260/306/332/387/390/749/750/1040/1248/1377/1439、171/260/306/332/387/390/611/749/750/1248/1377/1439、171/260/306/332/387/390/488/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1192/1248/1377/1439、171/260/306/332/387/390/749/750/1194/1248/1377/1439、171/260/306/332/387/390/619/749/750/1248/1377/1439、16/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/802/1248/1377/1439、171/211/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/836/750/1248/1377/1439、171/260/306/332/387/390/555/749/750/1248/1377/1439、171/260/306/332/387/390/536/749/750/1248/1377/1439、171/260/306/332/387/390/527/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/841/1248/1377/1439、171/260/306/320/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/837/1248/1377/1439、171/260/306/332/387/390/558/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/914/1248/1377/1439、171/260/306/312/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/681/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/838/1248/1377/1439、15/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1248/1377/1427/1439、18/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/683/749/750/1248/1377/1439、24/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/534/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/840/1248/1377/1439、171/260/306/332/387/390/749/750/1160/1248/1377/1439、171/260/306/332/387/390/551/749/750/1248/1377/1439、171/260/306/332/387/390/393/749/750/1248/1377/1439、171/260/306/332/387/390/393/747/749/750/752/811/819/923/1148 1248/1377/1439、171/260/306/332/387/390/393/749/750/751/775/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、171/260/306/332/387/390/393/732/749/750/1148/1248/1377/1439、171/260/306/332/387/390/749/750/775/1148/1248/1377/1439、171/260/306/332/387/390/393/749/750/752/753/775/793/797/1248/1377/1439、171/260/306/332/387/390/393/749/750/923/1248/1377/1439、171/260/306/332/387/390/393/749/750/923/1148/1248/1377/1439、171/260/306/332/387/390/393/747/749/750/751/1248/1377/1439、171/260/306/332/387/390/393/747/749/750/753/775/1148/1248/1377/1439、171/260/306/332/387/390/749/750/752/923/1051/1248/1377/1439、63/171/260/306/332/387/390/749/750/775/1248/1377/1439、63/171/260/306/332/387/390/393/749/750/752/775/793/1051/1053 1248/1377/1439、171/260/306/332/387/390/749/750/752/753/775/793/819/1248/1377/1439、63/171/260/306/332/387/390/749/750/1051/1248/1377/1439、63/171/260/306/332/387/390/747/749/750/752/753/775/811/819/923/1051 1248/1377/1439、171/260/306/332/387/390/393/749/750/752/787/1248/1377/1439、171/260/306/332/387/390/749/750/751/1248/1377/1439、63/171/260/306/332/387/390/749/750/1148/1248/1377/1439、63/171/260/306/332/387/390/747/749/750/752/753/819/923/1148 1248/1377/1439、171/260/306/332/387/390/749/750/1148/1248/1377/1439、171/260/306/332/387/390/747/749/750/752/753/793/811/1248/1377/1439、63/171/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/797/1148/1248/1377/1439、171/260/306/332/387/390/749/750/751/752/753/1051/1248/1377/1439、63/171/260/306/332/387/390/732/749/750/1051/1248/1377/1439、171/260/306/332/387/390/749/750/752/797/815/923/1051/1148 1248/1377/1439或171/260/306/332/387/390/747/749/750/753/1248/1377/1439,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at the following amino acid positions: 171/260/306/332/387/390/620/749/750/1248 /1377/1439、171/260/306/332/387/390/491/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1229/1248/1377 /1439、171/260/306/332/387/390/615/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1248/1283/1377/1439 ,171/260/306/332/387/390/749/750/822/1248/1377/1439, 171/260/306/328/332/387/390/749/750/1248/1377/1439, 171 /212/260/306/332/387/390/749/750/1248/1377/1439, 171/260/306/332/387/390/749/750/818/1248/1377/1439, 171/260 /306/332/387/390/555/684/749/750/1248/1377/1439, 171/260/306/332/387/390/749/750/828/1248/1377/1439, 171/260 /306/332/387/390/550/749/750/1248/1377/1439, 171/260/306/332/387/390/749/750/830/1248/1377/1439, 171/260/306 /332/387/390/749/750/839/1248/1377/1439, 13/171/260/306/332/387/390/749/750/1248/1377/1439, 14/171/260/306 /332/387/390/749/750/1248/1377/1439, 17/171/260/306/332/387/390/749/750/1248/1377/1439, 171/260/306/332/387 /390/749/750/836/1248/1377/1439, 171/260/306/332/387/390/749/750/1210/1248/1377/1439, 171/260/306/332/387/390 /749/750/1248/1281/1377/1439, 64/171/260/306/332/387/390/749/750/1248/1377/1439, 171/260/306/332/387/390/682 /749/750/1248/1377/1439, 171/260/306/318/332/387/390/749/750/1248/1377/1439, 20/171/260/306/332/387/390/749 /750/1248/1377/1439, 21/171/260/306/332/387/390/749/750/1248/1377/1439, 171/260/306/325/332/387/390/749/750 /1248/1377/1439、171/260/306/332/387/390/533/749/750/1248/1377/1439、19/171/260/306/332/387/390/749/750/1248 /1377/1439、171/260/306/332/387/390/749/750/817/1248/1377/1439、171/260/306/332/387/390/749/750/831/1248/1377 /1439、171/225/260/306/332/387/390/749/750/1248/1377/1439、171/260/306/332/387/390/749/750/1156/1248/1377/1439 ,171/260/306/332/387/390/393/747/749/750/1248/1377/1439, 171/260/306/332/387/390/749/750/753/1248/1377/1439 ,171/260/306/332/387/390/393/732/749/750/751/1248/1377/1439, 63/171/260/306/332/387/390/749/750/797/1248 /1377/1439、171/260/306/332/387/390/622/749/750/1248/1377/1439、171/260/306/332/387/390/617/749/750/1248/1377 /1439、171/260/306/332/387/390/749/750/907/1248/1377/1439、171/260/306/332/387/390/749/750/1040/1248/1377/1439 ,171/260/306/332/387/390/611/749/750/1248/1377/1439, 171/260/306/332/387/390/488/749/750/1248/1377/1439, 171 /260/306/332/387/390/749/750/1192/1248/1377/1439, 171/260/306/332/387/390/749/750/1194/1248/1377/1439, 171/260 /306/332/387/390/619/749/750/1248/1377/1439, 16/171/260/306/332/387/390/749/750/1248/1377/1439, 171/260/306 /332/387/390/749/750/802/1248/1377/1439, 171/211/260/306/332/387/390/749/750/1248/1377/1439, 171/260/306/332 /387/390/749/836/750/1248/1377/1439, 171/260/306/332/387/390/555/749/750/1248/1377/1439, 171/260/306/332/387 /390/536/749/750/1248/1377/1439, 171/260/306/332/387/390/527/749/750/1248/1377/1439, 171/260/306/332/387/390 /749/750/841/1248/1377/1439, 171/260/306/320/332/387/390/749/750/1248/1377/1439, 171/260/306/332/387/390/749 /750/837/1248/1377/1439, 171/260/306/332/387/390/558/749/750/1248/1377/1439, 171/260/306/332/387/390/749/750 /914/1248/1377/1439, 171/260/306/312/332/387/390/749/750/1248/1377/1439, 171/260/306/332/387/390/681/749/750 /1248/1377/1439, 171/260/306/332/387/390/749/750/838/1248/1377/1439, 15/171/260/306/332/387/390/749/750/1248 /1377/1439、171/260/306/332/387/390/749/750/1248/1377/1427/1439、18/171/260/306/332/387/390/749/750/1248/1377 /1439、171/260/306/332/387/390/683/749/750/1248/1377/1439、24/171/260/306/332/387/390/749/750/1248/1377/1439 ,171/260/306/332/387/390/534/749/750/1248/1377/1439, 171/260/306/332/387/390/749/750/840/1248/1377/1439, 171 /260/306/332/387/390/749/750/1160/1248/1377/1439, 171/260/306/332/387/390/551/749/750/1248/1377/1439, 171/260 /306/332/387/390/393/749/750/1248/1377/1439, 171/260/306/332/387/390/393/747/749/750/752/811/819/923/1148 1248/1377/1439, 171/260/306/332/387/390/393/749/750/751/775/1248/1377/1439, 63/171/260/306/332/387/390/393/ 732/749/750/775/1148/1248/1377/1439, 171/260/306/332/387/390/393/732/749/750/1148/1248/1377/1439, 171/260/306/ 332/387/390/749/750/775/1148/1248/1377/1439, 171/260/306/332/387/390/393/749/750/752/753/775/793/797/1248/ 1377/1439, 171/260/306/332/387/390/393/749/750/923/1248/1377/1439, 171/260/306/332/387/390/393/749/750/923/ 1148/1248/1377/1439, 171/260/306/332/387/390/393/747/749/750/751/1248/1377/1439, 171/260/306/332/387/390/393/ 747/749/750/753/775/1148/1248/1377/1439, 171/260/306/332/387/390/749/750/752/923/1051/1248/1377/1439, 63/171/ 260/306/332/387/390/749/750/775/1248/1377/1439, 63/171/260/306/332/387/390/393/749/750/752/775/793/1051/ 1053 1248/1377/1439, 171/260/306/332/387/390/749/750/752/753/775/793/819/1248/1377/1439, 63/171/260/306/332/387 /390/749/750/1051/1248/1377/1439, 63/171/260/306/332/387/390/747/749/750/752/753/775/811/819/923/1051 1248/ 1377/1439, 171/260/306/332/387/390/393/749/750/752/787/1248/1377/1439, 171/260/306/332/387/390/749/750/751/ 1248/1377/1439, 63/171/260/306/332/387/390/749/750/1148/1248/1377/1439, 63/171/260/306/332/387/390/747/749/ 750/752/753/819/923/1148 1248/1377/1439, 171/260/306/332/387/390/749/750/1148/1248/1377/1439, 171/260/306/332/387 /390/747/749/750/752/753/793/811/1248/1377/1439, 63/171/260/306/332/387/390/749/750/1248/1377/1439, 171/260 /306/332/387/390/749/750/797/1148/1248/1377/1439, 171/260/306/332/387/390/749/750/751/752/753/1051/1248/1377 /1439、63/171/260/306/332/387/390/732/749/750/1051/1248/1377/1439、171/260/306/332/387/390/749/750/752/797 /815/923/1051/1148 1248/1377/1439 or 171/260/306/332/387/390/747/749/750/753/1248/1377/1439, where the amino acid positions are relative to This reference sequence corresponds to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集171P/260T/306G/332P/387I/390A/620N/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/491E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/491/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/615N/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1283S/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/822S/1248D/1377D/1439E、171P/260T/306G/328G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/212L/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/818W/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1283L/1377D/1439E、171P/260T/306G/332P/387I/390A/555G/684G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/828K/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/550G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/830M/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/839A/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/822T/1248D/1377D/1439E、13Y/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、14G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、17V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/836V/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/839P/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1210W/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1281R/1377D/1439E、64D/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/212G/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/682R/749F/750D/1248D/1377D/1439E、14M/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/318C/332P/387I/390A/749F/750D/1248D/1377D/1439E、17S/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、20L/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/818G/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/836G/1248D/1377D/1439E、21M/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/836R/1248D/1377D/1439E、171P/260T/306G/325Y/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/533V/749F/750D/1248D/1377D/1439E、19G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、14V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/817D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/831W/1248D/1377D/1439E、171P/225R/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1156R/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/830V/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/A747D/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/753D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/S751Y/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/749F/750D/797W/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/622D/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/617E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/617N/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/907D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1040E/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/617D/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/611E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/620P/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/617G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/488G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1192D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1194P/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/619E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/615D/749F/750D/1248D/1377D/1439E、16A/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/802S/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/818V/1248D/1377D/1439E、171P/L211K/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/836W/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/555R/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/536A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/527A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/555E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/841W/1248D/1377D/1439E、171P/260T/306G/320Q/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/837G/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/558R/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/555G/749F/750D/1248D/1377D/1439E、171P/211R/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、64G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/320R/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/533Y/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/914V/1248D/1377D/1439E、16V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1283E/1377D/1439E、171P/260T/306G/332P/387I/390A/536M/749F/750D/1248D/1377D/1439E、171P/260T/306G/312L/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/681N/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/838T/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/536R/749F/750D/1248D/1377D/1439E、15G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/536P/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/558W/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/558E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1427Y/1439E、171P/260T/306G/332P/387I/390A/749F/750D/839G/1248D/1377D/1439E、18L/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、13G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1210M/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1156G/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/558L/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/839K/1248D/1377D/1439E、171P/211P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/211G/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/211Q/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、16D/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/M320G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/683W/749F/750D/1248D/1377D/1439E、24V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/534I/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/681A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/840G/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1160R/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/681C/749F/750D/1248D/1377D/1439E、171P/260T/306G/328Q/332P/387I/390A/749F/750D/1248D/1377D/1439E、15S/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/536K/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/536G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/533R/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/681E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/536W/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1156N/1248D/1377D/1439E、16P/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/817A/1248D/1377D/1439E、18R/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/551W/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/555T/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/681G/749F/750D/1248D/1377D/1439E、171P/212A/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、16G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/838G/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/681R/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/747D/749F/750D/752G/811F/819V/923M/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/749F/750D/751Y/775G/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/775G/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/749F/750D/752L/753D/775G/793G/797W/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/749F/750D/923M/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/749F/750D/923M/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/747D/749F/750D/751Y/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/747D/749F/750D/753D/775G/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/752L/923M/1051R/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/749F/750D/775G/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/749F/750D/752L/775G/793G/1051R/1053R 1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/752G/753D/775G/793G/819V/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/749F/750D/1051R/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/747D/749F/750D/752G/753D/775G/811F/819V/923M/1051R 1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/393G/749F/750D/752G/787W/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/751Y/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/749F/750D/1148N/1248D/1377D/1439E、63H/171P/260T/306G/332P/387I/390A/747D/749F/750D/752G/753D/819V/923M/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/747D/749F/750D/752L/753D/793G/811F/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/797W/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/751Y/752L/753D/1051R/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/732W/749F/750D/1051R/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/752G/797W/815I/923M/1051R/1148N 1248D/1377D/1439E或171P/260T/306G/332P/387I/390A/747D/749F/750D/753D/1248D/1377D/1439E,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 171P/260T/306G/332P/387I/390A/620N/749F/750D/1248D/1377D/1439E, 171P/260T/ 171P/260 T/306G/ 332P/387I/390A/615N/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1248D/1283S/1377D/1439E, 171P/260T/3 06G/332P/ 387I/390A/749F/750D/822S/1248D/1377D/1439E, 171P/260T/306G/328G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/212L/260T/30 6G/332P/ 387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/818W/1248D/1377D/1439E, 171P/260T/306G/332P/38 7I/390A/ 749F/750D/1248D/1283L/1377D/1439E, 171P/260T/306G/332P/387I/390A/555G/684G/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/3 87I/390A/ 749F/750D/828K/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/550G/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/39 0A/749F/ 750D/830M/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/839A/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/74 9F/750D/ 822T/1248D/1377D/1439E, 13Y/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 14G/171P/260T/306G/332P/387I/390A/749F /750D/ 1248D/1377D/1439E, 17V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/836 V/1248D/ 1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/839P/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1210W/12 48D/1377D/ 1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1281R/1377D/1439E、64D/171P/260T/306G/332P/387I/390A/749F/750D/1248D/137 7D/1439E、 171P/212G/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/682R/749F/750D/1248D/1377D/143 9E、14M/ 171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/318C/332P/387I/390A/749F/750D/1248D/1377D/1439E, 17 S/171P/ 260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 20L/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260 T/306G/ 332P/387I/390A/749F/750D/818G/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/836G/1248D/1377D/1439E, 21M/171P/260 T/306G/ 332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/836R/1248D/1377D/1439E, 171P/260T/306G/32 5Y/332P/ 387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/533V/749F/750D/1248D/1377D/1439E, 19G/171P/260T/306G/332 P/387I/ 390A/749F/750D/1248D/1377D/1439E, 14V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390 A/749F/ 750D/817D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/831W/1248D/1377D/1439E, 171P/225R/260T/306G/332P/387I/39 0A/749F/ 750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1156R/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/7 50D/830V/ 1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/393G/A747D/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/7 50D/753D/ 1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/S751Y/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/39 0A/749F/ 750D/797W/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/622D/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/61 7E/749F/ 750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/617N/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/75 0D/907D/ 1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1040E/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/617D/749F/7 50D/1248D/ 1377D/1439E, 171P/260T/306G/332P/387I/390A/611E/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/620P/749F/750D/124 8D/1377D/ 1439E、171P/260T/306G/332P/387I/390A/617G/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/488G/749F/750D/1248D/137 7D/1439E、 171P/260T/306G/332P/387I/390A/749F/750D/1192D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1194P/1248D/1377D/1 439E、171P/ 260T/306G/332P/387I/390A/619E/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/615D/749F/750D/1248D/1377D/1439E、16 A/171P/ 260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/802S/1248D/1377D/1439E, 171P/26 0T/306G/ 332P/387I/390A/749F/750D/818V/1248D/1377D/1439E, 171P/L211K/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/3 06G/332P/ 387I/390A/749F/836W/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/555R/749F/750D/1248D/1377D/1439E, 171P/260T/306G/33 2P/387I/ 390A/536A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/527A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/38 7I/390A/ 555E/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/841W/1248D/1377D/1439E, 171P/260T/306G/320Q/332P/38 7I/390A/ 749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/837G/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/55 8R/749F/ 750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/555G/749F/750D/1248D/1377D/1439E, 171P/211R/260T/306G/332P/387I/390A/74 9F/750D/ 1248D/1377D/1439E, 64G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/320R/332P/387I/390A/749F/750 D/1248D/ 1377D/1439E, 171P/260T/306G/332P/387I/390A/533Y/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/914V/124 8D/1377D/ 1439E、16V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/749F/750D/1248D/1283E/137 7D/1439E、 171P/260T/306G/332P/387I/390A/536M/749F/750D/1248D/1377D/1439E, 171P/260T/306G/312L/332P/387I/390A/749F/750D/1248D/1377D/143 9E、171P/ 17 1P/260T/ 306G/332P/387I/390A/536R/749F/750D/1248D/1377D/1439E, 15G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260 T/306G/ 332P/387I/390A/536P/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/558W/749F/750D/1248D/1377D/1439E, 171P/260T/30 6G/332P/ 387I/390A/558E/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1427Y/1439E, 171P/260T/306G/3 32P/387I/ 390A/749F/750D/839G/1248D/1377D/1439E, 18L/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 13G/171P/260T/306G/332P /387I/ 390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1210M/1248D/1377D/1439E, 171P/260T/306G/332P/387I/3 90A/749F/ 750D/1156G/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/558L/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/7 49F/750D/ 839K/1248D/1377D/1439E, 171P/211P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/211G/260T/306G/332P/387I/390A/74 9F/750D/ 1248D/1377D/1439E, 171P/211Q/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 16D/171P/260T/306G/332P/387I/390A/749F/750 D/1248D/ 1377D/1439E, 171P/260T/306G/M320G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/683W/749F/750D/12 48D/1377D/ 1439E、24V/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E、171P/260T/306G/332P/387I/390A/534I/749F/750D/1248D/1377 D/1439E、 171P/260T/306G/332P/387I/390A/681A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/840G/1248D/1377D/143 9E、171P/ 1 71P/260T/ 306G/328Q/332P/387I/390A/749F/750D/1248D/1377D/1439E, 15S/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260 T/306G/ 332P/387I/390A/536K/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/536G/749F/750D/1248D/1377D/1439E, 171P/260T/30 6G/332P/ 387I/390A/533R/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/681E/749F/750D/1248D/1377D/1439E, 171P/260T/306G/33 2P/387I/ 390A/536W/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/1156N/1248D/1377D/1439E, 16P/171P/260T/306G/33 2P/387I/ 390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/817A/1248D/1377D/1439E, 18R/171P/260T/306G/332P/387 I/390A/ 749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/551W/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/55 5T/749F/ 750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/681G/749F/750D/1248D/1377D/1439E, 171P/212A/260T/306G/332P/387I/390A/74 9F/750D/ 1248D/1377D/1439E, 16G/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/838 G/1248D/ 1377D/1439E, 171P/260T/306G/332P/387I/390A/681R/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/393G/749F/750D/124 8D/1377D/ 1439E、171P/260T/306G/332P/387I/390A/393G/747D/749F/750D/752G/811F/819V/923M/1148N/1248D/1377D/1439E、171P/260T/306G/332P/387 I/390A/ 393G/749F/750D/751Y/775G/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/143 9E、171P/ 260T/306G/332P/387I/390A/393G/732W/749F/750D/1148N/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/775G/1148N/124 8D/1377D/ 1439E, 171P/260T/306G/332P/387I/390A/393G/749F/750D/752L/753D/775G/793G/797W/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A /393G/ 749F/750D/923M/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/393G/749F/750D/923M/1148N/1248D/1377D/1439E, 171P/260T/306G/3 32P/387I/ 390A/393G/747D/749F/750D/751Y/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/393G/747D/749F/750D/753D/775G/1148N/1248D/137 7D/1439E、 171P/260T/306G/332P/387I/390A/749F/750D/752L/923M/1051R/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/749F/750D/775G/ 1248D/ 1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/749F/750D/752L/775G/793G/1051R/1053R 1248D/1377D/1439E, 171P/260T/306G/33 2P/387I/390A /749F/750D/752G/753D/775G/793G/819V/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/749F/750D/1051R/1248D/1377D/1439E, 63 Q/171P /260T/306G/332P/387I/390A/747D/749F/750D/752G/753D/775G/811F/819V/923M/1051R 1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A /393G/ 749F/750D/752G/787W/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/751Y/1248D/1377D/1439E, 63Q/171P/260T/306G/332 P/387I/ 390A/749F/750D/1148N/1248D/1377D/1439E, 63H/171P/260T/306G/332P/387I/390A/747D/749F/750D/752G/753D/819V/923M/1148N/1248D/137 7D/1439E、 171P/260T/306G/332P/387I/390A/749F/750D/1148N/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/747D/749F/750D/752L/753D/793G /811F/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/749F/750D/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/797 W/1148N/ 1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/751Y/752L/753D/1051R/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/38 7I/390A/ 732W/749F/750D/1051R/1248D/1377D/1439E, 171P/260T/306G/332P/387I/390A/749F/750D/752G/797W/815I/923M/1051R/1148N 1248D/1377D/ 1439E or 171P/260T /306G/332P/387I/390A/747D/749F/750D/753D/1248D/1377D/1439E, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:63/171/260/306/332/387/390/393/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/622/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/617/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/536/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/839/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/797/1148/1248/1377/1439、63/171/260/306/332/387/390/393/533/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/751/775/1148/1248/1377/1439、63/171/260/303/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/951/775/1148/1248/1377/1439、63/164/171/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/818/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/807/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/799/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/735/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/794/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/926/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/755/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/921/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/801/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/1094/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/968/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/929/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/924/1148/1248/1377/1439、63/171/260/306/332/387/390/393/698/732/749/750/775/1148/1248/1377/1439、63/168/171/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/581/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/916/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1428/1439、63/171/260/306/332/387/390/393/732/749/750/775/805/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/1114/1148/1248/1377/1439、63/171/260/306/311/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/737/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/693/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/809/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/757/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/1099/1148/1248/1377/1439、63/171/260/306/332/387/390/393/676/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/740/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/698/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/791/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/622/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/536/558/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/555/617/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/681/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/555/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/555/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/732/749/750/775/1148/1248/1377/1439、63/171/211/212/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/617/681/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/558/617/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/555/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/536/555/558/617/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/536/617/681/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/536/555/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/536/622/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/533/617/681/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/312/332/387/390/393/533/534/617/619/681/732/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/211/212/260/306/320/332/387/390/393/619/681/732/749/750/775/839/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/775/797/839/1148/1248/1377/1439、63/171/212/260/306/312/320/332/387/390/393/533/534/617/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/ 558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/619/681/732/749/750/775/797/839/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/558/619/749/750/775/839/1148/1248/1377/1439、63/171/211/212/260/306/312/332/387/390/393/534/558/619/681/749/750/775/839/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/534/558/619/749/750/775/797/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558/617/619/681/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/534/558/611/681/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/320/332/387/390/393/617/619/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558/617/681/732/749/750/775/797/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/ 534/619//749/750/775/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/ 619/681/732/749/750/775/1148/1248/1377/1439、63/171/211/212/260/306/332/387/390/393/534/558/619/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/619/681/732/749/750/775/797/839/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/611/732/749/750/775/839/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/312/332/387/390/393/533/617/681/732/749/750/775/797/839/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558/611/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/312/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/320/332/387/390/393/558/619/681/749/750/775/797/839/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/558/749/750/775/797/1148/1248/1377/1439、63/171/260/306/332/387/390/393/533/558/611/619/716//749/750/775/839/1148/1248/1377/1439、63/171/260/306/312/332/387/390/393/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/534/619/681/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/320/332/387/390/393/533/536/619/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558/617/681/732/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/533/534/681/732/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/332/387/390/393/534/619/681/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/617/619/681/732/749/750/775/1148/1248/1377/1439、63/171/211/212/260/306/320/332/387/390/393/558/617/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/332/387/390/393/534/558/681/732/749/750/775/797/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/312/332/387/390/393/619/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/312/332/387/390/393/619/732/749/750/775/839/1148/1248/1377/1439、63/171/210/212/260/306/320/332/387/390/393/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/312/332/387/390/393/534/681/732/749/750/775/797/839/1148/1248/1377/1439、63/171/211/260/306/320/332/387/390/393/558/732/749/750/775/839/1148/1248/1377/1439、63/171/260/294/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/732/749/750/759/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/538/732/749/750/775/1148/1248/1377/1439或63/171/260/306/332/387/390/393/732/749/750/775/1109/1148/1248/1377/1439,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at the following amino acid positions: 63/171/260/306/332/387/390/393/681/732 /749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/622/732/749/750/775/1148/1248/1377/1439, 63 /171/260/306/332/387/390/393/617/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387/390/393/558 /732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/536/732/749/750/775/1148/1248/1377/1439 , 63/171/211/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/320/332/387/390 /393/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775/839/1148/1248/1377 /1439、63/171/260/306/332/387/390/393/732/749/750/775/797/1148/1248/1377/1439、63/171/260/306/332/387/390 /393/533/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/751/775/1148/1248 /1377/1439、63/171/260/303/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387 /390/393/732/749/750/951/775/1148/1248/1377/1439, 63/164/171/260/306/332/387/390/393/732/749/750/775/1148 /1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775/818/1148/1248/1377/1439, 63/171/260/306/332 /387/390/393/732/749/750/775/807/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775/799 /1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/735/749/750/775/1148/1248/1377/1439, 63/171/260/306 /332/387/390/393/732/749/750/775/794/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775 /926/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/755/775/1148/1248/1377/1439, 63/171/260 /306/332/387/390/393/732/749/750/775/921/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750 /775/801/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775/1094/1148/1248/1377/1439, 63/171 /260/306/332/387/390/393/732/749/750/775/968/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749 /750/775/929/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775/924/1148/1248/1377/1439, 63 /171/260/306/332/387/390/393/698/732/749/750/775/1148/1248/1377/1439、63/168/171/260/306/332/387/390/393 /732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/581/732/749/750/775/1148/1248/1377/1439 , 63/171/260/306/332/387/390/393/732/749/750/775/916/1148/1248/1377/1439, 63/171/260/306/332/387/390/393 /732/749/750/775/1148/1248/1377/1428/1439, 63/171/260/306/332/387/390/393/732/749/750/775/805/1148/1248/1377 /1439、63/171/260/306/332/387/390/393/732/749/750/775/1114/1148/1248/1377/1439、63/171/260/306/311/332/387 /390/393/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/737/749/750/775/1148/1248 /1377/1439、63/171/260/306/332/387/390/393/693/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332/387 /390/393/732/749/750/775/809/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/757/775/1148 /1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775/1099/1148/1248/1377/1439, 63/171/260/306/332 /387/390/393/676/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/740/749/750/775 /1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/698/749/750/775/1148/1248/1377/1439, 63/171/260/306 /332/387/390/393/732/749/750/775/791/1148/1248/1377/1439、63/171/211/260/306/332/387/390/393/536/622/681 /732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/536/558/732/749/750/775/1148/1248/1377 /1439、63/171/211/260/306/332/387/390/393/536/555/617/749/750/775/1148/1248/1377/1439、63/171/211/260/306 /332/387/390/393/681/749/750/775/1148/1248/1377/1439, 63/171/211/260/306/332/387/390/393/536/555/732/749 /750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/555/732/749/750/775/1148/1248/1377/1439, 63/171 /211/260/306/332/387/390/393/536/732/749/750/775/1148/1248/1377/1439、63/171/211/212/260/306/332/387/390 /393/732/749/750/775/1148/1248/1377/1439, 63/171/211/260/306/332/387/390/393/536/617/681/749/750/775/1148 /1248/1377/1439, 63/171/211/260/306/332/387/390/393/536/558/617/681/732/749/750/775/1148/1248/1377/1439, 63 /171/260/306/332/387/390/393/555/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/536/555 /558/617/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/536/617/681/749/750/775/1148/1248 /1377/1439、63/171/260/306/332/387/390/393/536/555/732/749/750/775/1148/1248/1377/1439、63/171/260/306/332 /387/390/393/536/622/681/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/749/750/775 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/533/617/681/732/749/750/775/1148/1248/1377/1439 , 63/171/211/260/306/312/332/387/390/393/533/534/617/619/681/732/749/750/775/839/1148/1248/1377/1439, 63 /171/212/260/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439, 63/171/211/212/260/306/320/332/387 /390/393/619/681/732/749/750/775/839/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750/775 /797/839/1148/1248/1377/1439, 63/171/212/260/306/312/320/332/387/390/393/533/534/617/681/732/749/750/775 /1148/1248/1377/1439, 63/171/260/306/332/387/390/393/558/619/681/732/749/750/775/1148/1248/1377/1439, 63/171 /260/306/320/332/387/390/393/ 558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387 /390/393/534/619/681/732/749/750/775/797/839/1148/1248/1377/1439, 63/171/260/306/320/332/387/390/393/558 /619/749/750/775/839/1148/1248/1377/1439, 63/171/211/212/260/306/312/332/387/390/393/534/558/619/681/749 /750/775/839/1148/1248/1377/1439, 63/171/260/306/320/332/387/390/393/534/558/619/749/750/775/797/1148/1248 /1377/1439, 63/171/260/306/332/387/390/393/558/617/619/681/732/749/750/775/1148/1248/1377/1439, 63/171/211 /260/306/332/387/390/393/534/558/611/681/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306/320/332 /387/390/393/617/619/681/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/558/617/681 /732/749/750/775/797/1148/1248/1377/1439、63/171/260/306/320/332/387/390/393/ 534/619//749/750/775/1148/ 1248/1377/1439, 63/171/211/260/306/332/387/390/393/ 619/681/732/749/750/775/1148/1248/1377/1439, 63/171/211/ 212/260/306/332/387/390/393/534/558/619/749/750/775/839/1148/1248/1377/1439, 63/171/212/260/306/320/332/ 387/390/393/619/681/732/749/750/775/797/839/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/ 611/732/749/750/775/839/1148/1248/1377/1439, 63/171/260/306/320/332/387/390/393/558/619/681/732/749/750/ 775/1148/1248/1377/1439, 63/171/260/306/312/332/387/390/393/533/617/681/732/749/750/775/797/839/1148/1248/ 1377/1439, 63/171/260/306/332/387/390/393/558/611/681/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/ 312/332/387/390/393/732/749/750/775/1148/1248/1377/1439, 63/171/211/260/306/320/332/387/390/393/558/619/ 681/749/750/775/797/839/1148/1248/1377/1439, 63/171/260/306/320/332/387/390/393/558/749/750/775/797/1148/ 1248/1377/1439, 63/171/260/306/332/387/390/393/533/558/611/619/716//749/750/775/839/1148/1248/1377/1439, 63 /171/260/306/312/332/387/390/393/681/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/320/332/387/390 /393/534/619/681/732/749/750/775/1148/1248/1377/1439, 63/171/211/260/306/320/332/387/390/393/533/536/619 /732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/558/617/681/732/749/750/775/839/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63 /171/260/306/332/387/390/393/533/534/681/732/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/332 /387/390/393/534/619/681/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/617/619/681 /732/749/750/775/1148/1248/1377/1439, 63/171/211/212/260/306/320/332/387/390/393/558/617/681/732/749/750 /775/1148/1248/1377/1439, 63/171/212/260/306/332/387/390/393/534/558/681/732/749/750/775/797/1148/1248/1377 /1439、63/171/212/260/306/320/332/387/390/393/534/732/749/750/775/1148/1248/1377/1439、63/171/211/260/306 /312/332/387/390/393/619/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/312/332/387/390/393/619 /732/749/750/775/839/1148/1248/1377/1439, 63/171/210/212/260/306/320/332/387/390/393/558/681/732/749/750 /775/1148/1248/1377/1439, 63/171/212/260/306/312/332/387/390/393/534/681/732/749/750/775/797/839/1148/1248 /1377/1439, 63/171/211/260/306/320/332/387/390/393/558/732/749/750/775/839/1148/1248/1377/1439, 63/171/260 /294/306/332/387/390/393/732/749/750/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/732/749/750 /759/775/1148/1248/1377/1439, 63/171/260/306/332/387/390/393/538/732/749/750/775/1148/1248/1377/1439 or 63/171 /260/306/332/387/390/393/732/749/750/775/1109/1148/1248/1377/1439, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2 Reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集63Q/171P/260T/306G/332P/387I/390A/393G/681A/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/622D/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/617G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558L/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536K/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211Q/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320R/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558W/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/797W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/533R/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/751A/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/751T/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/951V/775G/1148N/1248D/1377D/1439E、63Q/164E/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/807L/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799A/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/735S/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/794R/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/926V/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/755P/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/921W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/801A/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1094S/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/968A/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/929Q/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/924W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/807P/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/698D/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/168G/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/929V/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818A/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818S/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/581K/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818P/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/698S/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/751G/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916C/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1428G/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805L/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/924M/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1114M/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/311G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737N/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805V/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/801I/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/751D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/693T/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818E/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/929A/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/311E/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737L/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/809W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/757A/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1099G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916I/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737F/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737M/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799P/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/807C/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916E/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/676Q/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/581V/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/968P/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/755Y/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916Q/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/735D/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/740G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/698Y/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/757G/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/791T/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1114A/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/735V/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536P/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/622D/681A/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536K/558L/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536R/555G/617G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/681R/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/555E/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536R/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/555E/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536P/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/212P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/617G/681A/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211R/260T/306G/332P/387I/390A/393G/536P/558L/617G/681A/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/555G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536P/555E/558L/617G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536K/617G/681A/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536K/555G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/536P/622D/681A/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320Q/332P/387I/390A/393G/533R/617E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/312L/332P/387I/390A/393G/533R/534I/617D/619E/681N/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/212A/260T/306G/320Q/332P/387I/390A/393G/619E/681G/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/312L/320Q/332P/387I/390A/393G/533R/534I/617E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320Q/332P/387I/390A/393G/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320Q/332P/387I/390A/393G/534I/619E/681G/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320R/332P/387I/390A/393G/558W/619E/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/211K/212A/260T/306G/312L/332P/387I/390A/393G/534I/558W/619E/681N/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320R/332P/387I/390A/393G/534I/558R/619E/749F/750D/775G/797W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558W/617D/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211Q/260T/306G/332P/387I/390A/393G/534I/558W/611E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/320R/332P/387I/390A/393G/617E/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558W/617D/681G/732W/749F/750D/775G/797W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320R/332P/387I/390A/393G/534I/619E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/332P/387I/390A/393G/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/212A/260T/306G/332P/387I/390A/393G/534I/558W/619E/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/619E/681N/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/611E/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320Q/332P/387I/390A/393G/558W/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/312L/332P/387I/390A/393G/533R/617D/681N/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558W/611E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/312L/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211Q/260T/306G/320R/332P/387I/390A/393G/558W/619E/681G/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320Q/332P/387I/390A/393G/558W/749F/750D/775G/797W/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/533R/558W/611E/619E/716L/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/312L/332P/387I/390A/393G/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/320Q/332P/387I/390A/393G/534I/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/320Q/332P/387I/390A/393G/533R/536L/619E/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/558W/617E/681N/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/533R/534I/681N/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/332P/387I/390A/393G/534I/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/617E/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211Q/212A/260T/306G/320R/332P/387I/390A/393G/558W/617E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/797W/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/312L/332P/387I/390A/393G/619E/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/312L/332P/387I/390A/393G/619E/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/210P/212A/260T/306G/320R/332P/387I/390A/393G/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/312L/332P/387I/390A/393G/534I/681N/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/306G/320R/332P/387I/390A/393G/558W/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/924Q/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916L/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/757T/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737K/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818V/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/801G/1148N/1248D/1377D/1439E、63Q/171P/260T/294G/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799S/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799E/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/791M/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737V/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805Q/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799Q/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737S/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916M/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/759S/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799V/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/538V/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1109G/1148N/1248D/1377D/1439E、63Q/168R/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/921R/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/926T/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916T/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/737G/749F/750D/775G/1148N/1248D/1377D/1439E或63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/801R/1148N/1248D/1377D/1439E,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 63Q/171P/260T/306G/332P/387I/390A/393G/681A/732W/749F/750D/775G/1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/622D/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306 G/332P/ 387I/390A/393G/617G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/558L/732W/749F/750D/ 775G/ 1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/536K/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/26 0T/306G/ 332P/387I/390A/393G/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211Q/260T/306G/332P/387I/390A/393G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320R/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/17 1P/260T/ 306G/332P/387I/390A/393G/558W/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/ 750D/ 775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/211K/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 6 3Q/171P/ 260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/797W/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/533R/ 732W/ 749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/751A/775G/1148N/1248D/1377D/14 39E, 63Q/ 171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/751T/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/ 732W/ 749F/750D/951V/775G/1148N/1248D/1377D/1439E, 63Q/164E/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/137 7D/1439E、 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/3 93G/ 732W/749F/750D/775G/807L/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799A/1148N/1248 D/1377D/ 1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/735S/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/ 390A/ 393G/732W/749F/750D/775G/794R/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/926V/1148N /1248D/ 1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/755P/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P /387I/ 390A/393G/732W/749F/750D/775G/921W/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/801A/ 1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1094S/1148N/1248D/1377D/1439E, 63Q/171P/260T/30 6G/332P/ 387I/390A/393G/732W/749F/750D/775G/968A/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/ 929Q/ 1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/924W/1148N/1248D/1377D/1439E, 63Q/171P/26 0T/306G/ 332P/387I/390A/393G/732W/749F/750D/775G/807P/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/698D/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/168G/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/17 1P/260T/ 306G/332P/387I/390A/393G/732W/749F/750D/775G/929V/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/ 750D/ 775G/818A/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/818S/1148N/1248D/1377D/1439E, 6 3Q/171P/ 260T/306G/332P/387I/390A/393G/581K/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/ 749F/ 750D/775G/818P/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916K/1148N/1248D/1377D/14 39E, 63Q/ 171P/260T/306G/332P/387I/390A/393G/698S/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/751G/306G/332P/387I/390A/ 393G/ 732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916C/1148N/1248D/137 7D/1439E、 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1428G/1439E, 63Q/171P/260T/306G/332P/387I/390A/ 393G/ 732W/749F/750D/775G/805L/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/924M/1148N/1248 D/1377D/ 1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1114M/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/311G/332P /387I/ 390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/737N/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805V/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P /387I/ 390A/393G/732W/749F/750D/775G/801I/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/751D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/693T/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306 G/332P/ 387I/390A/393G/732W/749F/750D/775G/818E/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/ 929A/ 1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/311E/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/26 0T/306G/ 332P/387I/390A/393G/732W/737L/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/ 775G/ 809W/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/757A/775G/1148N/1248D/1377D/1439E, 63Q/17 1P/260T/ 306G/332P/387I/390A/393G/732W/749F/750D/775G/1099G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F /750D/ 775G/799G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916I/1148N/1248D/1377D/1439E, 6 3Q/171P/ 260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/ 737F/ 749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/737M/749F/750D/775G/1148N/1248D/1377D/14 39E, 63Q/ 171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799P/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/ 732W/ 749F/750D/775G/807C/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916E/1148N/1248D/137 7D/1439E、 63Q/171P/260T/306G/332P/387I/390A/393G/676Q/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/3 93G/ 581V/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/968P/1148N/1248 D/1377D/ 1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/755Y/775G/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/ 390A/ 393G/732W/749F/750D/775G/916Q/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/735D/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/740G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P /387I/ 390A/393G/732W/698Y/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/757G/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/791T/1148N/1248D/1377D/1439E, 63Q/171P/260T/306 G/332P/ 387I/390A/393G/732W/749F/750D/775G/1114A/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/735V/749F/750D /775G/ 1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/30 6G/332P/ 387I/390A/393G/536P/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/622D/681A/ 732W/ 749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/536K/558L/732W/749F/750D/775G/1148N/1248D/137 7D/1439E、 63Q/171P/211R/260T/306G/332P/387I/390A/393G/536R/555G/617G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/3 32P/ 387I/390A/393G/681R/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/555E/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/536R/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/17 1P/260T/ 306G/332P/387I/390A/393G/555E/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/332P/387I/390A/393G/536P/ 732W/ 749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/212P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/137 7D/1439E、 63Q/171P/211R/260T/306G/332P/387I/390A/393G/536K/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/332P/3 87I/ 390A/393G/536K/617G/681A/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/332P/387I/390A/393G/732W/749F/750D/ 775G/ 1148N/1248D/1377D/1439E, 63Q/171P/211R/260T/306G/332P/387I/390A/393G/536P/558L/617G/681A/732W/749F/750D/775G/1148N/1248D/137 7D/1439E、 63Q/171P/260T/306G/332P/387I/390A/393G/555G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/5 36P/ 555E/558L/617G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/536K/617G/681A/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/536K/555G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260 T/306G/ 332P/387I/390A/393G/536P/622D/681A/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320Q/332P/387I/390A/393G/533R/617E/681G/732W/749F/750D/775G/1148N/1248 D/1377D/ 1439E、63Q/171P/211K/260T/306G/312L/332P/387I/390A/393G/533R/534I/617D/619E/681N/732W/749F/750D/775G/839K/1148N/1248D/1377D/ 1439E、 63Q/171P/212A/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211K/212A/260T/306G/320Q/3 32P/ 387I/390A/393G/619E/681G/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/ 750D/ 775G/797W/839K/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/312L/320Q/332P/387I/390A/393G/533R/534I/617E/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/14 39E, 63Q/ 171P/260T/306G/320Q/332P/387I/390A/393G/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320Q/ 332P/ 387I/390A/393G/534I/619E/681G/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320R/332P/387I/390A/ 393G/ 558W/619E/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/211K/212A/260T/306G/312L/332P/387I/390A/393G/534I/558W/619E/ 681N/ 749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320R/332P/387I/390A/393G/534I/558R/619E/749F/750D/775G/797W/ 1148N/ 63 Q/171P/ 211Q/260T/306G/332P/387I/390A/393G/534I/558W/611E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211K/260T/306G/ 320R/ 332P/387I/390A/393G/617E/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/558W/ 617D/ 681G/732W/749F/750D/775G/797W/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320R/332P/387I/390A/393G/534I/619E/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/211K/260T/306G/332P/387I/390A/393G/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171 P/211K/ 212A/260T/306G/332P/387I/390A/393G/534I/558W/619E/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/ 332P/ 387I/390A/393G/619E/681N/732W/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 611E/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320Q/332P/387I/390A/393G/558W/619E/681N/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/312L/332P/387I/390A/393G/533R/617D/681N/732W/749F/750D/775G/797W/839K/1148N /1248D/ 1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/558W/611E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T /306G/ 312L/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211Q/260T/306G/320R/332P/387I/390A/393G/558W/ 619E/ 681G/749F/750D/775G/797W/839K/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320Q/332P/387I/390A/393G/558W/749F/750D/775G/797W/ 1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/533R/558W/611E/619E/716L/749F/750D/775G/839K/1148N/1248D/1377D/143 9E, 63Q/ 171P/260T/306G/312L/332P/387I/390A/393G/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/320Q/332P/387I/ 390A/ 393G/534I/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211K/260T/306G/320Q/332P/387I/390A/393G/533R/536L/ 619E/ 732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/558W/617E/681N/732W/749F/750D/775G/839K/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/143 9E, 63Q/ 171P/260T/306G/332P/387I/390A/393G/533R/534I/681N/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 332P/ 387I/390A/393G/534I/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/617E/619E/ 681G/ 732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/211Q/212A/260T/306G/320R/332P/387I/390A/393G/558W/617E/681N/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/797W/1148N/1248 D/1377D/ 1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/211K/260T/ 306G/ 312L/332P/387I/390A/393G/619E/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/312L/332P/387I/390A/393G/ 619E/ 732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P/210P/212A/260T/306G/320R/332P/387I/390A/393G/558W/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/312L/332P/387I/390A/393G/534I/681N/732W/749F/750D/775G/797W/839K/1148N /1248D/ 1377D/1439E, 63Q/171P/211K/260T/306G/320R/332P/387I/390A/393G/558W/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E, 63Q/171P /260T/ 306G/332P/387I/390A/393G/732W/749F/750D/775G/924Q/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/ 750D/ 775G/916L/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/757T/775G/1148N/1248D/1377D/1439E, 6 3Q/171P/ 260T/306G/332P/387I/390A/393G/732W/737K/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/ 749F/ 750D/775G/818V/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/801G/1148N/1248D/1377D/14 39E, 63Q/ 171P/260T/294G/306G/332P/387I/390A/393G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/ 732W/ 749F/750D/775G/799S/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799E/1148N/1248D/137 7D/1439E、 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/3 93G/ 732W/749F/750D/775G/791M/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/737V/749F/750D/775G/1148N/1248 D/1377D/ 1439E、63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/805Q/1148N/1248D/1377D/1439E、63Q/171P/260T/306G/332P/387I/ 390A/ 393G/732W/749F/750D/775G/799Q/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/737S/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/916M/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P /387I/ 390A/393G/732W/749F/750D/759S/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/799V/ 1148N/ 1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/538V/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/260T/306 G/332P/ 387I/390A/393G/732W/749F/750D/775G/1109G/1148N/1248D/1377D/1439E, 63Q/168R/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D /775G/ 1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/775G/921R/1148N/1248D/1377D/1439E, 63Q/171P/26 0T/306G/ 332P/387I/390A/393G/732W/749F/750D/775G/926T/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/749F/750D/ 775G/ 916T/1148N/1248D/1377D/1439E, 63Q/171P/260T/306G/332P/387I/390A/393G/732W/737G/749F/750D/775G/1148N/1248D/1377D/1439E or 63Q/17 1P/260T/ 306G/332P/387I/390A/393G/732W/749F/750D/775G/801R/1148N/1248D/1377D/1439E, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1042/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1041/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1051/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1283/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1281/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/916/1148/1248/1377/1439、63/171/187/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/215/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1050/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1210/1248/1377/1439、63/104/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/615/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/610/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/618/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/621/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/614/681/732/749/750/775/1148/1248/1377/1439、63/110/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/301/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1078/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/812/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/786/1148/1248/1377/1439、63/127/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/175/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1088/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/650/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/535/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/806/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/700/732/749/750/775/1148/1248/1377/1439、63/132/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1076/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1084/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/498/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/756/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1108/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/746/749/750/775/1148/1248/1377/1439、63/160/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/543/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/310/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/584/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/918/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439/1452、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/790/1148/1248/1377/1439、63/171/212/260/292/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/800/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/892/1148/1248/1377/1439、63/171/212/260/304/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1116/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/752/775/1148/1248/1377/1439、63/171/212/260/281/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/917/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/712/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1080/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/806/1148/1248/1352/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1095/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/744/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1098/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/948/1148/1248/1377/1439、63/119/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/785/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1113/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/667/681/732/749/750/775/1148/1248/1377/1439、63/158/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/580/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/707/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/731/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1100/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1089/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1092/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/939/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1104/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/736/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1297/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1127/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/686/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1129/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1138/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/786/821/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/680/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/132/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1101/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/808/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/739/749/750/775/1148/1248/1377/1439、63/171/212/260/306/308/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/555/558/619/681/749/750/775/799/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/801/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/799/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/801/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/555/558/619/681/749/750/775/799/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/799/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/801/1148/1248/1377/1439、63/171/212/246/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/801/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/555/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/558/681/732/749/750/775/801/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/799/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/801/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/558/619/681/732/749/750/775/801/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/801/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/558/619/681/732/749/750/775/799/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/749/750/775/ 799/801/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/616/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/611/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/370/387/390/393/534/558/614/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1156/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1158/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/681/732/737/749/750/775/799/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/558/619/681/732/749/750/775/809/1109/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/555/558/619/681/732/737/749/750/775/799/809/839/916/921/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/916/1109/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/536/558/619/681/732/749/750/775/799/916/1109/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/807/1109/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/749/750/775/799/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/916/1109/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/681/732/749/750/775/921/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/916/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555/558/681/732/749/750/775/916/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/839/1148/1248/1377/1439或63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/799/1148/1248/1377/1439,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 63/171/212/260/306/320/332/387/390/393 /534/558/681/732/749/750/775/1042/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681 /732/749/750/775/1041/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750 /775/1051/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248 /1283/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1281/1377/1439 , 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/916/1148/1248/1377/1439, 63/171/187 /212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/215/260/306 /320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/178/212/260/306/320/332/387 /390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558 /681/732/749/750/775/1050/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749 /750/775/1148/1210/1248/1377/1439, 63/104/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/615/681/732/749/750/775/1148/1248/1377 /1439、63/171/212/260/306/320/332/387/390/393/534/558/610/681/732/749/750/775/1148/1248/1377/1439、63/171 /212/260/306/320/332/387/390/393/534/536/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306 /320/332/387/390/393/534/558/618/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387 /390/393/534/558/621/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534 /558/614/681/732/749/750/775/1148/1248/1377/1439, 63/110/171/212/260/306/320/332/387/390/393/534/558/681 /732/749/750/775/1148/1248/1377/1439, 63/171/212/260/301/306/320/332/387/390/393/534/558/681/732/749/750 /775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1078/1148/1248 /1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/812/1148/1248/1377/1439, 63 /171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/786/1148/1248/1377/1439、63/127/171/212 /260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/175/212/260/306/320 /332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393 /534/558/681/732/749/750/775/1093/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681 /732/749/750/775/1088/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/650/681/732/749 /750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/535/558/681/732/749/750/775/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/806/1148/1248/1377/1439 , 63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439, 63/171/212 /260/306/320/332/387/390/393/534/558/681/700/732/749/750/775/1148/1248/1377/1439、63/132/171/212/260/306 /320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390 /393/534/558/681/732/749/750/775/1076/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558 /681/732/749/750/775/1084/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/498/534/558/681/732 /749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/756/775 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1108/1148/1248/1377 /1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/746/749/750/775/1148/1248/1377/1439、63/160 /171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306 /320/332/387/390/393/534/543/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/310/320/332 /387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534 /558/584/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732 /749/750/775/918/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775 /1148/1248/1377/1439/1452, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/790/1148/1248 /1377/1439, 63/171/212/260/292/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63 /171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/800/1148/1248/1377/1439、63/167/171/212 /260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332 /387/390/393/534/558/681/732/749/750/775/892/1148/1248/1377/1439、63/171/212/260/304/306/320/332/387/390 /393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681 /732/749/750/775/1116/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750 /752/775/1148/1248/1377/1439, 63/171/212/260/281/306/320/332/387/390/393/534/558/681/732/749/750/775/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/917/1148/1248/1377/1439 , 63/171/212/260/306/320/332/387/390/393/534/558/681/712/732/749/750/775/1148/1248/1377/1439, 63/171/212 /260/306/320/332/387/390/393/534/558/681/732/749/750/775/1080/1148/1248/1377/1439、63/171/212/260/306/320 /332/387/390/393/534/558/681/732/749/750/775/806/1148/1248/1352/1377/1439、63/171/212/260/306/320/332/387 /390/393/534/558/681/732/749/750/775/1095/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534 /558/681/732/744/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732 /749/750/775/1098/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775 /948/1148/1248/1377/1439, 63/119/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248 /1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/785/1148/1248/1377/1439, 63 /171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1113/1148/1248/1377/1439、63/171/212/260 /306/320/332/387/390/393/534/558/667/681/732/749/750/775/1148/1248/1377/1439、63/158/171/212/260/306/320 /332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393 /534/558/580/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681 /707/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/731/732/749 /750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1100/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1089/1148/1248/1377/1439 , 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1092/1148/1248/1377/1439, 63/171/212 /260/306/320/332/387/390/393/534/558/681/732/749/750/775/939/1148/1248/1377/1439、63/171/212/260/306/320 /332/387/390/393/534/558/681/732/749/750/775/1104/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390 /393/534/558/681/732/736/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558 /681/732/749/750/775/1148/1248/1297/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749 /750/775/1127/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/686/732/749/750/775 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1129/1248/1377 /1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1138/1148/1248/1377/1439、63/171 /212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/786/821/1148/1248/1377/1439、63/171/212/260 /306/320/332/387/390/393/534/558/680/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/132/320 /332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393 /534/558/681/732/749/750/775/1101/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681 /732/749/750/775/808/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/739/749 /750/775/1148/1248/1377/1439, 63/171/212/260/306/308/320/332/387/390/393/534/558/681/732/749/750/775/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/536/555/558/619/681/749/750/775/799/805/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/801/1148/1248 /1377/1439, 63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/732/749/750/775/799/1148/1248/1377 /1439, 63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/801/805/1148/1248/1377 /1439, 63/171/212/260/306/320/332/387/390/393/534/536/555/558/619/681/749/750/775/799/1148/1248/1377/1439 , 63/171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/799/805/1148/1248/1377/1439, 63/171 /212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/801/1148/1248/1377/1439、63/171/212/246/260 /306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/801/1148/1248/1377/1439、63/171/212/260/306 /320/332/387/390/393/534/536/555/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320 /332/387/390/393/534/558/619/681/732/749/750/775/839/1148/1248/1377/1439、63/171/212/260/306/320/332/387 /390/393/534/558/619/681/732/749/750/775/799/805/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390 /393/534/536/558/681/732/749/750/775/801/805/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393 /534/555/558/619/681/732/749/750/775/799/805/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393 /534/558/619/681/732/749/750/775/801/805/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534 /555/558/619/681/732/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/536/558 /619/681/732/749/750/775/801/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732 /749/750/775/801/805/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/536/558/619/681/732 /749/750/775/799/805/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/555/558/619/681/749 /750/775/ 799/801/805/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/750/775 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/616/681/732/749/750/775/1148/1248/1377 /1439、63/171/212/260/306/320/332/387/390/393/534/558/611/681/732/749/750/775/1148/1248/1377/1439、63/171 /212/260/306/320/332/370/387/390/393/534/558/614/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260 /306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1156/1248/1377/1439、63/171/212/260/306/320/332 /387/390/393/534/558/681/732/749/750/775/1148/1158/1248/1377/1439、63/171/212/260/306/320/332/387/390/393 /534/555/558/681/732/737/749/750/775/799/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534 /536/558/619/681/732/749/750/775/809/1109/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534 /536/555/558/619/681/732/737/749/750/775/799/809/839/916/921/1148/1248/1377/1439、63/171/212/260/306/320 /332/387/390/393/534/558/681/732/749/750/775/916/1109/1148/1248/1377/1439, 63/171/212/260/306/320/332/387 /390/393/534/536/558/619/681/732/749/750/775/799/916/1109/1148/1248/1377/1439、63/171/212/260/306/320/332 /387/390/393/534/555/558/619/681/732/749/750/775/807/1109/1148/1248/1377/1439、63/171/212/260/306/320/332 /387/390/393/534/555/558/619/681/749/750/775/799/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390 /393/534/558/619/681/732/749/750/775/799/916/1109/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390 /393/534/558/619/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/555 /558/681/732/749/750/775/921/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/619/681 /732/749/750/775/916/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/555/558/681/732/749 /750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/749/750/775/1148/1248/1377 /1439、63/171/212/260/306/320/332/387/390/393/534/558/619/681/732/749/750/775/799/1148/1248/1377/1439、63 /171/212/260/306/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306 /320/332/387/390/393/534/555/558/681/732/749/750/775/916/1148/1248/1377/1439、63/171/212/260/306/320/332 /387/390/393/534/558/681/732/749/750/775/839/1148/1248/1377/1439 or 63/171/212/260/306/320/332/387/390/393 /534/558/681/732/749/750/775/799/1148/1248/1377/1439, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1042E/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1041N/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1051H/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1283H/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1283T/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281Q/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281P/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/916E/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1051W/1148N/1248D/1377D/1439E、63Q/171P/187C/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/215E/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/215P/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/215S/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/178C/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1050T/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1210T/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281K/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1042A/1148N/1248D/1377D/1439E、63Q/104S/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/615D/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610S/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610K/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610T/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/618Y/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/621W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/618P/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/614F/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/110H/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/301K/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1078S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/812G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/786C/1148N/1248D/1377D/1439E、63Q/127V/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/175G/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093W/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1088G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093T/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/650M/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/301M/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/535N/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/806R/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/132R/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1076G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1084L/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/498A/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/786L/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738F/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/535G/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/806E/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/756G/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/746P/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/160E/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/160T/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/178V/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543L/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/310G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700Q/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/584A/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/918S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E/1452L、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738P/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790W/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/292D/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800M/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108M/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1088S/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/892T/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790P/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800R/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738K/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/304G/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116G/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/752G/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108W/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738D/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/281A/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/917G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712M/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1080V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/806G/1148N/1248D/1352E/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1095G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/744A/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543G/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1098G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/281S/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/756T/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/948S/1148N/1248D/1377D/1439E、63Q/119V/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116L/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/785V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1113F/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700A/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/786D/1148N/1248D/1377D/1439E、63Q/171P/175A/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790M/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/667I/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/158G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/580S/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/707H/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/731I/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/918M/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1100S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1089S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712Y/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/175H/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1092G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/939E/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1104E/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/736F/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543W/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1297A/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712L/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1127V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/939S/1148N/1248D/1377D/1439E、63Q/171P/178M/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/731R/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/686W/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/736G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1129P/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1138Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/812V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/786D/821Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/535C/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/680R/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1089F/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/304E/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/178W/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1104C/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/744R/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738R/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712S/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/187G/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/132P/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/812I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1080G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800C/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1101G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/808K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/808S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/680L/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167R/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/752E/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093N/1148N/1248D/1377D/1439E、63Q/119G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116R/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/580Y/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/304A/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712Q/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/806S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/731L/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1084N/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1127L/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/308P/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093P/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093Y/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739R/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739P/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/310V/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712T/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167H/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093R/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/555E/558W/619E/681G/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/732W/749F/750D/775G/801G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/732W/749F/750D/775G/799S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/799S/801G/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/555E/558W/619E/681G/749F/750D/775G/799S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/801G/1148N/1248D/1377D/1439E、63Q/171P/212A/246D/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/799S/801G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/555E/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/681G/732W/749F/750D/775G/801G/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/732W/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/801G/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/619E/681G/732W/749F/750D/775G/801G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/801G/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/619E/681G/732W/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/749F/750D/775G/799S/801G/805Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281H/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/614H/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/616D/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/621K/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1050E/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610H/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/611D/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1042T/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/616Q/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/614N/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/370A/387I/390A/393G/534I/558W/614A/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1156D/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1210V/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/614T/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1158N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281S/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/618E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/681N/732W/737K/749F/750D/775G/799Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/619E/681G/732W/749F/750D/775G/809G/1109G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536K/555G/558W/619E/681G/732W/737K/749F/750D/775G/799Q/809G/839K/916T/921R/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/916T/1109G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536R/558W/619E/681N/732W/749F/750D/775G/799Q/916T/1109G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555G/558W/619E/681N/732W/749F/750D/775G/807R/1109G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681N/749F/750D/775G/799Q/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681N/732W/749F/750D/775G/799S/916T/1109G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555G/558W/681G/732W/749F/750D/775G/921R/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681N/732W/749F/750D/775G/916T/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555G/558W/619E/681N/732W/749F/750D/775G/799S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/799S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555G/558W/681G/732W/749F/750D/775G/916T/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E或63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/799Q/1148N/1248D/1377D/1439E,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 749F/750D/775G/1042E/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D /775G/ 1041N/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1051H/114 8N/1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1283H/1377D/143 9E, 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1283T/1377D/1439E, 63Q/171P/212A /260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281Q/1377D/1439E, 63Q/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281P/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A /393G/ 534I/558W/681G/732W/749F/750D/775G/916E/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/ 681G/ 732W/749F/750D/775G/1051W/1148N/1248D/1377D/1439E, 63Q/171P/187C/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W /749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/215E/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/215P/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377 D/1439E、 63Q/171P/212A/215S/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/1 78C/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1050T/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I /390A/ 393G/534I/558W/681G/732W/749F/750D/775G/1148N/1210T/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I /558W/ 681G/732W/749F/750D/775G/1148N/1248D/1281K/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W /749F/ 750D/775G/1042A/1148N/1248D/1377D/1439E, 63Q/104S/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D /775G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/615D/681G/732W/749F/750D/775G/1148N/1248 D/1377D/ 1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610S/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/ 171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610K/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 320R/332P/387I/390A/393G/534I/558W/610T/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/ 387I/ 390A/393G/534I/536P/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 558W/618Y/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/621W/ 681G/ 732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/618P/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/614F/681G/732W/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/110H/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/301K/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/ 260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1078S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/812G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/749F/750D/775G/786C/1148N/1248D/1377D/1439E, 63Q/127V/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 558W/ 681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/175G/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093W /1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1088G/1148N/1248D/137 7D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093T/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/650M/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/301M/ 306G/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/535N/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 558W/ 681G/732W/749F/750D/775G/806R/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 738E/ 749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/ 775G/ 1148N/1248D/1377D/1439E, 63Q/132R/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248 D/1377D/ 63Q /171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1084L/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 320R/332P/387I/390A/393G/498A/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/ 387I/ 390A/393G/534I/558W/681G/732W/749F/750D/775G/786L/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 558W/681G/732W/738F/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/535G/558W/ 681G/ 732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/ 775G/ 806E/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/756G/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108S/1148N/1248D/1377D/143 9E, 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093V/1148N/1248D/1377D/1439E, 63Q/171P/212A /260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/746P/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/160E/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/160T/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/178V/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 558W/ 681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543L/558W/681G/732W/ 749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/310G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700Q/732W/749F/750D/775G/1148N/1248D/1377 D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093A/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/584A/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/918S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E/1452L, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I /558W/ 681G/732W/738P/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 749F/ 750D/775G/790W/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/ 790I/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/292D/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248 D/1377D/ 1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800M/1148N/1248D/1377D/1439E、63Q/ 171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108M/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1088S/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 558W/681G/732W/749F/750D/775G/892T/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/ 732W/ 749F/750D/775G/790P/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/ 775G/ 800R/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738K/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/212A/260T/304G/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116G/1148N/1248D/1377D/1439E、63Q/171P/178Q /212A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/ 332P/ 387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116A/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A /393G/ 534I/558W/681G/732W/749F/750D/752G/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/ 681G/ 732W/749F/750D/775G/1108W/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738D /749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/281A/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/917G/1148N/1248D/1377 D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712M/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/2 12A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1080V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/806G/1148N/1248D/1352E/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P /387I/ 390A/393G/534I/558W/681G/732W/749F/750D/775G/1095G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G /534I/ 558W/681G/732W/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G /732W/ 744A/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543G/558W/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1098G/1148 N/1248D/ 1377D/1439E, 63Q/171P/212A/260T/281S/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/756T/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/ 260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/948S/1148N/1248D/1377D/1439E, 63Q/119V/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/749F/750D/775G/1116L/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W /681G/ 732W/749F/750D/775G/785V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/ 750D/ 775G/1113F/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700A/732W/749F/750D/775G /1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/786D/1148N/1248D/1377 D/1439E、 63Q/171P/175A/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/2 12A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790M/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/667I/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/158G/171P/212A/260T/306G/320R/332P/ 387I/ 390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 558W/ 580S/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/707H/ 732W/ 749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/731I/732W/749F/750D/ 775G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/918M/1148N/1248 D/1377D/ 1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1100S/1148N/1248D/1377D/1439E, 63Q /171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1089S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 320R/332P/387I/390A/393G/534I/558W/681G/712Y/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/175H/212A/260T/306G/320R/ 332P/ 387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 558W/681G/732W/749F/750D/775G/1092G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G /732W/ 749F/750D/775G/939E/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/ 775G/ 1104E/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800G/1148 N/1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/736F/749F/750D/775G/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543W/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/ 260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1297A/1377D/1439E, 63Q/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/558W/681G/712L/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/749F/750D/775G/1127V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W /681G/ 732W/749F/750D/775G/939S/1148N/1248D/1377D/1439E, 63Q/171P/178M/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/731R/732W/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/686W/732W/749F/750D/775G/1148N/1248D/1377 D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/2 12A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/736G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1129P/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I /390A/ 393G/534I/558W/681G/732W/749F/750D/775G/1138Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I /558W/ 681G/732W/749F/750D/775G/812V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 749F/ 750D/775G/786D/821Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/535C/558W/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/680R/681G/732W/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116I/1148N/1248D/1377D/143 9E, 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1089F/1148N/1248D/1377D/1439E, 63Q/171P/212A /260T/ 304E/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/178W/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/749F/750D/775G/1104C/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W /681G/ 732W/744R/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738R/ 749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093S /1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712S/732W/749F/750D/775G/1148N/1248D/1377 D/1439E、 63Q/171P/187G/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/2 12A/ 260T/306G/132P/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/812I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/558W/681G/732W/749F/750D/775G/1080G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I /558W/ 681G/732W/749F/750D/775G/800C/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 749F/ 750D/775G/1101G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G /808K/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/808S/1148N/1248 D/1377D/ 1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/790A/1148N/1248D/1377D/1439E、63Q/ 171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 320R/332P/387I/390A/393G/534I/558W/680L/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/167R/171P/212A/260T/306G/320R/ 332P/ 387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 558W/681G/732W/749F/750D/752E/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/ 732W/ 749F/750D/775G/1093N/1148N/1248D/1377D/1439E, 63Q/119G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F /750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1148N /1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1116R/1148N/1248D/1377D/143 9E, 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/580Y/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/ 260T/ 304A/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/ 332P/ 387I/390A/393G/534I/558W/681G/712Q/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/749F/750D/775G/806S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/ 681G/ 712G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/ 750D/ 775G/790G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1108V /1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/731L/732W/749F/750D/775G/1148N/1248D/1377 D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1084N/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1127L/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /308P/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/558W/681G/732W/749F/750D/775G/1076S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I /558W/ 681G/732W/749F/750D/775G/1093P/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W /749F/ 750D/775G/1093Y/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739R/749F/750D /775G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739P/749F/750D/775G/1148N/1248 D/1377D/ 1439E、63Q/171P/212A/260T/306G/310V/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/ 171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/712T/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/167H/171P/212A/ 260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/ 387I/ 390A/393G/534I/558W/681G/732W/749F/750D/775G/1093R/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G /534I/ 536P/555E/558W/619E/681G/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 555E/558W/619E/681G/732W/749F/750D/775G/801G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 555E/ 558W/619E/681G/732W/749F/750D/775G/799S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/ 619E/ 681G/732W/749F/750D/775G/799S/801G/805Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/ 555E/ 558W/619E/681G/749F/750D/775G/799S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/ 732W/ 749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/ 750D/ 775G/801G/1148N/1248D/1377D/1439E, 63Q/171P/212A/246D/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/ 775G/ 799S/801G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/555E/558W/619E/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/839K/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/799S/805Q/1148N/ 1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/681G/732W/749F/750D/775G/801G/805Q/1148N/1248D/ 1377D/ 1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/732W/749F/750D/775G/799S/805Q/1148N/1248D/1 377D/ 1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/801G/805Q/1148N/1248D/1377D/ 1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/1 71P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/536P/558W/619E/681G/732W/749F/750D/775G/801G/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/801G/805Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 320R/332P/387I/390A/393G/534I/536P/558W/619E/681G/732W/749F/750D/775G/799S/805Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 320R/332P/387I/390A/393G/534I/555E/558W/619E/681G/749F/750D/775G/799S/801G/805Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281H/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P /387I/ 390A/393G/534I/558W/681G/732W/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/ 614H/ 681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/616D/681G/732W/ 749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/621K/681G/732W/749F/750D/775G/ 1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1050E/1148N/1248D/137 7D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/610H/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/2 12A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/611D/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1042T/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I /390A/ 393G/534I/558W/616Q/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 558W/ 614N/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/370A/387I/390A/393G/534I/558W/614A/ 681G/ 732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/ 775G/ 1148N/1156D/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/121 0V/1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/614T/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1158N/1248D/1377D/1439E, 63Q/171P/212A /260T/ 306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1281S/1377D/1439E, 63Q/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/558W/618E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/555E/558W/681N/732W/737K/749F/750D/775G/799Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 536P/558W/619E/681G/732W/749F/750D/775G/809G/1109G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G /534I/ 536K/555G/558W/619E/681G/732W/737K/749F/750D/775G/799Q/809G/839K/916T/921R/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/916T/1109G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P /387I/ 390A/393G/534I/536R/558W/619E/681N/732W/749F/750D/775G/799Q/916T/1109G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/555G/558W/619E/681N/732W/749F/750D/775G/807R/1109G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/555E/558W/619E/681N/749F/750D/775G/799Q/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/558W/619E/681N/732W/749F/750D/775G/799S/916T/1109G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I /390A/ 393G/534I/558W/619E/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/ 555G/ 558W/681G/732W/749F/750D/775G/921R/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/ 681N/ 732W/749F/750D/775G/916T/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555G/558W/619E/681N/ 732W/ 749F/750D/775G/799S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/555E/558W/681G/732W/749F/ 750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/749F/750D/775G/1148N/1248D/137 7D/1439E、 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/799S/1148N/1248D/1377D/1439E, 63Q/1 71P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/619E/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/ 390A/ 393G/534I/555G/558W/681G/732W/749F/750D/775G/916T/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/ 534I/ 558W/681G/732W/749F/750D/775G/839K/1148N/1248D/1377D/1439E or 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/ 732W/ 749F/750D/775G/799Q/1148N/1248D/1377D/1439E, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1076/1093/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/752/775/800/805/808/809/1116/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/800/809/1076/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/800/805/808/809/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/700/732/738/749/750/775/805/808/809/1076/1116/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1076/1148/1248/1377/1439、63/167/171/212/260/306/320/332/387/390/393/534/558/681/700/732/739/749/750/775/1076/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/800/808/809/1148/1248/1377/1439、63/167/171/L178/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/1093/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/1093/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/752/775/1093/1148/1248/1377/1439、63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/752/775/805/808/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/808/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1076/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/808/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1076/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/799/800/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/800/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/752/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/752/775/799/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/799/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/799/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/739/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/739/749/750/775/800/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/800/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/800/805/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/809/1116/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1076/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1076/1116/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/739/749/750/775/805/808/809/1076/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/499/534/558/681/700/732/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/1116/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/543P/558/681/732/738/739/749/750/775/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/543/558/681/732/738/749/750/752/775/1116/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/543/558/681/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/320/332/387/390/393/534/558/681/700/732/749/750/775/1093/1148/1248/1377/1414/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/752/775/799/800/809/1116/1148/1248/1339/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/800/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/808/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/844/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/805/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1076/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/800/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/800/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/866/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1116/1148/1248/1377/1439、63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/738/739/749/750/752/775/809/1076/1116/1148/1248/1377/1439、63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/800/809/1148/1248/1377/1439、63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775/800/808/809/1076/1148/1248/1377/1439、63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1116/1148/1248/1377/1439、63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/809/1148/1248/1377/1439、63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/800/805/808/809/1148/1248/1377/1439、63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/805/809/866/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/739/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/749/750/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/739/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/749/750/775/800/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/749/750/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/749/750/775/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/739/749/750/752/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/739/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/739/749/750/752/775/800/805/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/739/749/750/775/800/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/739/749/750/775/805/808/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/739/749/750/752/775/800/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/800/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/809/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/800/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/799/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/775/800/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/775/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/799/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/805/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/799/800/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/805/808/809/1076/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/514/534/543/558/681/732/738/749/750/775/805/808/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/805/808/809/1148/1248/1377/1439或63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/805/809/1116/1148/1248/1377/1439,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 63/167/171/212/260/306/318/320/332/387 /390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439, 63/167/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/749/750/775/1076/1093/1148/1248/1377/1439, 63/167/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/749/750/752/775/800/805/808/809/1116/1148/1248/1377/1439、63/167/171/212/260/306/318 /320/332/387/390/393/534/558/681/732/738/749/750/775/800/809/1076/1148/1248/1377/1439、63/167/171/212/260 /306/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439、63/167/171/212/260/306/320 /332/387/390/393/534/558/681/732/738/749/750/775/800/805/808/809/1148/1248/1377/1439、63/167/171/212/260 /306/320/332/387/390/393/534/558/681/700/732/738/749/750/775/805/808/809/1076/1116/1148/1248/1377/1439, 63 /167/171/212/260/306/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1148/1248/1377/1439, 63/167 /171/212/260/306/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1076/1148/1248/1377/1439, 63/167 /171/212/260/306/320/332/387/390/393/534/558/681/700/732/739/749/750/775/1076/1148/1248/1377/1439, 63/167 /171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/800/808/809/1148/1248/1377/1439, 63 /167/171/L178/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/1093/1148/1248 /1377/1439, 63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1148/1248 /1377/1439, 63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/1093/1148 /1248/1377/1439, 63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/752/775/1093 /1148/1248/1377/1439, 63/167/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/752/775 /805/808/809/1093/1116/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738 /749/750/775/808/809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738 /749/750/775/1076/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750 /775/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/808/809 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1076/1148/1248 /1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/1148/1248/1377/1439 , 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/809/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/809/1093/1116/1148/1248/1377/1439 , 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/1093/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/752/775/1093/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/799/800/1093/1148/1248/1377/1439 , 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/775/1116/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/800/1148/1248/1377/1439, 63/171/212 /260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306 /318/320/332/387/390/393/534/558/681/732/749/750/752/775/1148/1248/1377/1439、63/171/212/260/306/318/320 /332/387/390/393/534/558/681/732/749/750/752/775/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332 /387/390/393/534/558/681/732/749/750/752/775/799/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387 /390/393/534/558/681/732/749/750/775/799/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387 /390/393/534/558/681/732/749/750/775/799/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/738/739/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393 /534/558/681/732/738/739/749/750/775/800/809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/738/749/750/775/800/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393 /534/558/681/732/738/749/750/775/800/805/809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/738/749/750/775/809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393 /534/558/681/732/738/749/750/775/809/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393 /534/558/681/732/738/749/750/775/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/738/749/750/775/809/1116/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393 /534/558/681/732/738/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681 /732/738/749/750/775/1076/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/738 /749/750/775/1076/1116/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/739 /749/750/775/805/808/809/1076/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/499/534/558/681 /700/732/749/750/775/809/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/738 /749/750/775/1093/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750 /752/775/1093/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/732/738/749/750/775 /1116/1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/543P/558/681/732/738/739/749/750/775 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/543/558/681/732/738/749/750/752/775/1116 /1148/1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/543/558/681/732/738/749/750/775/1093/1148 /1248/1377/1439, 63/171/212/260/306/320/332/387/390/393/534/558/681/700/732/749/750/775/1093/1148/1248/1377 /1414/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1148/1248/1377/1439 , 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/1148/1248/1377/1439, 63/171/212 /260/306/318/320/332/387/390/393/534/558/681/732/739/749/750/752/775/799/800/809/1116/1148/1248/1339/1377 /1439、63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/749/750/775/800/1148/1248/1377/1439、63 /171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1093/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1148/1248/1377/1439, 63/171 /212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/1093/1116/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/809/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1093/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/808/809/1093/1116/1148 /1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775/1093 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/844 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/805 /809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1093 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/775/1093/1116 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1148 /1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/1076/1148 /1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/800/809 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775/800 /1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775 /809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775 /866/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/732/738/749/750/752/775 /1116/1148/1248/1377/1439, 63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/738/739/749/750/752 /775/809/1076/1116/1148/1248/1377/1439, 63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/738/749 /750/775/800/809/1148/1248/1377/1439, 63/171/178/212/260/306/320/332/387/390/393/534/558/681/732/738/749 /750/775/800/808/809/1076/1148/1248/1377/1439, 63/171/178/212/260/306/318/320/332/387/390/393/534/558/681 /732/738/749/750/775/1148/1248/1377/1439, 63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/732 /749/750/775/1116/1148/1248/1377/1439, 63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/732/738 /749/750/752/775/809/1148/1248/1377/1439, 63/171/178/212/260/306/318/320/332/387/390/393/534/558/681/700 /732/738/749/750/775/800/805/808/809/1148/1248/1377/1439, 63/171/178/212/260/306/318/320/332/387/390/393 /534/558/681/732/738/749/750/775/805/809/866/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390 /393/534/558/681/732/738/749/750/775/1116/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393 /534/543/558/681/732/738/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534 /543/558/681/732/739/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387/390/393/534 /543/558/681/732/749/750/775/809/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534 /543/558/681/732/738/739/749/750/775/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393 /534/543/558/681/732/738/749/750/775/800/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387 /390/393/534/543/558/681/732/738/749/750/775/809/1093/1148/1248/1377/1439、63/171/212/260/306/318/320/332 /387/390/393/534/543/558/681/732/738/749/750/775/809/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318 /320/332/387/390/393/534/543/558/681/732/739/749/750/752/775/809/1093/1148/1248/1377/1439、63/171/212/260 /306/318/320/332/387/390/393/534/543/558/681/732/739/749/750/752/775/1093/1148/1248/1377/1439, 63/171/212 /260/306/318/320/332/387/390/393/534/543/558/681/732/738/739/749/750/752/775/800/805/809/1093/1148/1248 /1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/739/749/750/775/800/1093 /1116/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/739/749/750 /775/805/808/809/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732 /738/749/750/752/775/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543/558/681/700 /732/738/749/750/752/775/809/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543 /558/681/732/738/749/750/775/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543 /558/681/700/732/738/749/750/775/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/543 /558/681/700/732/739/749/750/752/775/800/1093/1116/1148/1248/1377/1439、63/171/212/260/306/318/320/332/387 /390/393/534/543/558/681/700/732/738/749/750/775/809/1148/1248/1377/1439、63/171/212/260/306/318/320/332 /387/390/393/534/543/558/681/700/732/738/749/750/775/1093/1148/1248/1377/1439、63/171/212/260/306/318/320 /332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/800/1093/1148/1248/1377/1439、63/171/212/260 /306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/809/1116/1148/1248/1377/1439, 63 /171/212/260/306/318/320/332/387/390/393/534/543/558/681/700/732/738/749/750/752/775/1093/1148/1248/1377 /1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/800/1093/1148/1248 /1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/739/749/750/775/799/1093/1148 /1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/775/800/1093/1148 /1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/749/750/775/1116/1148/1248 /1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/809/1093/1148 /1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/775/1093/1116 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775 /1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750/752/775 /809/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738/749/750 /752/775/799/1116/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681/700/732/738 /749/750/752/775/805/809/1093/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558/681 /700/732/738/749/750/775/799/800/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558 /681/700/732/738/749/750/775/1116/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390/393/534/558 /681/700/732/738/749/750/775/805/808/809/1076/1148/1248/1377/1439, 63/171/212/260/306/318/320/332/387/390 /393/514/534/543/558/681/732/738/749/750/775/805/808/809/1148/1248/1377/1439、63/171/212/260/306/318/320 /332/387/390/393/534/558/681/732/738/749/750/775/805/808/809/1148/1248/1377/1439 or 63/171/212/260/306/318 /320/332/387/390/393/534/558/681/732/738/749/750/775/805/809/1116/1148/1248/1377/1439, where the amino acid positions are relative To the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1076S/1093G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/752E/775G/800V/805Q/808S/809G/1116I/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/809G/1076S/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/805Q/808S/809G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/805Q/808S/809G/1076S/1116I/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1076S/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/1076S/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/800V/808S/809G/1148N/1248D/1377D/1439E、63Q/167G/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/752E/775G/805Q/808S/809G/1093A/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/808S/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/808S/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/809G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/799S/800V/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/752E/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/752E/775G/799S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/799S/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/799S/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/739G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/739G/749F/750D/775G/800V/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/805Q/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/809G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/809G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1076S/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/739G/749F/750D/775G/805Q/808S/809G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/I499L/534I/558W/681G/700E/732W/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/739G/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681N/732W/738E/749F/750D/752E/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/1093A/1148N/1248D/1377D/1414N/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/739G/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/739G/749F/750D/752E/775G/799S/800V/809G/1116I/1148N/1248D/1339C/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/739G/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/800V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/800V/805Q/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/752E/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/739G/749F/750D/775G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/752E/775G/808S/809G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/844H/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/805Q/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/800V/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/800V/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/866A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/739G/749F/750D/752E/775G/809G/1076S/1116I/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/809G/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/800V/808S/809G/1076S/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/800V/805Q/808S/809G/1148N/1248D/1377D/1439E、63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/805Q/809G/866A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/739G/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/739G/749F/750D/775G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/800V/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/809G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/732W/739G/749F/750D/752E/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/732W/739G/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/732W/738E/739G/749F/750D/752E/775G/800V/805Q/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/739G/749F/750D/775G/800V/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/739G/749F/750D/775G/805Q/808S/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/738E/749F/750D/752E/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/739G/749F/750D/752E/775G/800V/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/752E/775G/800V/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/752E/775G/809G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/800V/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/799S/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/800V/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/808S/809G/1093G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/809G/1093G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/799S/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/805Q/809G/1093A/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/799S/800V/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1116I/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/805Q/808S/809G/1076S/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/514L/534I/543P/558W/681N/732W/738E/749F/750D/775G/805Q/808S/809G/1148N/1248D/1377D/1439E、63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/805Q/808S/809G/1148N/1248D/1377D/1439E或63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/805Q/809G/1116I/1148N/1248D/1377D/1439E,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/ 681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/ 681G/ 732W/749F/750D/775G/1076S/1093G/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558 W/681G/ 732W/749F/750D/752E/775G/800V/805Q/808S/809G/1116I/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/318G/320R/332P/387I /390A/ 393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/809G/1076S/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R/332P /387I/ 390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/738E/749F/750D/775G/800V/805Q/808S/809G/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R/332P/ 387I/ 390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R/332P/387I/390A/ 393G/ 534I/558W/681N/700E/732W/738E/749F/750D/775G/805Q/808S/809G/1076S/1116I/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306 G/320R/ 332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R/ 332P/ 387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1076S/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/320R /332P/ 387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/1076S/1148N/1248D/1377D/1439E, 63Q/167G/171P/212A/260T/306G/318G /320R/ 332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/800V/808S/809G/1148N/1248D/1377D/1439E, 63Q/167G/171P/178Q/212A/260T/ 306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/167G/171P /212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E、63Q/167G/171P/ 212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/167G /171P/ 212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q /167G/ 171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/752E/775G/805Q/808S/809G/1093A/1116I/1 148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/808S/809G/1 148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1076S/1148N /1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/808S/809G/1148N/1248D/1377D/1439E, 63Q/ 171P/ 212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/1076S/1148N/1248D/1377D/1439E, 63Q/171P/212A /260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 318G/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/809G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306 G/318G/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G /320R/ 332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G /320R/ 332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/799S/800V/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /318G/ 320R/332P/387I/390A/393G/534I/558W/681G/732W/739G/749F/750D/775G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G /320R/ 332P/387I/390A/393G/534I/558W/681G/732W/749F/750D/775G/800V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/ 387I/ 390A/393G/534I/558W/681G/732W/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A /393G/ 534I/558W/681G/732W/749F/750D/752E/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/ 558W/ 681G/732W/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W /681G/ 732W/749F/750D/752E/775G/799S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/ 732W/ 749F/750D/775G/799S/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G /732W/ 749F/750D/775G/799S/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W /738E/ 739G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/ 739G/ 749F/750D/775G/800V/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 738E/ 749F/750D/775G/800V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/ 749F/ 750D/775G/800V/805Q/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/ 738E/ 749F/750D/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/ 749F/ 750D/775G/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E /749F/ 750D/775G/809G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732 W/738E/ 749F/750D/775G/809G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E /749F/ 750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/ 1076S/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1076S/1116 I/1148N/ 1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/739G/749F/750D/775G/805Q/808S/8 09G/ 1076S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/I499L/534I/558W/681G/700E/732W/749F/750D/775 G/809G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093A/1148 N/1248D/ 1377D/1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1093A/1148N/1248D /1377D/ 1439E, 63Q/171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1116I/1148N/1248D/1377D/1439 E. 63Q/ 171P/212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/739G/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/ 171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681N/732W/738E/749F/750D/752E/775G/1116I/1148N/1248D/1377D/1439E, 63Q /171P/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/1093A/1148N/1248D/1377D/1439E, 63Q/171P /212A/ 260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/1093A/1148N/1248D/1377D/1414N/1439E, 63Q/171P/212 A/260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 318G/ 320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/ 387I/ 390A/393G/534I/558W/681N/732W/739G/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I /390A/ 393G/534I/558W/681N/732W/739G/749F/750D/752E/775G/799S/800V/809G/1116I/1148N/1248D/1339C/1377D/1439E, 63Q/171P/212A/260T/306 G/318G/ 320R/332P/387I/390A/393G/534I/558W/681N/732W/739G/749F/750D/775G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G /320R/ 332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/800V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/ 387I/ 390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/800V/805Q/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/ 332P/ 387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R /332P/ 387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/752E/775G/1093A/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R /332P/ 387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R /332P/ 387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/ 387I/ 390A/393G/534I/558W/681N/700E/732W/739G/749F/750D/775G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320 R/332P/ 387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/ 332P/ 387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R /332P/ 387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/752E/775G/808S/809G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212 A/260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P /212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/844H/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/700E/732W/738E/749F/750D/775G/805Q/809G/1148N/1248D/1377D/1439E, 63Q/ 171P/ 212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093A/1148N/1248D/1377D/1439E, 63Q/171P /212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A /260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212 A/260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/ 306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1076S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/800V/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/ 260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/800V/1093G/1148N/1248D/1377D/1439E, 63Q/171P /212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/866A/1148N/1248D/1377D/1439E, 63Q/171P/ 212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P /212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/1116I/1148N/1248D/1377D/1439E, 63Q/171P /178Q/ 212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/739G/749F/750D/752E/775G/809G/1076S/1116I/1148N/1248D/1377 D/1439E、 63Q/171P/178Q/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/775G/800V/809G/1148N/1248D/1377D/1 439E. 63Q/171P/178Q/212A/260T/306G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/800V/808S/809G/1076S/1148N/12 48D/ 1377D/1439E, 63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/738E/749F/750D/775G/1148N/1248D/ 1377D/ 1439E、63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681N/732W/749F/750D/775G/1116I/1148N/1248D/1377D /1439E、 63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/752E/775G/809G/1148N/1248D/13 77D/ 1439E, 63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/800V/805Q/808 S/ 809G/1148N/1248D/1377D/1439E, 63Q/171P/178Q/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/750D/ 775G/ 805Q/809G/866A/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/732W/738E/749F/ 750D/ 775G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F /750D/ 775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/739G/749F/750D/ 775G/ 809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/749F/750D/775G/ 809G/ 1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/739G/749F /750D/ 775G/1093A/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F /750D/ 775G/800V/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732 W/738E/ 749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G /732W/ 738E/749F/750D/775G/809G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543 P/558W/ 681N/732W/739G/749F/750D/752E/775G/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G /534I/ 543P/558W/681N/732W/739G/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A /393G/ 534I/543P/558W/681N/732W/738E/739G/749F/750D/752E/775G/800V/805Q/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /318G/ 320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/739G/749F/750D/775G/800V/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171 P/212A/ 260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/739G/749F/750D/775G/805Q/808S/809G/1148N/1248D/1377D/ 1439E、 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/738E/749F/750D/752E/775G/1148N/1248D/13 77D/ 1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681N/700E/732W/738E/749F/750D/752E/775G/809G/109 3G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/732W/738E/749F/750D/775G/ 1093G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/ 775G/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700E/732W/739G/749F/750D/ 752E/ 775G/800V/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/700 E/732W/ 738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W/681G/ 700E/ 732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/558W /681G/ 700E/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/543P/ 558W/ 681G/700E/732W/738E/749F/750D/752E/775G/800V/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A /393G/ 534I/543P/558W/681G/700E/732W/738E/749F/750D/752E/775G/809G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R /332P/ 387I/390A/393G/534I/543P/558W/681G/700E/732W/738E/749F/750D/752E/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /318G/ 320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/ 320R/ 332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/800V/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /318G/ 320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/739G/749F/750D/775G/799S/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/800V/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/749F/750D/775G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G /318G/ 320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/ 318G/ 320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/809G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1093G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T /306G/ 318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/775G/1093G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212 A/260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/1148N/1248D/1377D/1439E, 63Q/171P/212A/ 260T/ 306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/808S/809G/1093G/1116I/1148N/1248D/1377 D/1439E、 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/809G/1093G/1148N/12 48D/ 1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/775G/799S/11 16I/ 1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E/749F/750D/752E/ 775G/ 805Q/809G/1093A/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/738E /749F/ 750D/775G/799S/800V/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W/ 738E/ 749F/750D/775G/1116I/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/534I/558W/681G/700E/732W /738E/ 749F/750D/775G/805Q/808S/809G/1076S/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/393G/514L/534I /543P/ 558W/681N/732W/738E/749F/750D/775G/805Q/808S/809G/1148N/1248D/1377D/1439E, 63Q/171P/212A/260T/306G/318G/320R/332P/387I/390A/ 393G/ 534I/558W/681G/732W/738E/749F/750D/775G/805Q/808S/809G/1148N/1248D/1377D/1439E or 63Q/171P/212A/260T/306G/318G/320R/332P/387I/ 390A/ 393G/534I/558W/681G/732W/738E/749F/750D/775G/805Q/809G/1116I/1148N/1248D/1377D/1439E, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2 the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在 表4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之位置處的取代,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one of the amino acid sequences in Tables 4.1 , 4.2 , 5.1, 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1, 10.2 , 11.1 and Substitutions at the positions set forth in 15.1 , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代集,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1, 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 The set of substitutions set forth in , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在 表4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之位置處的取代或取代集,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one of the amino acid sequences in Tables 4.1 , 4.2 , 5.1, 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1, 10.2 , 11.1 and A substitution or set of substitutions at the positions set forth in 15.1 , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之變異體的取代或取代集,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1, 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 A substitution or set of substitutions of a variant set forth in , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 or a reference sequence corresponding to SEQ ID NO: 252, The reference sequence of 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity of the amino acid sequence.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其限制條件為該重組因子VIII多肽不包括SEQ ID NO: 2之胺基酸序列。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 or a reference sequence corresponding to SEQ ID NO: 252, The reference sequence of 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity of the amino acid sequence, the restriction being the recombination factor VIII polypeptide does not include the amino acid sequence of SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO. 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的參考序列或與對應於SEQ ID NO. 4-2346及2350-2870中之偶數編號SEQ ID NO.之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列。In some embodiments, a recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NO. 4-2346 and 2360-2870 or corresponding to SEQ ID NO. The reference sequences of the even-numbered SEQ ID NO. in 4-2346 and 2350-2870 have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, Amino acid sequences with 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 or a reference sequence corresponding to SEQ ID NO: 252, The reference sequence of 504, 706, 840, 1200, 1514 or 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises Relative to this reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 or relative to SEQ ID NO: 252, 504, 706, 840, 1200, One or more substitutions of 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:13、14、15、16、17、18、19、20、21、24、37、56、57、58、59、61、63、64、65、85、96、104、110、119、127、132、158、160、164、167、168、171、175、178、186、187、205、210、211、212、215、225、246、257、260、265、281、292、294、301、303、304、306、308、310、311、312、318、320、321、325、328、332、334、335、344、346、347、349、351、353、354、355、356、358、359、362、370、387、388、390、392、393、397、407、428、429、433、435、436、481、487、488、489、491、498、499、503、514、527、533、534、535、536、538、543、550、551、555、558、569、580、581、584、610、611、612、613、614、615、616、617、618、619、620、621、622、643、646、650、665、667、676、680、681、682、683、684、686、693、696、698、700、706、707、708、712、716、724、726、729、731、732、734、735、736、737、738、739、740、744、746、747、748、749、750、751、752、753、754、755、756、757、759、770、773、775、785、786、787、790、791、792、793、794、795、797、798、799、800、801、802、805、806、807、808、809、810、811、812、815、816、817、818、819、821、822、824、825、826、828、830、831、836、837、838、839、840、841、844、866、873、879、892、896、897、903、907、914、916、917、918、919、921、922、923、924、926、929、938、939、945、948、951、968、999、1037、1040、1041、1042、1043、1049、1050、1051、1053、1054、1076、1078、1080、1084、1088、1089、1092、1093、1094、1095、1098、1099、1100、1101、1104、1108、1109、1113、1114、1116、1127、1129、1138、1145、1148、1151、1156、1158、1160、1186、1192、1193、1194、1205、1210、1218、1220、1221、1222、1224、1229、1245、1248、1250、1259、1264、1269、1270、1274、1281、1283、1292、1297、1339、1352、1373、1377、1378、1380、1389、1414、1422、1427、1428、1439、1440、1442或1452或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 37, 56, 57, 58, 59, 61, 63, 64, 65, 85, 96, 104, 110, 119, 127, 132, 158, 160, 164, 167, 168, 171, 175, 178, 186, 187, 205, 210, 211, 212, 215, 225, 246, 257, 260, 265, 281, 292, 294, 301, 303, 304, 306, 308, 310, 311, 312, 318, 320, 321, 325, 328, 332, 334, 335, 344, 346, 347, 349, 351, 353, 354, 355, 356, 358, 359, 362, 370, 387, 388, 390, 392, 393, 397, 407, 428, 429, 433, 435, 436, 481, 487, 488, 489, 491, 498, 499, 503, 514, 527, 533, 534, 535, 536, 538, 543, 550, 551, 555, 558, 569, 580, 581, 584, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 643, 646, 650, 665, 667, 676, 680, 681, 682, 683, 684, 686, 693, 696, 698, 700, 706, 707, 708, 712, 716, 724, 726, 729, 731, 732, 734, 735, 736, 737, 738, 739, 740, 744, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 759, 770, 773, 775, 785, 786, 787, 790, 791, 792, 793, 794, 795, 797, 798, 799, 800, 801, 802, 805, 806, 807, 808, 809, 810, 811, 812, 815, 816, 817, 818, 819, 821, 822, 824, 825, 826, 828, 830, 831, 836, 837, 838, 839, 840, 841, 844, 866, 873, 879, 892, 896, 897, 903, 907, 914, 916, 917, 918, 919, 921, 922, 923, 924, 926, 929, 938, 939, 945, 948, 951, 968, 999, 1037, 1040, 1041, 1042, 1043, 1049, 1050, 1051, 1053, 1054, 1076, 1078, 1080, 1084, 1088, 1089, 1092, 1093, 1094, 1095, 1098, 1099, 1100, 1101, 1104, 1108, 1109, 1113, 1114, 1116, 1127, 1129, 1138, 1145, 1148, 1151, 1156, 1158, 1160, 118 6. 1192, 1193, 1194, 1205, 1210, 1218, 1220, 1221, 1222, 1224, 1229, 1245, 1248, 1250, 1259, 1264, 1269, 1270, 1274, 1281, 1283, 1292, 1297, 1339, 135 2. 1373, 1377, 1378, 1380, 1389, 1414, 1422, 1427, 1428, 1439, 1440, 1442 or 1452 or a combination thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706 , 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基13G/Y、14G/M/V、15G/S、16A/D/G/P/V、17S/V、18L/R、19G、20L、21M、24V、37H、56E/P、57A/L/S/T/V、58K、59D/G/L/M/Q/R/S/V/W、61Q/S、63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、64D/G、65A、85Q、96I/L/R/V/W、104S、110H、119G/V、127V、132P/R、158G、160E/T、164E、167G/H/R、168G/R、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、175A/G/H、178C/M/Q/V/W、186A、187C/G、205R、210P、211G/K/P/Q/R、212A/F/G/L/K/M/N/P/R/S/V/Y、215E/P/S、225R、246D、257I、260E/K/T、265R/S/W、281A/S、292D、294G、301K/M、303G/T、304A/E/G、306A/D/G/P/S/T、308P、310G/V、311E/G、312L、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、321Y、325Y、328G/Q/S、332A/F/G/H/N/P/Q/R/T/V/W/Y、334G、335E/P、344A/E/L、346R/V、347N、349G、351S、353S、354R、355C、356L/N、358K/S、359E/G、362E/G/N/P/T/V/W、370A、387A/G/I/L/Q/R/S/T/V/W、388A/P、390A/E/G/L/M/P/S/T/V、392A、393A/F/G/H/M/Q/R/W/Y、397G/N、407V、428F、429L/S、433A/G、435Q、436D/G、481V、487N、488G、489E/F/Q/R、491E、498A、499C/L、503S、514L、527A、533R/V/Y、534I/F/L/M、535C/G/N、536A/G/K/L/M/P/R/W、538V、543G/L/P/W、550G、551W、555E/G/R/T、558A/E/G/L/P/Q/R/S/T/V/W、569T、580S/Y、581K/V、584A、610H/K/L/R/S/T、611D/E、612G/S/T、613S、614A/F/H/I/N/T、615D/N、616D/E/G/Q/W、617D/E/G/N、618C/E/G/P/Y、619E、620N/P、621K/M/R/T/W、622D、643N、646I、650M、665G、667I、676Q、680L/R、681A/C/E/F/G/L/N/R/Q/S/T/W、682R、683W、684G/K、686W、693T、696E、698D/S/W/Y、700A/E/Q/T/V、706A/G/M/Y、707H、708A/K/T/V、712G/L/M/Q/S/T/Y、716K/L/W、724I、726A/L、729T、731I/L/R、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、734I/R/S、735D/S/V、736F/G、737F/G/K/L/M/N/S/V、738A/D/E/F/H/K/N/P/R/S/T/Y、739G/P/R、740G、744A/R、746P、747D、748F/G/K/N/S/V、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S/V、753D、754W、755G/L/P/Q/S/Y、756G/P/R/T、757A/G/K/T、759S、770W、773H、775E/G/K/N/P/S/V、785V、786C/D/L、787W、790A/G/I/M/P/W、791M/T、792H/W/Y、793G、794R、795C/N/S/T、797C/G/P/Q/T/W/Y、798C/R/T、799A/E/G/M/P/Q/R/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、801A/G/I/R、802S/V、805C/G/H/K/L/M/P/Q/R/S/V/W、806E/G/R/S、807C/L/P/R、808K/S、809A/C/G/I/K/L/N/Q/R/S/T/V/W、810V、811F、812G/I/V、815I、816V/W、817A/D、818A/E/G/P/S/V/W、819V、821Q、822S/T、824W、825L、826G、828K、830M/V、831W、836G/R/V/W、837G、838G/T、839A/G/K/P、840G、841W、844H、866A、873L/Q/T、879Q、892T、896L/V、897G/K/R、903E、907D、914V、916C/E/I/K/L/M/Q/T、917G、918M/S、919G、921R/W、922W、923M、924I/M/P/Q/W、926T/V、929A/Q/V、938R/V、939E/S、945K、948S、951V、968A/P、999R、1037H/M/N/P、1040E、1041G/H/N、1042A/E/T、1043E/R、1049G/W、1050E/P/Q/S/T、1051E/H/K/R/S/W、1053A/R、1054C、1076G/S、1078S、1080G/V、1084L/N、1088G/S、1089F/S、1092G、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1094S、1095G、1098G、1099G、1100I/S、1101G、1104C/E、1108M/S/V/W、1109G、1113F、1114A/M、1116A/G/I/L/R、1127L/V、1129P、1138Q、1145R、1148A/C/E/L/M/N/Q/R/S、1151S、1156D/G/N/R、1158N、1160R、1186E、1192D、1193A/E/G/I/L、1194P、1205L、1210M/T/V/W、1218A/G/L/M/P、1220D/E/L/T、1221G/S/T/V、1222F、1224P、1229D、1245R、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1250A/P/S/T、1259T、1264L/R/W、1269F、1270V、1274N/V、1281H/K/P/Q/R/S、1283E/H/L/S/T、1292Y、1297A、1339C、1352E、1373S、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1378A/C/D/E、1380A/G/W、1389W、1414A/C/D/E/G/H/N/P/T/W、1422I、1427Y、1428G、1439A/E/H/L/S/T、1440A/C/E/G/S/T或1442T或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or amino acid residue 13G/Y, 14G/M/V, 15G/S, 16A/D/G/P/V, 17S /V, 18L/R, 19G, 20L, 21M, 24V, 37H, 56E/P, 57A/L/S/T/V, 58K, 59D/G/L/M/Q/R/S/V/W , 61Q/S, 63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y, 64D/G, 65A, 85Q, 96I/L/R /V/W, 104S, 110H, 119G/V, 127V, 132P/R, 158G, 160E/T, 164E, 167G/H/R, 168G/R, 171A/D/E/F/H/K/N /M/P/Q/R/S/T/V/W/Y, 175A/G/H, 178C/M/Q/V/W, 186A, 187C/G, 205R, 210P, 211G/K/P /Q/R, 212A/F/G/L/K/M/N/P/R/S/V/Y, 215E/P/S, 225R, 246D, 257I, 260E/K/T, 265R/S /W, 281A/S, 292D, 294G, 301K/M, 303G/T, 304A/E/G, 306A/D/G/P/S/T, 308P, 310G/V, 311E/G, 312L, 318C /G/K/L/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V, 321Y, 325Y, 328G/Q/S, 332A/F/G /H/N/P/Q/R/T/V/W/Y, 334G, 335E/P, 344A/E/L, 346R/V, 347N, 349G, 351S, 353S, 354R, 355C, 356L/N , 358K/S, 359E/G, 362E/G/N/P/T/V/W, 370A, 387A/G/I/L/Q/R/S/T/V/W, 388A/P, 390A /E/G/L/M/P/S/T/V, 392A, 393A/F/G/H/M/Q/R/W/Y, 397G/N, 407V, 428F, 429L/S, 433A /G, 435Q, 436D/G, 481V, 487N, 488G, 489E/F/Q/R, 491E, 498A, 499C/L, 503S, 514L, 527A, 533R/V/Y, 534I/F/L/M , 535C/G/N, 536A/G/K/L/M/P/R/W, 538V, 543G/L/P/W, 550G, 551W, 555E/G/R/T, 558A/E/G /L/P/Q/R/S/T/V/W, 569T, 580S/Y, 581K/V, 584A, 610H/K/L/R/S/T, 611D/E, 612G/S/T , 613S, 614A/F/H/I/N/T, 615D/N, 616D/E/G/Q/W, 617D/E/G/N, 618C/E/G/P/Y, 619E, 620N /P, 621K/M/R/T/W, 622D, 643N, 646I, 650M, 665G, 667I, 676Q, 680L/R, 681A/C/E/F/G/L/N/R/Q/S /T/W, 682R, 683W, 684G/K, 686W, 693T, 696E, 698D/S/W/Y, 700A/E/Q/T/V, 706A/G/M/Y, 707H, 708A/K /T/V, 712G/L/M/Q/S/T/Y, 716K/L/W, 724I, 726A/L, 729T, 731I/L/R, 732C/D/E/G/L/R /W/K/M/Q/S/T/V/Y, 734I/R/S, 735D/S/V, 736F/G, 737F/G/K/L/M/N/S/V, 738A /D/E/F/H/K/N/P/R/S/T/Y, 739G/P/R, 740G, 744A/R, 746P, 747D, 748F/G/K/N/S/V , 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A/D/G/K/M/N/P/Q/R /S/T/V/W, 751A/D/E/Y, 752D/E/F/G/L/M/Q/R/S/V, 753D, 754W, 755G/L/P/Q/S /Y, 756G/P/R/T, 757A/G/K/T, 759S, 770W, 773H, 775E/G/K/N/P/S/V, 785V, 786C/D/L, 787W, 790A /G/I/M/P/W, 791M/T, 792H/W/Y, 793G, 794R, 795C/N/S/T, 797C/G/P/Q/T/W/Y, 798C/R /T, 799A/E/G/M/P/Q/R/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 801A/G /I/R, 802S/V, 805C/G/H/K/L/M/P/Q/R/S/V/W, 806E/G/R/S, 807C/L/P/R, 808K /S, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 810V, 811F, 812G/I/V, 815I, 816V/W, 817A/D, 818A /E/G/P/S/V/W, 819V, 821Q, 822S/T, 824W, 825L, 826G, 828K, 830M/V, 831W, 836G/R/V/W, 837G, 838G/T, 839A /G/K/P, 840G, 841W, 844H, 866A, 873L/Q/T, 879Q, 892T, 896L/V, 897G/K/R, 903E, 907D, 914V, 916C/E/I/K/L /M/Q/T, 917G, 918M/S, 919G, 921R/W, 922W, 923M, 924I/M/P/Q/W, 926T/V, 929A/Q/V, 938R/V, 939E/S , 945K, 948S, 951V, 968A/P, 999R, 1037H/M/N/P, 1040E, 1041G/H/N, 1042A/E/T, 1043E/R, 1049G/W, 1050E/P/Q/S /T, 1051E/H/K/R/S/W, 1053A/R, 1054C, 1076G/S, 1078S, 1080G/V, 1084L/N, 1088G/S, 1089F/S, 1092G, 1093A/E/G /M/N/P/Q/R/S/T/V/W/Y, 1094S, 1095G, 1098G, 1099G, 1100I/S, 1101G, 1104C/E, 1108M/S/V/W, 1109G, 1113F , 1114A/M, 1116A/G/I/L/R, 1127L/V, 1129P, 1138Q, 1145R, 1148A/C/E/L/M/N/Q/R/S, 1151S, 1156D/G/N /R, 1158N, 1160R, 1186E, 1192D, 1193A/E/G/I/L, 1194P, 1205L, 1210M/T/V/W, 1218A/G/L/M/P, 1220D/E/L/T , 1221G/S/T/V, 1222F, 1224P, 1229D, 1245R, 1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y , 1250A/P/S/T, 1259T, 1264L/R/W, 1269F, 1270V, 1274N/V, 1281H/K/P/Q/R/S, 1283E/H/L/S/T, 1292Y, 1297A , 1339C, 1352E, 1373S, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1378A/C/D/E, 1380A/G/W, 1389W , 1414A/C/D/E/G/H/N/P/T/W, 1422I, 1427Y, 1428G, 1439A/E/H/L/S/T, 1440A/C/E/G/S/T or 1442T or a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代:63、171、212、260、306、317、320、332、387、390、393、534、558、681、732、738、749、750、775、1148、1248、1377或1439或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution at the following amino acid positions: 63, 171, 212, 260, 306, 317, 320, 332, 387, 390, 393, 534, 558, 681, 732, 738, 749, 750, 775, 1148, 1248, 1377 or 1439 or combinations thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706, 840 , 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、212A/F/G/L/K/M/N/P/R/S/V/Y、260E/K/T、306A/D/G/P/S/T、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、332A/F/G/H/N/P/Q/R/T/V/W/Y、387A/G/I/L/Q/R/S/T/V/W、390A/E/G/L/M/P/S/T/V、393A/F/G/H/M/Q/R/W/Y、499C/L、534I/F/L/M、558A/E/G/L/P/Q/R/S/T/V/W、681A/C/E/F/G/L/N/R/Q/S/T/W、700A/E/Q/T/V、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、738A/D/E/F/H/K/N/P/R/S/T/Y、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、752D/E/F/G/L/M/Q/R/S/V、775E/G/K/N/P/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、805C/G/H/K/L/M/P/Q/R/S/V/W、809A/C/G/I/K/L/N/Q/R/S/T/V/W、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1148A/C/E/L/M/N/Q/R/S、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1414A/C/D/E/G/H/N/P/T/W或1439A/E/H/L/S/T或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or amino acid residue 63C/E/F/G/H/I/K/L/M/N/Q/R/S /T/W/Y, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y, 212A/F/G/L/K/M /N/P/R/S/V/Y, 260E/K/T, 306A/D/G/P/S/T, 318C/G/K/L/M/Q/R/T/V, 320G /I/L/P/Q/R/S/T/V, 332A/F/G/H/N/P/Q/R/T/V/W/Y, 387A/G/I/L/Q /R/S/T/V/W, 390A/E/G/L/M/P/S/T/V, 393A/F/G/H/M/Q/R/W/Y, 499C/L , 534I/F/L/M, 558A/E/G/L/P/Q/R/S/T/V/W, 681A/C/E/F/G/L/N/R/Q/S /T/W, 700A/E/Q/T/V, 732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y, 738A/D/E/F /H/K/N/P/R/S/T/Y, 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A /D/G/K/M/N/P/Q/R/S/T/V/W, 752D/E/F/G/L/M/Q/R/S/V, 775E/G/K /N/P/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y, 805C/G/H/K/L/M/P/Q /R/S/V/W, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 1093A/E/G/M/N/P/Q/R /S/T/V/W/Y, 1148A/C/E/L/M/N/Q/R/S, 1248A/C/D/E/F/G/H/I/K/M/P /Q/R/S/T/W/Y, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1414A/C/D/E/G /H/N/P/T/W or 1439A/E/H/L/S/T or a combination thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或胺基酸殘基63Q、171P、212A、260T、306G、317G、320R、332P、387I、390A、393G、534I、558W、681G、732W、7338E、749F、750D、775G、1148N、1248D、1377D或1439E或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or amino acid residue 63Q, 171P, 212A, 260T, 306G, 317G, 320R, 332P, 387I, 390A, 393G, 534I, 558W , 681G, 732W, 7338E, 749F, 750D, 775G, 1148N, 1248D, 1377D or 1439E or combinations thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 252之殘基20-1457的參考序列或與對應於SEQ ID NO: 252之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 252之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 252之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 252 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 One or more substitutions of the reference sequence of SEQ ID NO: 252.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1380、388、1043、610、1274、1220、1442、1193、621、1054、755、1041、748、1049、1221、1051、612、1037、616、387、489、750、1224、618、1050、1053、896、897、749、260、481、613、756、63、265、752、1218、1378、614、1440、1439、1205、1222、1389、1269、390、397/1218、757、1373、346、63/1248、349、306/355/1422、1422、306/346/708、1148、171/346/1248、63/797/799/1248/1422、171/799、362、1248、171/306/346/999/1248、171/1148、734/799/1248/1422、63/732、63/171/306/346/732、171、171/1422、63/362/732/799/1248、999/1148/1422、346/349、306/349、63/171/1148/1151、306、344/349/354/1250、1250、63/306/344/349/354/503/1248、59/63/332/349/503/706/708、63/306/344/349/354/706/1248、59/63、332/706/708/1248/1250、503、59/63/349/354、59/349/708、59/306/344/1248、344/1248/1250、708、63/344/349、59、63/344/349/354、706、59/306/770、63/347/354/1248或354/503,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1380, 388, 1043, 610, 1274, 1220, 1442, 1193, 621, 1054 ,755,1041,748,1049,1221,1051,612,1037,616,387,489,750,1224,618,1050,1053,896,897,749,260,481,613,756,63,265 ,752,1218,1378,614,1440,1439,1205,1222,1389,1269,390,397/1218,757,1373,346,63/1248,349,306/355/1422,1422,306/346 /708、1148、171/346/1248、63/797/799/1248/1422、171/799、362、1248、171/306/346/999/1248、171/1148、734/799/1248/1422 , 63/732, 63/171/306/346/732, 171, 171/1422, 63/362/732/799/1248, 999/1148/1422, 346/349, 306/349, 63/171/1148 /1151, 306, 344/349/354/1250, 1250, 63/306/344/349/354/503/1248, 59/63/332/349/503/706/708, 63/306/344/349 /354/706/1248, 59/63, 332/706/708/1248/1250, 503, 59/63/349/354, 59/349/708, 59/306/344/1248, 344/1248/1250 , 708, 63/344/349, 59, 63/344/349/354, 706, 59/306/770, 63/347/354/1248 or 354/503, where the amino acid positions are relative to the corresponding The reference sequence at SEQ ID NO: 252.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集1380W、388A、1043E、1043R、610R、1274N、1220T、1442T、1193L、621T、1054C、755Q、1041G、748S、1049G、1221V、1051E、612G、1037H、616E、1041H、387S、489R、621M、489Q、750G、1224P、618C、616G、612T、1050Q、1053A、616W、896V、489F、1050P、897G、749T、1274V、1220L、260E、481V、613S、387G、621R、756R、63R、265S、1221T、1380G、752G、748K、755L、1218A、748N、1378E、614I、749F、387V、750T、1193G、749V、1378A、750V、387T、387Q、750A、1037N、1440A、1051S、1221G、1378D、1440S、387R、1193A、387I、1218M、265W、1440E、1439L、1440T、612S、1049W、1221S、1220D、749G、749S、1218G、1205L、1222F、1193E、1050S、1389W、1439E、260T、1037P、1051K、1269F、265R、1051R、1218L、897R、388P、748G、756P、748F、390A、610L、755G、749R、748V、1380A、1440C、397N/1218M、1037M、1218P、757K、1373S、1440G、1193I、1439T、750D、390G、756G、1220E、1378C、618G、346R、63Q/1248D、349G、306G/355C/1422I、1422I、306G/346R/708T、1148N、171P/346R/1248D、63Q/797T/799R/1248D/1422I、171P/799R、362P、1248D、63Q、171P/306G/346R/999R/1248D、171P/1148N、734S/799R/1248D/1422I、63Q/732E、63Q/171P/306G/346R/732G、171P、171P/1422I、63Q/362P/732G/799R/1248D、999R/1148N/1422I、346R/349G、306G/349G、63Q/171P/1148N/1151S、306G、344E/349G/354R/1250T、63G、1250T、63R/306G/344E/349G/354R/503S/1248R、59D/63S/332P/349G/503S/706M/708K、63S/306G/344A/349G/354R/706M/1248R、1248R、59D/63G、332P/706M/708K/1248R/1250T、503S、59D/63R/349G/354R、59D/349G/708K、59D/306G/344E/1248R、344E/1248R/1250T、708K、63R/344E/349G、59D、63S/344A/349G/354R、706M、59D/306G/770W、63G/347N/354R/1248R或354R/503S,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 1380W, 388A, 1043E, 1043R, 610R, 1274N, 1220T, 1442T, 1193L, 621T, 1054C, 755Q, 1041G, 748S, 1049G, 1221V, 1051E, 612G, 1037H, 616E, 1041H, 387S, 489R, 621M, 489Q, 750G, 1224P, 618C, 616G, 612T, 1050Q, 1053A, 616W, 896V, 489F, 1050P, 897G ,749T,1274V, 1220L, 260E, 481V, 613S, 387G, 621R, 756R, 63R, 265S, 1221T, 1380G, 752G, 748K, 755L, 1218A, 748N, 1378E, 614I, 749F, 387V, 750T, 1193G, 749V, 137 8A, 750V, 387T, 387Q, 750A, 1037N, 1440A, 1051S, 1221G, 1378D, 1440S, 387R, 1193A, 387I, 1218M, 265W, 1440E, 1439L, 1440T, 612S, 1049W, 1221S, 1220D, 749G ,749S,1218G,1205L, 1222F, 1193E, 1050S, 1389W, 1439E, 260T, 1037P, 1051K, 1269F, 265R, 1051R, 1218L, 897R, 388P, 748G, 756P, 748F, 390A, 610L, 755G, 749R, 748V, 138 0A, 1440C, 397N/ 1218M, 1037M, 1218P, 757K, 1373S, 1440G, 1193I, 1439T, 750D, 390G, 756G, 1220E, 1378C, 618G, 346R, 63Q/1248D, 349G, 306G/355C/1422I, 1422I, 30 6G/346R/708T, 1148N, 171P/346R/1248D, 63Q/797T/799R/1248D/1422I, 171P/799R, 362P, 1248D, 63Q, 171P/306G/346R/999R/1248D, 171P/1148N, 734S/799R/124 8D/1422I、 63Q/732E, 63Q/171P/306G/346R/732G, 171P, 171P/1422I, 63Q/362P/732G/799R/1248D, 999R/1148N/1422I, 346R/349G, 306G/349G, 63Q/171P/114 8N/ 1151S, 306G, 344E/349G/354R/1250T, 63G, 1250T, 63R/306G/344E/349G/354R/503S/1248R, 59D/63S/332P/349G/503S/706M/708K, 63S/306G/344A / 349G/354R/706M/1248R, 1248R, 59D/63G, 332P/706M/708K/1248R/1250T, 503S, 59D/63R/349G/354R, 59D/349G/708K, 59D/306G/344E/1248R, 344E / 1248R/1250T, 708K, 63R/344E/349G, 59D, 63S/344A/349G/354R, 706M, 59D/306G/770W, 63G/347N/354R/1248R or 354R/503S, where the amino acid position is Relative to the reference sequence corresponding to SEQ ID NO: 252.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集M1380W、I388A、F1043E、F1043R、I610R、I1274N、S1220T、I1442T、F1193L、Q621T、L1054C、A755Q、Y1041G、Y748S、Y1049G、L1221V、M1051E、R612G、F1037H、N616E、Y1041H、F387S、S489R、Q621M、S489Q、L750G、S1224P、A618C、N616G、R612T、I1050Q、T1053A、N616W、I896V、S489F、I1050P、M897G、L749T、I1274V、S1220L、S260E、L481V、F613S、F387G、Q621R、I756R、V63R、I265S、L1221T、M1380G、K752G、Y748K、A755L、F1218A、Y748N、T1378E、L614I、L749F、F387V、L750T、F1193G、L749V、T1378A、L750V、F387T、F387Q、L750A、F1037N、H1440A、M1051S、L1221G、T1378D、H1440S、F387R、F1193A、F387I、F1218M、I265W、H1440E、V1439L、H1440T、R612S、Y1049W、L1221S、S1220D、L749G、L749S、F1218G、I1205L、Y1222F、F1193E、I1050S、S1389W、V1439E、S260T、F1037P、M1051K、I1269F、I265R、M1051R、F1218L、M897R、I388P、Y748G、I756P、Y748F、I390A、I610L、A755G、L749R、Y748V、M1380A、H1440C、H397N/F1218M、F1037M、F1218P、E757K、V1373S、H1440G、F1193I、V1439T、L750D、I390G、I756G、S1220E、T1378C、A618G、D346R、V63Q/L1248D、P349G、E306G/R355C/L1422I、L1422I、E306G/D346R/I708T、T1148N、L171P/D346R/L1248D、V63Q/M797T/K799R/L1248D/L1422I、L171P/K799R、A362P、L1248D、V63Q、L171P/E306G/D346R/Q999R/L1248D、L171P/T1148N、T734S/K799R/L1248D/L1422I、V63Q/K732E、V63Q/L171P/E306G/D346R/K732G、L171P、L171P/L1422I、V63Q/A362P/K732G/K799R/L1248D、Q999R/T1148N/L1422I、D346R/P349G、E306G/P349G、V63Q/L171P/T1148N/G1151S、E306G、K344E/P349G/L354R/V1250T、V63G、V1250T、V63R/E306G/K344E/P349G/L354R/R503S/L1248R、F59D/V63S/S332P/P349G/R503S/L706M/I708K、V63S/E306G/K344A/P349G/L354R/L706M/L1248R、L1248R、F59D/V63G、S332P/L706M/I708K/L1248R/V1250T、R503S、F59D/V63R/P349G/L354R、F59D/P349G/I708K、F59D/E306G/K344E/L1248R、K344E/L1248R/V1250T、I708K、V63R/K344E/P349G、F59D、V63S/K344A/P349G/L354R、L706M、F59D/E306G/R770W、V63G/S347N/L354R/L1248R或L354R/R503S,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set M1380W, I388A, F1043E, F1043R, I610R, I1274N, S1220T, I1442T, F1193L, Q621T, L1054C, A755Q, Y1041G, Y748S, Y1049G, L1221V, M1051E, R612G, F1037H, N616E, Y1041H, F387S, S489R, Q621M, S489Q, L750G, S1224P, A618C, N616G, R612T, I1050Q, T1053A, N616W, I8 96V, S489F, I1050P, M897G, L749T, I1274V, S1220L, S260E, L481V, F613S, F387G, Q621R, I756R, V63R, I265S, L1221T, M1380G, K752G, Y748K, A755L, F1218A, Y748N, T1378E, L614I, L749F, F387V, L750T, F1193G, L749V, T1378A, L750V, F387T, F387Q, L750A, F1037N, H1440A, M1051S, L1221G, T1378D, H1440S, F387R, F1193A, F387I, F1218M, I265W, H1440E, V1439L, H1440T, R612S, Y1049 W, L1221S, S1220D, L749G, L749S, F1218G, I1205L, Y1222F, F1193E, I1050S, S1389W, V1439E, S260T, F1037P, M1051K, I1269F, I265R, M1051R, F1218L, M897R, I388P, Y748G, I756P, Y748F, I390A, I610L, A755G, L749R, Y748V, M1380A, H1440C, H397N/ F1218M, F1037M, F1218P, E757K, V1373S, H1440G, F1193I, V1439T, L750D, I390G, I756G, S1220E, T1378C, A618G, D346R, V63Q/L1248D, P349G, E306G/R 355C/L1422I, L1422I, E306G/D346R/I708T, T1148N, L171P/D346R/L1248D, V63Q/M797T/K799R/L1248D/L1422I, L171P/K799R, A362P, L1248D, V63Q, L171P/E306G/D346R/Q999R/L1248D, L171P/ T1148N, T734S/K799R/L1248D/L1422I, V63Q/K732E, V63Q/L171P/E306G/D346R/K732G, L171P, L171P/L1422I, V63Q/A362P/K732G/K799R/L1248D, Q999R/T1148N/L1422I, D346R/P349G, E30 6G/P349G, V63Q/L171P/T1148N/ G1151S, E306G, K344E/P349G/L354R/V1250T, V63G, V1250T, V63R/E306G/K344E/P349G/L354R/R503S/L1248R, F59D/V63S/S332P/P349G/R503S/L706 M/I708K, V63S/E306G/K344A/ P349G/L354R/L706M/L1248R, L1248R, F59D/V63G, S332P/L706M/I708K/L1248R/V1250T, R503S, F59D/V63R/P349G/L354R, F59D/P349G/I708K, F59D/ E306G/K344E/L1248R, K344E/ L1248R/V1250T, I708K, V63R/K344E/P349G, F59D, V63S/K344A/P349G/L354R, L706M, F59D/E306G/R770W, V63G/S347N/L354R/L1248R or L354R/R503S, Wherein the amino acid positions are Relative to the reference sequence corresponding to SEQ ID NO: 252.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 504之殘基20-1457的參考序列或與對應於SEQ ID NO: 504之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 504之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 504之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 504 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 One or more substitutions of the reference sequence of SEQ ID NO: 504.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:750、1051、260、756、1193、332、897、387、1037、306/749、1270、489、487、488、903、171/1248/1440、260/1148/1378、171/260/387/750/1248、171/260、171/260/387/750/1051/1148、171、750/1051/1148、171/260/756、171/1248、171/1148、59、1440、332/750/1248、756/1248、1248、171/387/1248/1440、750/1440、59/171/750、171/1193/1248、750/1148/1193/1440、1148、171/387/1051、748、306、306/387/390/749/1220、390、306/390/1037、306/612/749、387/390/749、63/390/503/749、1220、63/306、749、306/390/749/1037、306/749/1220、306/387/390/612/749/1037或328,其中該等胺基酸位置係相對於對應於SEQ ID NO: 504之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 750, 1051, 260, 756, 1193, 332, 897, 387, 1037, 306 /749, 1270, 489, 487, 488, 903, 171/1248/1440, 260/1148/1378, 171/260/387/750/1248, 171/260, 171/260/387/750/1051/1148 ,171,750/1051/1148,171/260/756,171/1248,171/1148,59,1440,332/750/1248,756/1248,1248,171/387/1248/1440,750/1440 ,59/171/750,171/1193/1248,750/1148/1193/1440,1148,171/387/1051,748,306,306/387/390/749/1220,390,306/390/1037 ,306/612/749, 387/390/749, 63/390/503/749, 1220, 63/306, 749, 306/390/749/1037, 306/749/1220, 306/387/390/612 /749/1037 or 328, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 504.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集750D、1051K、1051S、260T、756P、1193A、332P、897R、387Q、1037N、387R、306G/749F、1270V、489E、487N、488G、903E、171P/1248D/1440T、260T/1148N/1378D、171P/260T/387I/750D/1248D、171P/260T、171P/260T/387I/750D/1051S/1148N、171P、750D/1051S/1148N、171P/260T/756P、171P/1248D、171P/1148N、387I、59D、1440S、332P/750D/1248D、756P/1248D、1248D、171P/387I/1248D/1440S、750D/1440S、59D/171P/750D、171P/1193A/1248D、750D/1148N/1193A/1440S、1148N、171P/387I/1051K、748G、306G、306G/387R/390A/749F/1220D、390A、306G/390A/1037N、306G/612S/749F、387V/390A/749F、63S/390A/503S/749F、387R/390A/749R、1220D、63S/306G、749F、306G/390A/749F/1037N、387V、306G/749F/1220D、306G/387V/390A/612S/749F/1037N或328S,其中該等胺基酸位置係相對於對應於SEQ ID NO: 504之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 750D, 1051K, 1051S, 260T, 756P, 1193A, 332P, 897R, 387Q, 1037N, 387R, 306G/749F, 1270V, 489E, 487N, 488G, 903E, 171P/1248D/1440T, 260T/1148N/1378D, 171P/260T/387I/750D/1248D, 171P/260T, 171P/260T/387I/750D/1051S/1148N, 1 71P, 750D/ 1051S/1148N, 171P/260T/756P, 171P/1248D, 171P/1148N, 387I, 59D, 1440S, 332P/750D/1248D, 756P/1248D, 1248D, 171P/387I/1248D/1440S, 750D /1440S、59D/ 171P/750D, 171P/1193A/1248D, 750D/1148N/1193A/1440S, 1148N, 171P/387I/1051K, 748G, 306G, 306G/387R/390A/749F/1220D, 390A, 306G/390A/ 1037N, 306G/ 612S/749F, 387V/390A/749F, 63S/390A/503S/749F, 387R/390A/749R, 1220D, 63S/306G, 749F, 306G/390A/749F/1037N, 387V, 306G/749F/1220D, 30 6G/ 387V/390A/612S/749F/1037N or 328S, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 504.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集L750D、M1051K、M1051S、S260T、I756P、F1193A、S332P、M897R、F387Q、F1037N、F387R、E306G/L749F、I1270V、S489E、Q487N、A488G、Q903E、L171P/L1248D/H1440T、S260T/T1148N/T1378D、L171P/S260T/F387I/L750D/L1248D、L171P/S260T、L171P/S260T/F387I/L750D/M1051S/T1148N、L171P、L750D/M1051S/T1148N、L171P/S260T/I756P、L171P/L1248D、L171P/T1148N、F387I、F59D、H1440S、S332P/L750D/L1248D、I756P/L1248D、L1248D、L171P/F387I/L1248D/H1440S、L750D/H1440S、F59D/L171P/L750D、L171P/F1193A/L1248D、L750D/T1148N/F1193A/H1440S、T1148N、L171P/F387I/M1051K、Y748G、E306G、E306G/F387R/I390A/L749F/S1220D、I390A、E306G/I390A/F1037N、E306G/R612S/L749F、F387V/I390A/L749F、V63S/I390A/R503S/L749F、F387R/I390A/L749R、S1220D、V63S/E306G、L749F、E306G/I390A/L749F/F1037N、F387V、E306G/L749F/S1220D、E306G/F387V/I390A/R612S/L749F/F1037N或F328S,其中該等胺基酸位置係相對於對應於SEQ ID NO: 504之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set L750D, M1051K, M1051S, S260T, I756P, F1193A, S332P, M897R, F387Q, F1037N, F387R, E306G/L749F, I1270V, S489E, Q487N, A488G, Q903E, L171P/L1248D/H1440T, S260T/T1148N/T1378D, L171P/S260T/F387I/L750D/L1248D, L171P/S260T, L171P/S260T/F387I /L750D/M1051S/T1148N, L171P, L750D/ M1051S/T1148N, L171P/S260T/I756P, L171P/L1248D, L171P/T1148N, F387I, F59D, H1440S, S332P/L750D/L1248D, I756P/L1248D, L1248D, L171P/F38 7I/L1248D/H1440S, L750D/H1440S, F59D/ L171P/L750D, L171P/F1193A/L1248D, L750D/T1148N/F1193A/H1440S, T1148N, L171P/F387I/M1051K, Y748G, E306G, E306G/F387R/I390A/L749F/S12 20D, I390A, E306G/I390A/F1037N, E306G/ F387 V、E306G/L749F/S1220D、E306G/ F387V/I390A/R612S/L749F/F1037N or F328S, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 504.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 706之殘基20-1457的參考序列或與對應於SEQ ID NO: 706之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 706之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 706之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 706 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 One or more substitutions of the reference sequence of SEQ ID NO: 706.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1051、1221、1218、387、749/1218、332、897、696、816、824、826、393、825、698、332/387/390/1148、328/387/749、749、306/328/332/390/1051/1193/1218、63/306/332/1051/1148、63/306/332/387/1051、387/390/1051、186/306/328/332/390/749/1051/1148/1193、387/390/756/1051、306/390/1051、306/332/390/749、306/387/390/1148、306/328/332/387/390/749/1051/1148/1193、332/387/390/749/1148、387/390/749、306/387/749/1051/1148、387/749、306/945/1051/1193/1221、306/390/749/1051、63/306/332/390、306/387/390/749/1148/1193/1221、306/332/387/390/749/1218、63/306/332/390/1051/1148/1193/1218、924、755、752、751、923、797、754、793、753、922、896、938、775、732、810、747、393/407、819、787、802、811、392或397,其中該等胺基酸位置係相對於對應於SEQ ID NO: 706之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1051, 1221, 1218, 387, 749/1218, 332, 897, 696, 816 ,824,826,393,825,698,332/387/390/1148,328/387/749,749,306/328/332/390/1051/1193/1218,63/306/332/1051/1148 , 63/306/332/387/1051, 387/390/1051, 186/306/328/332/390/749/1051/1148/1193, 387/390/756/1051, 306/390/1051, 306 /332/390/749, 306/387/390/1148, 306/328/332/387/390/749/1051/1148/1193, 332/387/390/749/1148, 387/390/749, 306 /387/749/1051/1148、387/749、306/945/1051/1193/1221、306/390/749/1051、63/306/332/390、306/387/390/749/1148/1193 /1221, 306/332/387/390/749/1218, 63/306/332/390/1051/1148/1193/1218, 924, 755, 752, 751, 923, 797, 754, 793, 753, 922 , 896, 938, 775, 732, 810, 747, 393/407, 819, 787, 802, 811, 392 or 397, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 706 .
在一些實施例中,重組因子VIII多肽包含具有至少一個取代或取代集1051K、1221G、1218G、387R、1051R、749F/1218G、387T、332P、897K、696E、816W、824W、826G、393W、825L、897R、816V、698W、393Q、332P/387R/390A/1148N、328S/387R/749F、749F、306G/328S/332P/390A/1051R/1193A/1218G、63Q/306G/332P/1051R/1148N、63Q/306G/332P/387T/1051K、387T/390A/1051R、186A/306G/328S/332P/390A/749F/1051K/1148N/1193A、387T/390A/756P/1051R、306G/390A/1051R、306G/332P/390A/749F、306G/387R/390A/1148N、306G/328S/332P/387T/390A/749F/1051R/1148N/1193A、332P/387R/390A/749F/1148N、387R/390A/749F、306G/387T/749F/1051K/1148N、387R/749F、306G/945K/1051R/1193A/1221G、306G/390A/749F/1051K、63Q/306G/332P/390A、306G/387T/390A/749F/1148N/1193A/1221G、306G/332P/387R/390A/749F/1218M、63Q/306G/332P/390A/1051R/1148N/1193A/1218G、924I、755S、752F、751Y、923M、797Y、754W、793G、753D、922W、896L、938R、775G、751E、732W、752G、810V、938V、747D、755G、393G/407V、797W、819V、393G、787W、393R、802V、775E、924P、732G、811F、802S、752L、392A或397G之胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 706之該參考序列。In some embodiments, a recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions 1051K, 1221G, 1218G, 387R, 1051R, 749F/1218G, 387T, 332P, 897K, 696E, 816W, 824W, 826G, 393W, 825L, 897R, 816V, 698W, 393Q, 332P/387R/390A/1148N, 328S/387R/749F, 749F, 306G/328S/332P/390A/1051R/1193A/1218G, 63Q/306G/332P/1051R/1148 N、63Q/ 306G/332P/387T/1051K, 387T/390A/1051R, 186A/306G/328S/332P/390A/749F/1051K/1148N/1193A, 387T/390A/756P/1051R, 306G/390A/1051R, 3 06G/332P/ 390A/749F, 306G/387R/390A/1148N, 306G/328S/332P/387T/390A/749F/1051R/1148N/1193A, 332P/387R/390A/749F/1148N, 387R/390A/749F, 306 G/387T/ 749F/1051K/1148N, 387R/749F, 306G/945K/1051R/1193A/1221G, 306G/390A/749F/1051K, 63Q/306G/332P/390A, 306G/387T/390A/749F/1148N/11 93A/1221G、 306G/332P/387R/390A/749F/1218M, 63Q/306G/332P/390A/1051R/1148N/1193A/1218G, 924I, 755S, 752F, 751Y, 923M, 797Y, 754W, 793G, 753D, 922W ,896L, 938R, 775G, 751E, 732W, 752G, 810V, 938V, 747D, 755G, 393G/407V, 797W, 819V, 393G, 787W, 393R, 802V, 775E, 924P, 732G, 811F, 802S, 752L, 392A or 397 G of An amino acid sequence, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 706.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集M1051K、L1221G、F1218G、I387R、M1051R、L749F/F1218G、I387T、S332P、M897K、T696E、F816W、F824W、A826G、V393W、I825L、M897R、F816V、F698W、V393Q、S332P/I387R/I390A/T1148N、F328S/I387R/L749F、L749F、E306G/F328S/S332P/I390A/M1051R/F1193A/F1218G、V63Q/E306G/S332P/M1051R/T1148N、V63Q/E306G/S332P/I387T/M1051K、I387T/I390A/M1051R、D186A/E306G/F328S/S332P/I390A/L749F/M1051K/T1148N/F1193A、I387T/I390A/I756P/M1051R、E306G/I390A/M1051R、E306G/S332P/I390A/L749F、E306G/I387R/I390A/T1148N、E306G/F328S/S332P/I387T/I390A/L749F/M1051R/T1148N/F1193A、S332P/I387R/I390A/L749F/T1148N、I387R/I390A/L749F、E306G/I387T/L749F/M1051K/T1148N、I387R/L749F、E306G/Q945K/M1051R/F1193A/L1221G、E306G/I390A/L749F/M1051K、V63Q/E306G/S332P/I390A、E306G/I387T/I390A/L749F/T1148N/F1193A/L1221G、E306G/S332P/I387R/I390A/L749F/F1218M、V63Q/E306G/S332P/I390A/M1051R/T1148N/F1193A/F1218G、G924I、A755S、K752F、S751Y、Q923M、M797Y、N754W、I793G、N753D、R922W、I896L、K938R、I775G、S751E、K732W、K752G、N810V、K938V、A747D、A755G、V393G/A407V、M797W、K819V、V393G、I787W、V393R、F802V、I775E、G924P、K732G、Q811F、F802S、K752L、S392A或H397G,其中該等胺基酸位置係相對於對應於SEQ ID NO: 706之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set M1051K, L1221G, F1218G, I387R, M1051R, L749F/F1218G, I387T, S332P, M897K, T696E, F816W, F824W, A826G, V393W, I825L, M897R, F816V, F698W, V393Q, S332P/I387R/I390A/T1148N, F328S/I387R/L749F, L749F, E306G/F328S/S332P/I390A/M1051R/F1193A/F 1218G, V63Q/E306G/S332P/M1051R/ T1148N, V63Q/E306G/S332P/I387T/M1051K, I387T/I390A/M1051R, D186A/E306G/F328S/S332P/I390A/L749F/M1051K/T1148N/F1193A, I387T/I390A /I756P/M1051R, E306G/I390A/M1051R, E306G/S332P/I390A/L749F, E306G/I387R/I390A/T1148N, E306G/F328S/S332P/I387T/I390A/L749F/M1051R/T1148N/F1193A, S332P/I387R/I390A/ L749F/T1148N, I387R/I390A/L749F, E306G/I387T/L749F/M1051K/T1148N, I387R/L749F, E306G/Q945K/M1051R/F1193A/L1221G, E306G/I390A/L749F/M1051K, V63Q/E306G/S332P/I390A ,E306G/I387T/I390A/L749F/T1148N/ F1193A/L1221G, E306G/S332P/I387R/I390A/L749F/F1218M, V63Q/E306G/S332P/I390A/M1051R/T1148N/F1193A/F1218G, G924I, A755S, K752F, S751 Y, Q923M, M797Y, N754W, I793G, N753D, R922W, I896L, K938R, I775G, S751E, K732W, K752G, N810V, K938V, A747D, A755G, V393G/A407V, M797W, K819V, V393G, I787W, V393R, F802V, I775E, G924 P, K732G, Q811F, F802S, K752L, S392A or H397G, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 706.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 840之殘基20-1457的參考序列或與對應於SEQ ID NO: 840之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 840之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 840之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 840 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 One or more substitutions of the reference sequence of SEQ ID NO: 840.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:620、491、1229、615、1283、822、328、212、818、555/684、828、550、830、839、13、14、17、836、1210、1281、64、682、318、20、21、325、533、19、817、831、225、1156、393/747、753、393/732/751、63/797、622、617、907、1040、611、488、1192、1194、619、16、802、211、555、536、527、841、320、837、558、914、312、681、838、15、1427、18、683、24、534、840、1160、551、393、393/747/752/811/819/923/1148、393/751/775、63/393/732/775/1148、393/732/1148、775/1148、393/752/753/775/793/797、393/923、393/923/1148、393/747/751、393/747/753/775/1148、752/923/1051、63/775、63/393/752/775/793/1051/1053、752/753/775/793/819、63/1051、63/747/752/753/775/811/819/923/1051、393/752/787、751、63/1148、63/747/752/753/819/923/1148、1148、747/752/753/793/811、63、797/1148、751/752/753/1051、63/732/1051、752/797/815/923/1051/1148或747/753,其中該等胺基酸位置係相對於對應於SEQ ID NO: 840之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 620, 491, 1229, 615, 1283, 822, 328, 212, 818, 555 /684, 828, 550, 830, 839, 13, 14, 17, 836, 1210, 1281, 64, 682, 318, 20, 21, 325, 533, 19, 817, 831, 225, 1156, 393/747 ,753,393/732/751,63/797,622,617,907,1040,611,488,1192,1194,619,16,802,211,555,536,527,841,320,837,558 ,914,312,681,838,15,1427,18,683,24,534,840,1160,551,393,393/747/752/811/819/923/1148,393/751/775,63 /393/732/775/1148, 393/732/1148, 775/1148, 393/752/753/775/793/797, 393/923, 393/923/1148, 393/747/751, 393/747 /753/775/1148、752/923/1051、63/775、63/393/752/775/793/1051/1053、752/753/775/793/819、63/1051、63/747/752 /753/775/811/819/923/1051, 393/752/787, 751, 63/1148, 63/747/752/753/819/923/1148, 1148, 747/752/753/793/811 , 63, 797/1148, 751/752/753/1051, 63/732/1051, 752/797/815/923/1051/1148 or 747/753, wherein the amino acid positions are relative to those corresponding to SEQ. The reference sequence of ID NO: 840.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集620N、491E、1229D、615N、1283S、822S、328G、212L、818W、1283L、555G/684G、828K、550G、830M、839A、822T、13Y、14G、17V、836V、839P、1210W、1281R、64D、212G、682R、14M、318C、17S、20L、818G、836G、21M、836R、325Y、533V、19G、14V、817D、831W、225R、1156R、830V、393G/747D、753D、393G/732W/751Y、63Q/797W、622D、617E、617N、907D、1040E、617D、611E、620P、617G、488G、1192D、1194P、619E、615D、16A、802S、818V、211K、836W、555R、536A、527A、555E、841W、320Q、837G、558R、555G、211R、64G、320R、533Y、914V、16V、1283E、536M、312L、681N、838T、536R、15G、536P、558W、558E、1427Y、839G、18L、13G、1210M、1156G、558L、839K、211P、211G、211Q、16D、320G、683W、24V、534I、681A、840G、1160R、681C、328Q、15S、536K、536G、533R、681E、536W、1156N、16P、817A、18R、551W、555T、681G、212A、16G、838G、681R、393G、393G/747D/752G/811F/819V/923M/1148N、393G/751Y/775G、63Q/393G/732W/775G/1148N、393G/732W/1148N、775G/1148N、393G/752L/753D/775G/793G/797W、393G/923M、393G/923M/1148N、393G/747D/751Y、393G/747D/753D/775G/1148N、752L/923M/1051R、63Q/775G、63Q/393G/752L/775G/793G/1051R/1053R、752G/753D/775G/793G/819V、63Q/1051R、63Q/747D/752G/753D/775G/811F/819V/923M/1051R、393G/752G/787W、751Y、63Q/1148N、63H/747D/752G/753D/819V/923M/1148N、1148N、747D/752L/753D/793G/811F、63Q、797W/1148N、751Y/752L/753D/1051R、63Q/732W/1051R、752G/797W/815I/923M/1051R/1148N或747D/753D,其中該等胺基酸位置係相對於對應於SEQ ID NO: 840之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 620N, 491E, 1229D, 615N, 1283S, 822S, 328G, 212L, 818W, 1283L, 555G/684G, 828K, 550G, 830M, 839A, 822T, 13Y, 14G, 17V, 836V, 839P, 1210W, 1281R, 64D, 212G, 682R, 14M, 318C, 17S, 20L, 818G, 836G, 21M, 836R, 325Y, 533V, 19G, 14V, 817D, 831W, 225R, 1156R, 830V, 393G/747D, 753D, 393G/732W/751Y, 63Q/797W, 622D, 617E, 617N, 907D, 1040E, 617D, 611E, 620P, 617G, 488G, 1192D, 1 194P、 619E、615D、16A、802S、818V、211K、836W、555R、536A、527A、555E、841W、320Q、837G、558R、555G、211R、64G、320R、533Y、914V、16V、1283E、536M、312L、 681N、838T、536R、15G、536P、558W、558E、1427Y、839G、18L、13G、1210M、1156G、558L、839K、211P、211G、211Q、16D、320G、683W、24V、534I、681A、840G、 1160R、681C、328Q、15S、536K、536G、533R、681E、536W、1156N、16P、817A、18R、551W、555T、681G、212A、16G、838G、681R、393G、393G/747D/752G/811F/ 819V/923M/1148N, 393G/751Y/775G, 63Q/393G/732W/775G/1148N, 393G/732W/1148N, 775G/1148N, 393G/752L/753D/775G/793G/797W, 393G/923M, 393G/ 923M/1148N, 393G/747D/751Y, 393G/747D/753D/775G/1148N, 752L/923M/1051R, 63Q/775G, 63Q/393G/752L/775G/793G/1051R/1053R, 752G/753D/ 775G/ 793G/819V, 63Q/1051R, 63Q/747D/752G/753D/775G/811F/819V/923M/1051R, 393G/752G/787W, 751Y, 63Q/1148N, 63H/747D/752G/753D/819V/923M / 1148N, 1148N, 747D/752L/753D/793G/811F, 63Q, 797W/1148N, 751Y/752L/753D/1051R, 63Q/732W/1051R, 752G/797W/815I/923M/1051R/1148N or 747 D/753D, The amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 840.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集V620N、P491E、M1229D、P615N、I1283S、H822S、F328G、H212L、K818W、I1283L、F555G/E684G、V828K、R550G、R830M、S839A、H822T、L13Y、L14G、C17V、M836V、S839P、K1210W、Y1281R、V64D、H212G、V682R、L14M、L318C、C17S、A20L、K818G、M836G、T21M、M836R、F325Y、T533V、S19G、L14V、Q817D、L831W、K225R、H1156R、R830V、V393G/A747D、N753D、V393G/K732W/S751Y、V63Q/M797W、L622D、P617E、P617N、P907D、N1040E、P617D、Q611E、V620P、P617G、A488G、P1192D、S1194P、G619E、P615D、F16A、F802S、K818V、L211K、M836W、F555R、V536A、I527A、F555E、H841W、M320Q、S837G、M558R、F555G、L211R、V64G、M320R、T533Y、L914V、F16V、I1283E、V536M、F312L、M681N、S838T、V536R、R15G、V536P、M558W、M558E、L1427Y、S839G、F18L、L13G、K1210M、H1156G、M558L、S839K、L211P、L211G、L211Q、F16D、M320G、Y683W、Y24V、V534I、M681A、P840G、F1160R、M681C、F328Q、R15S、V536K、V536G、T533R、M681E、V536W、H1156N、F16P、Q817A、F18R、Y551W、F555T、M681G、H212A、F16G、S838G、M681R、V393G、V393G/A747D/K752G/Q811F/K819V/Q923M/T1148N、V393G/S751Y/I775G、V63Q/V393G/K732W/I775G/T1148N、V393G/K732W/T1148N、I775G/T1148N、V393G/K752L/N753D/I775G/I793G/M797W、V393G/Q923M、V393G/Q923M/T1148N、V393G/A747D/S751Y、V393G/A747D/N753D/I775G/T1148N、K752L/Q923M/M1051R、V63Q/I775G、V63Q/V393G/K752L/I775G/I793G/M1051R/T1053R、K752G/N753D/I775G/I793G/K819V、V63Q/M1051R、V63Q/A747D/K752G/N753D/I775G/Q811F/K819V/Q923M/M1051R、V393G/K752G/I787W、S751Y、V63Q/T1148N、V63H/A747D/K752G/N753D/K819V/Q923M/T1148N、T1148N、A747D/K752L/N753D/I793G/Q811F、V63Q、M797W/T1148N、S751Y/K752L/N753D/M1051R、V63Q/K732W/M1051R、K752G/M797W/S815I/Q923M/M1051R/T1148N或A747D/N753D,其中該等胺基酸位置係相對於對應於SEQ ID NO: 840之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set V620N, P491E, M1229D, P615N, I1283S, H822S, F328G, H212L, K818W, I1283L, F555G/E684G, V828K, R550G, R830M, S839A, H822T, L13Y, L14G, C17V, M836V, S839P, K1210W, Y1281R, V64D, H212G, V682R, L14M, L318C, C17S, A20L, K818G, M836G, T21M, M836R, F325 Y, T533V, S19G, L14V, Q817D, L831W, K225R, H1156R, R830V, V393G/A747D, N753D, V393G/K732W/S751Y, V63Q/M797W, L622D, P617E, P617N, P907D, N1040E, P617D, Q611E, V62 0P, P617G, A488G, P1192D, S1194P, G619E, P615D, F16A, F802S, K818V, L211K, M836W, F555R, V536A, I527A, F555E, H841W, M320Q, S837G, M558R, F555G, L211R, V64G, M320R, T533Y, L914V, F16V, I1283E, V536M, F312L, M681N, S838T, V536R, R15G, V536P, M558W, M558E, L1427Y, S839G, F18L, L13G, K1210M, H1156G, M558L, S839K, L211P, L211G, L211Q, F16D, M320G, Y683W , Y24V, V534I, M681A, P840G, F1160R, M681C, F328Q, R15S, V536K, V536G, T533R, M681E, V536W, H1156N, F16P, Q817A, F18R, Y551W, F555T, M681G, H212A, F16G, S838G, M681R, V393G, V393G/A747D/K752G/Q811F/ K819V/Q923M/T1148N, V393G/S751Y/I775G, V63Q/V393G/K732W/I775G/T1148N, V393G/K732W/T1148N, I775G/T1148N, V393G/K752L/N753D/I775G/I 793G/M797W, V393G/Q923M, V393G/ Q923M/T1148N, V393G/A747D/S751Y, V393G/A747D/N753D/I775G/T1148N, K752L/Q923M/M1051R, V63Q/I775G, V63Q/V393G/K752L/I775G/I793G/M10 51R/T1053R, K752G/N753D/I775G/ I793G/K819V, V63Q/M1051R, V63Q/A747D/K752G/N753D/I775G/Q811F/K819V/Q923M/M1051R, V393G/K752G/I787W, S751Y, V63Q/T1148N, V63H/A747D /K752G/N753D/K819V/Q923M/ T1148N, T1148N, A747D/K752L/N753D/I793G/Q811F, V63Q, M797W/T1148N, S751Y/K752L/N753D/M1051R, V63Q/K732W/M1051R, K752G/M797W/S815I/Q 923M/M1051R/T1148N or A747D/N753D, The amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 840.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 1200之殘基20-1457的參考序列或與對應於SEQ ID NO: 1200之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 1200之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 1200之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 or at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 1200 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 One or more substitutions of the reference sequence of SEQ ID NO: 1200.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:681、622、617、558、536、211、320、839、797、533、751、303、951、164、818、807、799、735、794、926、755、921、801、1094、968、929、924、698、168、581、916、1428、805、1114、311、737、693、809、757、1099、676、740、791、211/536/622/681、536/558、211/536/555/617/732、211/681/732、211/536/555、555、211/536、211/212、211/536/617/681/732、211/536/558/617/681、555/732、536/555/558/617/732、536/617/681/732、536/555、536/622/681、732、212/320/533/617/681、211/312/533/534/617/619/681/839、212、211/212/320/619/681/839、797/839、212/312/320/533/534/617/681、558/619/681、320/558/681、212/320/534/619/681/797/839、320/558/619/732/839、211/212/312/534/558/619/681/732/839、320/534/558/619/732/797、558/617/619/681、211/534/558/611/681、211/320/617/619/681、558/617/681/797、320/534/619/732、211/619/681、211/212/534/558/619/732/839、212/320/619/681/797/839、212/320/611/839、320/558/619/681、312/533/617/681/797/839、558/611/681、312、211/320/558/619/681/732/797/839、320/558/732/797、533/558/611/619/716/732/839、312/681、320/534/619/681、211/320/533/536/619、558/617/681/839、212/320/534/558/681、533/534/681/839、212/534/619/681、617/619/681、211/212/320/558/617/681、212/534/558/681/797、212/320/534、211/312/619、212/312/619/839、210/212/320/558/681、212/312/534/681/797/839、211/320/558/839、294、759、538或1109,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1200之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide comprises at least one substitution or set of substitutions at the following amino acid positions: 681, 622, 617, 558, 536, 211, 320, 839, 797, 533 ,751,303,951,164,818,807,799,735,794,926,755,921,801,1094,968,929,924,698,168,581,916,1428,805,1114,311 ,737,693,809,757,1099,676,740,791,211/536/622/681,536/558,211/536/555/617/732,211/681/732,211/536/555 ,555,211/536,211/212,211/536/617/681/732,211/536/558/617/681,555/732,536/555/558/617/732,536/617/681 /732, 536/555, 536/622/681, 732, 212/320/533/617/681, 211/312/533/534/617/619/681/839, 212, 211/212/320/619 /681/839、797/839、212/312/320/533/534/617/681、558/619/681、320/558/681、212/320/534/619/681/797/839、320 /558/619/732/839, 211/212/312/534/558/619/681/732/839, 320/534/558/619/732/797, 558/617/619/681, 211/534 /558/611/681、211/320/617/619/681、558/617/681/797、320/534/619/732、211/619/681、211/212/534/558/619/732 /839、212/320/619/681/797/839、212/320/611/839、320/558/619/681、312/533/617/681/797/839、558/611/681、312 ,211/320/558/619/681/732/797/839, 320/558/732/797, 533/558/611/619/716/732/839, 312/681, 320/534/619/681 ,211/320/533/536/619, 558/617/681/839, 212/320/534/558/681, 533/534/681/839, 212/534/619/681, 617/619/681 ,211/212/320/558/617/681, 212/534/558/681/797, 212/320/534, 211/312/619, 212/312/619/839, 210/212/320/558 /681, 212/312/534/681/797/839, 211/320/558/839, 294, 759, 538 or 1109, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 1200 Reference sequence.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集681A、622D、617G、558L、536K、681G、211Q、320R、558W、839K、211K、797W、533R、751A、303T、951V、164E、818G、807L、799A、735S、794R、926V、755P、921W、801A、1094S、968A、929Q、924W、807P、698D、168G、929V、818A、818S、581K、818P、916K、698S、303G、916C、1428G、805L、924M、1114M、311G、737N、805V、801I、751D、693T、818E、929A、311E、737L、809W、757A、1099G、799G、916I、805G、737F、737M、799P、807C、916E、676Q、581V、968P、755Y、916Q、735D、740G、698Y、757G、791T、1114A、735V、536P、211R/536K/622D/681A、536K/558L、211R/536R/555G/617G/732K、211R/681R/732K、211R/536K/555E、536R、555E、211R/536P、211R/212P、211R/536K、211R/536K/617G/681A/732K、211R、211R/536P/558L/617G/681A、555G/732K、536P/555E/558L/617G/732K、536K/617G/681A/732K、536K/555G、536P/622D/681A、732K、212A/320Q/533R/617E/681G、211K/312L/533R/534I/617D/619E/681N/839K、212A、211K/212A/320Q/619E/681G/839K、797W/S839K、212A/312L/320Q/533R/534I/617E/681G、558W/619E/681G、320Q/558W/681G、212A/320Q/534I/619E/681G/797W/839K、320R/558W/619E/732K/839K、211K/212A/312L/534I/558W/619E/681N/732K/839K、320R/534I/558R/619E/732K/797W、558W/617D/619E/681N、211Q/534I/558W/611E/681N、211K/320R/617E/619E/681G、558W/617D/681G/797W、320R/534I/619E/732K、211K/619E/681N、211K/212A/534I/558W/619E/732K/839K、212A/320R/619E/681N/797W/839K、212A/320R/611E/839K、320Q/558W/619E/681N、312L/533R/617D/681N/797W/839K、558W/611E/681N、312L、211Q/320R/558W/619E/681G/732K/797W/839K、320Q/558W/732K/797W、533R/558W/611E/619E/716L/732K/839K、312L/681G、320Q/534I/619E/681N、211K/320Q/533R/536L/619E、558W/617E/681N/839K、212A/320R/534I/558W/681G、533R/534I/681N/839K、212A/534I/619E/681G、617E/619E/681G、211Q/212A/320R/558W/617E/681N、212A/534I/558W/681N/797W、212A/320R/534I、211K/312L/619E、212A/312L/619E/839K、210P/212A/320R/558W/681G、212A/312L/534I/681N/797W/839K、211K/320R/558W/839K、924Q、916L、757T、737K、818V、801G、294G、799S、799E、809G、791M、737V、805Q、799Q、737S、916M、759S、799V、538V、1109G、168R、921R、926T、916T、737G或801R,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1200之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 681A, 622D, 617G, 558L, 536K, 681G, 211Q, 320R, 558W, 839K, 211K, 797W, 533R, 751A, 303T、951V、164E、818G、807L、799A、735S、794R、926V、755P、921W、801A、1094S、968A、929Q、924W、807P、698D、168G、929V、818A、818S、581K、818P、91 6K, 698S, 303G, 916C, 1428G, 805L, 924M, 1114M, 311G, 737N, 805V, 801I, 751D, 693T, 818E, 929A, 311E, 737L, 809W, 757A, 1099G, 799G, 916I, 805G, 737F, 737M, 799P, 807C, 916E, 676Q, 581V, 968P, 755Y, 916Q, 735D, 740G, 698Y, 757G, 791T, 1114A, 735V, 536P, 211R/536K/622D/681A, 536K/558L, 211R/536R/55 5G/ 617G/732K, 211R/681R/732K, 211R/536K/555E, 536R, 555E, 211R/536P, 211R/212P, 211R/536K, 211R/536K/617G/681A/732K, 211R, 211R/536P/558 L/ 617G/681A, 555G/732K, 536P/555E/558L/617G/732K, 536K/617G/681A/732K, 536K/555G, 536P/622D/681A, 732K, 212A/320Q/533R/617E/681G, 211 K/ 312L/533R/534I/617D/619E/681N/839K, 212A, 211K/212A/320Q/619E/681G/839K, 797W/S839K, 212A/312L/320Q/533R/534I/617E/681G, 558W/61 9E/ 681G, 320Q/558W/681G, 212A/320Q/534I/619E/681G/797W/839K, 320R/558W/619E/732K/839K, 211K/212A/312L/534I/558W/619E/681N/732K/839 K. 320R/534I/558R/619E/732K/797W, 558W/617D/619E/681N, 211Q/534I/558W/611E/681N, 211K/320R/617E/619E/681G, 558W/617D/681G/797W, 320 R/ 534I/619E/732K, 211K/619E/681N, 211K/212A/534I/558W/619E/732K/839K, 212A/320R/619E/681N/797W/839K, 212A/320R/611E/839K, 320Q/558 W/ 533 R/ 558W/611E/619E/716L/732K/839K, 312L/681G, 320Q/534I/619E/681N, 211K/320Q/533R/536L/619E, 558W/617E/681N/839K, 212A/320R/534I/558 W/ 681G、533R/534I/681N/839K、212A/534I/619E/681G、617E/619E/681G、211Q/212A/320R/558W/617E/681N、212A/534I/558W/681N/797W、212A/320 R/ 534I, 211K/312L/619E, 212A/312L/619E/839K, 210P/212A/320R/558W/681G, 212A/312L/534I/681N/797W/839K, 211K/320R/558W/839K, 924Q, 916 L. 757T, 737K, 818, 801G, 294G, 799S, 799E, 809G, 791M, 737V, 805Q, 799Q, 737S, 916M, 759S, 799V, 538V, 1109G, 168R, 926T, 916T, 737G, or 801R, of which this of which is this. Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1200.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集M681A、L622D、P617G、M558L、V536K、M681G、L211Q、M320R、M558W、S839K、L211K、M797W、T533R、S751A、A303T、T951V、G164E、K818G、E807L、K799A、G735S、S794R、E926V、A755P、Q921W、D801A、E1094S、L968A、K929Q、G924W、E807P、F698D、S168G、K929V、K818A、K818S、R581K、K818P、S916K、F698S、A303G、S916C、T1428G、Y805L、G924M、L1114M、T311G、Y737N、Y805V、D801I、S751D、S693T、K818E、K929A、T311E、Y737L、E809W、E757A、A1099G、K799G、S916I、Y805G、Y737F、Y737M、K799P、E807C、S916E、T676Q、R581V、L968P、A755Y、S916Q、G735D、D740G、F698Y、E757G、D791T、L1114A、G735V、V536P、L211R/V536K/L622D/M681A、V536K/M558L、L211R/V536R/F555G/P617G/W732K、L211R/M681R/W732K、L211R/V536K/F555E、V536R、F555E、L211R/V536P、L211R/H212P、L211R/V536K、L211R/V536K/P617G/M681A/W732K、L211R、L211R/V536P/M558L/P617G/M681A、F555G/W732K、V536P/F555E/M558L/P617G/W732K、V536K/P617G/M681A/W732K、V536K/F555G、V536P/L622D/M681A、W732K、H212A/M320Q/T533R/P617E/M681G、L211K/F312L/T533R/V534I/P617D/G619E/M681N/S839K、H212A、L211K/H212A/M320Q/G619E/M681G/S839K、M797W/S839K、H212A/F312L/M320Q/T533R/V534I/P617E/M681G、M558W/G619E/M681G、M320Q/M558W/M681G、H212A/M320Q/V534I/G619E/M681G/M797W/S839K、M320R/M558W/G619E/W732K/S839K、L211K/H212A/F312L/V534I/M558W/G619E/M681N/W732K/S839K、M320R/V534I/M558R/G619E/W732K/M797W、M558W/P617D/G619E/M681N、L211Q/V534I/M558W/Q611E/M681N、L211K/M320R/P617E/G619E/M681G、M558W/P617D/M681G/M797W、M320R/V534I/G619E/W732K、L211K/G619E/M681N、L211K/H212A/V534I/M558W/G619E/W732K/S839K、H212A/M320R/G619E/M681N/M797W/S839K、H212A/M320R/Q611E/S839K、M320Q/M558W/G619E/M681N、F312L/T533R/P617D/M681N/M797W/S839K、M558W/Q611E/M681N、F312L、L211Q/M320R/M558W/G619E/M681G/W732K/M797W/S839K、M320Q/M558W/W732K/M797W、T533R/M558W/Q611E/G619E/F716L/W732K/S839K、F312L/M681G、M320Q/V534I/G619E/M681N、L211K/M320Q/T533R/V536L/G619E、M558W/P617E/M681N/S839K、H212A/M320R/V534I/M558W/M681G、T533R/V534I/M681N/S839K、H212A/V534I/G619E/M681G、P617E/G619E/M681G、L211Q/H212A/M320R/M558W/P617E/M681N、H212A/V534I/M558W/M681N/M797W、H212A/M320R/V534I、L211K/F312L/G619E、H212A/F312L/G619E/S839K、T210P/H212A/M320R/M558W/M681G、H212A/F312L/V534I/M681N/M797W/S839K、L211K/M320R/M558W/S839K、G924Q、S916L、E757T、Y737K、K818V、D801G、T294G、K799S、K799E、E809G、D791M、Y737V、Y805Q、K799Q、Y737S、S916M、R759S、K799V、D538V、E1109G、S168R、Q921R、E926T、S916T、Y737G或D801R,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1200之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set M681A, L622D, P617G, M558L, V536K, M681G, L211Q, M320R, M558W, S839K, L211K, M797W, T533R, S751A, A303T, T951V, G164E, K818G, E807L, K799A, G735S, S794R, E926V, A755P, Q921W, D801A, E1094S, L968A, K929Q, G924W, E807P, F698D, S168G, K929V, K81 8A, K818S, R581K, K818P, S916K, F698S, A303G, S916C, T1428G, Y805L, G924M, L1114M, T311G, Y737N, Y805V, D801I, S751D, S693T, K818E, K929A, T311E, Y737L, E809W, E757A, A1099G, K 799G, S916I, Y805G, Y737F, Y737M, K799P, E807C, S916E, T676Q, R581V, L968P, A755Y, S916Q, G735D, D740G, F698Y, E757G, D791T, L1114A, G735V, V536P, L211R/V536K/L622D/M681A, V53 6K/M558L, L211R/V536R/F555G/ P617G/W732K, L211R/M681R/W732K, L211R/V536K/F555E, V536R, F555E, L211R/V536P, L211R/H212P, L211R/V536K, L211R/V536K/P617G/M681A/W732 K, L211R, L211R/V536P/M558L/ P617G/M681A, F555G/W732K, V536P/F555E/M558L/P617G/W732K, V536K/P617G/M681A/W732K, V536K/F555G, V536P/L622D/M681A, W732K, H212A/M320 Q/T533R/P617E/M681G, L211K/ F312L/T533R/V534I/P617D/G619E/M681N/S839K, H212A, L211K/H212A/M320Q/G619E/M681G/S839K, M797W/S839K, H212A/F312L/M320Q/T533R/V534 I/P617E/M681G, M558W/G619E/ M681G, M320Q/M558W/M681G, H212A/M320Q/V534I/G619E/M681G/M797W/S839K, M320R/M558W/G619E/W732K/S839K, L211K/H212A/F312L/V534I/M558 W/G619E/M681N/W732K/S839K, M320R/V534I/M558R/G619E/W732K/M797W, M558W/P617D/G619E/M681N, L211Q/V534I/M558W/Q611E/M681N, L211K/M320R/P617E/G619E/M681G, M558 W/P617D/M681G/M797W, M320R/ V534I/G619E/W732K, L211K/G619E/M681N, L211K/H212A/V534I/M558W/G619E/W732K/S839K, H212A/M320R/G619E/M681N/M797W/S839K, H212A/M320 R/Q611E/S839K, M320Q/M558W/ G619E/M681N, F312L/T533R/P617D/M681N/M797W/S839K, M558W/Q611E/M681N, F312L, L211Q/M320R/M558W/G619E/M681G/W732K/M797W/S839K, M320 Q/M558W/W732K/M797W, T533R/ M558W/Q611E/G619E/F716L/W732K/S839K, F312L/M681G, M320Q/V534I/G619E/M681N, L211K/M320Q/T533R/V536L/G619E, M558W/P617E/M681N/S839 K. H212A/M320R/V534I/M558W/ M681G, T533R/V534I/M681N/S839K, H212A/V534I/G619E/M681G, P617E/G619E/M681G, L211Q/H212A/M320R/M558W/P617E/M681N, H212A/V534I/M558 W/M681N/M797W, H212A/M320R/ V534I, L211K/F312L/G619E, H212A/F312L/G619E/S839K, T210P/H212A/M320R/M558W/M681G, H212A/F312L/V534I/M681N/M797W/S839K, L211K/M320 R/M558W/S839K, G924Q, S916L, E757T, Y737K, K818V, D801G, T294G, K799S, K799E, E809G, D791M, Y737V, Y805Q, K799Q, Y737S, S916M, R759S, K799V, D538V, E1109G, S168R, Q921R, E92 6T, S916T, Y737G or D801R, which Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1200.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 1514之殘基20-1457的參考序列或與對應於SEQ ID NO: 1514之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 1514之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 1514之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 or is at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 1514 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 One or more substitutions of the reference sequence of SEQ ID NO: 1514.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:1042、1041、1051、1283、1281、916、187、215、178、1050、1210、104、615、610、536、618、621、614、110、301、1078、812、786、127、175、1093、1088、650、535、806、738、700、132、1076、1084、498、756、1108、746、160、543、310、584、918、1452、790、292、800、167、892、304、1116、752、281、917、712、1080、806/1352、1095、744、1098、948、119、785、1113、667、158、580、707、731、1100、1089、1092、939、1104、736、1297、1127、686、1129、1138、786/821、680、1101、808、739、308、536/555/619/732/799/805、555/619/801、555/619/799、619/799/801/805、536/555/619/732/799、799/805、801、246/619/799/801、536/555/619、619/839、619/799/805、536/801/805、555/619/799/805、619/801/805、555/619、536/619/801、801/805、536/619/799/805、555/619/732/799/801/805、749、616、611、370/614、1156、1158、555/681/737/799、536/619/809/1109、536/555/619/737/799/809/839/916/921、916/1109、536/619/681/799/916/1109、555/619/681/807/1109、555/619/681/737/799、619/681/799/916/1109、619/681、555/921、619/681/916、555/619/681/799、555、732、619/799、619、681、555/916、839或799,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1514之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 1042, 1041, 1051, 1283, 1281, 916, 187, 215, 178, 1050 ,1210,104,615,610,536,618,621,614,110,301,1078,812,786,127,175,1093,1088,650,535,806,738,700,132,1076,1084 ,498,756,1108,746,160,543,310,584,918,1452,790,292,800,167,892,304,1116,752,281,917,712,1080,806/1352,1095 ,744,1098,948,119,785,1113,667,158,580,707,731,1100,1089,1092,939,1104,736,1297,1127,686,1129,1138,786/821,680 ,1101,808,739,308,536/555/619/732/799/805,555/619/801,555/619/799,619/799/801/805,536/555/619/732/799 ,799/805,801,246/619/799/801,536/555/619,619/839,619/799/805,536/801/805,555/619/799/805,619/801/805 ,555/619,536/619/801,801/805,536/619/799/805,555/619/732/799/801/805,749,616,611,370/614,1156,1158,555 /681/737/799, 536/619/809/1109, 536/555/619/737/799/809/839/916/921, 916/1109, 536/619/681/799/916/1109, 555 /619/681/807/1109, 555/619/681/737/799, 619/681/799/916/1109, 619/681, 555/921, 619/681/916, 555/619/681/799 , 555, 732, 619/799, 619, 681, 555/916, 839 or 799, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1514.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集1042E、1041N、1051H、1283H、1283T、1281Q、1281P、916E、1051W、187C、215E、215P、215S、178C、1050T、1210T、1281K、1042A、104S、615D、610S、610K、610T、536P、618Y、621W、618P、614F、110H、301K、1078S、812G、786C、127V、175G、1093W、1088G、1093T、650M、301M、535N、806R、738E、700E、132R、1076G、1084L、498A、786L、738F、535G、806E、756G、1108S、1093V、746P、160E、160T、178V、543L、310G、700Q、1093A、584A、918S、1452L、738P、790W、790I、292D、800M、1108M、1088S、167G、892T、790P、800R、738K、304G、1116G、178Q、1116A、752G、1108W、738D、281A、917G、712M、1080V、806G/1352E、1095G、1093G、744A、543G、1098G、281S、756T、948S、119V、1116L、785V、1113F、700A、786D、175A、790M、667I、158G、580S、707H、731I、918M、1100S、1089S、712Y、175H、1092G、939E、1104E、800G、736F、543W、1297A、712L、1127V、939S、178M、731R、686W、543P、736G、1129P、1138Q、812V、786D/821Q、535C、680R、1116I、1089F、304E、178W、1104C、744R、738R、1093S、712S、187G、132P、812I、1080G、800C、1101G、808K、808S、790A、800V、680L、167R、752E、1093N、119G、739G、1116R、580Y、304A、712Q、806S、712G、790G、1108V、731L、1084N、1127L、308P、1076S、1093P、1093Y、739R、739P、310V、712T、167H、1093R、536P/555E/619E/732K/799S/805Q、555E/619E/801G、555E/619E/799S、619E/799S/801G/805Q、536P/555E/619E/732K/799S、799S/805Q、801G、246D/619E/799S/801G、536P/555E/619E、619E/839K、619E/799S/805Q、536P/801G/805Q、555E/619E/799S/805Q、619E/801G/805Q、555E/619E、536P/619E/801G、801G/805Q、536P/619E/799S/805Q、555E/619E/732K/799S/801G/805Q、1281H、749L、614H、616D、621K、1050E、610H、611D、1042T、616Q、614N、370A/614A、1156D、1210V、614T、1158N、1281S、618E、555E/681N/737K/799Q、536P/619E/809G/1109G、536K/555G/619E/737K/799Q/809G/839K/916T/921R、916T/1109G、536R/619E/681N/799Q/916T/1109G、555G/619E/681N/807R/1109G、555E/619E/681N/737K/799Q、619E/681N/799S/916T/1109G、619E/681N、555G/921R、619E/681N/916T、555G/619E/681N/799S、555E、732K、619E/799S、619E、681N、555G/916T、839K或799Q,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1514之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions 1042E, 1041N, 1051H, 1283H, 1283T, 1281Q, 1281P, 916E, 1051W, 187C, 215E, 215P, 215S, 178C, 1050T, 1210T, 1281K, 1042A, 104S, 615D, 610S, 610K, 610T, 536P, 618Y, 621W, 618P, 614F, 110H, 301K, 1078S, 812G, 786C, 127V, 175G, 1093W, 1088G, 1 093T、650M、 301M, 535N, 806R, 738E, 700E, 132R, 1076G, 1084L, 498A, 786L, 738F, 535G, 806E, 756G, 1108S, 1093V, 746P, 160E, 160T, 178V, 543L, 310G, 700Q, 1093 A、584A、 918S, 1452L, 738P, 790W, 790I, 292D, 800M, 1108M, 1088S, 167G, 892T, 790P, 800R, 738K, 304G, 1116G, 178Q, 1116A, 752G, 1108W, 738D, 281A, 917G, 71 2M, 1080V, 806G/1352E、1095G、1093G、744A、543G、1098G、281S、756T、948S、119V、1116L、785V、1113F、700A、786D、175A、790M、667I、158G、580S、707H、731I、91 8M, 1100S, 5 35C, 680R, 1116I, 1089F, 304E, 178W, 1104C, 744R, 738R, 1093S, 712S, 187G, 132P, 812I, 1080G, 800C, 1101G, 808K, 808S, 790A, 800V, 680L, 167R, 752E, 1093N, 1 19G, 739G, 1116R, 580Y, 304A, 712Q, 806S, 712G, 790G, 1108V, 731L, 1084N, 1127L, 308P, 1076S, 1093P, 1093Y, 739R, 739P, 310V, 712T, 167H, 1093R, 536P/555E/ 619E/732K/ 536 P/ 555E/619E, 619E/839K, 619E/799S/805Q, 536P/801G/805Q, 555E/619E/799S/805Q, 619E/801G/805Q, 555E/619E, 536P/619E/801G, 801G/805Q, 536 P/ 619E/799S/805Q, 555E/619E/732K/799S/801G/805Q, 1281H, 749L, 614H, 616D, 621K, 1050E, 610H, 611D, 1042T, 616Q, 614N, 370A/614A, 1156D, 1210 V、614T、 1158N, 1281S, 618E, 555E/681N/737K/799Q, 536P/619E/809G/1109G, 536K/555G/619E/737K/799Q/809G/839K/916T/921R, 916T/1109G, 536R/619E /681N/ 799Q/916T/1109G, 555G/619E/681N/807R/1109G, 555E/619E/681N/737K/799Q, 619E/681N/799S/916T/1109G, 619E/681N, 555G/921R, 619E/681N/ 916T、 555G/619E/681N/799S, 555E, 732K, 619E/799S, 619E, 681N, 555G/916T, 839K or 799Q, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1514.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集R1042E、Y1041N、M1051H、I1283H、I1283T、Y1281Q、Y1281P、S916E、M1051W、L187C、I215E、I215P、I215S、L178C、I1050T、K1210T、Y1281K、R1042A、V104S、P615D、I610S、I610K、I610T、V536P、A618Y、Q621W、A618P、L614F、M110H、R301K、I1078S、S812G、E786C、A127V、Y175G、K1093W、F1088G、K1093T、L650M、R301M、T535N、D806R、Y738E、S700E、E132R、E1076G、S1084L、G498A、E786L、Y738F、T535G、D806E、I756G、F1108S、K1093V、S746P、L160E、L160T、L178V、S543L、I310G、S700Q、K1093A、Q584A、E918S、E1452L、Y738P、D790W、D790I、G292D、E800M、F1108M、F1088S、A167G、V892T、D790P、E800R、Y738K、S304G、S1116G、L178Q、S1116A、K752G、F1108W、Y738D、T281A、Y917G、H712M、S1080V、D806G/K1352E、E1095G、K1093G、D744A、S543G、M1098G、T281S、I756T、M948S、A119V、S1116L、E785V、M1113F、S700A、E786D、Y175A、D790M、F667I、Q158G、Q580S、W707H、D731I、E918M、L1100S、T1089S、H712Y、Y175H、K1092G、T939E、Y1104E、E800G、D736F、S543W、N1297A、H712L、I1127V、T939S、L178M、D731R、T686W、S543P、D736G、E1129P、L1138Q、S812V、E786D/R821Q、T535C、K680R、S1116I、T1089F、S304E、L178W、Y1104C、D744R、Y738R、K1093S、H712S、L187G、E132P、S812I、S1080G、E800C、Y1101G、D808K、D808S、D790A、E800V、K680L、A167R、K752E、K1093N、A119G、E739G、S1116R、Q580Y、S304A、H712Q、D806S、H712G、D790G、F1108V、D731L、S1084N、I1127L、S308P、E1076S、K1093P、K1093Y、E739R、E739P、I310V、H712T、A167H、K1093R、V536P/F555E/G619E/W732K/K799S/Y805Q、F555E/G619E/D801G、F555E/G619E/K799S、G619E/K799S/D801G/Y805Q、V536P/F555E/G619E/W732K/K799S、K799S/Y805Q、D801G、A246D/G619E/K799S/D801G、V536P/F555E/G619E、G619E/S839K、G619E/K799S/Y805Q、V536P/D801G/Y805Q、F555E/G619E/K799S/Y805Q、G619E/D801G/Y805Q、F555E/G619E、V536P/G619E/D801G、D801G/Y805Q、V536P/G619E/K799S/Y805Q、F555E/G619E/W732K/K799S/D801G/Y805Q、Y1281H、F749L、L614H、N616D、Q621K、I1050E、I610H、Q611D、R1042T、N616Q、L614N、T370A/L614A、H1156D、K1210V、L614T、R1158N、Y1281S、A618E、F555E/G681N/Y737K/K799Q、V536P/G619E/E809G/E1109G、V536K/F555G/G619E/Y737K/K799Q/E809G/S839K/S916T/Q921R、S916T/E1109G、V536R/G619E/G681N/K799Q/S916T/E1109G、F555G/G619E/G681N/E807R/E1109G、F555E/G619E/G681N/Y737K/K799Q、G619E/G681N/K799S/S916T/E1109G、G619E/G681N、F555G/Q921R、G619E/G681N/S916T、F555G/G619E/G681N/K799S、F555E、W732K、G619E/K799S、G619E、G681N、F555G/S916T、S839K或K799Q,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1514之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set R1042E, Y1041N, M1051H, I1283H, I1283T, Y1281Q, Y1281P, S916E, M1051W, L187C, I215E, I215P, I215S, L178C, I1050T, K1210T, Y1281K, R1042A, V104S, P615D, I610S, I610K, I610T, V536P, A618Y, Q621W, A618P, L614F, M110H, R301K, I1078S, S812G, E786C, A127V , Y175G, K1093W, F1088G, K1093T, L650M, R301M, T535N, D806R, Y738E, S700E, E132R, E1076G, S1084L, G498A, E786L, Y738F, T535G, D806E, I756G, F1108S, K1093V, S746P, L160E, L160T, L178V, S543L, I310G, S700Q, K1093A, Q584A, E918S, E1452L, Y738P, D790W, D790I, G292D, E800M, F1108M, F1088S, A167G, V892T, D790P, E800R, Y738K, S304G, S1116G, L178Q, S1116A, K752G, F1108 W, Y738D, T281A, Y917G, H712M, S1080V, D806G/K1352E, E1095G, K1093G, D744A, S543G, M1098G, T281S, I756T, M948S, A119V, S1116L, E785V, M1113F, S700A, E786D, Y175A, D790M, F667I, Q158 G, Q580S, W707H, D731I, E918M, L1100S, T1089S, H712Y, Y175H, K1092G, T939E, Y1104E, E800G, D736F, S543W, N1297A, H712L, I1127V, T939S, L178M, D731R, T686W, S543P, D736G, E1129P, L113 8Q, S812V, E786D/R821Q, T535C, K680R, S1116I, T1089F, S304E, L178W, Y1104C, D744R, Y738R, K1093S, H712S, L187G, E132P, S812I, S1080G, E800C, Y1101G, D808K, D808S, D790A, E800V, K680 L, A167R, K752E, K1093N, A119G, E739G, S1116R, Q580Y, S304A, H712Q, D806S, H712G, D790G, F1108V, D731L, S1084N, I1127L, S308P, E1076S, K1093P, K1093Y, E739R, E739P, I310V, H712T, A16 7H, K1093R, V536P/F555E/G619E/W732K/ K799S/Y805Q, F555E/G619E/D801G, F555E/G619E/K799S, G619E/K799S/D801G/Y805Q, V536P/F555E/G619E/W732K/K799S, K799S/Y805Q, D801G, A246 D/G619E/K799S/D801G, V536P/ F555E/G619E, G619E/S839K, G619E/K799S/Y805Q, V536P/D801G/Y805Q, F555E/G619E/K799S/Y805Q, G619E/D801G/Y805Q, F555E/G619E, V536P/G619 E/D801G, D801G/Y805Q, V536P/ G619E/K799S/Y805Q, F555E/G619E/W732K/K799S/D801G/Y805Q, Y1281H, F749L, L614H, N616D, Q621K, I1050E, I610H, Q611D, R1042T, N616Q, L614N, T 370A/L614A, H1156D, K1210V, L614T, R1158N, Y1281S, A618E, F555E/G681N/Y737K/K799Q, V536P/G619E/E809G/E1109G, V536K/F555G/G619E/Y737K/K799Q/E809G/S839K/S916T/Q921R, S 916T/E1109G, V536R/G619E/G681N/ K799Q/S916T/E1109G, F555G/G619E/G681N/E807R/E1109G, F555E/G619E/G681N/Y737K/K799Q, G619E/G681N/K799S/S916T/E1109G, G619E/G681N, F 555G/Q921R, G619E/G681N/S916T, F555G/G619E/G681N/K799S, F555E, W732K, G619E/K799S, G619E, G681N, F555G/S916T, S839K or K799Q, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1514.
在一些實施例中,重組因子VIII多肽包含與對應於SEQ ID NO: 2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2072之該參考序列的一或多個取代。In some embodiments, the recombinant Factor VIII polypeptide comprises a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 or at least 70%, 75%, 80% identical to a reference sequence corresponding to SEQ ID NO: 2072 , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 or relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 One or more substitutions of the reference sequence of SEQ ID NO: 2072.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個在下列胺基酸位置處的取代或取代集:167、167/738/1076/1093、167/738/752/800/805/808/809/1116、167/800/809/1076、167/318、167/318/800/805/808/809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167、167/738/1076/1093、167/738/752/800/805/808/809/1116、167/800/809/1076、167/318、167/318/800/805/808/809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167/318/700/1076、167/318/700/738/739/1076、167/681/738/800/808/809、167/178/700/752/1093、167/700、167/700/738/739/1093、167/700/738/752/1093、167/700/738/752/805/808/809/1093/1116、808/809、1076、738、738/808/809、738/1076、738/739、738/739/809、738/739/809/1093/1116、738/739/1093、738/739/752/1093、738/739/799/800/1093、738/739/1116、738/800、738/1093、738/752、738/752/1093、738/752/799、738/799/809/1093、738/799/1093、739、739/800/809、800、800/805/809、809、809/1093、809/1093/1116、809/1116、318、318/1076、318/1076/1116、318/739/805/808/809/1076、318/499/700/738/809、318/1093、318/752/1093、318/1116、318/543/739、318/543/681/752/1116、318/543/1093、318/700/738/1093/1414、681、681/738、681/738/739/1093、681/738/739/752/799/800/809/1116/1339、681/738/739/1116、681/738/800、681/800/805/809、681/809/1093、681/752/1093、681/752/1093、681/700、681/700/738/739/1093/1116、681/700/809、681/700/1093、681/700/752/808/809/1093/1116、681/700/752/1093、681/700/844、681/700/805/809、1093、1093/1116、752、752/1076、752/800/809、752/800/1093、752/809、752/866、752/1093、752/1116、178/318/739/752/809/1076/1116、178/318/800/809、178/318/681/800/808/809/1076、178/681、178/681/738/1116、178/752/809、178/700/800/805/808/809、178/805/809/866、1116、543、543/738/739/809、543/738/809/1093、543/739/1093、543/800/1093/1116、543/809/1093、543/809/1093/1116、543/681/738/739/752/809/1093、543/681/738/739/752/1093、543/681/739/752/800/805/809/1093、543/681/700/738/739/800/1093/1116、543/681/700/738/739/805/808/809、543/681/700/752、543/681/700/752/809/1093、543/1093、543/700、543/700/738/739/752/800/1093/1116、543/700/809、543/700/1093、543/700/752、543/700/752/800/1093、543/700/752/809/1116、543/700/752/1093、700、700/738/739/800/1093、700/738/739/799/1093、700/738/800/1093、700/738/1116、700/809、700/809/1093、700/1093、700/1093/1116、700/752、700/752/808/809/1093/1116、700/752/809/1093、700/752/799/1116、700/752/805/809/1093、700/799/800、700/1116、700/805/808/809/1076、514/543/681/805/808/809、805/808/809或805/809/1116,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or set of substitutions at the following amino acid positions: 167, 167/738/1076/1093, 167/738/752/800/805 /808/809/1116, 167/800/809/1076, 167/318, 167/318/800/805/808/809, 167/318/681, 167/318/681/700/805/808/809 /1076/1116, 167/318/700, 167, 167/738/1076/1093, 167/738/752/800/805/808/809/1116, 167/800/809/1076, 167/318, 167 /318/800/805/808/809, 167/318/681, 167/318/681/700/805/808/809/1076/1116, 167/318/700, 167/318/700/1076, 167 /318/700/738/739/1076, 167/681/738/800/808/809, 167/178/700/752/1093, 167/700, 167/700/738/739/1093, 167/700 /738/752/1093, 167/700/738/752/805/808/809/1093/1116, 808/809, 1076, 738, 738/808/809, 738/1076, 738/739, 738/739 /809、738/739/809/1093/1116、738/739/1093、738/739/752/1093、738/739/799/800/1093、738/739/1116、738/800、738/1093 ,738/752, 738/752/1093, 738/752/799, 738/799/809/1093, 738/799/1093, 739, 739/800/809, 800, 800/805/809, 809, 809 /1093, 809/1093/1116, 809/1116, 318, 318/1076, 318/1076/1116, 318/739/805/808/809/1076, 318/499/700/738/809, 318/1093 ,318/752/1093, 318/1116, 318/543/739, 318/543/681/752/1116, 318/543/1093, 318/700/738/1093/1414, 681, 681/738, 681 /738/739/1093、681/738/739/752/799/800/809/1116/1339、681/738/739/1116、681/738/800、681/800/805/809、681/809 /1093、681/752/1093、681/752/1093、681/700、681/700/738/739/1093/1116、681/700/809、681/700/1093、681/700/752/808 /809/1093/1116, 681/700/752/1093, 681/700/844, 681/700/805/809, 1093, 1093/1116, 752, 752/1076, 752/800/809, 752/800 /1093、752/809、752/866、752/1093、752/1116、178/318/739/752/809/1076/1116、178/318/800/809、178/318/681/800/808 /809/1076, 178/681, 178/681/738/1116, 178/752/809, 178/700/800/805/808/809, 178/805/809/866, 1116, 543, 543/738 /739/809、543/738/809/1093、543/739/1093、543/800/1093/1116、543/809/1093、543/809/1093/1116、543/681/738/739/752 /809/1093、543/681/738/739/752/1093、543/681/739/752/800/805/809/1093、543/681/700/738/739/800/1093/1116、543 /681/700/738/739/805/808/809, 543/681/700/752, 543/681/700/752/809/1093, 543/1093, 543/700, 543/700/738/739 /752/800/1093/1116, 543/700/809, 543/700/1093, 543/700/752, 543/700/752/800/1093, 543/700/752/809/1116, 543/700 /752/1093, 700, 700/738/739/800/1093, 700/738/739/799/1093, 700/738/800/1093, 700/738/1116, 700/809, 700/809/1093 ,700/1093, 700/1093/1116, 700/752, 700/752/808/809/1093/1116, 700/752/809/1093, 700/752/799/1116, 700/752/805/809 /1093, 700/799/800, 700/1116, 700/805/808/809/1076, 514/543/681/805/808/809, 805/808/809 or 805/809/1116, among which Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2072.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集167G、167G/738Y/1076S/1093G、167G/738Y/752E/800V/805Q/808S/809G/1116I、167G/800V/809G/1076S、167G/318L、167G/318L/800V/805Q/808S/809G、167G/318L/681N、167G/318L/681N/700E/805Q/808S/809G/1076S/1116I、167G/318L/700E、167G/318L/700E/1076S、167G/318L/700E/738Y/739G/1076S、167G/681N/738Y/800V/808S/809G、167G/178Q/700E/752E/1093G、167G/700E、167G/700E/738Y/739G/1093G、167G/700E/738Y/752E/1093G、167G/700E/738Y/752E/805Q/808S/809G/1093A/1116I、808S/809G、1076S、738Y、738Y/808S/809G、738Y/1076S、738Y/739G、738Y/739G/809G、738Y/739G/809G/1093G/1116I、738Y/739G/1093G、738Y/739G/752E/1093G、738Y/739G/799S/800V/1093G、738Y/739G/1116I、738Y/800V、738Y/1093G、738Y/752E、738Y/752E/1093G、738Y/752E/799S、738Y/799S/809G/1093G、738Y/799S/1093G、739G、739G/800V/809G、800V、800V/805Q/809G、809G、809G/1093G、809G/1093G/1116I、809G/1116I、318L、318L/1076S、318L/1076S/1116I、318L/739G/805Q/808S/809G/1076S、318L/499L/700E/738Y/809G、318L/1093A、318L/752E/1093A、318L/1116I、318L/543P/739G、318L/543P/681N/752E/1116I、318L/543P/1093A、318L/700E/738Y/1093A/1414N、681N、681N/738Y、681N/738Y/739G/1093G、681N/738Y/739G/752E/799S/800V/809G/1116I/1339C、681N/738Y/739G/1116I、681N/738Y/800V、681N/800V/805Q/809G、681N/809G/1093G、681N/752E/1093A、681N/752E/1093G、681N/700E、681N/700E/738Y/739G/1093G/1116I、681N/700E/809G、681N/700E/1093G、681N/700E/752E/808S/809G/1093G/1116I、681N/700E/752E/1093G、681N/700E/844H、681N/700E/805Q/809G、1093A、1093G、1093G/1116I、752E、752E/1076S、752E/800V/809G、752E/800V/1093G、752E/809G、752E/866A、752E/1093G、752E/1116I、178Q/318L/739G/752E/809G/1076S/1116I、178Q/318L/800V/809G、178Q/318L/681N/800V/808S/809G/1076S、178Q/681N、178Q/681N/738Y/1116I、178Q/752E/809G、178Q/700E/800V/805Q/808S/809G、178Q/805Q/809G/866A、1116I、543P、543P/738Y/739G/809G、543P/738Y/809G/1093G、543P/739G/1093A、543P/800V/1093G/1116I、543P/809G/1093G、543P/809G/1093G/1116I、543P/681N/738Y/739G/752E/809G/1093G、543P/681N/738Y/739G/752E/1093G、543P/681N/739G/752E/800V/805Q/809G/1093G、543P/681N/700E/738Y/739G/800V/1093G/1116I、543P/681N/700E/738Y/739G/805Q/808S/809G、543P/681N/700E/752E、543P/681N/700E/752E/809G/1093G、543P/1093G、543P/700E、543P/700E/738Y/739G/752E/800V/1093G/1116I、543P/700E/809G、543P/700E/1093G、543P/700E/752E、543P/700E/752E/800V/1093G、543P/700E/752E/809G/1116I、543P/700E/752E/1093G、700E、700E/738Y/739G/800V/1093G、700E/738Y/739G/799S/1093G、700E/738Y/800V/1093G、700E/738Y/1116I、700E/809G、700E/809G/1093G、700E/1093G、700E/1093G/1116I、700E/752E、700E/752E/808S/809G/1093G/1116I、700E/752E/809G/1093G、700E/752E/799S/1116I、700E/752E/805Q/809G/1093A、700E/799S/800V、700E/1116I、700E/805Q/808S/809G/1076S、514L/543P/681N/805Q/808S/809G、805Q/808S/809G或805Q/809G/1116I,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set 167G, 167G/738Y/1076S/1093G, 167G/738Y/752E/800V/805Q/808S/809G/1116I, 167G/ 800V/809G/1076S, 167G/318L, 167G/318L/800V/805Q/808S/809G, 167G/318L/681N, 167G/318L/681N/700E/805Q/808S/809G/1076S/1116I, 167G/ 318L/ 700E, 167G/318L/700E/1076S, 167G/318L/700E/738Y/739G/1076S, 167G/681N/738Y/800V/808S/809G, 167G/178Q/700E/752E/1093G, 167G/700E, 167G/ 700E/738Y/739G/1093G, 167G/700E/738Y/752E/1093G, 167G/700E/738Y/752E/805Q/808S/809G/1093A/1116I, 808S/809G, 1076S, 738Y, 738Y/808 S/809G, 738Y/1076S, 738Y/739G, 738Y/739G/809G, 738Y/739G/809G/1093G/1116I, 738Y/739G/1093G, 738Y/739G/752E/1093G, 738Y/739G/799S/800V/109 3G、738Y/ 739G/1116I, 738Y/800V, 738Y/1093G, 738Y/752E, 738Y/752E/1093G, 738Y/752E/799S, 738Y/799S/809G/1093G, 738Y/799S/1093G, 739G, 739G/800 V/809G, 800V, 800V/805Q/809G, 809G, 809G/1093G, 809G/1093G/1116I, 809G/1116I, 318L, 318L/1076S, 318L/1076S/1116I, 318L/739G/805Q/808S/809G/1 076S, 318L/ 499L/700E/738Y/809G, 318L/1093A, 318L/752E/1093A, 318L/1116I, 318L/543P/739G, 318L/543P/681N/752E/1116I, 318L/543P/1093A, 318L/700 E/738Y/ 1093A/1414N, 681N, 681N/738Y, 681N/738Y/739G/1093G, 681N/738Y/739G/752E/799S/800V/809G/1116I/1339C, 681N/738Y/739G/1116I, 681N/73 8Y/800V, 681N/800V/805Q/809G, 681N/809G/1093G, 681N/752E/1093A, 681N/752E/1093G, 681N/700E, 681N/700E/738Y/739G/1093G/1116I, 681N/700E/809 G、681N/ 700E/1093G, 681N/700E/752E/808S/809G/1093G/1116I, 681N/700E/752E/1093G, 681N/700E/844H, 681N/700E/805Q/809G, 1093A, 1093G, 1093G/1 116I, 752E, 17 8Q/318L/ 800V/809G, 178Q/318L/681N/800V/808S/809G/1076S, 178Q/681N, 178Q/681N/738Y/1116I, 178Q/752E/809G, 178Q/700E/800V/805Q/808S/809G, 1 78Q/ 805Q/809G/866A, 1116I, 543P, 543P/738Y/739G/809G, 543P/738Y/809G/1093G, 543P/739G/1093A, 543P/800V/1093G/1116I, 543P/809G/1093G, 54 3P/809G/ 1093G/1116I, 543P/681N/738Y/739G/752E/809G/1093G, 543P/681N/738Y/739G/752E/1093G, 543P/681N/739G/752E/800V/805Q/809G/1093G, 543 P/681N/ 700E/738Y/739G/800V/1093G/1116I, 543P/681N/700E/738Y/739G/805Q/808S/809G, 543P/681N/700E/752E, 543P/681N/700E/752E/809G/1093G, 543P/ 1093G, 543P/700E, 543P/700E/738Y/739G/752E/800V/1093G/1116I, 543P/700E/809G, 543P/700E/1093G, 543P/700E/752E, 543P/700E/752E/800V /1093G、 543P/700E/752E/809G/1116I, 543P/700E/752E/1093G, 700E, 700E/738Y/739G/800V/1093G, 700E/738Y/739G/799S/1093G, 700E/738Y/800V/1093 G、700E/ 738Y/1116I, 700E/809G, 700E/809G/1093G, 700E/1093G, 700E/1093G/1116I, 700E/752E, 700E/752E/808S/809G/1093G/1116I, 700E/752E/809G/1 093G、700E/ 752E/799S/1116I, 700E/752E/805Q/809G/1093A, 700E/799S/800V, 700E/1116I, 700E/805Q/808S/809G/1076S, 514L/543P/681N/805Q/808S/809G ,805Q/ 808S/809G or 805Q/809G/1116I, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2072.
在一些實施例中,重組因子VIII多肽之胺基酸序列包含至少一個取代或取代集A167G、A167G/E738Y/E1076S/K1093G、A167G/E738Y/K752E/E800V/Y805Q/D808S/E809G/S1116I、A167G/E800V/E809G/E1076S、A167G/G318L、A167G/G318L/E800V/Y805Q/D808S/E809G、A167G/G318L/G681N、A167G/G318L/G681N/S700E/Y805Q/D808S/E809G/E1076S/S1116I、A167G/G318L/S700E、A167G/G318L/S700E/E1076S、A167G/G318L/S700E/E738Y/E739G/E1076S、A167G/G681N/E738Y/E800V/D808S/E809G、A167G/L178Q/S700E/K752E/K1093G、A167G/S700E、A167G/S700E/E738Y/E739G/K1093G、A167G/S700E/E738Y/K752E/K1093G、A167G/S700E/E738Y/K752E/Y805Q/D808S/E809G/K1093A/S1116I、D808S/E809G、E1076S、E738Y、E738Y/D808S/E809G、E738Y/E1076S、E738Y/E739G、E738Y/E739G/E809G、E738Y/E739G/E809G/K1093G/S1116I、E738Y/E739G/K1093G、E738Y/E739G/K752E/K1093G、E738Y/E739G/K799S/E800V/K1093G、E738Y/E739G/S1116I、E738Y/E800V、E738Y/K1093G、E738Y/K752E、E738Y/K752E/K1093G、E738Y/K752E/K799S、E738Y/K799S/E809G/K1093G、E738Y/K799S/K1093G、E739G、E739G/E800V/E809G、E800V、E800V/Y805Q/E809G、E809G、E809G/K1093G、E809G/K1093G/S1116I、E809G/S1116I、G318L、G318L/E1076S、G318L/E1076S/S1116I、G318L/E739G/Y805Q/D808S/E809G/E1076S、G318L/I499L/S700E/E738Y/E809G、G318L/K1093A、G318L/K752E/K1093A、G318L/S1116I、G318L/S543P/E739G、G318L/S543P/G681N/K752E/S1116I、G318L/S543P/K1093A、G318L/S700E/E738Y/K1093A/S1414N、G681N、G681N/E738Y、G681N/E738Y/E739G/K1093G、G681N/E738Y/E739G/K752E/K799S/E800V/E809G/S1116I/G1339C、G681N/E738Y/E739G/S1116I、G681N/E738Y/E800V、G681N/E800V/Y805Q/E809G、G681N/E809G/K1093G、G681N/K752E/K1093A、G681N/K752E/K1093G、G681N/S700E、G681N/S700E/E738Y/E739G/K1093G/S1116I、G681N/S700E/E809G、G681N/S700E/K1093G、G681N/S700E/K752E/D808S/E809G/K1093G/S1116I、G681N/S700E/K752E/K1093G、G681N/S700E/R844H、G681N/S700E/Y805Q/E809G、K1093A、K1093G、K1093G/S1116I、K752E、K752E/E1076S、K752E/E800V/E809G、K752E/E800V/K1093G、K752E/E809G、K752E/G866A、K752E/K1093G、K752E/S1116I、L178Q/G318L/E739G/K752E/E809G/E1076S/S1116I、L178Q/G318L/E800V/E809G、L178Q/G318L/G681N/E800V/D808S/E809G/E1076S、L178Q/G681N、L178Q/G681N/E738Y/S1116I、L178Q/K752E/E809G、L178Q/S700E/E800V/Y805Q/D808S/E809G、L178Q/Y805Q/E809G/G866A、S1116I、S543P、S543P/E738Y/E739G/E809G、S543P/E738Y/E809G/K1093G、S543P/E739G/K1093A、S543P/E800V/K1093G/S1116I、S543P/E809G/K1093G、S543P/E809G/K1093G/S1116I、S543P/G681N/E738Y/E739G/K752E/E809G/K1093G、S543P/G681N/E738Y/E739G/K752E/K1093G、S543P/G681N/E739G/K752E/E800V/Y805Q/E809G/K1093G、S543P/G681N/S700E/E738Y/E739G/E800V/K1093G/S1116I、S543P/G681N/S700E/E738Y/E739G/Y805Q/D808S/E809G、S543P/G681N/S700E/K752E、S543P/G681N/S700E/K752E/E809G/K1093G、S543P/K1093G、S543P/S700E、S543P/S700E/E738Y/E739G/K752E/E800V/K1093G/S1116I、S543P/S700E/E809G、S543P/S700E/K1093G、S543P/S700E/K752E、S543P/S700E/K752E/E800V/K1093G、S543P/S700E/K752E/E809G/S1116I、S543P/S700E/K752E/K1093G、S700E、S700E/E738Y/E739G/E800V/K1093G、S700E/E738Y/E739G/K799S/K1093G、S700E/E738Y/E800V/K1093G、S700E/E738Y/S1116I、S700E/E809G、S700E/E809G/K1093G、S700E/K1093G、S700E/K1093G/S1116I、S700E/K752E、S700E/K752E/D808S/E809G/K1093G/S1116I、S700E/K752E/E809G/K1093G、S700E/K752E/K799S/S1116I、S700E/K752E/Y805Q/E809G/K1093A、S700E/K799S/E800V、S700E/S1116I、S700E/Y805Q/D808S/E809G/E1076S、V514L/S543P/G681N/Y805Q/D808S/E809G、Y805Q/D808S/E809G或Y805Q/E809G/S1116I,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2072之該參考序列。In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide includes at least one substitution or substitution set A167G, A167G/E738Y/E1076S/K1093G, A167G/E738Y/K752E/E800V/Y805Q/D808S/E809G/S1116I, A167G/ E800V/E809G/E1076S, A167G/G318L, A167G/G318L/E800V/Y805Q/D808S/E809G, A167G/G318L/G681N, A167G/G318L/G681N/S700E/Y805Q/D808S/E80 9G/E1076S/S1116I, A167G/G318L/ S700E, A167G/G318L/S700E/E1076S, A167G/G318L/S700E/E738Y/E739G/E1076S, A167G/G681N/E738Y/E800V/D808S/E809G, A167G/L178Q/S700E/K7 52E/K1093G, A167G/S700E, A167G/ S700E/E738Y/E739G/K1093G, A167G/S700E/E738Y/K752E/K1093G, A167G/S700E/E738Y/K752E/Y805Q/D808S/E809G/K1093A/S1116I, D808S/E809G, E1076S, E738Y, E738Y/D808S/E809G, E738Y/E1076S, E738Y/E739G, E738Y/E739G/E809G, E738Y/E739G/E809G/K1093G/S1116I, E738Y/E739G/K1093G, E738Y/E739G/K752E/K1093G, E738Y /E739G/K799S/E800V/K1093G, E738Y/ E739G/S1116I, E738Y/E800V, E738Y/K1093G, E738Y/K752E, E738Y/K752E/K1093G, E738Y/K752E/K799S, E738Y/K799S/E809G/K1093G, E738Y/K799S/ K1093G, E739G, E739G/E800V/E809G, E800V, E800V/Y805Q/E809G, E809G, E809G/K1093G, E809G/K1093G/S1116I, E809G/S1116I, G318L, G318L/E1076S, G318L/E1076S/S1116I, G318L/E73 9G/Y805Q/D808S/E809G/E1076S, G318L/ I499L/S700E/E738Y/E809G, G318L/K1093A, G318L/K752E/K1093A, G318L/S1116I, G318L/S543P/E739G, G318L/S543P/G681N/K752E/S1116I, G318L/ S543P/K1093A, G318L/S700E/E738Y/ K1093A/S1414N, G681N, G681N/E738Y, G681N/E738Y/E739G/K1093G, G681N/E738Y/E739G/K752E/K799S/E800V/E809G/S1116I/G1339C, G681N/E738Y /E739G/S1116I、G681N/E738Y/E800V、 G681N/E800V/Y805Q/E809G, G681N/E809G/K1093G, G681N/K752E/K1093A, G681N/K752E/K1093G, G681N/S700E, G681N/S700E/E738Y/E739G/K1093G/ S1116I, G681N/S700E/E809G, G681N/ S700E/K1093G, G681N/S700E/K752E/D808S/E809G/K1093G/S1116I, G681N/S700E/K752E/K1093G, G681N/S700E/R844H, G681N/S700E/Y805Q/E809G, K1093A, K1093G, K1093G/S1116I, K752E, K752E/E1076S, K752E/E800V/E809G, K752E/E800V/K1093G, K752E/E809G, K752E/G866A, K752E/K1093G, K752E/S1116I, L178Q/G318L/E739G/K752E/ E809G/E1076S/S1116I, L178Q/G318L/ E800V/E809G, L178Q/G318L/G681N/E800V/D808S/E809G/E1076S, L178Q/G681N, L178Q/G681N/E738Y/S1116I, L178Q/K752E/E809G, L178Q/S700E/E8 00V/Y805Q/D808S/E809G, L178Q/ Y805Q/E809G/G866A, S1116I, S543P, S543P/E738Y/E739G/E809G, S543P/E738Y/E809G/K1093G, S543P/E739G/K1093A, S543P/E800V/K1093G/S1116I ,S543P/E809G/K1093G,S543P/E809G/ K1093G/S1116I, S543P/G681N/E738Y/E739G/K752E/E809G/K1093G, S543P/G681N/E738Y/E739G/K752E/K1093G, S543P/G681N/E739G/K752E/E800V/ Y805Q/E809G/K1093G, S543P/G681N/ S700E/E738Y/E739G/E800V/K1093G/S1116I, S543P/G681N/S700E/E738Y/E739G/Y805Q/D808S/E809G, S543P/G681N/S700E/K752E, S543P/G681N/S7 00E/K752E/E809G/K1093G, S543P/ K1093G, S543P/S700E, S543P/S700E/E738Y/E739G/K752E/E800V/K1093G/S1116I, S543P/S700E/E809G, S543P/S700E/K1093G, S543P/S700E/K752E, S543P/S700E/K752E/E800V/K1093G, S543P/S700E/K752E/E809G/S1116I, S543P/S700E/K752E/K1093G, S700E, S700E/E738Y/E739G/E800V/K1093G, S700E/E738Y/E739G/K799S/K1093G, S700E/E738Y/E800V/K1093G, S700E/ E738Y/S1116I, S700E/E809G, S700E/E809G/K1093G, S700E/K1093G, S700E/K1093G/S1116I, S700E/K752E, S700E/K752E/D808S/E809G/K1093G/S111 6I, S700E/K752E/E809G/K1093G, S700E/ K752E/K799S/S1116I, S700E/K752E/Y805Q/E809G/K1093A, S700E/K799S/E800V, S700E/S1116I, S700E/Y805Q/D808S/E809G/E1076S, V514L/S543P/ G681N/Y805Q/D808S/E809G, Y805Q/ D808S/E809G or Y805Q/E809G/S1116I, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2072.
在一些實施例中,重組因子VIII多肽包含有包含至少一個在 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之胺基位置處的取代之胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, a recombinant Factor VIII polypeptide comprises at least one of the peptides listed in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2, 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 Substituted amino acid sequences at set forth amine positions relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, a recombinant Factor VIII polypeptide comprises at least one of the compounds described in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 The amino acid sequence of the substitution set, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代或取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, a recombinant Factor VIII polypeptide comprises at least one of the compounds described in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 An amino acid sequence of a substitution or set of substitutions, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之變異體的取代或取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, a recombinant Factor VIII polypeptide comprises at least one of the compounds described in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 Amino acid sequences of substitutions or sets of substitutions of variants, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO. 4-2346及2350-2870中之偶數編號SEQ ID NO.之胺基酸序列,其中任擇地,胺基酸序列包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代、插入或缺失。在一些實施例中,胺基酸序列任擇地包括1、2、3、4或5個胺基酸取代、插入或缺失。在前述之一些實施例中,胺基酸序列任擇地包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代,或1、2、3、4或5個取代。在一些實施例中,取代包含非守恆取代。在一些實施例中,取代包含守恆取代。4-4 -The amino acid sequence of the even-numbered SEQ ID NO. in 2346 and 2350-2870, wherein optionally, the amino acid sequence includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or up to 10 Amino acid substitution, insertion or deletion. In some embodiments, the amino acid sequence optionally includes 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions. In some of the foregoing embodiments, the amino acid sequence optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or up to 10 amino acid substitutions, or 1, 2, 3, 4 or 5 substitutions. In some embodiments, substitutions include non-conservative substitutions. In some embodiments, substitutions include conservative substitutions.
在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 4-316中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 4-316中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 318-410或412-666中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 318-410或412-666中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 668-700或702-780中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 668-700或702-780中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 782-818或820-934中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 782-818或820-934中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 936-1028或1030-1250中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 936-1028或1030-1250中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 1252-1408或1410-1588中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 1252-1408或1410-1588中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 1590-1648或1650-2068中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 1590-1648或1650-2068中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 2070-2346中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 2070-2346中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的胺基酸序列或包含SEQ ID NO: 2350-2870中之偶數編號SEQ ID NO.之胺基酸序列。在一些實施例中,胺基酸序列任擇地包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代、插入或缺失。在一些實施例中,重組因子VIII多肽之胺基酸序列任擇地包括1、2、3、4或5個胺基酸取代、插入或缺失。在前述之一些實施例中,胺基酸序列任擇地包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代,或1、2、3、4或5個胺基酸取代。在一些實施例中,取代包含非守恆取代。在一些實施例中,取代包含守恆取代。In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NO: 4-316 or comprising one of SEQ ID NO: 4-316 Amino acid sequence of even-numbered SEQ ID NO. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. of SEQ ID NO: 318-410 or 412-666 or comprising SEQ ID NO: 318 -The amino acid sequence of the even-numbered SEQ ID NO. 410 or 412-666. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. of SEQ ID NO: 668-700 or 702-780 or comprising SEQ ID NO: 668 -The amino acid sequence of the even-numbered SEQ ID NO. 700 or 702-780. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. of SEQ ID NO: 782-818 or 820-934 or comprising SEQ ID NO: 782 -The amino acid sequence of the even-numbered SEQ ID NO. 818 or 820-934. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. of SEQ ID NO: 936-1028 or 1030-1250 or comprising SEQ ID NO: 936 -The amino acid sequence of the even-numbered SEQ ID NO. 1028 or 1030-1250. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. of SEQ ID NO: 1252-1408 or 1410-1588 or comprising SEQ ID NO: 1252 -The amino acid sequence of the even-numbered SEQ ID NO. 1408 or 1410-1588. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. of SEQ ID NO: 1590-1648 or 1650-2068 or comprising SEQ ID NO: 1590 -The amino acid sequence of an even-numbered SEQ ID NO. from 1648 or 1650-2068. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NO: 2070-2346 or comprising one of SEQ ID NO: 2070-2346 Amino acid sequence of even-numbered SEQ ID NO. In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of even-numbered SEQ ID NO. in SEQ ID NO: 2360-2870 or comprising one of SEQ ID NO: 2350-2870 Amino acid sequence of even-numbered SEQ ID NO. In some embodiments, the amino acid sequence optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 amino acid substitutions, insertions, or deletions. In some embodiments, the amino acid sequence of the recombinant Factor VIII polypeptide optionally includes 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions. In some of the foregoing embodiments, the amino acid sequence optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or up to 10 amino acid substitutions, or 1, 2, 3, 4 or 5 amino acid substitutions. In some embodiments, substitutions include non-conservative substitutions. In some embodiments, substitutions include conservative substitutions.
在一些實施例中,重組因子VIII多肽包含有包含SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的胺基酸序列或包含SEQ ID NO: 252、504、706、840、1200、1514或2072之胺基酸序列。在一些實施例中,胺基酸序列任擇地包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代、插入或缺失。在一些實施例中,任擇地重組因子VIII多肽之胺基酸序列包括1、2、3、4或5個胺基酸取代、插入或缺失。在前述之一些實施例中,任擇地胺基酸序列包括1、2、3、4、5、6、7、8、9或至多10個胺基酸取代,或1、2、3、4或5個胺基酸取代。在一些實施例中,取代包含非守恆取代。在一些實施例中,取代包含守恆取代。In some embodiments, a recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 or comprising SEQ ID NO: 252, 504 , 706, 840, 1200, 1514 or 2072 amino acid sequences. In some embodiments, the amino acid sequence optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 amino acid substitutions, insertions, or deletions. In some embodiments, the amino acid sequence of the optionally recombinant Factor VIII polypeptide includes 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions. In some of the foregoing embodiments, the amino acid sequence optionally includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or up to 10 amino acid substitutions, or 1, 2, 3, 4 or 5 amino acid substitutions. In some embodiments, substitutions include non-conservative substitutions. In some embodiments, substitutions include conservative substitutions.
在一些實施例中,本文所描述之重組因子VIII多肽具有凝血活性。在一些實施例中,重組因子VIII多肽與參考因子VIII多肽相比具有改良之特性,其中參考因子VIII多肽具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列。In some embodiments, recombinant Factor VIII polypeptides described herein have coagulation activity. In some embodiments, a recombinant Factor VIII polypeptide has improved properties compared to a reference Factor VIII polypeptide, wherein the reference Factor VIII polypeptide has a property corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 The sequence of residues 20-1457 or the sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽與參考因子VIII多肽相比具有增加之活性,其中參考因子VIII多肽具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列。In some embodiments, a recombinant Factor VIII polypeptide has increased activity compared to a reference Factor VIII polypeptide, wherein the reference Factor VIII polypeptide has an activity corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 The sequence of residues 20-1457 or the sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,與具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽相比,增加之活性為凝血活性,尤其為增加之效能。In some embodiments, with a sequence having residues 20-1457 corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 or corresponding to SEQ ID NO: 2, 252, 504, Compared with the reference Factor VIII polypeptide of the sequence 706, 840, 1200, 1514 or 2072, the increased activity is coagulation activity, especially the increased potency.
在一些實施例中,與具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽相比,重組因子VIII多肽對血清及/或血漿暴露,尤其來自A型血友病患者之血清或血漿的穩定性增加。In some embodiments, with a sequence having residues 20-1457 corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 or corresponding to SEQ ID NO: 2, 252, 504, Compared with the reference Factor VIII polypeptide of the sequence 706, 840, 1200, 1514 or 2072, the recombinant Factor VIII polypeptide has increased stability to serum and/or plasma exposure, especially serum or plasma from hemophilia A patients.
在一些實施例中,重組因子VIII多肽在約pH 7.4下比具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽更穩定。In some embodiments, the recombinant Factor VIII polypeptide has a sequence corresponding to residues 20-1457 of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 at about pH 7.4 or corresponds to SEQ The reference Factor VIII polypeptide with the sequence of ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 is more stable.
在一些實施例中,重組因子VIII多肽與參考因子VIII多肽相比具有增加之熱穩定性,其中參考因子VIII多肽具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列。In some embodiments, the recombinant Factor VIII polypeptide has increased thermal stability compared to a reference Factor VIII polypeptide, wherein the reference Factor VIII polypeptide has a polypeptide corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or The sequence of residues 20-1457 of 2072 or the sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組因子VIII多肽之特徵在於與具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽相比,經表現載體轉染之細胞的表現及/或分泌增加。In some embodiments, a recombinant Factor VIII polypeptide is characterized by having a sequence corresponding to residues 20-1457 of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 or corresponding to SEQ ID NO. : Compared with the reference Factor VIII polypeptide of the sequence 2, 252, 504, 706, 840, 1200, 1514 or 2072, the expression and/or secretion of cells transfected with the expression vector is increased.
在一些實施例中,重組因子VIII多肽之特徵在於與具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽相比,經基因療法組成物(例如AAV、mRNA或脂質奈米顆粒)轉導之細胞的轉導及/或分泌增加。In some embodiments, a recombinant Factor VIII polypeptide is characterized by having a sequence corresponding to residues 20-1457 of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514, or 2072 or corresponding to SEQ ID NO. : 2, 252, 504, 706, 840, 1200, 1514 or 2072 sequence of reference Factor VIII polypeptide compared to the transduction of cells transduced with gene therapy compositions (such as AAV, mRNA or lipid nanoparticles) and /or increased secretion.
在一些實施例中,改良之特性係與具有對應於SEQ ID NO: 2之殘基20-1457的序列或對應於SEQ ID NO: 2之序列的參考因子VIII多肽進行比較。In some embodiments, the improved properties are compared to a reference Factor VIII polypeptide having a sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or a sequence corresponding to SEQ ID NO: 2.
在一些實施例中,與具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的序列或具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列的參考因子VIII多肽相比,本揭露內容之重組因子VIII多肽展現至少一種選自下列之改良特性:i)增加之活性/效能;ii)增加之凝血活性/效能;iii)增加之血漿或血清穩定性;iv)增加之熱穩定性;v)降低之免疫原性;vi)增加之來自經表現載體轉染之細胞的表現及/或分泌;vii)增加之來自經基因療法載體(例如AAV、mRNA或脂質奈米顆粒)轉導之細胞的轉導及/或分泌,或i)、ii)、iii)、iv)、v)、vi)及/或vii)中之任一者之組合。在一些實施例中,參考重組因子VIII多肽具有對應於SEQ ID NO: 2之殘基20-1457之序列或具有對應於SEQ ID NO: 2之序列。In some embodiments, with a sequence having residues 20-1457 corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 or having a sequence corresponding to SEQ ID NO: 2, 252, 504 , 706, 840, 1200, 1514 or 2072, the recombinant Factor VIII polypeptide of the present disclosure exhibits at least one improved property selected from the following: i) increased activity/potency; ii) increased Coagulation activity/potency; iii) increased plasma or serum stability; iv) increased thermal stability; v) reduced immunogenicity; vi) increased expression and/or secretion from cells transfected with the expression vector; vii) Increased transduction and/or secretion from cells transduced with gene therapy vectors (e.g. AAV, mRNA or lipid nanoparticles), or i), ii), iii), iv), v), vi) and/or a combination of any of vii). In some embodiments, the reference recombinant Factor VIII polypeptide has a sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or has a sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組因子VIII多肽為「去免疫性」重組因子VIII多肽(例如,如 表 12.1、 12.2、 12.3、 12.4、 12.5、 12.6、 12.7、 12.8及 15.2中之實例中所呈現)。在一些實施例中,重組因子VIII多肽之特徵在於相比於參考因子VIII多肽,總免疫原性分數(TIS)及/或免疫原性命中計數(IHC)降低,其中參考因子VIII多肽具有對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之序列,諸如於實例中之 表 12.1、 12.2、 12.3、 12.4、 12.5、 12.6、 12.7、 12.8及 15.2中提供。 In some embodiments, the recombinant Factor VIII polypeptide is a "deimmunized" recombinant Factor VIII polypeptide (e.g., as presented in the examples in Tables 12.1 , 12.2 , 12.3 , 12.4 , 12.5 , 12.6 , 12.7 , 12.8 , and 15.2 ). In some embodiments, a recombinant Factor VIII polypeptide is characterized by a reduced total immunogenicity score (TIS) and/or immunogenic hit count (IHC) compared to a reference Factor VIII polypeptide, wherein the reference Factor VIII polypeptide has a property corresponding to Sequences of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072, such as those provided in Tables 12.1 , 12.2 , 12.3 , 12.4 , 12.5 , 12.6 , 12.7 , 12.8 and 15.2 in the Examples.
在一些實施例中,「去免疫性」重組因子VIII多肽包含胺基酸序列,該胺基酸序列包含選自以下之序列的殘基20-1457或殘基1-1457:SEQ ID NO: 4、6、8、10、12、14、16、18、20、26、28、32、34、36、38、40、42、44、46、48、50、52、54、56、60、64、66、68、72、74、76、78、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、130、132、134、136、138、140、142、146、148、150、152、154、156、158、160、162、164、166、168、170、172、174、176、178、180、182、184、186、188、190、192、194、196、198、200、202、204、206、208、210、212、214、216、218、220、222、224、226、228、230、232、234、236、238、242、244、248、252、260、262、266、270、274、278、280、282、284、286、288、290、292、296、298、300、302、310、312、320、322、324、326、328、330、332、334、336、338、340、342、344、346、348、350、352、354、356、358、360、362、364、366、368、370、372、374、376、378、380、382、384、386、388、390、392、394、396、398、400、402、404、406、408、410、412、414、416、418、420、424、426、428、430、432、434、436、438、442、444、446、448、452、454、456、458、460、462、464、466、468、470、472、474、476、478、480、482、484、486、488、490、492、498、500、502、504、506、508、510、512、514、516、518、520、522、524、526、530、532、534、536、538、540、542、544、546、548、550、552、554、556、558、560、562、564、566、568、570、574、578、580、582、584、586、588、590、592、594、596、598、600、602、604、606、608、610、612、614、618、620、622、624、626、628、630、632、634、636、638、640、642、644、646、648、650、652、654、656、658、660、662、664、666、668、670、672、674、676、678、680、682、684、686、688、690、692、694、696、698、700、702、704、706、708、710、712、714、716、718、720、722、724、728、730、732、734、736、738、740、742、744、746、748、750、752、754、756、758、760、762、764、766、768、770、772、774、776、778、780、782、784、786、788、790、792、794、796、798、800、802、804、806、808、810、812、814、816、818、820、822、824、826、828、830、832、834、836、838、840、842、844、846、848、850、852、854、856、858、860、862、864、868、876、878、880、882、884、886、890、892、896、900、904、906、908、910、912、914、922、932、934、936、938、940、942、944、946、948、952、956、958、960、962、964、966、970、974、976、978、980、982、986、988、990、996、998、1002、1006、1008、1012、1014、1018、1020、1022、1024、1026、1028、1030、1032、1034、1036、1038、1040、1042、1044、1046、1048、1050、1052、1054、1056、1058、1064、1066、1068、1070、1072、1074、1076、1078、1080、1082、1084、1086、1088、1090、1092、1096、1098、1100、1102、1104、1108、1110、1112、1114、1116、1120、1124、1126、1128、1130、1132、1134、1136、1138、1140、1142、1144、1146、1148、1150、1152、1154、1156、1158、1160、1162、1164、1166、1168、1170、1172、1174、1176、1178、1180、1182、1184、1186、1188、1190、1192、1194、1196、1198、1200、1202、1204、1206、1208、1210、1212、1214、1216、1218、1220、1222、1224、1226、1228、1232、1234、1236、1238、1240、1242、1244、1246、1248、1250、1252、1254、1256、1258、1260、1262、1264、1266、1268、1270、1272、1274、1276、1278、1280、1286、1300、1306、1310、1314、1316、1320、1322、1324、1326、1328、1330、1332、1334、1336、1344、1352、1356、1368、1370、1372、1380、1384、1386、1388、1390、1392、1394、1400、1406、1410、1412、1414、1416、1418、1420、1422、1424、1426、1428、1430、1432、1434、1436、1438、1440、1442、1444、1446、1448、1450、1452、1454、1456、1458、1460、1462、1464、1466、1468、1470、1472、1474、1476、1478、1480、1482、1484、1486、1488、1490、1492、1494、1496、1498、1500、1502、1504、1506、1508、1510、1512、1514、1516、1518、1520、1522、1524、1526、1528、1530、1532、1534、1536、1540、1550、1552、1554、1564、1568、1570、1584、1590、1592、1594、1596、1598、1600、1602、1604、1606、1608、1610、1612、1614、1616、1618、1620、1622、1624、1626、1628、1630、1632、1634、1636、1638、1640、1642、1644、1646、1648、1650、1654、1658、1660、1662、1664、1666、1670、1676、1690、1694、1698、1706、1710、1712、1714、1720、1724、1726、1728、1732、1734、1740、1746、1748、1750、1752、1754、1756、1760、1762、1772、1778、1782、1784、1786、1788、1792、1794、1796、1798、1806、1810、1814、1820、1826、1846、1854、1858、1860、1868、1870、1872、1878、1880、1882、1898、1906、1908、1910、1920、1924、1926、1930、1932、1940、1942、1950、1954、1956、1958、1960、1962、1964、1966、1970、1972、1974、1976、1978、1980、1982、1984、1986、1990、1992、1994、1998、2000、2002、2004、2006、2008、2010、2012、2014、2016、2018、2020、2022、2024、2026、2028、2030、2032、2034、2038、2040、2042、2044、2046、2050、2052、2054、2056、2058、2060、2064、2066、2068、2070、2098、2102、2104、2106、2122、2138、2142、2190、2204、2206、2210、2212、2214、2216、2220、2226、2228、2234、2236、2242、2250、2252、2254、2266、2268、2272、2276、2278、2280、2282、2284、2288、2290、2302、2306、2308、2310、2314、2316、2318、2320、2322、2324、2326、2330、2334、2336、2338、2340、2370、2372、2374、2380、2382、2386、2390、2392、2394、2396、2398、2402、2406、2408、2412、2420、2422、2432、2436、2440、2446、2448、2450、2454、2456、2460、2464、2466、2468、2472、2476、2478、2484、2486、2488、2494、2496、2498、2500、2504、2506、2510、2518、2520、2526、2530、2534、2542、2544、2554、2556、2560、2562、2564、2570、2574、2576、2578、2586、2588、2590、2592、2594、2598、2600、2602、2604、2610、2614、2618、2622、2628、2632、2638、2644、2646、2648、2650、2652、2654、2656、2662、2664、2672、2674、2676、2682、2684、2688、2690、2694、2702、2704、2708、2710、2712、2714、2728、2734、2736、2738、2742、2748、2750、2754、2760、2762、2764、2766、2768、2770、2774、2776、2778、2780、2782、2784、2790、2794、2798、2800、2802、2804、2806、2808、2810、2818、2820、2824、2826、2828、2830、2832、2834、2836、2840、2842、2844、2848、2850、2852、2854、2856、2858、2860、2862、2864、2866、2868或2870。In some embodiments, a "deimmunized" recombinant Factor VIII polypeptide comprises an amino acid sequence comprising residues 20-1457 or residues 1-1457 selected from the following sequence: SEQ ID NO: 4 ,6,8,10,12,14,16,18,20,26,28,32,34,36,38,40,42,44,46,48,50,52,54,56,60,64 ,66,68,72,74,76,78,82,84,86,88,90,92,94,96,98,100,102,104,106,108,110,112,114,116,118 ,120,122,130,132,134,136,138,140,142,146,148,150,152,154,156,158,160,162,164,166,168,170,172,174,176 ,178,180,182,184,186,188,190,192,194,196,198,200,202,204,206,208,210,212,214,216,218,220,222,224,226 ,228,230,232,234,236,238,242,244,248,252,260,262,266,270,274,278,280,282,284,286,288,290,292,296,298 ,300,302,310,312,320,322,324,326,328,330,332,334,336,338,340,342,344,346,348,350,352,354,356,358,360 ,362,364,366,368,370,372,374,376,378,380,382,384,386,388,390,392,394,396,398,400,402,404,406,408,410 ,412,414,416,418,420,424,426,428,430,432,434,436,438,442,444,446,448,452,454,456,458,460,462,464,466 ,468,470,472,474,476,478,480,482,484,486,488,490,492,498,500,502,504,506,508,510,512,514,516,518,520 ,522,524,526,530,532,534,536,538,540,542,544,546,548,550,552,554,556,558,560,562,564,566,568,570,574 ,578,580,582,584,586,588,590,592,594,596,598,600,602,604,606,608,610,612,614,618,620,622,624,626,628 ,630,632,634,636,638,640,642,644,646,648,650,652,654,656,658,660,662,664,666,668,670,672,674,676,678 ,680,682,684,686,688,690,692,694,696,698,700,702,704,706,708,710,712,714,716,718,720,722,724,728,730 ,732,734,736,738,740,742,744,746,748,750,752,754,756,758,760,762,764,766,768,770,772,774,776,778,780 ,782,784,786,788,790,792,794,796,798,800,802,804,806,808,810,812,814,816,818,820,822,824,826,828,830 ,832,834,836,838,840,842,844,846,848,850,852,854,856,858,860,862,864,868,876,878,880,882,884,886,890 ,892,896,900,904,906,908,910,912,914,922,932,934,936,938,940,942,944,946,948,952,956,958,960,962,964 ,966,970,974,976,978,980,982,986,988,990,996,998,1002,1006,1008,1012,1014,1018,1020,1022,1024,1026,1028,1030,1032 ,1034,1036,1038,1040,1042,1044,1046,1048,1050,1052,1054,1056,1058,1064,1066,1068,1070,1072,1074,1076,1078,1080,1082,1084,10 86 ,1088,1090,1092,1096,1098,1100,1102,1104,1108,1110,1112,1114,1116,1120,1124,1126,1128,1130,1132,1134,1136,1138,1140,1142,11 44 ,1146,1148,1150,1152,1154,1156,1158,1160,1162,1164,1166,1168,1170,1172,1174,1176,1178,1180,1182,1184,1186,1188,1190,1192,11 94 ,1196,1198,1200,1202,1204,1206,1208,1210,1212,1214,1216,1218,1220,1222,1224,1226,1228,1232,1234,1236,1238,1240,1242,1244,12 46 ,1248,1250,1252,1254,1256,1258,1260,1262,1264,1266,1268,1270,1272,1274,1276,1278,1280,1286,1300,1306,1310,1314,1316,1320,13 22 ,1324,1326,1328,1330,1332,1334,1336,1344,1352,1356,1368,1370,1372,1380,1384,1386,1388,1390,1392,1394,1400,1406,1410,1412,14 14 ,1416,1418,1420,1422,1424,1426,1428,1430,1432,1434,1436,1438,1440,1442,1444,1446,1448,1450,1452,1454,1456,1458,1460,1462,14 64 ,1466,1468,1470,1472,1474,1476,1478,1480,1482,1484,1486,1488,1490,1492,1494,1496,1498,1500,1502,1504,1506,1508,1510,1512,15 14 ,1516,1518,1520,1522,1524,1526,1528,1530,1532,1534,1536,1540,1550,1552,1554,1564,1568,1570,1584,1590,1592,1594,1596,1598,16 00 ,1602,1604,1606,1608,1610,1612,1614,1616,1618,1620,1622,1624,1626,1628,1630,1632,1634,1636,1638,1640,1642,1644,1646,1648,16 50 ,1654,1658,1660,1662,1664,1666,1670,1676,1690,1694,1698,1706,1710,1712,1714,1720,1724,1726,1728,1732,1734,1740,1746,1748,17 50 ,1752,1754,1756,1760,1762,1772,1778,1782,1784,1786,1788,1792,1794,1796,1798,1806,1810,1814,1820,1826,1846,1854,1858,1860,18 68 , 1870, 1872, 1878, 1880, 1882, 1898, 1906, 1908, 1910, 1920, 1924, 1926, 1930, 1932, 1940, 1942, 1950, 1954, 1956, 1958, 1960, 1962, 1964, 1966, 19 70 ,1972,1974,1976,1978,1980,1982,1984,1986,1990,1992,1994,1998,2000,2002,2004,2006,2008,2010,2012,2014,2016,2018,2020,2022,20 24 , 2026, 2028, 2030, 2032, 2034, 2038, 2040, 2042, 2044, 2046, 2050, 2052, 2054, 2056, 2058, 2060, 2064, 2066, 2068, 2070, 2098, 2102, 2104, 2106, 21 22 ,2138,2142,2190,2204,2206,2210,2212,2214,2216,2220,2226,2228,2234,2236,2242,2250,2252,2254,2266,2268,2272,2276,2278,2280,22 82 ,2284,2288,2290,2302,2306,2308,2310,2314,2316,2318,2320,2322,2324,2326,2330,2334,2336,2338,2340,2370,2372,2374,2380,2382,23 86 ,2390,2392,2394,2396,2398,2402,2406,2408,2412,2420,2422,2432,2436,2440,2446,2448,2450,2454,2456,2460,2464,2466,2468,2472,24 76 ,2478,2484,2486,2488,2494,2496,2498,2500,2504,2506,2510,2518,2520,2526,2530,2534,2542,2544,2554,2556,2560,2562,2564,2570,25 74 ,2576,2578,2586,2588,2590,2592,2594,2598,2600,2602,2604,2610,2614,2618,2622,2628,2632,2638,2644,2646,2648,2650,2652,2654,26 56 ,2662,2664,2672,2674,2676,2682,2684,2688,2690,2694,2702,2704,2708,2710,2712,2714,2728,2734,2736,2738,2742,2748,2750,2754,27 60 ,2762,2764,2766,2768,2770,2774,2776,2778,2780,2782,2784,2790,2794,2798,2800,2802,2804,2806,2808,2810,2818,2820,2824,2826,28 28 , 2830, 2832, 2834, 2836, 2840, 2842, 2844, 2848, 2850, 2852, 2854, 2856, 2858, 2860, 2862, 2864, 2866, 2868 or 2870.
在一些實施例中,對於本文所揭示之重組因子VIII多肽中之任一者,重組因子VIII多肽經純化或為經純化製劑。In some embodiments, for any of the recombinant Factor VIII polypeptides disclosed herein, the recombinant Factor VIII polypeptide is purified or is a purified preparation.
在一些實施例中,重組因子VIII多肽包含本文所描述之重組因子VIII多肽中之任一者的全長重組因子VIII多肽。在一些實施例中,重組因子VIII多肽包含本文所描述之重組因子VIII多肽中之任一者的「前原蛋白」或「前原多肽」。在一些實施例中,全長重組因子VIII多肽或「前原蛋白」或「前原多肽」的信號序列可包含任何相容信號序列,包括合成、小鼠(例如IgG)或人類信號序列。在一些實施例中,例示性重組因子VIII多肽中所存在之信號序列經相容信號序列(例如合成或小鼠)置換。在一些實施例中,信號序列包含天然存在之人類因子VIII多肽中之信號序列。In some embodiments, a recombinant Factor VIII polypeptide comprises a full-length recombinant Factor VIII polypeptide of any of the recombinant Factor VIII polypeptides described herein. In some embodiments, a recombinant Factor VIII polypeptide comprises a "preproprotein" or "prepropolypeptide" of any of the recombinant Factor VIII polypeptides described herein. In some embodiments, the signal sequence of a full-length recombinant Factor VIII polypeptide or "preproprotein" or "prepropolypeptide" can comprise any compatible signal sequence, including synthetic, mouse (eg, IgG), or human signal sequences. In some embodiments, a signal sequence present in an exemplary recombinant Factor VIII polypeptide is replaced with a compatible signal sequence (eg, synthetic or mouse). In some embodiments, the signal sequence comprises a signal sequence in a naturally occurring human Factor VIII polypeptide.
在一些實施例中,重組因子VIII多肽經處理或裂解為例如缺乏信號序列之原多肽或原蛋白形式。在一些實施例中,重組因子VIII多肽經處理或裂解為重組因子VIII多肽之成熟形式,諸如本文所描述。在一些實施例中,重組因子VIII多肽之成熟形式包含重組因子VIII多肽之活性形式,尤其與FIX相互作用之多肽(例如,因子VIII之輕鏈及重鏈的等效形式) (參見例如Orlova等人,Acta Naturae, 2013, 5(2): 19-39:3983-3996;Lenting等人,Blood, 1998, 92(11);以引用之方式併入本文中)。In some embodiments, the recombinant Factor VIII polypeptide is processed or cleaved, for example, into a pro-polypeptide or pro-protein form lacking a signal sequence. In some embodiments, the recombinant Factor VIII polypeptide is processed or cleaved to the mature form of the recombinant Factor VIII polypeptide, such as described herein. In some embodiments, mature forms of recombinant Factor VIII polypeptides comprise active forms of recombinant Factor VIII polypeptides, particularly polypeptides that interact with FIX (e.g., equivalent forms of the light and heavy chains of Factor VIII) (see, e.g., Orlova et al. Human, Acta Naturae, 2013, 5(2): 19-39:3983-3996; Lenting et al., Blood, 1998, 92(11); incorporated herein by reference).
因此,對於本文所描述之各重組因子VIII多肽,本揭露內容提供重組因子VIII多肽之前原多肽、原多肽或成熟生物活性形式,包括 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所揭示之各重組因子VIII多肽。 Therefore, for each recombinant Factor VIII polypeptide described herein, the present disclosure provides the pre-polypeptide, pro-polypeptide or mature biologically active form of the recombinant Factor VIII polypeptide, including Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 each of the recombinant Factor VIII polypeptides disclosed.
在一些實施例中,本揭露內容進一步提供本文所描述之重組因子VIII多肽之功能性或生物活性片段。在一些實施例中,功能性或生物活性片段具有由其衍生之重組因子多肽(亦即,親代工程改造因子VIII)之活性的至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%。在一些實施例中,功能性或生物活性片段包含重組因子VIII多肽之親代序列之至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%。在一些實施例中,功能性片段被截斷少於5個、少於10個、少於15個、少於10個、少於25個、少於30個、少於35個、少於40個、少於45個及少於50個胺基酸。重組因子VIII多肽之例示性生物或功能性片段包括包含SEQ ID NO: 2350、2352、2354、2356或2358之胺基酸序列,其活性展示於 圖 3中。 In some embodiments, the present disclosure further provides functional or biologically active fragments of recombinant Factor VIII polypeptides described herein. In some embodiments, the functional or biologically active fragment has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the functional or biologically active fragment comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, of the parental sequence of the recombinant Factor VIII polypeptide. 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the functional fragments are truncated to less than 5, less than 10, less than 15, less than 10, less than 25, less than 30, less than 35, less than 40 , less than 45 and less than 50 amino acids. Exemplary biological or functional fragments of recombinant Factor VIII polypeptides include the amino acid sequence comprising SEQ ID NO: 2350, 2352, 2354, 2356, or 2358, the activity of which is shown in Figure 3 .
在一些實施例中,本文中所描述之重組因子VIII多肽之功能性或生物活性片段包括本文中所描述之重組因子VIII之胺基酸序列中的至少一個突變或突變集。因此,在一些實施例中,重組因子VIII之功能性或生物活性片段呈現出與親代重組因子VIII多肽中之突變或突變集相關的增強或改良之特性。In some embodiments, functional or biologically active fragments of recombinant Factor VIII polypeptides described herein include at least one mutation or set of mutations in the amino acid sequence of recombinant Factor VIII described herein. Thus, in some embodiments, a functional or biologically active fragment of recombinant Factor VIII exhibits enhanced or improved properties associated with a mutation or set of mutations in the parent recombinant Factor VIII polypeptide.
在一些其他實施例中,如本文所論述,功能性片段或生物活性片段涵蓋重組因子VIII多肽之生物學處理多肽,諸如在哺乳動物細胞或患者中表現後或當向患者投予重組因子VIII多肽時產生之功能性或生物活性片段。在一些實施例中,由一或多個裂解產生之重組因子VIII多肽之生物學處理功能性或生物活性片段出現在殘基760至773之間,且在一些實施例中,額外一或多個裂解出現在殘基391與392之間,其中該等位置係相對於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列。在一些實施例中,功能性或生物活性片段來源於 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中呈現之重組因子VIII多肽。在一些實施例中,功能性或生物活性片段來源於包含選自SEQ ID NO: 4-2346及2350-2870中之偶數編號SEQ ID NO.之胺基酸序列的重組因子VIII多肽。 編碼重組多肽之聚核苷酸、表現載體及宿主細胞 In some other embodiments, as discussed herein, functional fragments or biologically active fragments encompass biologically processed polypeptides of recombinant Factor VIII polypeptides, such as after expression in mammalian cells or in a patient or when the recombinant Factor VIII polypeptide is administered to a patient Functional or biologically active fragments produced. In some embodiments, the biologically processed functional or biologically active fragment of the recombinant Factor VIII polypeptide resulting from one or more cleavages occurs between residues 760 to 773, and in some embodiments, the additional one or more Cleavage occurs between residues 391 and 392, where these positions are relative to the reference sequence of SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072. In some embodiments, functional or biologically active fragments are derived from recombinants presented in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1, 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 , and 15.1 Factor VIII polypeptide. In some embodiments, the functional or biologically active fragment is derived from a recombinant Factor VIII polypeptide comprising an amino acid sequence of an even-numbered SEQ ID NO. selected from SEQ ID NOs: 4-2346 and 2350-2870. Polynucleotides, expression vectors and host cells encoding recombinant polypeptides
在另一態樣中,本揭露內容提供編碼本文所描述之經工程改造因子VIII多肽的聚核苷酸。在一些實施例中,聚核苷酸可操作地連接至控制基因表現之一或多個異源或同源調節序列以產生能夠表現多肽之重組聚核苷酸。含有編碼重組因子VIII多肽之異源聚核苷酸的表現構築體可引入適當宿主細胞中以表現相應重組因子VIII多肽。In another aspect, the present disclosure provides polynucleotides encoding engineered Factor VIII polypeptides described herein. In some embodiments, a polynucleotide is operably linked to one or more heterologous or homologous regulatory sequences that control gene expression to produce a recombinant polynucleotide capable of expressing a polypeptide. Expression constructs containing heterologous polynucleotides encoding recombinant Factor VIII polypeptides can be introduced into appropriate host cells to express the corresponding recombinant Factor VIII polypeptides.
如熟習此項技術者顯而易知,蛋白質序列之可獲得性以及對與各種胺基酸對應之密碼子的瞭解提供能夠編碼本發明多肽之所有聚核苷酸的描述。遺傳密碼之簡倂性,其中相同胺基酸係由替代或同義密碼子編碼,允許產生極大量核酸,其皆編碼重組因子VIII多肽。因此,在已瞭解特定胺基酸序列的情況下,熟習此項技術者可藉由簡單地以不改變蛋白質之胺基酸序列之方式修飾一或多個密碼子之序列來製造任何數目個不同核酸。在此方面,本發明藉由以可能性密碼子選項為主來選擇組合以特定地考慮可被製造之編碼本文所描述之多肽之聚核苷酸的每一個可能性變異,且所有該等變異皆將被視為針對本文所描述之任何多肽加以特定地揭露,包括 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所提供之變異體。 As will be apparent to those skilled in the art, the availability of protein sequences and knowledge of the codons corresponding to various amino acids provide a description of all polynucleotides capable of encoding the polypeptides of the invention. The simplicity of the genetic code, in which identical amino acids are encoded by alternative or synonymous codons, allows the production of extremely large numbers of nucleic acids, all of which encode recombinant Factor VIII polypeptides. Thus, given knowledge of a particular amino acid sequence, one skilled in the art can make any number of different codons by simply modifying the sequence of one or more codons in a manner that does not alter the amino acid sequence of the protein. nucleic acids. In this regard, the present invention specifically considers every possible variation in the polynucleotides that can be made that encodes the polypeptides described herein by selecting combinations based on possible codon options, and all such variations will be deemed to be specifically disclosed for any polypeptide described herein, including Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2, 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 Variants provided in .
在一些實施例中,較佳選擇適於其中正產生蛋白質之宿主細胞的密碼子。舉例而言,用於細菌中之較佳密碼子係用於在細菌中表現,用於真菌中之較佳密碼子係典型地用於在真菌中表現,且用於哺乳動物中之較佳密碼子係用於在哺乳動物及哺乳動物細胞中表現。在一些實施例中,編碼經工程改造之因子多肽的經密碼子最佳化之聚核苷酸在全長編碼區之密碼子位置之約40%、50%、60%、70%、80%或超過90%處含有較佳密碼子。在一些實施例中,本發明提供其中密碼子經最佳化以用於人類細胞或組織中之表現的重組聚核苷酸序列。In some embodiments, it is preferred to select codons that are appropriate for the host cell in which the protein is being produced. For example, the preferred codon systems for use in bacteria are for expression in bacteria, the preferred codon systems for fungi are typically for expression in fungi, and the preferred codon systems for mammals are Sublines are designed for expression in mammals and mammalian cells. In some embodiments, the codon-optimized polynucleotide encoding the engineered factor polypeptide is located at about 40%, 50%, 60%, 70%, 80%, or 40% of the codon positions of the full-length coding region. More than 90% of the sites contain better codons. In some embodiments, the invention provides recombinant polynucleotide sequences in which codons are optimized for expression in human cells or tissues.
如上文所論述,應理解,本揭露內容提供編碼本文所描述之各重組因子VIII多肽或其生物或功能活性片段的重組聚核苷酸。As discussed above, it is to be understood that the present disclosure provides recombinant polynucleotides encoding each of the recombinant Factor VIII polypeptides described herein, or biologically or functionally active fragments thereof.
因此,藉助於實例而非限制,在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽或其生物活性重組因子VIII片段之聚核苷酸序列,其包含與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列的一或多個取代。Thus, by way of example and not limitation, in some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide or a biologically active recombinant Factor VIII fragment thereof, which includes and corresponds to SEQ ID NO: 2. A reference sequence for residues 20-1457 of 252, 504, 706, 840, 1200, 1514 or 2072 or a reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 Have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, An amino acid sequence with 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity, wherein the amino acid sequence comprises an amino acid sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence or one or relative to the reference sequence corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 Multiple substitutions.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 2之殘基20-1457的參考序列或與對應於SEQ ID NO: 2之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or corresponding to The reference sequence of SEQ ID NO: 2 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 2 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 The reference sequence of residues 20-1457 or has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or an amino acid sequence with greater sequence identity, wherein the amino acid sequence comprises the reference sequence relative to residues 20-1457 corresponding to SEQ ID NO: 2 or relative to the reference sequence corresponding to SEQ ID NO: 2 One or more substitutions of the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO. 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的參考序列或與對應於SEQ ID NO. 4-2346及2350-2870中之偶數編號SEQ ID NO.之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an even numbered SEQ ID corresponding to SEQ ID NOs. 4-2346 and 2360-2870. The reference sequence of residues 20-1457 of SEQ ID NO. or has at least 70%, 75%, 80%, or 81% similarity with the reference sequence corresponding to the even-numbered SEQ ID NO. in SEQ ID NO. 4-2346 and 2350-2870 , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % or 99% or more sequence identity to an amino acid sequence, wherein the amino acid sequence comprises the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2 or relative to the reference sequence corresponding to SEQ ID NO: 2 : One or more substitutions of the reference sequence in 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代之胺基酸序列:13、14、15、16、17、18、19、20、21、24、37、56、57、58、59、61、63、64、65、85、96、104、110、119、127、132、158、160、164、167、168、171、175、178、186、187、205、210、211、212、215、225、246、257、260、265、281、292、294、301、303、304、306、308、310、311、312、318、320、321、325、328、332、334、335、344、346、347、349、351、353、354、355、356、358、359、362、370、387、388、390、392、393、397、407、428、429、433、435、436、481、487、488、489、491、498、499、503、514、527、533、534、535、536、538、543、550、551、555、558、569、580、581、584、610、611、612、613、614、615、616、617、618、619、620、621、622、643、646、650、665、667、676、680、681、682、683、684、686、693、696、698、700、706、707、708、712、716、724、726、729、731、732、734、735、736、737、738、739、740、744、746、747、748、749、750、751、752、753、754、755、756、757、759、770、773、775、785、786、787、790、791、792、793、794、795、797、798、799、800、801、802、805、806、807、808、809、810、811、812、815、816、817、818、819、821、822、824、825、826、828、830、831、836、837、838、839、840、841、844、866、873、879、892、896、897、903、907、914、916、917、918、919、921、922、923、924、926、929、938、939、945、948、951、968、999、1037、1040、1041、1042、1043、1049、1050、1051、1053、1054、1076、1078、1080、1084、1088、1089、1092、1093、1094、1095、1098、1099、1100、1101、1104、1108、1109、1113、1114、1116、1127、1129、1138、1145、1148、1151、1156、1158、1160、1186、1192、1193、1194、1205、1210、1218、1220、1221、1222、1224、1229、1245、1248、1250、1259、1264、1269、1270、1274、1281、1283、1292、1297、1339、1352、1373、1377、1378、1380、1389、1414、1422、1427、1428、1439、1440、1442或1452或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid sequence comprising at least one substitution at the following amino acid position: 13 ,14,15,16,17,18,19,20,21,24,37,56,57,58,59,61,63,64,65,85,96,104,110,119,127,132 ,158,160,164,167,168,171,175,178,186,187,205,210,211,212,215,225,246,257,260,265,281,292,294,301,303 ,304,306,308,310,311,312,318,320,321,325,328,332,334,335,344,346,347,349,351,353,354,355,356,358,359 ,362,370,387,388,390,392,393,397,407,428,429,433,435,436,481,487,488,489,491,498,499,503,514,527,533 ,534,535,536,538,543,550,551,555,558,569,580,581,584,610,611,612,613,614,615,616,617,618,619,620,621 ,622,643,646,650,665,667,676,680,681,682,683,684,686,693,696,698,700,706,707,708,712,716,724,726,729 ,731,732,734,735,736,737,738,739,740,744,746,747,748,749,750,751,752,753,754,755,756,757,759,770,773 ,775,785,786,787,790,791,792,793,794,795,797,798,799,800,801,802,805,806,807,808,809,810,811,812,815 ,816,817,818,819,821,822,824,825,826,828,830,831,836,837,838,839,840,841,844,866,873,879,892,896,897 ,903,907,914,916,917,918,919,921,922,923,924,926,929,938,939,945,948,951,968,999,1037,1040,1041,1042,1043 ,1049,1050,1051,1053,1054,1076,1078,1080,1084,1088,1089,1092,1093,1094,1095,1098,1099,1100,1101,1104,1108,1109,1113,1114,11 16 ,1127,1129,1138,1145,1148,1151,1156,1158,1160,1186,1192,1193,1194,1205,1210,1218,1220,1221,1222,1224,1229,1245,1248,1250,12 59 , 1264, 1269, 1270, 1274, 1281, 1283, 1292, 1297, 1339, 1352, 1373, 1377, 1378, 1380, 1389, 1414, 1422, 1427, 1428, 1439, 1440, 1442 or 1452 or combinations thereof, The amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個取代或胺基酸殘基13G/Y、14G/M/V、15G/S、16A/D/G/P/V、17S/V、18L/R、19G、20L、21M、24V、37H、56E/P、57A/L/S/T/V、58K、59D/G/L/M/Q/R/S/V/W、61Q/S、63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、64D/G、65A、85Q、96I/L/R/V/W、104S、110H、119G/V、127V、132P/R、158G、160E/T、164E、167G/H/R、168G/R、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、175A/G/H、178C/M/Q/V/W、186A、187C/G、205R、210P、211G/K/P/Q/R、212A/F/G/K/L/M/N/P/R/S/V/Y、215E/P/S、225R、246D、257I、260E/K/T、265R/S/W、281A/S、292D、294G、301K/M、303G/T、304A/E/G、306A/D/G/P/S/T、308P、310G/V、311E/G、312L、318C/G/K/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、321Y、325Y、328G/Q/S、332A/F/G/H/N/P/Q/R/T/V/W/Y、334G、335E/P、344A/E/L、346R/V、347N、349G、351S、353S、354R、355C、356L/N、358K/S、359E/G、362E/G/N/P/T/V/W、370A、387A/G/I/L/Q/R/S/T/V/W、388A/P、390A/E/G/L/M/P/S/T/V、392A、393A/F/G/H/M/Q/R/W/Y、397G/N、407V、428F、429L/S、433A/G、435Q、436D/G、481V、487N、488G、489E/F/Q/R、491E、498A、499C/L、503S、514L、527A、533R/V/Y、534F/I/L/M、535C/G/N、536A/G/K/L/M/P/R/W、538V、543G/L/P/W、550G、551W、555E/G/R/T、558A/E/G/L/P/Q/R/S/T/V/W、569T、580S/Y、581K/V、584A、610H/K/L/R/S/T、611D/E、612G/S/T、613S、614A/F/H/I/N/T、615D/N、616D/E/G/Q/W、617D/E/G/N、618C/E/G/P/Y、619E、620N/P、621K/M/R/T/W、622D、643N、646I、650M、665G、667I、676Q、680L/R、681A/C/E/F/G/L/N/R/Q/S/T/W、682R、683W、684G/K、686W、693T、696E、698D/S/W/Y、700A/E/Q/T/V、706A/G/M/Y、707H、708A/K/T/V、712G/L/M/Q/S/T/Y、716K/L/W、724I、726A/L、729T、731I/L/R、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、734I/R/S、735D/S/V、736F/G、737F/G/K/L/M/N/S/V、738A/D/E/F/H/K/N/P/R/S/T、739G/P/R、740G、744A/R、746P、747D、748F/G/K/N/S/V、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S/V、753D、754W、755G/L/P/Q/S/Y、756G/P/R/T、757A/G/K/T、759S、770W、773H、775E/G/K/N/P/S/V、785V、786C/D/L、787W、790A/G/I/M/P/W、791M/T、792H/W/Y、793G、794R、795C/N/S/T、797C/G/P/Q/T/W/Y、798C/R/T、799A/E/G/M/P/Q/R/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、801A/G/I/R、802S/V、805C/G/H/K/L/M/P/Q/R/S/V/W、806E/G/R/S、807C/L/P/R、808K/S、809A/C/G/I/K/L/N/Q/R/S/T/V/W、810V、811F、812G/I/V、815I、816V/W、817A/D、818A/E/G/P/S/V/W、819V、821Q、822S/T、824W、825L、826G、828K、830M/V、831W、836G/R/V/W、837G、838G/T、839A/G/K/P、840G、841W、844H、866A、873L/Q/T、879Q、892T、896L/V、897G/K/R、903E、907D、914V、916C/E/I/K/L/M/Q/T、917G、918M/S、919G、921R/W、922W、923M、924I/M/P/Q/W、926T/V、929A/Q/V、938R/V、939E/S、945K、948S、951V、968A/P、999R、1037H/M/N/P、1040E、1041G/H/N、1042A/E/T、1043E/R、1049G/W、1050E/P/Q/S/T、1051E/H/K/R/S/W、1053A/R、1054C、1076G/S、1078S、1080G/V、1084L/N、1088G/S、1089F/S、1092G、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1094S、1095G、1098G、1099G、1100I/S、1101G、1104C/E、1108M/S/V/W、1109G、1113F、1114A/M、1116A/G/I/L/R、1127L/V、1129P、1138Q、1145R、1148A/C/E/L/M/N/Q/R/S、1151S、1156D/G/N/R、1158N、1160R、1186E、1192D、1193A/E/G/I/L、1194P、1205L、1210M/T/V/W、1218A/G/L/M/P、1220D/E/L/T、1221G/S/T/V、1222F、1224P、1229D、1245R、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1250A/P/S/T、1259T、1264L/R/W、1269F、1270V、1274N/V、1281H/K/P/Q/R/S、1283E/H/L/S/T、1292Y、1297A、1339C、1352E、1373S、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1378A/C/D/E、1380A/G/W、1389W、1414A/C/D/E/G/H/N/P/T/W、1422I、1427Y、1428G、1439A/E/H/L/S/T、1440A/C/E/G/S/T、1442T或1452L或其組合的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one substitution or amino acid residue 13G/Y, 14G/M/V , 15G/S, 16A/D/G/P/V, 17S/V, 18L/R, 19G, 20L, 21M, 24V, 37H, 56E/P, 57A/L/S/T/V, 58K, 59D /G/L/M/Q/R/S/V/W, 61Q/S, 63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W /Y, 64D/G, 65A, 85Q, 96I/L/R/V/W, 104S, 110H, 119G/V, 127V, 132P/R, 158G, 160E/T, 164E, 167G/H/R, 168G /R, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y, 175A/G/H, 178C/M/Q/V/W , 186A, 187C/G, 205R, 210P, 211G/K/P/Q/R, 212A/F/G/K/L/M/N/P/R/S/V/Y, 215E/P/S , 225R, 246D, 257I, 260E/K/T, 265R/S/W, 281A/S, 292D, 294G, 301K/M, 303G/T, 304A/E/G, 306A/D/G/P/S /T, 308P, 310G/V, 311E/G, 312L, 318C/G/K/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V, 321Y , 325Y, 328G/Q/S, 332A/F/G/H/N/P/Q/R/T/V/W/Y, 334G, 335E/P, 344A/E/L, 346R/V, 347N , 349G, 351S, 353S, 354R, 355C, 356L/N, 358K/S, 359E/G, 362E/G/N/P/T/V/W, 370A, 387A/G/I/L/Q/R /S/T/V/W, 388A/P, 390A/E/G/L/M/P/S/T/V, 392A, 393A/F/G/H/M/Q/R/W/Y , 397G/N, 407V, 428F, 429L/S, 433A/G, 435Q, 436D/G, 481V, 487N, 488G, 489E/F/Q/R, 491E, 498A, 499C/L, 503S, 514L, 527A , 533R/V/Y, 534F/I/L/M, 535C/G/N, 536A/G/K/L/M/P/R/W, 538V, 543G/L/P/W, 550G, 551W , 555E/G/R/T, 558A/E/G/L/P/Q/R/S/T/V/W, 569T, 580S/Y, 581K/V, 584A, 610H/K/L/R /S/T, 611D/E, 612G/S/T, 613S, 614A/F/H/I/N/T, 615D/N, 616D/E/G/Q/W, 617D/E/G/N , 618C/E/G/P/Y, 619E, 620N/P, 621K/M/R/T/W, 622D, 643N, 646I, 650M, 665G, 667I, 676Q, 680L/R, 681A/C/E /F/G/L/N/R/Q/S/T/W, 682R, 683W, 684G/K, 686W, 693T, 696E, 698D/S/W/Y, 700A/E/Q/T/V , 706A/G/M/Y, 707H, 708A/K/T/V, 712G/L/M/Q/S/T/Y, 716K/L/W, 724I, 726A/L, 729T, 731I/L /R, 732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y, 734I/R/S, 735D/S/V, 736F/G, 737F/G /K/L/M/N/S/V, 738A/D/E/F/H/K/N/P/R/S/T, 739G/P/R, 740G, 744A/R, 746P, 747D , 748F/G/K/N/S/V, 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A/D/G /K/M/N/P/Q/R/S/T/V/W, 751A/D/E/Y, 752D/E/F/G/L/M/Q/R/S/V, 753D , 754W, 755G/L/P/Q/S/Y, 756G/P/R/T, 757A/G/K/T, 759S, 770W, 773H, 775E/G/K/N/P/S/V , 785V, 786C/D/L, 787W, 790A/G/I/M/P/W, 791M/T, 792H/W/Y, 793G, 794R, 795C/N/S/T, 797C/G/P /Q/T/W/Y, 798C/R/T, 799A/E/G/M/P/Q/R/S/V, 800C/G/I/L/M/N/P/Q/R /T/V/W/Y, 801A/G/I/R, 802S/V, 805C/G/H/K/L/M/P/Q/R/S/V/W, 806E/G/R /S, 807C/L/P/R, 808K/S, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 810V, 811F, 812G/I/V , 815I, 816V/W, 817A/D, 818A/E/G/P/S/V/W, 819V, 821Q, 822S/T, 824W, 825L, 826G, 828K, 830M/V, 831W, 836G/R /V/W, 837G, 838G/T, 839A/G/K/P, 840G, 841W, 844H, 866A, 873L/Q/T, 879Q, 892T, 896L/V, 897G/K/R, 903E, 907D , 914V, 916C/E/I/K/L/M/Q/T, 917G, 918M/S, 919G, 921R/W, 922W, 923M, 924I/M/P/Q/W, 926T/V, 929A /Q/V, 938R/V, 939E/S, 945K, 948S, 951V, 968A/P, 999R, 1037H/M/N/P, 1040E, 1041G/H/N, 1042A/E/T, 1043E/R , 1049G/W, 1050E/P/Q/S/T, 1051E/H/K/R/S/W, 1053A/R, 1054C, 1076G/S, 1078S, 1080G/V, 1084L/N, 1088G/S , 1089F/S, 1092G, 1093A/E/G/M/N/P/Q/R/S/T/V/W/Y, 1094S, 1095G, 1098G, 1099G, 1100I/S, 1101G, 1104C/E , 1108M/S/V/W, 1109G, 1113F, 1114A/M, 1116A/G/I/L/R, 1127L/V, 1129P, 1138Q, 1145R, 1148A/C/E/L/M/N/Q /R/S, 1151S, 1156D/G/N/R, 1158N, 1160R, 1186E, 1192D, 1193A/E/G/I/L, 1194P, 1205L, 1210M/T/V/W, 1218A/G/L /M/P, 1220D/E/L/T, 1221G/S/T/V, 1222F, 1224P, 1229D, 1245R, 1248A/C/D/E/F/G/H/I/K/M/P /Q/R/S/T/W/Y, 1250A/P/S/T, 1259T, 1264L/R/W, 1269F, 1270V, 1274N/V, 1281H/K/P/Q/R/S, 1283E /H/L/S/T, 1292Y, 1297A, 1339C, 1352E, 1373S, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y, 1378A/C /D/E, 1380A/G/W, 1389W, 1414A/C/D/E/G/H/N/P/T/W, 1422I, 1427Y, 1428G, 1439A/E/H/L/S/T , 1440A/C/E/G/S/T, 1442T or 1452L, or the amino acid sequence of a combination thereof, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代之胺基酸序列:63、171、212、260、306、317、320、332、387、390、393、534、558、681、732、738、749、750、775、1148、1248、1377或1439或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid sequence comprising at least one substitution at the following amino acid position: 63 , 171, 212, 260, 306, 317, 320, 332, 387, 390, 393, 534, 558, 681, 732, 738, 749, 750, 775, 1148, 1248, 1377 or 1439 or a combination thereof, wherein the Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個取代或胺基酸殘基63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、212A/F/G/L/K/M/N/P/R/S/V/Y、260E/K/T、306A/D/G/P/S/T、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、332A/F/G/H/N/P/Q/R/T/V/W/Y、387A/G/I/L/Q/R/S/T/V/W、390A/E/G/L/M/P/S/T/V、393A/F/G/H/M/Q/R/W/Y、499C/L、534I/F/L/M、558A/E/G/L/P/Q/R/S/T/V/W、681A/C/E/F/G/L/N/R/Q/S/T/W、700A/E/Q/T/V、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、738A/D/E/F/H/K/N/P/R/S/T/Y、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、752D/E/F/G/L/M/Q/R/S/V、775E/G/K/N/P/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、805C/G/H/K/L/M/P/Q/R/S/V/W、809A/C/G/I/K/L/N/Q/R/S/T/V/W、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1148A/C/E/L/M/N/Q/R/S、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1414A/C/D/E/G/H/N/P/T/W或1439A/E/H/L/S/T或其組合的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one substitution or amino acid residue 63C/E/F/G/H /I/K/L/M/N/Q/R/S/T/W/Y, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V /W/Y, 212A/F/G/L/K/M/N/P/R/S/V/Y, 260E/K/T, 306A/D/G/P/S/T, 318C/G /K/L/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V, 332A/F/G/H/N/P/Q/R/T /V/W/Y, 387A/G/I/L/Q/R/S/T/V/W, 390A/E/G/L/M/P/S/T/V, 393A/F/G /H/M/Q/R/W/Y, 499C/L, 534I/F/L/M, 558A/E/G/L/P/Q/R/S/T/V/W, 681A/C /E/F/G/L/N/R/Q/S/T/W, 700A/E/Q/T/V, 732C/D/E/G/L/R/W/K/M/Q /S/T/V/Y, 738A/D/E/F/H/K/N/P/R/S/T/Y, 749A/C/D/F/G/I/K/L/M /P/Q/R/S/T/V/Y, 750A/D/G/K/M/N/P/Q/R/S/T/V/W, 752D/E/F/G/L /M/Q/R/S/V, 775E/G/K/N/P/S/V, 800C/G/I/L/M/N/P/Q/R/T/V/W/Y , 805C/G/H/K/L/M/P/Q/R/S/V/W, 809A/C/G/I/K/L/N/Q/R/S/T/V/W , 1093A/E/G/M/N/P/Q/R/S/T/V/W/Y, 1148A/C/E/L/M/N/Q/R/S, 1248A/C/D /E/F/G/H/I/K/M/P/Q/R/S/T/W/Y, 1377A/C/D/E/G/H/I/M/P/R/S /V/T/Y, 1414A/C/D/E/G/H/N/P/T/W or 1439A/E/H/L/S/T or the amino acid sequence of a combination thereof, wherein Amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:1148、85/708/1148、798、706、171、335、63、344、428、879、59、429、205、1264、797、1248、873、792、708、57、96、362、1292、346、433、65、795、684/798、353、332、1259、356、436、1245、1145、716、56、773、734、358、729、665、359、61、1250、726、37/96/171/429/708/799/1148、171/429/732/1148、96/171、171/919/1151、171/792/797/799/1148、171/569/1148、96/171/429/792/797/799、171/429/708/1422、171/429、321/362/732/797/799、171/1100、708/1148/1186、429/724/732/1148、171/362/795/797/799、171/429/732、96/171/643/797/799、171/792/797/799、503、171/732、1148/1193、96/171/362/429/732/795/797、334、732、351、1377、999、306、349、257、646、435或58,其中該等位置係相對於對應於SEQ ID NO: 2之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 1148, 85/708/1148, 798, 706, 171, 335, 63, 344, 428, 879, 59, 429, 205, 1264, 797, 1248, 873, 792, 708, 57, 96, 362, 1292, 346, 433, 65, 795, 684/798, 353, 332, 1259, 356, 436, 1245, 1145, 716, 56, 773, 734, 358, 729, 665, 359, 61, 1250, 726, 37/96/171/429/708/799/1148, 171/429/732/1148, 96/171, 171/919/1151, 171/792/797/799/1148, 171/569/1148, 96/ 171/429/792/797/799, 171/429/708/1422, 171/429, 321/362/732/797/799, 171/1100, 708/1148/1186, 429/724/732/1148, 171/362/795/797/799, 171/429/732, 96/171/643/797/799, 171/792/797/799, 503, 171/732, 1148/1193, 96/171/362/ 429/732/795/797, 334, 732, 351, 1377, 999, 306, 349, 257, 646, 435 or 58, where these positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含在 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之胺基酸位置處的取代之胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a polynucleotide sequence contained in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , Substituted amino acid sequences at the amino acid positions set forth in 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2 the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之胺基位置處的取代或取代集之胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one of the peptides in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , Amino acid sequences of substitutions or sets of substitutions at the amine positions set forth in 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2 of this reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之變異體的取代或取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , amino acid sequences of substitutions or sets of substitutions of the variants set forth in SEQ ID NO: 2 the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 The reference sequence of residues 20-1457 or has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or amino acid sequences with greater sequence identity.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO. 4-2346及2360-2870中之偶數編號SEQ ID NO.之殘基20-1457的參考序列或與對應於SEQ ID NO. 4-2346及2350-2870中之偶數編號SEQ ID NO.之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an even numbered SEQ ID corresponding to SEQ ID NOs. 4-2346 and 2360-2870 The reference sequence of residues 20-1457 of SEQ ID NO. or has at least 70%, 75%, 80%, or 81% similarity with the reference sequence corresponding to the even-numbered SEQ ID NO. in SEQ ID NO. 4-2346 and 2350-2870 , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % or amino acid sequences with 99% or more sequence identity.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之參考序列具有至少75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514, or 2072 The reference sequence of residues 20-1457 or has at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more Sequence identity amino acid sequence, wherein the amino acid sequence comprises relative to the reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072 or relative to One or more substitutions of the reference sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代之胺基酸序列:13、14、15、16、17、18、19、20、21、24、37、56、57、58、59、61、63、64、65、85、96、104、110、119、127、132、158、160、164、167、168、171、175、178、186、187、205、210、211、212、215、225、246、257、260、265、281、292、294、301、303、304、306、308、310、311、312、318、320、321、325、328、332、334、335、344、346、347、349、351、353、354、355、356、358、359、362、370、387、388、390、392、393、397、407、428、429、433、435、436、481、487、488、489、491、498、499、503、514、527、533、534、535、536、538、543、550、551、555、558、569、580、581、584、610、611、612、613、614、615、616、617、618、619、620、621、622、643、646、650、665、667、676、680、681、682、683、684、686、693、696、698、700、706、707、708、712、716、724、726、729、731、732、734、735、736、737、738、739、740、744、746、747、748、749、750、751、752、753、754、755、756、757、759、770、773、775、785、786、787、790、791、792、793、794、795、797、798、799、800、801、802、805、806、807、808、809、810、811、812、815、816、817、818、819、821、822、824、825、826、828、830、831、836、837、838、839、840、841、844、866、873、879、892、896、897、903、907、914、916、917、918、919、921、922、923、924、926、929、938、939、945、948、951、968、999、1037、1040、1041、1042、1043、1049、1050、1051、1053、1054、1076、1078、1080、1084、1088、1089、1092、1093、1094、1095、1098、1099、1100、1101、1104、1108、1109、1113、1114、1116、1127、1129、1138、1145、1148、1151、1156、1158、1160、1186、1192、1193、1194、1205、1210、1218、1220、1221、1222、1224、1229、1245、1248、1250、1259、1264、1269、1270、1274、1281、1283、1292、1297、1339、1352、1373、1377、1378、1380、1389、1414、1422、1427、1428、1439、1440、1442或1452或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid sequence comprising at least one substitution at the following amino acid position: 13 ,14,15,16,17,18,19,20,21,24,37,56,57,58,59,61,63,64,65,85,96,104,110,119,127,132 ,158,160,164,167,168,171,175,178,186,187,205,210,211,212,215,225,246,257,260,265,281,292,294,301,303 ,304,306,308,310,311,312,318,320,321,325,328,332,334,335,344,346,347,349,351,353,354,355,356,358,359 ,362,370,387,388,390,392,393,397,407,428,429,433,435,436,481,487,488,489,491,498,499,503,514,527,533 ,534,535,536,538,543,550,551,555,558,569,580,581,584,610,611,612,613,614,615,616,617,618,619,620,621 ,622,643,646,650,665,667,676,680,681,682,683,684,686,693,696,698,700,706,707,708,712,716,724,726,729 ,731,732,734,735,736,737,738,739,740,744,746,747,748,749,750,751,752,753,754,755,756,757,759,770,773 ,775,785,786,787,790,791,792,793,794,795,797,798,799,800,801,802,805,806,807,808,809,810,811,812,815 ,816,817,818,819,821,822,824,825,826,828,830,831,836,837,838,839,840,841,844,866,873,879,892,896,897 ,903,907,914,916,917,918,919,921,922,923,924,926,929,938,939,945,948,951,968,999,1037,1040,1041,1042,1043 ,1049,1050,1051,1053,1054,1076,1078,1080,1084,1088,1089,1092,1093,1094,1095,1098,1099,1100,1101,1104,1108,1109,1113,1114,11 16 ,1127,1129,1138,1145,1148,1151,1156,1158,1160,1186,1192,1193,1194,1205,1210,1218,1220,1221,1222,1224,1229,1245,1248,1250,12 59 , 1264, 1269, 1270, 1274, 1281, 1283, 1292, 1297, 1339, 1352, 1373, 1377, 1378, 1380, 1389, 1414, 1422, 1427, 1428, 1439, 1440, 1442 or 1452 or combinations thereof, The amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個取代或胺基酸殘基13G/Y、14G/M/V、15G/S、16A/D/G/P/V、17S/V、18L/R、19G、20L、21M、24V、37H、56E/P、57A/L/S/T/V、58K、59D/G/L/M/Q/R/S/V/W、61Q/S、63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W/Y、64D/G、65A、85Q、96I/L/R/V/W、104S、110H、119G/V、127V、132P/R、158G、160E/T、164E、167G/H/R、168G/R、171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y、175A/G/H、178C/M/Q/V/W、186A、187C/G、205R、210P、211G/K/P/Q/R、212A/F/G/L/K/M/N/P/R/S/V/Y、215E/P/S、225R、246D、257I、260E/K/T、265R/S/W、281A/S、292D、294G、301K/M、303G/T、304A/E/G、306A/D/G/P/S/T、308P、310G/V、311E/G、312L、318C/G/K/L/M/Q/R/T/V、320G/I/L/P/Q/R/S/T/V、321Y、325Y、328G/Q/S、332A/F/G/H/N/P/Q/R/T/V/W/Y、334G、335E/P、344A/E/L、346R/V、347N、349G、351S、353S、354R、355C、356L/N、358K/S、359E/G、362E/G/N/P/T/V/W、370A、387A/G/I/L/Q/R/S/T/V/W、388A/P、390A/E/G/L/M/P/S/T/V、392A、393A/F/G/H/M/Q/R/W/Y、397G/N、407V、428F、429L/S、433A/G、435Q、436D/G、481V、487N、488G、489E/F/Q/R、491E、498A、499C/L、503S、514L、527A、533R/V/Y、534I/F/L/M、535C/G/N、536A/G/K/L/M/P/R/W、538V、543G/L/P/W、550G、551W、555E/G/R/T、558A/E/G/L/P/Q/R/S/T/V/W、569T、580S/Y、581K/V、584A、610H/K/L/R/S/T、611D/E、612G/S/T、613S、614A/F/H/I/N/T、615D/N、616D/E/G/Q/W、617D/E/G/N、618C/E/G/P/Y、619E、620N/P、621K/M/R/T/W、622D、643N、646I、650M、665G、667I、676Q、680L/R、681A/C/E/F/G/L/N/R/Q/S/T/W、682R、683W、684G/K、686W、693T、696E、698D/S/W/Y、700A/E/Q/T/V、706A/G/M/Y、707H、708A/K/T/V、712G/L/M/Q/S/T/Y、716K/L/W、724I、726A/L、729T、731I/L/R、732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y、734I/R/S、735D/S/V、736F/G、737F/G/K/L/M/N/S/V、738A/D/E/F/H/K/N/P/R/S/T/Y、739G/P/R、740G、744A/R、746P、747D、748F/G/K/N/S/V、749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y、750A/D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S/V、753D、754W、755G/L/P/Q/S/Y、756G/P/R/T、757A/G/K/T、759S、770W、773H、775E/G/K/N/P/S/V、785V、786C/D/L、787W、790A/G/I/M/P/W、791M/T、792H/W/Y、793G、794R、795C/N/S/T、797C/G/P/Q/T/W/Y、798C/R/T、799A/E/G/M/P/Q/R/S/V、800C/G/I/L/M/N/P/Q/R/T/V/W/Y、801A/G/I/R、802S/V、805C/G/H/K/L/M/P/Q/R/S/V/W、806E/G/R/S、807C/L/P/R、808K/S、809A/C/G/I/K/L/N/Q/R/S/T/V/W、810V、811F、812G/I/V、815I、816V/W、817A/D、818A/E/G/P/S/V/W、819V、821Q、822S/T、824W、825L、826G、828K、830M/V、831W、836G/R/V/W、837G、838G/T、839A/G/K/P、840G、841W、844H、866A、873L/Q/T、879Q、892T、896L/V、897G/K/R、903E、907D、914V、916C/E/I/K/L/M/Q/T、917G、918M/S、919G、921R/W、922W、923M、924I/M/P/Q/W、926T/V、929A/Q/V、938R/V、939E/S、945K、948S、951V、968A/P、999R、1037H/M/N/P、1040E、1041G/H/N、1042A/E/T、1043E/R、1049G/W、1050E/P/Q/S/T、1051E/H/K/R/S/W、1053A/R、1054C、1076G/S、1078S、1080G/V、1084L/N、1088G/S、1089F/S、1092G、1093A/E/G/M/N/P/Q/R/S/T/V/W/Y、1094S、1095G、1098G、1099G、1100I/S、1101G、1104C/E、1108M/S/V/W、1109G、1113F、1114A/M、1116A/G/I/L/R、1127L/V、1129P、1138Q、1145R、1148A/C/E/L/M/N/Q/R/S、1151S、1156D/G/N/R、1158N、1160R、1186E、1192D、1193A/E/G/I/L、1194P、1205L、1210M/T/V/W、1218A/G/L/M/P、1220D/E/L/T、1221G/S/T/V、1222F、1224P、1229D、1245R、1248A/C/D/E/F/G/H/I/K/M/P/Q/R/S/T/W/Y、1250A/P/S/T、1259T、1264L/R/W、1269F、1270V、1274N/V、1281H/K/P/Q/R/S、1283E/H/L/S/T、1292Y、1297A、1339C、1352E、1373S、1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y、1378A/C/D/E、1380A/G/W、1389W、1414A/C/D/E/G/H/N/P/T/W、1422I、1427Y、1428G、1439A/E/H/L/S/T、1440A/C/E/G/S/T、1442T或1452L或其組合的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one substitution or amino acid residue 13G/Y, 14G/M/V , 15G/S, 16A/D/G/P/V, 17S/V, 18L/R, 19G, 20L, 21M, 24V, 37H, 56E/P, 57A/L/S/T/V, 58K, 59D /G/L/M/Q/R/S/V/W, 61Q/S, 63C/E/F/G/H/I/K/L/M/N/Q/R/S/T/W /Y, 64D/G, 65A, 85Q, 96I/L/R/V/W, 104S, 110H, 119G/V, 127V, 132P/R, 158G, 160E/T, 164E, 167G/H/R, 168G /R, 171A/D/E/F/H/K/N/M/P/Q/R/S/T/V/W/Y, 175A/G/H, 178C/M/Q/V/W , 186A, 187C/G, 205R, 210P, 211G/K/P/Q/R, 212A/F/G/L/K/M/N/P/R/S/V/Y, 215E/P/S , 225R, 246D, 257I, 260E/K/T, 265R/S/W, 281A/S, 292D, 294G, 301K/M, 303G/T, 304A/E/G, 306A/D/G/P/S /T, 308P, 310G/V, 311E/G, 312L, 318C/G/K/L/M/Q/R/T/V, 320G/I/L/P/Q/R/S/T/V , 321Y, 325Y, 328G/Q/S, 332A/F/G/H/N/P/Q/R/T/V/W/Y, 334G, 335E/P, 344A/E/L, 346R/V , 347N, 349G, 351S, 353S, 354R, 355C, 356L/N, 358K/S, 359E/G, 362E/G/N/P/T/V/W, 370A, 387A/G/I/L/Q /R/S/T/V/W, 388A/P, 390A/E/G/L/M/P/S/T/V, 392A, 393A/F/G/H/M/Q/R/W /Y, 397G/N, 407V, 428F, 429L/S, 433A/G, 435Q, 436D/G, 481V, 487N, 488G, 489E/F/Q/R, 491E, 498A, 499C/L, 503S, 514L , 527A, 533R/V/Y, 534I/F/L/M, 535C/G/N, 536A/G/K/L/M/P/R/W, 538V, 543G/L/P/W, 550G , 551W, 555E/G/R/T, 558A/E/G/L/P/Q/R/S/T/V/W, 569T, 580S/Y, 581K/V, 584A, 610H/K/L /R/S/T, 611D/E, 612G/S/T, 613S, 614A/F/H/I/N/T, 615D/N, 616D/E/G/Q/W, 617D/E/G /N, 618C/E/G/P/Y, 619E, 620N/P, 621K/M/R/T/W, 622D, 643N, 646I, 650M, 665G, 667I, 676Q, 680L/R, 681A/C /E/F/G/L/N/R/Q/S/T/W, 682R, 683W, 684G/K, 686W, 693T, 696E, 698D/S/W/Y, 700A/E/Q/T /V, 706A/G/M/Y, 707H, 708A/K/T/V, 712G/L/M/Q/S/T/Y, 716K/L/W, 724I, 726A/L, 729T, 731I /L/R, 732C/D/E/G/L/R/W/K/M/Q/S/T/V/Y, 734I/R/S, 735D/S/V, 736F/G, 737F /G/K/L/M/N/S/V, 738A/D/E/F/H/K/N/P/R/S/T/Y, 739G/P/R, 740G, 744A/R , 746P, 747D, 748F/G/K/N/S/V, 749A/C/D/F/G/I/K/L/M/P/Q/R/S/T/V/Y, 750A /D/G/K/M/N/P/Q/R/S/T/V/W、751A/D/E/Y、752D/E/F/G/L/M/Q/R/S /V, 753D, 754W, 755G/L/P/Q/S/Y, 756G/P/R/T, 757A/G/K/T, 759S, 770W, 773H, 775E/G/K/N/P /S/V, 785V, 786C/D/L, 787W, 790A/G/I/M/P/W, 791M/T, 792H/W/Y, 793G, 794R, 795C/N/S/T, 797C /G/P/Q/T/W/Y, 798C/R/T, 799A/E/G/M/P/Q/R/S/V, 800C/G/I/L/M/N/P /Q/R/T/V/W/Y, 801A/G/I/R, 802S/V, 805C/G/H/K/L/M/P/Q/R/S/V/W, 806E /G/R/S, 807C/L/P/R, 808K/S, 809A/C/G/I/K/L/N/Q/R/S/T/V/W, 810V, 811F, 812G /I/V, 815I, 816V/W, 817A/D, 818A/E/G/P/S/V/W, 819V, 821Q, 822S/T, 824W, 825L, 826G, 828K, 830M/V, 831W , 836G/R/V/W, 837G, 838G/T, 839A/G/K/P, 840G, 841W, 844H, 866A, 873L/Q/T, 879Q, 892T, 896L/V, 897G/K/R , 903E, 907D, 914V, 916C/E/I/K/L/M/Q/T, 917G, 918M/S, 919G, 921R/W, 922W, 923M, 924I/M/P/Q/W, 926T /V, 929A/Q/V, 938R/V, 939E/S, 945K, 948S, 951V, 968A/P, 999R, 1037H/M/N/P, 1040E, 1041G/H/N, 1042A/E/T , 1043E/R, 1049G/W, 1050E/P/Q/S/T, 1051E/H/K/R/S/W, 1053A/R, 1054C, 1076G/S, 1078S, 1080G/V, 1084L/N , 1088G/S, 1089F/S, 1092G, 1093A/E/G/M/N/P/Q/R/S/T/V/W/Y, 1094S, 1095G, 1098G, 1099G, 1100I/S, 1101G , 1104C/E, 1108M/S/V/W, 1109G, 1113F, 1114A/M, 1116A/G/I/L/R, 1127L/V, 1129P, 1138Q, 1145R, 1148A/C/E/L/M /N/Q/R/S, 1151S, 1156D/G/N/R, 1158N, 1160R, 1186E, 1192D, 1193A/E/G/I/L, 1194P, 1205L, 1210M/T/V/W, 1218A /G/L/M/P, 1220D/E/L/T, 1221G/S/T/V, 1222F, 1224P, 1229D, 1245R, 1248A/C/D/E/F/G/H/I/K /M/P/Q/R/S/T/W/Y, 1250A/P/S/T, 1259T, 1264L/R/W, 1269F, 1270V, 1274N/V, 1281H/K/P/Q/R /S, 1283E/H/L/S/T, 1292Y, 1297A, 1339C, 1352E, 1373S, 1377A/C/D/E/G/H/I/M/P/R/S/V/T/Y , 1378A/C/D/E, 1380A/G/W, 1389W, 1414A/C/D/E/G/H/N/P/T/W, 1422I, 1427Y, 1428G, 1439A/E/H/L /S/T, 1440A/C/E/G/S/T, 1442T or 1452L or the amino acid sequence of a combination thereof, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 252, 504, 706 , 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:63、171、212、260、306、317、320、332、387、390、393、534、558、681、732、738、749、750、775、1148、1248、1377或1439或其組合,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252、504、706、840、1200、1514或2072之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 63, 171, 212, 260, 306, 317, 320, 332, 387, 390, 393, 534, 558, 681, 732, 738, 749, 750, 775, 1148, 1248, 1377 or 1439 or combinations thereof , wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 252之殘基20-1457的參考序列或與對應於SEQ ID NO: 252之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 252之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 252之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 252 or corresponding to The reference sequence of SEQ ID NO: 252 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 252 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 252.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:1380、388、1043、610、1274、1220、1442、1193、621、1054、755、1041、748、1049、1221、1051、612、1037、616、387、489、750、1224、618、1050、1053、896、897、749、260、481、613、756、63、265、752、1218、1378、614、1440、1439、1205、1222、1389、1269、390、397/1218、757、1373、346、63/1248、349、306/355/1422、1422、306/346/708、1148、171/346/1248、63/797/799/1248/1422、171/799、362、1248、171/306/346/999/1248、171/1148、734/799/1248/1422、63/732、63/171/306/346/732、171、171/1422、63/362/732/799/1248、999/1148/1422、346/349、306/349、63/171/1148/1151、306、344/349/354/1250、1250、63/306/344/349/354/503/1248、59/63/332/349/503/706/708、63/306/344/349/354/706/1248、59/63、332/706/708/1248/1250、503、59/63/349/354、59/349/708、59/306/344/1248、344/1248/1250、708、63/344/349、59、63/344/349/354、706、59/306/770、63/347/354/1248或354/503,其中該等胺基酸位置係相對於對應於SEQ ID NO: 252之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 1380, 388, 1043, 610, 1274, 1220, 1442, 1193, 621, 1054, 755, 1041, 748, 1049, 1221, 1051, 612, 1037, 616, 387, 489, 750, 1224, 618, 1050, 1053, 896, 897, 749, 260, 481, 613, 756, 63, 265, 752, 1218, 1378, 614, 1440, 1439, 1205, 1222, 1389, 1269, 390, 397/1218, 757, 1373, 346, 63/1248, 349, 306/355/1422, 1422, 306/346/708, 1148, 171/346/1248, 63/797/799/1248/1422, 171/799, 362, 1248, 171/306/346/999/1248, 171/1148, 734/799/1248/1422, 63/732, 63/171/306/346/732, 171, 171/1422, 63/362/732/799/ 1248, 999/1148/1422, 346/349, 306/349, 63/171/1148/1151, 306, 344/349/354/1250, 1250, 63/306/344/349/354/503/1248, 59/63/332/349/503/706/708, 63/306/344/349/354/706/1248, 59/63, 332/706/708/1248/1250, 503, 59/63/349/ 354, 59/349/708, 59/306/344/1248, 344/1248/1250, 708, 63/344/349, 59, 63/344/349/354, 706, 59/306/770, 63/ 347/354/1248 or 354/503, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 252.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 504之殘基20-1457的參考序列或與對應於SEQ ID NO: 504之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 504之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 504之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 504 or corresponding to The reference sequence of SEQ ID NO: 504 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 504 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 504.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:750、1051、260、756、1193、332、897、387、1037、306/749、1270、489、487、488、903、171/1248/1440、260/1148/1378、171/260/387/750/1248、171/260、171/260/387/750/1051/1148、171、750/1051/1148、171/260/756、171/1248、171/1148、59、1440、332/750/1248、756/1248、1248、171/387/1248/1440、750/1440、59/171/750、171/1193/1248、750/1148/1193/1440、1148、171/387/1051、748、306、306/387/390/749/1220、390、306/390/1037、306/612/749、387/390/749、63/390/503/749、1220、63/306、749、306/390/749/1037、306/749/1220、306/387/390/612/749/1037或328,其中該等胺基酸位置係相對於對應於SEQ ID NO: 504之該參考序列。In some embodiments, a recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequences: 750, 1051, 260, 756, 1193, 332, 897, 387, 1037, 306/749, 1270, 489, 487, 488, 903, 171/1248/1440, 260/1148/1378, 171/260/ 387/750/1248, 171/260, 171/260/387/750/1051/1148, 171, 750/1051/1148, 171/260/756, 171/1248, 171/1148, 59, 1440, 332/ 750/1248, 756/1248, 1248, 171/387/1248/1440, 750/1440, 59/171/750, 171/1193/1248, 750/1148/1193/1440, 1148, 171/387/1051, 748, 306, 306/387/390/749/1220, 390, 306/390/1037, 306/612/749, 387/390/749, 63/390/503/749, 1220, 63/306, 749, 306/390/749/1037, 306/749/1220, 306/387/390/612/749/1037 or 328, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 504.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 706之殘基20-1457的參考序列或與對應於SEQ ID NO: 706之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 706之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 706之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 706 or corresponding to The reference sequence of SEQ ID NO: 706 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 706 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 706.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:1051、1221、1218、387、749/1218、332、897、696、816、824、826、393、825、698、332/387/390/1148、328/387/749、749、306/328/332/390/1051/1193/1218、63/306/332/1051/1148、63/306/332/387/1051、387/390/1051、186/306/328/332/390/749/1051/1148/1193、387/390/756/1051、306/390/1051、306/332/390/749、306/387/390/1148、306/328/332/387/390/749/1051/1148/1193、332/387/390/749/1148、387/390/749、306/387/749/1051/1148、387/749、306/945/1051/1193/1221、306/390/749/1051、63/306/332/390、306/387/390/749/1148/1193/1221、306/332/387/390/749/1218、63/306/332/390/1051/1148/1193/1218、924、755、752、751、923、797、754、793、753、922、896、938、775、732、810、747、393/407、819、787、802、811、392或397,其中該等胺基酸位置係相對於對應於SEQ ID NO: 706之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 1051, 1221, 1218, 387, 749/1218, 332, 897, 696, 816, 824, 826, 393, 825, 698, 332/387/390/1148, 328/387/749, 749, 306/ 328/332/390/1051/1193/1218, 63/306/332/1051/1148, 63/306/332/387/1051, 387/390/1051, 186/306/328/332/390/749/ 1051/1148/1193, 387/390/756/1051, 306/390/1051, 306/332/390/749, 306/387/390/1148, 306/328/332/387/390/749/1051/ 1148/1193, 332/387/390/749/1148, 387/390/749, 306/387/749/1051/1148, 387/749, 306/945/1051/1193/1221, 306/390/749/ 1051, 63/306/332/390, 306/387/390/749/1148/1193/1221, 306/332/387/390/749/1218, 63/306/332/390/1051/1148/1193/ 1218, 924, 755, 752, 751, 923, 797, 754, 793, 753, 922, 896, 938, 775, 732, 810, 747, 393/407, 819, 787, 802, 811, 392 or 397, The amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 706.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 840之殘基20-1457的參考序列或與對應於SEQ ID NO: 840之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 840之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 840之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 840 or corresponding to The reference sequence of SEQ ID NO: 840 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 840 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 840.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:620、491、1229、615、1283、822、328、212、818、555/684、828、550、830、839、13、14、17、836、1210、1281、64、682、318、20、21、325、533、19、817、831、225、1156、393/747、753、393/732/751、63/797、622、617、907、1040、611、488、1192、1194、619、16、802、211、555、536、527、841、320、837、558、914、312、681、838、15、1427、18、683、24、534、840、1160、551、393、393/747/752/811/819/923/1148、393/751/775、63/393/732/775/1148、393/732/1148、775/1148、393/752/753/775/793/797、393/923、393/923/1148、393/747/751、393/747/753/775/1148、752/923/1051、63/775、63/393/752/775/793/1051/1053、752/753/775/793/819、63/1051、63/747/752/753/775/811/819/923/1051、393/752/787、751、63/1148、63/747/752/753/819/923/1148、1148、747/752/753/793/811、63、797/1148、751/752/753/1051、63/732/1051、752/797/815/923/1051/1148或747/753,其中該等胺基酸位置係相對於對應於SEQ ID NO: 840之該參考序列。In some embodiments, a recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 620, 491, 1229, 615, 1283, 822, 328, 212, 818, 555/684, 828, 550, 830, 839, 13, 14, 17, 836, 1210, 1281, 64, 682, 318, 20, 21, 325, 533, 19, 817, 831, 225, 1156, 393/747, 753, 393/732/751, 63/797, 622, 617, 907, 1040, 611, 488, 1192, 1194, 619, 16, 802, 211, 555, 536, 527, 841, 320, 837, 558, 914, 312, 681, 838, 15, 1427, 18, 683, 24, 534, 840, 1160, 551, 393, 393/747/752/811/819/923/1148, 393/751/775, 63/393/732/775/1148, 393/732/1148, 775/1148, 393/752/753/775/793/ 797, 393/923, 393/923/1148, 393/747/751, 393/747/753/775/1148, 752/923/1051, 63/775, 63/393/752/775/793/1051/ 1053, 752/753/775/793/819, 63/1051, 63/747/752/753/775/811/819/923/1051, 393/752/787, 751, 63/1148, 63/747/ 752/753/819/923/1148, 1148, 747/752/753/793/811, 63, 797/1148, 751/752/753/1051, 63/732/1051, 752/797/815/923/ 1051/1148 or 747/753, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 840.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 1200之殘基20-1457的參考序列或與對應於SEQ ID NO: 1200之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 1200之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 1200之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1200 or corresponding to The reference sequence of SEQ ID NO: 1200 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence of residues 20-1457 of ID NO: 1200 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 1200.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:681、622、617、558、536、211、320、839、797、533、751、303、951、164、818、807、799、735、794、926、755、921、801、1094、968、929、924、698、168、581、916、1428、805、1114、311、737、693、809、757、1099、676、740、791、211/536/622/681、536/558、211/536/555/617/732、211/681/732、211/536/555、555、211/536、211/212、211/536/617/681/732、211/536/558/617/681、555/732、536/555/558/617/732、536/617/681/732、536/555、536/622/681、732、212/320/533/617/681、211/312/533/534/617/619/681/839、212、211/212/320/619/681/839、797/839、212/312/320/533/534/617/681、558/619/681、320/558/681、212/320/534/619/681/797/839、320/558/619/732/839、211/212/312/534/558/619/681/732/839、320/534/558/619/732/797、558/617/619/681、211/534/558/611/681、211/320/617/619/681、558/617/681/797、320/534/619/732、211/619/681、211/212/534/558/619/732/839、212/320/619/681/797/839、212/320/611/839、320/558/619/681、312/533/617/681/797/839、558/611/681、312、211/320/558/619/681/732/797/839、320/558/732/797、533/558/611/619/716/732/839、312/681、320/534/619/681、211/320/533/536/619、558/617/681/839、212/320/534/558/681、533/534/681/839、212/534/619/681、617/619/681、211/212/320/558/617/681、212/534/558/681/797、212/320/534、211/312/619、212/312/619/839、210/212/320/558/681、212/312/534/681/797/839、211/320/558/839、294、759、538或1109,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1200之該參考序列。In some embodiments, a recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 681, 622, 617, 558, 536, 211, 320, 839, 797, 533, 751, 303, 951, 164, 818, 807, 799, 735, 794, 926, 755, 921, 801, 1094, 968, 929, 924, 698, 168, 581, 916, 1428, 805, 1114, 311, 737, 693, 809, 757, 1099, 676, 740, 791, 211/536/622/681, 536/558, 211/536/555/617/732, 211/681/732, 211/536/555, 555, 211/536, 211/212, 211/536/617/681/732, 211/536/558/617/ 681, 555/732, 536/555/558/617/732, 536/617/681/732, 536/555, 536/622/681, 732, 212/320/533/617/681, 211/312/ 533/534/617/619/681/839, 212, 211/212/320/619/681/839, 797/839, 212/312/320/533/534/617/681, 558/619/681, 320/558/681, 212/320/534/619/681/797/839, 320/558/619/732/839, 211/212/312/534/558/619/681/732/839, 320/ 534/558/619/732/797, 558/617/619/681, 211/534/558/611/681, 211/320/617/619/681, 558/617/681/797, 320/534/ 619/732、211/619/681、211/212/534/558/619/732/839、212/320/619/681/797/839、212/320/611/839、320/558/619/ 681, 312/533/617/681/797/839, 558/611/681, 312, 211/320/558/619/681/732/797/839, 320/558/732/797, 533/558/ 611/619/716/732/839, 312/681, 320/534/619/681, 211/320/533/536/619, 558/617/681/839, 212/320/534/558/681, 533/534/681/839, 212/534/619/681, 617/619/681, 211/212/320/558/617/681, 212/534/558/681/797, 212/320/534, 211/312/619、212/312/619/839、210/212/320/558/681、212/312/534/681/797/839、211/320/558/839、294、759、538 or 1109, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 1200.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 1514之殘基20-1457的參考序列或與對應於SEQ ID NO: 1514之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 1514之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 1514之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 1514 or corresponding to The reference sequence of SEQ ID NO: 1514 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 1514 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 1514.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含具有至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:1042、1041、1051、1283、1281、916、187、215、178、1050、1210、104、615、610、536、618、621、614、110、301、1078、812、786、127、175、1093、1088、650、535、806、738、700、132、1076、1084、498、756、1108、746、160、543、310、584、918、1452、790、292、800、167、892、304、1116、752、281、917、712、1080、806/1352、1095、744、1098、948、119、785、1113、667、158、580、707、731、1100、1089、1092、939、1104、736、1297、1127、686、1129、1138、786/821、680、1101、808、739、308、536/555/619/732/799/805、555/619/801、555/619/799、619/799/801/805、536/555/619/732/799、799/805、801、246/619/799/801、536/555/619、619/839、619/799/805、536/801/805、555/619/799/805、619/801/805、555/619、536/619/801、801/805、536/619/799/805、555/619/732/799/801/805、749、616、611、370/614、1156、1158、555/681/737/799、536/619/809/1109、536/555/619/737/799/809/839/916/921、916/1109、536/619/681/799/916/1109、555/619/681/807/1109、555/619/681/737/799、619/681/799/916/1109、619/681、555/921、619/681/916、555/619/681/799、555、732、619/799、619、681、555/916、839或799,其中該等胺基酸位置係相對於對應於SEQ ID NO: 1514之該參考序列。In some embodiments, a recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid sequence having at least one substitution or set of substitutions at the following amino acid positions: : 1042, 1041, 1051, 1283, 1281, 916, 187, 215, 178, 1050, 1210, 104, 615, 610, 536, 618, 621, 614, 110, 301, 1078, 812, 786, 127, 175 ,1093,1088,650,535,806,738,700,132,1076,1084,498,756,1108,746,160,543,310,584,918,1452,790,292,800,167,892 ,304,1116,752,281,917,712,1080,806/1352,1095,744,1098,948,119,785,1113,667,158,580,707,731,1100,1089,1092,939 ,1104,736,1297,1127,686,1129,1138,786/821,680,1101,808,739,308,536/555/619/732/799/805,555/619/801,555/619 /799, 619/799/801/805, 536/555/619/732/799, 799/805, 801, 246/619/799/801, 536/555/619, 619/839, 619/799/805 ,536/801/805,555/619/799/805,619/801/805,555/619,536/619/801,801/805,536/619/799/805,555/619/732/799 /801/805, 749, 616, 611, 370/614, 1156, 1158, 555/681/737/799, 536/619/809/1109, 536/555/619/737/799/809/839/916 /921, 916/1109, 536/619/681/799/916/1109, 555/619/681/807/1109, 555/619/681/737/799, 619/681/799/916/1109, 619 /681, 555/921, 619/681/916, 555/619/681/799, 555, 732, 619/799, 619, 681, 555/916, 839 or 799, where the amino acid positions are relative To the reference sequence corresponding to SEQ ID NO: 1514.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含與對應於SEQ ID NO: 2072之殘基20-1457的參考序列或與對應於SEQ ID NO: 2072之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的胺基酸序列,其中該胺基酸序列包含相對於對應於SEQ ID NO: 2072之殘基20-1457的該參考序列或相對於對應於SEQ ID NO: 2072之該參考序列的一或多個取代。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a reference sequence corresponding to residues 20-1457 of SEQ ID NO: 2072 or corresponding to The reference sequence of SEQ ID NO: 2072 has at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, An amino acid sequence with 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, wherein the amino acid sequence contains an amino acid sequence corresponding to SEQ. The reference sequence for residues 20-1457 of ID NO: 2072 or one or more substitutions relative to the reference sequence corresponding to SEQ ID NO: 2072.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個在下列胺基酸位置處的取代或取代集之胺基酸序列:167、167/738/1076/1093、167/738/752/800/805/808/809/1116、167/800/809/1076、167/318、167/318/800/805/808/809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167、167/738/1076/1093、167/738/752/800/805/808/809/1116、167/800/809/1076、167/318、167/318/800/805/808/809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167/318/700/1076、167/318/700/738/739/1076、167/681/738/800/808/809、167/178/700/752/1093、167/700、167/700/738/739/1093、167/700/738/752/1093、167/700/738/752/805/808/809/1093/1116、808/809、1076、738、738/808/809、738/1076、738/739、738/739/809、738/739/809/1093/1116、738/739/1093、738/739/752/1093、738/739/799/800/1093、738/739/1116、738/800、738/1093、738/752、738/752/1093、738/752/799、738/799/809/1093、738/799/1093、739、739/800/809、800、800/805/809、809、809/1093、809/1093/1116、809/1116、318、318/1076、318/1076/1116、318/739/805/808/809/1076、318/499/700/738/809、318/1093、318/752/1093、318/1116、318/543/739、318/543/681/752/1116、318/543/1093、318/700/738/1093/1414、681、681/738、681/738/739/1093、681/738/739/752/799/800/809/1116/1339、681/738/739/1116、681/738/800、681/800/805/809、681/809/1093、681/752/1093、681/752/1093、681/700、681/700/738/739/1093/1116、681/700/809、681/700/1093、681/700/752/808/809/1093/1116、681/700/752/1093、681/700/844、681/700/805/809、1093、1093/1116、752、752/1076、752/800/809、752/800/1093、752/809、752/866、752/1093、752/1116、178/318/739/752/809/1076/1116、178/318/800/809、178/318/681/800/808/809/1076、178/681、178/681/738/1116、178/752/809、178/700/800/805/808/809、178/805/809/866、1116、543、543/738/739/809、543/738/809/1093、543/739/1093、543/800/1093/1116、543/809/1093、543/809/1093/1116、543/681/738/739/752/809/1093、543/681/738/739/752/1093、543/681/739/752/800/805/809/1093、543/681/700/738/739/800/1093/1116、543/681/700/738/739/805/808/809、543/681/700/752、543/681/700/752/809/1093、543/1093、543/700、543/700/738/739/752/800/1093/1116、543/700/809、543/700/1093、543/700/752、543/700/752/800/1093、543/700/752/809/1116、543/700/752/1093、700、700/738/739/800/1093、700/738/739/799/1093、700/738/800/1093、700/738/1116、700/809、700/809/1093、700/1093、700/1093/1116、700/752、700/752/808/809/1093/1116、700/752/809/1093、700/752/799/1116、700/752/805/809/1093、700/799/800、700/1116、700/805/808/809/1076、514/543/681/805/808/809、805/808/809或805/809/1116,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2072之該參考序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an amino acid comprising at least one substitution or set of substitutions at the following amino acid positions: Sequence: 167, 167/738/1076/1093, 167/738/752/800/805/808/809/1116, 167/800/809/1076, 167/318, 167/318/800/805/808/ 809、167/318/681、167/318/681/700/805/808/809/1076/1116、167/318/700、167、167/738/1076/1093、167/738/752/800/ 805/808/809/1116, 167/800/809/1076, 167/318, 167/318/800/805/808/809, 167/318/681, 167/318/681/700/805/808/ 809/1076/1116, 167/318/700, 167/318/700/1076, 167/318/700/738/739/1076, 167/681/738/800/808/809, 167/178/700/ 752/1093, 167/700, 167/700/738/739/1093, 167/700/738/752/1093, 167/700/738/752/805/808/809/1093/1116, 808/809, 1076, 738, 738/808/809, 738/1076, 738/739, 738/739/809, 738/739/809/1093/1116, 738/739/1093, 738/739/752/1093, 738/ 739/799/800/1093, 738/739/1116, 738/800, 738/1093, 738/752, 738/752/1093, 738/752/799, 738/799/809/1093, 738/799/ 1093, 739, 739/800/809, 800, 800/805/809, 809, 809/1093, 809/1093/1116, 809/1116, 318, 318/1076, 318/1076/1116, 318/739/ 805/808/809/1076, 318/499/700/738/809, 318/1093, 318/752/1093, 318/1116, 318/543/739, 318/543/681/752/1116, 318/ 543/1093, 318/700/738/1093/1414, 681, 681/738, 681/738/739/1093, 681/738/739/752/799/800/809/1116/1339, 681/738/ 739/1116, 681/738/800, 681/800/805/809, 681/809/1093, 681/752/1093, 681/752/1093, 681/700, 681/700/738/739/1093/ 1116, 681/700/809, 681/700/1093, 681/700/752/808/809/1093/1116, 681/700/752/1093, 681/700/844, 681/700/805/809, 1093, 1093/1116, 752, 752/1076, 752/800/809, 752/800/1093, 752/809, 752/866, 752/1093, 752/1116, 178/318/739/752/809/ 1076/1116, 178/318/800/809, 178/318/681/800/808/809/1076, 178/681, 178/681/738/1116, 178/752/809, 178/700/800/ 805/808/809, 178/805/809/866, 1116, 543, 543/738/739/809, 543/738/809/1093, 543/739/1093, 543/800/1093/1116, 543/ 809/1093, 543/809/1093/1116, 543/681/738/739/752/809/1093, 543/681/738/739/752/1093, 543/681/739/752/800/805/ 809/1093、543/681/700/738/739/800/1093/1116、543/681/700/738/739/805/808/809、543/681/700/752、543/681/700/ 752/809/1093, 543/1093, 543/700, 543/700/738/739/752/800/1093/1116, 543/700/809, 543/700/1093, 543/700/752, 543/ 700/752/800/1093, 543/700/752/809/1116, 543/700/752/1093, 700, 700/738/739/800/1093, 700/738/739/799/1093, 700/ 738/800/1093, 700/738/1116, 700/809, 700/809/1093, 700/1093, 700/1093/1116, 700/752, 700/752/808/809/1093/1116, 700/ 752/809/1093, 700/752/799/1116, 700/752/805/809/1093, 700/799/800, 700/1116, 700/805/808/809/1076, 514/543/681/ 805/808/809, 805/808/809 or 805/809/1116, wherein the amino acid positions are relative to the reference sequence corresponding to SEQ ID NO: 2072.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含在 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之胺基位置處的取代之胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising a polynucleotide sequence contained in Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , Substituted amino acid sequences at the amine positions set forth in 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2, 252 , 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之取代或取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , amino acid sequences of substitutions or sets of substitutions, wherein the amino acid positions are relative to those corresponding to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含至少一個 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之變異體的取代或取代集的胺基酸序列,其中該等胺基酸位置係相對於對應於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之該參考序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising at least one of Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , amino acid sequences of substitutions or sets of substitutions of the variants set forth in SEQ ID NO: 2 , 252, 504, 706, 840, 1200, 1514 or 2072 of the reference sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之偶數編號SEQ ID NO.之序列的殘基20-1457或包含 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之偶數編號SEQ ID NO.之序列的胺基酸序列。 In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising Table 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , residues 20-1457 of the even-numbered SEQ ID NO. sequences set forth in Tables 4.1 , 4.2 , 5.1 , 5.2, 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , the amino acid sequence of the even-numbered SEQ ID NO. sequence.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含SEQ ID NO: 4-2346及2360-2870中之偶數編號SEQ ID NO.的殘基20-1457或包含SEQ ID NO: 4-2346及2350-2870中之偶數編號SEQ ID NO.的胺基酸序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising an even-numbered SEQ ID NO: 4-2346 and 2360-2870. . or residues 20-1457 of SEQ ID NOs: 4-2346 and 2350-2870 including the amino acid sequences of even-numbered SEQ ID NO.
在一些實施例中,重組聚核苷酸包含編碼重組因子VIII多肽之聚核苷酸序列,該重組因子VIII多肽包含有包含SEQ ID NO: 252、504、706、840、1200、1514或2072之殘基20-1457或包含SEQ ID NO: 252、504、706、840、1200、1514或2072的胺基酸序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide comprising SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072. Residues 20-1457 or comprise the amino acid sequence of SEQ ID NO: 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組聚核苷酸包含編碼本文所描述之重組因子VIII多肽之全長多肽或前原蛋白或前原多肽的聚核苷酸序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a full-length polypeptide or preproprotein or prepropolypeptide of a recombinant Factor VIII polypeptide described herein.
在一些實施例中,重組聚核苷酸包含編碼原蛋白或原多肽或本文所描述之重組因子VIII多肽之成熟形式的聚核苷酸序列。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a proprotein or propolypeptide or mature form of a recombinant Factor VIII polypeptide described herein.
在一些實施例中,重組聚核苷酸包含編碼本文所描述之重組VIII多肽之生物或功能活性片段的聚核苷酸序列。在一些實施例中,重組聚核苷酸包含編碼在胺基酸殘基760至773之間具有一或多個裂解之生物或功能活性片段的聚核苷酸序列,且該多肽不含對應於胺基酸760-773之一些或全部胺基酸序列,其中該等位置係相對於SEQ ID NO: 2、252、504、706、840、1200、1514或2072。在一些實施例中,重組聚核苷酸包含編碼在胺基酸殘基391至392之間具有裂解之生物或功能活性片段的聚核苷酸序列,其中該等位置係相對於SEQ ID NO: 2、252、504、706、840、1200、1514或2072之參考序列。In some embodiments, a recombinant polynucleotide comprises a polynucleotide sequence encoding a biologically or functionally active fragment of a recombinant VIII polypeptide described herein. In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a biologically or functionally active fragment with one or more cleavages between amino acid residues 760 to 773, and the polypeptide does not contain a fragment corresponding to Some or all of the amino acid sequences of amino acids 760-773, wherein these positions are relative to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072. In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding a biologically or functionally active fragment having cleavage between amino acid residues 391 to 392, wherein these positions are relative to SEQ ID NO: 2. Reference sequence of 252, 504, 706, 840, 1200, 1514 or 2072.
在一些實施例中,重組聚核苷酸包含與對應於SEQ ID NO: 3-2345及2359-2869中之奇數編號SEQ ID NO.之核苷酸殘基58-4371的參考聚核苷酸序列或與對應於SEQ ID NO: 3-2345及2349-2869中之奇數編號SEQ ID NO.之參考聚核苷酸序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的聚核苷酸序列,其中該重組聚核苷酸編碼重組因子VIII多肽。In some embodiments, the recombinant polynucleotide comprises a reference polynucleotide sequence corresponding to nucleotide residues 58-4371 of odd-numbered SEQ ID NO. in SEQ ID NOs: 3-2345 and 2359-2869 Or have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more A sequence identical polynucleotide sequence, wherein the recombinant polynucleotide encodes a recombinant Factor VIII polypeptide.
在一些實施例中,重組聚核苷酸包含與對應於SEQ ID NO: 1、251、503、705、839、1199、1513或2071之核苷酸殘基58-4371的參考聚核苷酸序列或與對應於SEQ ID NO: 1、251、503、705、839、1199、1513或2071之參考聚核苷酸序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的聚核苷酸序列,其中該重組聚核苷酸編碼重組因子VIII多肽。In some embodiments, the recombinant polynucleotide comprises a reference polynucleotide sequence corresponding to nucleotide residues 58-4371 of SEQ ID NO: 1, 251, 503, 705, 839, 1199, 1513, or 2071 Or have at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more A sequence identical polynucleotide sequence, wherein the recombinant polynucleotide encodes a recombinant Factor VIII polypeptide.
在一些實施例中,重組聚核苷酸包含編碼本文所描述之重組因子VIII多肽之聚核苷酸序列,其中該聚核苷酸序列經密碼子最佳化以用於表現經編碼重組因子VIII多肽。在一些實施例中,聚核苷酸序列經密碼子最佳化以用於在原核細胞或真核細胞中表現。在一些實施例中,聚核苷酸序列經密碼子最佳化以在哺乳動物細胞中表現。在一些實施例中,聚核苷酸序列經密碼子最佳化以用於在人類細胞中表現。In some embodiments, a recombinant polynucleotide comprises a polynucleotide sequence encoding a recombinant Factor VIII polypeptide described herein, wherein the polynucleotide sequence is codon-optimized for expression of encoded recombinant Factor VIII Peptides. In some embodiments, polynucleotide sequences are codon-optimized for expression in prokaryotic or eukaryotic cells. In some embodiments, polynucleotide sequences are codon-optimized for expression in mammalian cells. In some embodiments, the polynucleotide sequence is codon-optimized for expression in human cells.
在一些實施例中,重組聚核苷酸包含聚核苷酸序列,該聚核苷酸序列包含SEQ ID NO: 3-2345及2359-2869中之奇數編號SEQ ID NO.的核苷酸殘基58-4371,或包含SEQ ID NO: 3-2345及2349-2869中之奇數編號SEQ ID NO.。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence comprising the odd-numbered nucleotide residues of SEQ ID NO. in SEQ ID NOs: 3-2345 and 2359-2869 58-4371, or odd-numbered SEQ ID NO. including SEQ ID NO: 3-2345 and 2349-2869.
在一些實施例中,重組聚核苷酸包含聚核苷酸序列,該聚核苷酸序列包含SEQ ID NO: 1、251、503、705、839、1199、1513或2071之核苷酸殘基58-4371,或包含SEQ ID NO. 1、251、503、705、839、1199、1513或2071。In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence comprising the nucleotide residues of SEQ ID NO: 1, 251, 503, 705, 839, 1199, 1513, or 2071 58-4371, or contains SEQ ID NO. 1, 251, 503, 705, 839, 1199, 1513 or 2071.
在一些實施例中,本揭露內容提供一種能夠在高度嚴格條件下與編碼本文所描述之重組因子VIII之參考聚核苷酸雜交之重組聚核苷酸,例如 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所提供之重組聚核苷酸或其反向補體。在一些實施例中,本揭露內容提供一種能夠在高度嚴格條件下與編碼本文所描述之重組因子VIII多肽之參考聚核苷酸的反向補體雜交的重組聚核苷酸,其中在嚴格條件下雜交之重組聚核苷酸編碼包含與SEQ ID NO: 2、252、504、706、840、1200、1514或2072相比在選自 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所闡述之任何位置之殘基位置處具有一或多個殘基差異之胺基酸序列的重組因子VIII多肽。 In some embodiments, the present disclosure provides a recombinant polynucleotide capable of hybridizing under highly stringent conditions to a reference polynucleotide encoding recombinant Factor VIII described herein, such as Tables 4.1 , 4.2 , 5.1 , 5.2 , The recombinant polynucleotides or their reverse complements provided in 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 . In some embodiments, the present disclosure provides a recombinant polynucleotide capable of hybridizing under highly stringent conditions to the reverse complement of a reference polynucleotide encoding a recombinant Factor VIII polypeptide described herein, wherein under stringent conditions The hybridized recombinant polynucleotide encoding a polynucleotide selected from Table 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 compared to SEQ ID NO: 2, 252, 504, 706, 840, 1200, 1514 or 2072. , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , a recombinant Factor VIII polypeptide having an amino acid sequence that differs by one or more residues at any residue position.
在一些實施例中,在高度嚴格條件下雜交之重組聚核苷酸包含與對應於SEQ ID NO: 1、251、503、705、839、1199、1513或2071之核苷酸殘基58-4371的參考聚核苷酸序列或與SEQ ID NO: 1、251、503、705、839、1199、1513或2071之參考序列具有至少70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的聚核苷酸序列。在一些其他實施例中,在高度嚴格條件下雜交之重組聚核苷酸包含與對應於 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所提供之聚核苷酸序列的核苷酸殘基58-4371的至少一個聚核苷酸參考序列或 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所提供之聚核苷酸序列具有至少75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%或更多序列一致性的聚核苷酸序列,其中在嚴格條件下雜交之該重組聚核苷酸編碼重組因子VIII多肽。 In some embodiments, the recombinant polynucleotide that hybridizes under highly stringent conditions comprises nucleotide residues 58-4371 corresponding to SEQ ID NO: 1, 251, 503, 705, 839, 1199, 1513, or 2071 The reference polynucleotide sequence or is at least 70%, 75%, 80%, 81%, 82%, 83% identical to the reference sequence of SEQ ID NO: 1, 251, 503, 705, 839, 1199, 1513 or 2071 , 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more Multiple sequence identity polynucleotide sequences. In some other embodiments, the recombinant polynucleotides that hybridize under highly stringent conditions include those corresponding to Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1, 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , At least one polynucleotide reference sequence for nucleotide residues 58-4371 of the polynucleotide sequences provided in 10.2 , 11.1 and 15.1 or Tables 4.1 , 4.2 , 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , The polynucleotide sequences provided in 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 have at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, Polynucleotide sequences with 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity , wherein the recombinant polynucleotide that hybridizes under stringent conditions encodes a recombinant Factor VIII polypeptide.
在一些實施例中,編碼本文所提供之重組因子VIII多肽中之任一者的經分離之聚核苷酸係以各種方式經操縱以提供多肽表現。在一些實施例中,編碼多肽之聚核苷酸係以表現載體形式提供,其中一或多個控制序列係存在以調節聚核苷酸及/或多肽之表現。經分離之聚核苷酸在其插入載體中之前的操作可視表現載體而為合乎需要或必需的。利用重組DNA方法修飾聚核苷酸及核酸序列之技術在此項技術中已熟知。In some embodiments, an isolated polynucleotide encoding any of the recombinant Factor VIII polypeptides provided herein is manipulated in various ways to provide polypeptide expression. In some embodiments, a polynucleotide encoding a polypeptide is provided in an expression vector in which one or more control sequences are present to modulate the expression of the polynucleotide and/or polypeptide. Manipulation of the isolated polynucleotide prior to its insertion into the vector may be desirable or necessary depending on the expression vector. Techniques for modifying polynucleotides and nucleic acid sequences using recombinant DNA methods are well known in the art.
在一些實施例中,除其他序列以外,控制序列亦包括啟動子序列、Kozak序列、前導序列、聚腺苷酸化序列、原肽序列、信號肽序列、用於基因療法保持之以DNA為主之調節元件以及轉錄終止子。如此項技術中所知,可基於所用宿主細胞來選擇適合啟動子。用於絲狀真菌宿主細胞之例示性啟動子包括獲自以下之基因的啟動子:米麴黴( Aspergillus oryzae) TAKA澱粉酶、米黑根毛黴( Rhizomucor miehei)天冬胺酸蛋白酶、黑麴黴( Aspergillus niger)中性α-澱粉酶、黑麴黴酸穩定性α-澱粉酶、黑麴黴或泡盛麴菌( Aspergillus awamori)葡萄糖澱粉酶(FVIIIA)、米黑根毛黴脂肪酶、米麴黴鹼性蛋白酶、米麴黴丙醣磷酸異構酶、構巢麴黴( Aspergillus nidulans)乙醯胺酶以及錘形黴菌( Fusarium oxysporum)胰蛋白酶樣蛋白酶(參見例如WO 96/00787),以及NA2-tpi啟動子(來自黑麴黴中性α-澱粉酶及米麴黴丙醣磷酸異構酶之基因的啟動子雜交體),以及其突變、截斷及雜交啟動子。例示性酵母細胞啟動子可來自以下酶的基因:釀酒酵母菌( Saccharomyces cerevisiae)烯醇酶(ENO-1)、釀酒酵母菌半乳糖激酶(GAL1)、釀酒酵母菌酒精去氫酶/甘油醛-3-磷酸酯去氫酶(ADH2/GAP)以及釀酒酵母菌3-磷酸甘油酯激酶。可用於酵母宿主細胞之其他啟動子為此項技術中已知的(參見例如Romanos等人,1992, Yeast 8:423-488)。例示性用於哺乳動物細胞中之啟動子包括但不限於來自巨細胞病毒(CMV)之啟動子、與CMV強化子融合之雞β-肌動蛋白啟動子、來自猴空泡病毒40 (SV40)之啟動子、來自智人磷酸甘油酯激酶、β肌動蛋白、伸長因子-1a或甘油醛-3-磷酸去氫酶之啟動子或來自雞( Gallus gallus) β-肌動蛋白之啟動子。 In some embodiments, the control sequence also includes, among other sequences, a promoter sequence, a Kozak sequence, a leader sequence, a polyadenylation sequence, a propeptide sequence, a signal peptide sequence, a DNA-based sequence for gene therapy maintenance Regulatory elements and transcription terminators. As is known in the art, a suitable promoter can be selected based on the host cell used. Exemplary promoters for use in filamentous fungal host cells include promoters obtained from the genes Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic acid protease, Aspergillus oryzae ( Aspergillus niger ) neutral α-amylase, Kojima niger acid-stable α-amylase, Kojima niger or Aspergillus awamori ( Aspergillus awamori ) glucoamylase (FVIIIA), Rhizomucor oryzae lipase, Kojima oryzae Alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetaminase and Fusarium oxysporum trypsin-like protease (see for example WO 96/00787), and NA2- The tpi promoter (a promoter hybrid from the genes of Kojima niger neutral α-amylase and Kojima oryzae triose phosphate isomerase), as well as its mutated, truncated and hybridized promoters. Exemplary yeast cell promoters may be derived from genes for the following enzymes: Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde- 3-Phosphate dehydrogenase (ADH2/GAP) and Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other promoters useful in yeast host cells are known in the art (see, eg, Romanos et al., 1992, Yeast 8:423-488). Exemplary promoters for use in mammalian cells include, but are not limited to, promoters from cytomegalovirus (CMV), chicken beta-actin promoter fused to the CMV enhancer, monkey vacuolating virus 40 (SV40) promoters from Homo sapiens phosphoglycerate kinase, β-actin, elongation factor-1a or glyceraldehyde-3-phosphate dehydrogenase or promoters from chicken ( Gallus gallus ) β-actin.
在一些實施例中,控制序列為合適轉錄終止序列,該合適轉錄終止序列為由宿主細胞辨識之用於終止轉錄之序列。終止序列可操作地連接於編碼多肽之核酸序列之3'端。在所選宿主細胞中具有功能之任何終止子均可用於本發明中。舉例而言,用於絲狀真菌宿主細胞之例示性轉錄終止子可獲自用於以下的基因:米麴黴TAKA澱粉酶、黑麴黴澱粉酶、構巢麴黴鄰胺基苯甲酸酯合成酶、黑麴黴α-葡萄糖苷酶及錘形黴菌胰蛋白酶樣蛋白酶。用於酵母菌宿主細胞之例示性終止子可獲自以下酶的基因:釀酒酵母烯醇酶、釀酒酵母細胞色素C (CYC1)以及釀酒酵母甘油醛-3-磷酸酯去氫酶。用於酵母宿主細胞之其他適用啟動子為此項技術中已知的(參見例如Romanos等人,同上)。例示性用於哺乳動物細胞之終止子包括但不限於來自巨細胞病毒(CMV)之終止子、來自猴空泡病毒40 (SV40)之終止子、來自智人生長激素hGH之終止子、來自牛生長激素BGH之終止子以及來自人類或兔β球蛋白之終止子。In some embodiments, the control sequence is a suitable transcription termination sequence that is a sequence recognized by the host cell for terminating transcription. The termination sequence is operably linked to the 3' end of the nucleic acid sequence encoding the polypeptide. Any terminator that is functional in the host cell of choice can be used in the present invention. For example, exemplary transcription terminators for use in filamentous fungal host cells can be obtained from genes for: M. oryzae TAKA amylase, M. nidulans amylase, M. nidulans anthranilate synthesis enzymes, A. niger alpha-glucosidase and A. malleus trypsin-like protease. Exemplary terminators for yeast host cells can be obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other suitable promoters for use in yeast host cells are known in the art (see, eg, Romanos et al., supra). Exemplary terminators for use in mammalian cells include, but are not limited to, terminators from cytomegalovirus (CMV), terminators from simian vacuolating virus 40 (SV40), terminators from Homo sapiens growth hormone hGH, terminators from bovine Terminator for the growth hormone BGH and terminator from human or rabbit beta-globulin.
在一些實施例中,控制序列為合適前導序列,亦即5'-帽修飾、5' UTR等。在一些實施例中,此等調節序列元件介導與參與mRNA運輸及轉譯之分子之結合,抑制5'-核酸外切降解且賦予抗去帽性。前導序列可操作地連接至編碼多肽之核酸序列的5'端。可使用在所選宿主細胞中具有功能之任何前導序列。用於絲狀真菌宿主細胞之例示性前導序列獲自米麴黴TAKA澱粉酶以及構巢麴黴丙醣磷酸酯異構酶的基因。適用於酵母宿主細胞的前導序列包括(但不限於)獲自以下酶之基因的彼等前導序列:釀酒酵母烯醇酶(ENO-1)、釀酒酵母3-磷酸甘油酯激酶、釀酒酵母菌α-因子以及釀酒酵母酒精去氫酶/甘油醛-3-磷酸酯去氫酶(ADH2/GAP)。適用於哺乳動物宿主細胞之前導序列包括但不限於存在於正痘病毒mRNA中之5'-UTR元件。In some embodiments, the control sequence is a suitable leader sequence, i.e. 5'-cap modification, 5' UTR, etc. In some embodiments, these regulatory sequence elements mediate binding to molecules involved in mRNA transport and translation, inhibit 5'-exonucleolytic degradation and confer resistance to decapping. The leader sequence is operably linked to the 5' end of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice can be used. Exemplary leader sequences for use in filamentous fungal host cells are obtained from the genes for M. oryzae TAKA amylase and M. nidulans triose phosphate isomerase. Suitable leaders for use in yeast host cells include, but are not limited to, those obtained from genes for the following enzymes: Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha. -factor and Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP). Suitable leader sequences for use in mammalian host cells include, but are not limited to, 5'-UTR elements present in orthopoxvirus mRNA.
在一些實施例中,控制序列包含3'非轉譯核酸區以及聚腺苷酸化尾核酸序列、可操作地連接至編碼蛋白質之核酸序列之3'端的介導與參與mRNA運輸及轉譯之蛋白質之結合以及mRNA半衰期的序列。在所選宿主細胞中具有功能之任何聚腺苷酸化序列以及3' UTR均可用於本發明中。用於絲狀真菌宿主細胞之例示性聚腺苷酸化序列包括(但不限於)來自以下酶之基因的彼等聚腺苷酸化序列:米麴黴TAKA澱粉酶、黑麴黴澱粉酶、構巢麴黴鄰胺基苯甲酸酯合成酶、錘形黴菌胰蛋白酶樣蛋白酶,及黑麴黴α-葡萄糖苷酶。適用於酵母宿主細胞的聚腺苷酸化序列亦為此項技術中已知的(參見例如Guo及Sherman,Mol. Cell. Biol., 1995, 15:5983-5990)。可用於哺乳動物宿主細胞之聚腺苷酸化以及3' UTR序列包括但不限於具有數個提高mRNA穩定性且增加mRNA轉譯之序列元件的α-血球蛋白mRNA及β-血球蛋白mRNA的3'-UTR。In some embodiments, the control sequence includes a 3' non-translated nucleic acid region and a polyadenylation tail nucleic acid sequence operably linked to the 3' end of the protein-encoding nucleic acid sequence that mediates binding to proteins involved in mRNA transport and translation. and sequences of mRNA half-lives. Any polyadenylation sequence and 3' UTR that is functional in the host cell of choice can be used in the present invention. Exemplary polyadenylation sequences for use in filamentous fungal host cells include, but are not limited to, those from genes for the following enzymes: M. oryzae TAKA amylase, M. niger amylase, M. nidulans Koji mold anthranilate synthase, A malleus trypsin-like protease, and Koji mold alpha-glucosidase. Suitable polyadenylation sequences for yeast host cells are also known in the art (see, eg, Guo and Sherman, Mol. Cell. Biol., 1995, 15:5983-5990). Polyadenylation and 3' UTR sequences useful in mammalian host cells include, but are not limited to, alpha-hemoglobin mRNA and beta-hemoglobin mRNA 3 that have several sequence elements that increase mRNA stability and increase mRNA translation. '-UTR.
在一些實施例中,控制序列為編碼連接至多肽胺基端之胺基酸序列且將經編碼多肽導引至細胞分泌路徑中之信號肽編碼區。核酸序列之編碼序列的5'端可固有地含有在轉譯閱讀框架中與編碼所分泌多肽之編碼區段天然連接的信號肽編碼區。可替代地,編碼序列之5'端可含有對於編碼序列而言外來之信號肽編碼區。將經表現多肽導引至所選宿主細胞之分泌路徑中之任何信號肽編碼區均可用於本文所提供之重組因子VIII多肽的表現。用於絲狀真菌宿主細胞之有效信號肽編碼區包括(但不限於)獲自以下之基因的信號肽編碼區:米麴黴TAKA澱粉酶、黑麴黴中性澱粉酶、黑麴黴澱粉酶、米黑根毛黴( Rhizomucor miehei)天冬胺酸蛋白酶、特異腐質黴( Humicola insolens)纖維素酶及柔毛腐質黴( Humicola lanuginosa)脂肪酶。適用於酵母宿主細胞之信號肽包括(但不限於)來自釀酒酵母菌α-因子以及釀酒酵母菌轉化酶之基因的信號肽。適用於哺乳動物宿主細胞之信號肽包括(但不限於)來自免疫球蛋白γ (IgG)之基因的信號肽。在一些實施例中,信號肽為人類細胞中表現之蛋白質之信號肽。 In some embodiments, the control sequence is a signal peptide coding region that encodes an amino acid sequence linked to the amino terminus of the polypeptide and directs the encoded polypeptide into the secretory pathway of the cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in the translation reading frame to the coding segment encoding the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region foreign to the coding sequence. Any signal peptide coding region in the secretory pathway that directs the expressed polypeptide to the host cell of choice can be used for expression of the recombinant Factor VIII polypeptides provided herein. Effective signal peptide coding regions for filamentous fungal host cells include, but are not limited to, signal peptide coding regions obtained from the following genes: M. oryzae TAKA amylase, M. niger neutral amylase, M. niger amylase , Rhizomucor miehei aspartic acid protease, Humicola insolens cellulase and Humicola lanuginosa lipase. Signal peptides suitable for use in yeast host cells include, but are not limited to, signal peptides from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Signal peptides suitable for use in mammalian host cells include, but are not limited to, signal peptides from the gene for immunoglobulin gamma (IgG). In some embodiments, the signal peptide is that of a protein expressed in human cells.
在另一態樣中,本揭露內容亦提供重組表現載體,其包含編碼重組因子VIII多肽之聚核苷酸,及一或多種表現調節區,諸如啟動子及終止子、複製起點等,視其欲引入之宿主的類型而定。在一些實施例中,上述之各種核酸及控制序列接合在一起以產生重組表現載體,該重組表現載體包括一或多個便利限制位點以允許在此類位點插入或取代編碼重組因子VIII多肽之核酸序列。或者,本揭露內容之聚核苷酸序列藉由將聚核苷酸序列或包含該聚核苷酸序列之核酸構築體插入至適當載體中以進行表現來表現。在產生表現載體時,將編碼序列定位於載體中,使得編碼序列可操作地連接適用於表現的控制序列。In another aspect, the present disclosure also provides a recombinant expression vector comprising a polynucleotide encoding a recombinant Factor VIII polypeptide, and one or more expression regulatory regions, such as a promoter and terminator, an origin of replication, etc., as appropriate. Depends on the type of host being introduced. In some embodiments, the various nucleic acids and control sequences described above are joined together to produce a recombinant expression vector that includes one or more convenient restriction sites to allow insertion or substitution of a recombinant Factor VIII polypeptide encoding at such sites. The nucleic acid sequence. Alternatively, the polynucleotide sequences of the present disclosure are expressed by inserting the polynucleotide sequence or a nucleic acid construct comprising the polynucleotide sequence into an appropriate vector for expression. In creating an expression vector, the coding sequence is positioned in the vector such that the coding sequence is operably linked to control sequences suitable for expression.
重組表現載體可為任何載體(例如,質體或病毒包括(但不限於)腺病毒(AV)、腺相關病毒(AAV)、慢病毒(LV)及非病毒載體,諸如脂質體),其可方便地進行重組DNA程序且可引起重組因子VIII聚核苷酸序列之表現。載體之選擇將通常視載體與載體被引入之宿主細胞之相容性而定。載體可為線性或封閉式環形質體。The recombinant expression vector can be any vector (e.g., plasmids or viruses including, but not limited to, adenovirus (AV), adeno-associated virus (AAV), lentivirus (LV), and non-viral vectors such as liposomes), which can Recombinant DNA procedures are conveniently performed and can result in the expression of recombinant Factor VIII polynucleotide sequences. The choice of vector will generally depend on the compatibility of the vector with the host cell into which the vector is introduced. The carrier can be a linear or closed circular plastid.
在一些實施例中,表現載體為自主複製載體(亦即,以染色體外實體形式存在的載體,其複製與染色體複製無關,諸如質體、染色體外元件、微型染色體或人工染色體)。載體可含有用於確保自我複製之任何構件。在一些替代實施例中,載體可為當被引入宿主細胞中時整合至基因體中且與其已被整合至其中之染色體一起複製的載體。另外,可使用單一載體或質體,或合起來含有將被引入宿主細胞基因體中之總DNA的二個或更多個載體或質體,或轉座子。In some embodiments, the expression vector is an autonomously replicating vector (i.e., a vector that exists as an extrachromosomal entity that replicates independently of chromosomal replication, such as a plastid, extrachromosomal element, minichromosome, or artificial chromosome). The vector may contain any means for ensuring self-replication. In some alternative embodiments, the vector may be one that, when introduced into a host cell, integrates into the genome and replicates with the chromosome into which it has been integrated. Additionally, a single vector or plasmid, or two or more vectors or plasmids that together contain the total DNA to be introduced into the host cell genome, or transposons, can be used.
在一些實施例中,表現載體較佳含有容許經轉型之細胞容易被選擇的一或多個可選標記物。「可選標記物」為基因,其產物提供殺生物劑或病毒抗性、對重金屬的抗性、對營養缺陷型的原養性及其類似者。適用於酵母宿主細胞的標記物包括(但不限於) ADE2、HIS3、LEU2、LYS2、MET3、TRP1以及URA3。用於絲狀真菌宿主細胞中的可選標記物包括(但不限於) amdS (乙醯胺酶)、argB (鳥胺酸胺甲醯基轉移酶)、bar (草銨膦乙醯基轉移酶)、hph (潮黴素磷酸轉移酶)、niaD (硝酸還原酶)、pyrG (乳清酸核苷-5'-磷酸酯去羧酶)、sC (硫酸腺苷醯基轉移酶)及trpC (鄰胺基苯甲酸酯合成酶)以及其等效物。In some embodiments, the expression vector preferably contains one or more selectable markers that allow the transformed cells to be readily selected. "Selectable markers" are genes whose products provide biocide or viral resistance, resistance to heavy metals, auxotrophic prototrophy, and the like. Suitable markers for yeast host cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2, MET3, TRP1 and URA3. Selectable markers for use in filamentous fungal host cells include (but are not limited to) amdS (acetaminase), argB (ornithine amine formyltransferase), bar (glufosinate acetyltransferase ), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotic acid nucleoside-5'-phosphate decarboxylase), sC (adenosyl sulfate chelate transferase) and trpC ( anthranilate synthase) and its equivalents.
在另一態樣中,本發明提供一種宿主細胞,其包含編碼至少一種本文所描述之重組因子VIII多肽的聚核苷酸,該聚核苷酸以操作方式連接至一或多個用於在宿主細胞中表現重組因子VIII多肽之控制序列。用於表現由本發明之表現載體編碼之多肽之宿主細胞為此項技術中眾所周知的且包括但不限於真菌細胞,諸如酵母菌細胞(例如釀酒酵母菌及巴斯德畢赤酵母菌( Pichia pastoris),例如ATCC登錄號201178);昆蟲細胞(例如果蠅S2細胞及夜蛾Sf9細胞)、植物細胞、動物細胞(例如CHO、CHO-K1、COS及BHK)以及人類細胞(例如HEK293T、人類纖維母細胞、THP-1、Jurkat及Bowes黑色素瘤細胞株)。在一些實施例中,宿主細胞為獲自或衍生自患有A型血友病之個體的人類細胞。 In another aspect, the invention provides a host cell comprising a polynucleotide encoding at least one recombinant Factor VIII polypeptide described herein operably linked to one or more cells for use in Control sequences for expression of recombinant Factor VIII polypeptides in host cells. Host cells for expressing polypeptides encoded by expression vectors of the invention are well known in the art and include, but are not limited to, fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae and Pichia pastoris ) , such as ATCC accession number 201178); insect cells (such as Drosophila S2 cells and Spodoptera exigua Sf9 cells), plant cells, animal cells (such as CHO, CHO-K1, COS and BHK) and human cells (such as HEK293T, human fibroblast cells, THP-1, Jurkat and Bowes melanoma cell lines). In some embodiments, the host cells are human cells obtained or derived from an individual with hemophilia A.
因此,在另一態樣中,本揭露內容提供一種用於產生重組因子VIII多肽之方法,其中該方法包含在適合於表現多肽之條件下培養能夠表現編碼重組因子VIII多肽之聚核苷酸的宿主細胞。在一些實施例中,該方法進一步包含分離重組因子VIII多肽之步驟,諸如自培養基或細胞分離。在一些實施例中,該方法進一步包含純化如本文所描述之經表現之重組因子VIII多肽的步驟。Accordingly, in another aspect, the present disclosure provides a method for producing a recombinant Factor VIII polypeptide, wherein the method comprises culturing a polynucleotide capable of expressing a polynucleotide encoding a recombinant Factor VIII polypeptide under conditions suitable for expressing the polypeptide. host cell. In some embodiments, the method further comprises the step of isolating the recombinant Factor VIII polypeptide, such as from culture medium or cells. In some embodiments, the method further comprises the step of purifying the expressed recombinant Factor VIII polypeptide as described herein.
適用於上述宿主細胞之培養基以及生長條件在此項技術中已熟知。用於重組因子VIII多肽表現之聚核苷酸可藉由此項技術中已知之各種方法引入細胞中。技術尤其包括電穿孔、基因槍粒子轟擊、脂質體介導之轉染、氯化鈣轉染以及原生質體融合。Suitable media and growth conditions for the host cells described above are well known in the art. Polynucleotides for expression of recombinant Factor VIII polypeptides can be introduced into cells by various methods known in the art. Techniques include, inter alia, electroporation, gene gun particle bombardment, liposome-mediated transfection, calcium chloride transfection, and protoplast fusion.
具有本文所揭示之特性的重組因子VIII多肽可藉由對編碼天然存在或重組因子VIII多肽之聚核苷酸進行此項技術中已知且如本文所描述之突變誘發及/或定向進化方法而獲得。例示性定向進化技術為突變誘發及/或DNA改組(參見例如Stemmer,Proc. Natl. Acad. Sci. USA, 1994, 91:10747-10751;WO 95/22625;WO 97/0078;WO 97/35966;WO 98/27230;WO 00/42651;WO 01/75767以及美國專利6,537,746)。可使用之其他定向進化程序尤其包括交錯延伸方法(StEP)、活體外重組(參見例如Zhao等人,Nat. Biotechnol., 1998, 16:258-261)、突變誘發PCR (參見例如Caldwell等人,PCR Methods Appl., 1994, 3:S136-S140)以及卡匣突變誘發(參見例如Black等人,Proc. Natl. Acad. Sci. USA, 1996, 93:3525-3529)。Recombinant Factor VIII polypeptides having the properties disclosed herein can be produced by subjecting polynucleotides encoding naturally occurring or recombinant Factor VIII polypeptides to mutagenesis and/or directed evolution methods known in the art and described herein. obtain. Exemplary directed evolution techniques are mutagenesis and/or DNA shuffling (see, eg, Stemmer, Proc. Natl. Acad. Sci. USA, 1994, 91:10747-10751; WO 95/22625; WO 97/0078; WO 97/35966 ; WO 98/27230; WO 00/42651; WO 01/75767 and US Patent 6,537,746). Other directed evolution procedures that can be used include inter alia the staggered extension method (StEP), in vitro recombination (see, e.g., Zhao et al., Nat. Biotechnol., 1998, 16:258-261), mutation-induced PCR (see, e.g., Caldwell et al., PCR Methods Appl., 1994, 3:S136-S140) and cassette mutagenesis (see, e.g., Black et al., Proc. Natl. Acad. Sci. USA, 1996, 93:3525-3529).
舉例而言,突變誘發以及定向進化方法可易於應用於聚核苷酸以生成可經表現、篩選以及分析之變異體庫。突變誘發及定向進化方法為此項技術中所熟知(參見例如美國專利第5,605,793號、第5,811,238號、第5,830,721號、第5,834,252號、第5,837,458號、第5,928,905號、第6,096,548號、第6,117,679號、第6,132,970號、第6,165,793號、第6,180,406號、第6,251,674號、第6,277,638號、第6,287,861號、第6,287,862號、第6,291,242號、第6,297,053號、第6,303,344號、第6,309,883號、第6,319,713號、第6,319,714號、第6,323,030號、第6,326,204號、第6,335,160號、第6,335,198號、第6,344,356號、第6,352,859號、第6,355,484號、第6,358,740號、第6,358,742號、第6,365,377號、第6,365,408號、第6,368,861號、第6,372,497號、第6,376,246號、第6,379,964號、第6,387,702號、第6,391,552號、第6,391,640號、第6,395,547號、第6,406,855號、第6,406,910號、第6,413,745號、第6,413,774號、第6,420,175號、第6,423,542號、第6,426,224號、第6,436,675號、第6,444,468號、第6,455,253號、第6,479,652號、第6,482,647號、第6,489,146號、第6,506,602號、第6,506,603號、第6,519,065號、第6,521,453號、第6,528,311號、第6,537,746號、第6,573,098號、第6,576,467號、第6,579,678號、第6,586,182號、第6,602,986號、第6,613,514號、第6,653,072號、第6,716,631號、第6,946,296號、第6,961,664號、第6,995,017號、第7,024,312號、第7,058,515號、第7,105,297號、第7,148,054號、第7,288,375號、第7,421,347號、第7,430,477號、第7,534,564號、第7,620,500號、第7,620,502號、第7,629,170號、第7,702,464號、第7,747,391號、第7,747,393號、第7,751,986號、第7,776,598號、第7,783,428號、第7,795,030號、第7,853,410號、第7,868,138號、第7,873,499號、第7,904,249號、第7,957,912號、第8,383,346號、第8,504,498號、第8,849,575號、第8,876,066號、第8,768,871號、第9,593,326號,及所有相關非美國對應物;Ling等人,Anal. Biochem ., 1997, 254(2):157-78;Dale等人,Meth. Mol. Biol ., 1996, 57:369-74;Smith,Ann. Rev. Genet ., 1985, 19:423-462;Botstein等人,Science, 1985, 229:1193-1201;Carter,Biochem. J ., 1986, 237:1-7;Kramer等人,1984, Cell, 38:879-887;Wells等人,Gene, 1985, 34:315-323;Minshull等人,Curr. Op. Chem. Biol., 1999, 3:284-290;Christians等人,Nat. Biotechnol., 1999, 17:259-264;Crameri等人,Nature, 1998, 391:288-291;Crameri等人,Nat. Biotechnol., 1997, 15:436-438;Zhang等人,Proc. Nat. Acad. Sci. USA, 1997, 94:4504-4509;Crameri等人,Nat. Biotechnol. ,1996, 14:315-319;Stemmer,Nature, 1994, 370:389-391;Stemmer,Proc. Nat. Acad. Sci. USA, 1994, 91:10747-10751;美國專利公開案第2008/0220990號、第US 2009/0312196號、第US2014/0005057號、第US2014/0214391號、第US2014/0221216;US2015/0050658號、第US2015/0133307號、第US2015/0134315號及所有相關非美國對應物;WO 95/22625、WO 97/0078、WO 97/35966、WO 98/27230、WO 00/42651、WO 01/75767及WO 2009/152336;其全部以引用的方式併入本文中)。 For example, mutagenesis and directed evolution methods can be readily applied to polynucleotides to generate libraries of variants that can be expressed, screened, and analyzed. Mutation induction and directed evolution methods are well known in the art (see, for example, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, 5,837,458, 5,928,905, 6,096,548, 6,117,679, No. 6,132,970, No. 6,165,793, No. 6,180,406, No. 6,251,674, No. 6,277,638, No. 6,287,861, No. 6,287,862, No. 6,291,242, No. 6,297,053, No. 6,303,344, No. 6,3 No. 09,883, No. 6,319,713, No. 6,319,714 No. 6,323,030, 6,326,204, 6,335,160, 6,335,198, 6,344,356, 6,352,859, 6,355,484, 6,358,740, 6,358,742, 6,365,377, 6 , No. 365,408, No. 6,368,861, No. 6,372,497, No. 6,376,246, No. 6,379,964, No. 6,387,702, No. 6,391,552, No. 6,391,640, No. 6,395,547, No. 6,406,855, No. 6,406,910, No. 6,413,745, No. 6,4 No. 13,774, No. 6,420,175, No. 6,423,542 No. 6,426,224, 6,436,675, 6,444,468, 6,455,253, 6,479,652, 6,482,647, 6,489,146, 6,506,602, 6,506,603, 6,519,065, 6 , No. 521,453, No. 6,528,311, No. 6,537,746, No. 6,573,098, No. 6,576,467, No. 6,579,678, No. 6,586,182, No. 6,602,986, No. 6,613,514, No. 6,653,072, No. 6,716,631, No. 6,946,296, No. 6,9 No. 61,664, No. 6,995,017, No. 7,024,312 No. 7,058,515, 7,105,297, 7,148,054, 7,288,375, 7,421,347, 7,430,477, 7,534,564, 7,620,500, 7,620,502, 7,629,170, 7 , No. 702,464, No. 7,747,391, No. 7,747,393, No. 7,751,986, No. 7,776,598, No. 7,783,428, No. 7,795,030, No. 7,853,410, No. 7,868,138, No. 7,873,499, No. 7,904,249, No. 7,957,912, No. 8,3 No. 83,346, No. 8,504,498, No. 8,849,575 No. 8,876,066, 8,768,871, 9,593,326, and all related non-U.S. counterparts; Ling et al., Anal. Biochem . , 1997, 254(2):157-78; Dale et al., Meth. Mol. Biol . , 1996, 57:369-74; Smith, Ann. Rev. Genet . , 1985, 19:423-462; Botstein et al., Science, 1985, 229:1193-1201; Carter, Biochem. J. , 1986 , 237:1-7; Kramer et al., 1984, Cell, 38:879-887; Wells et al., Gene, 1985, 34:315-323; Minshull et al., Curr. Op. Chem. Biol., 1999, 3:284-290; Christians et al., Nat. Biotechnol., 1999, 17:259-264; Crameri et al., Nature, 1998, 391:288-291; Crameri et al., Nat. Biotechnol., 1997, 15: 436-438; Zhang et al., Proc. Nat. Acad. Sci. USA, 1997, 94:4504-4509; Crameri et al., Nat. Biotechnol. , 1996, 14:315-319; Stemmer, Nature, 1994, 370 :389-391; Stemmer, Proc. Nat. Acad. Sci. USA, 1994, 91:10747-10751; U.S. Patent Publication No. 2008/0220990, No. US 2009/0312196, No. US2014/0005057, No. US2014 /0214391, US2014/0221216; US2015/0050658, US2015/0133307, US2015/0134315 and all related non-US counterparts; WO 95/22625, WO 97/0078, WO 97/35966, WO 98 /27230, WO 00/42651, WO 01/75767 and WO 2009/152336; all of which are incorporated herein by reference).
在一些實施例中,藉由使蛋白質變異體經受限定的溫度(或其他分析條件)且量測在處理或其他分析條件之後保持之蛋白質活性的量來篩選在突變誘發處理之後獲得的蛋白質變異體。接著自宿主細胞分離含有編碼因子VIII多肽之聚核苷酸的DNA,定序以識別核苷酸序列變化(若存在),且用於在不同或相同宿主細胞中表現蛋白質。量測表現庫之蛋白質活性可使用此項技術中已知的任何適合方法(諸如實例中所提供)來進行。In some embodiments, protein variants obtained after a mutagenesis treatment are screened by subjecting the protein variants to defined temperatures (or other analytical conditions) and measuring the amount of protein activity that is retained after the treatment or other analytical conditions. . DNA containing the polynucleotide encoding the Factor VIII polypeptide is then isolated from the host cell, sequenced to identify nucleotide sequence changes, if any, and used to express the protein in different or the same host cell. Measuring protein activity of a library of expressions can be performed using any suitable method known in the art (such as provided in the Examples).
對於具有已知序列之經工程改造多肽而言,編碼多肽之聚核苷酸可根據已知合成方法、藉由標準固相方法來製備。在一些實施例中,聚核苷酸片段可經個別地合成,隨後連接(例如藉由酶或化學接合方法或聚合酶介導之方法)以形成任何所需連續序列。舉例而言,本文所揭露之聚核苷酸以及寡核苷酸可藉由使用經典胺基亞磷酸酯方法(參見例如Beaucage等人,Tetra. Lett., 1981, 22:1859-69;以及Matthes等人,EMBO J., 1984, 3:801-05)進行化學合成來製備,如典型地以自動化合成方法實施一般。For engineered polypeptides of known sequence, the polynucleotide encoding the polypeptide can be prepared by standard solid phase methods according to known synthetic methods. In some embodiments, polynucleotide fragments can be synthesized individually and subsequently ligated (eg, by enzymatic or chemical ligation methods or polymerase-mediated methods) to form any desired contiguous sequence. For example, the polynucleotides and oligonucleotides disclosed herein can be synthesized by using classical aminophosphite methods (see, e.g., Beaucage et al., Tetra. Lett., 1981, 22:1859-69; and Matthes et al., EMBO J., 1984, 3:801-05) are prepared by chemical synthesis, as is typically performed by automated synthesis methods.
因此,在一些實施例中,用於製備重組因子VIII多肽之方法可包含:(a)合成編碼包含胺基酸序列之多肽的聚核苷酸,該胺基酸序列選自 表 4.1、 4.2、 5.1、 5.2、 6.1、 6.2、 7.1、 7.2、 8.1、 8.2、 9.1、 9.2、 10.1、 10.2、 11.1及 15.1中所提供之任何變異體之胺基酸序列,以及SEQ ID NO: 2-2346及2350-2870,(b)表現由聚核苷酸編碼之重組因子VIII多肽。在該方法之一些實施例中,由聚核苷酸編碼之胺基酸序列可任擇地具有一或數個(例如至多3、4、5個或至多10個)胺基酸殘基缺失、插入及/或取代。在一些實施例中,胺基酸序列任擇地具有1-2、1-3、1-4、1-5、1-6、1-7、1-8、1-9、1-10、1-15、1-20、1-21、1-22、1-23、1-24、1-25、1-30、1-35、1-40、1-45或1-50個胺基酸殘基缺失、插入及/或取代。在一些實施例中,胺基酸序列任擇地具有1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、30、30、35、40、45或50個胺基酸殘基缺失、插入及/或取代。在一些實施例中,胺基酸序列任擇地具有1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、18、20、21、22、23、24或25個胺基酸殘基缺失、插入及/或取代。在一些實施例中,取代包含守恆或非守恆取代。 Accordingly, in some embodiments, a method for preparing a recombinant Factor VIII polypeptide may comprise: (a) synthesizing a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from Tables 4.1 , 4.2 , The amino acid sequence of any variant provided in 5.1 , 5.2 , 6.1 , 6.2 , 7.1 , 7.2 , 8.1 , 8.2 , 9.1 , 9.2 , 10.1 , 10.2 , 11.1 and 15.1 , and SEQ ID NOs: 2-2346 and 2350 -2870, (b) represents a recombinant Factor VIII polypeptide encoded by a polynucleotide. In some embodiments of this method, the amino acid sequence encoded by the polynucleotide may optionally have one or several (eg, up to 3, 4, 5, or up to 10) amino acid residues deleted, Insertion and/or replacement. In some embodiments, the amino acid sequence optionally has 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-15, 1-20, 1-21, 1-22, 1-23, 1-24, 1-25, 1-30, 1-35, 1-40, 1-45 or 1-50 amine groups Acid residue deletions, insertions and/or substitutions. In some embodiments, the amino acid sequence optionally has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 30, 35, 40, 45 or 50 amino acid residues are deleted, inserted and/or substituted. In some embodiments, the amino acid sequence optionally has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 21, 22, 23, 24 or 25 amino acid residues are deleted, inserted and/or substituted. In some embodiments, substitutions include conservative or non-conservative substitutions.
經表現之重組因子VIII多肽可使用此項技術中已知之任何適合之分析(包括(但不限於)本文所描述之分析及條件)來評估任何所需改良之特性(例如,活性/效能、選擇性、穩定性、血清/血漿穩定性、鹼性pH耐受性、蛋白酶敏感性等)。Expressed recombinant Factor VIII polypeptides can be evaluated for any desired improved properties (e.g., activity/potency, selection) using any suitable assay known in the art, including, but not limited to, the assays and conditions described herein. properties, stability, serum/plasma stability, alkaline pH tolerance, protease sensitivity, etc.).
在一些實施例中,使用任何一或多種已知的蛋白質純化技術自細胞及/或培養基中回收宿主細胞中表現的任何重組因子VIII多肽,包括(尤其包括)溶菌酶或洗滌劑處理、音波處理、過濾、鹽析、超速離心及層析。In some embodiments, any recombinant Factor VIII polypeptide expressed in the host cell is recovered from the cell and/or culture medium using any one or more known protein purification techniques, including, inter alia, lysozyme or detergent treatment, sonication , filtration, salting out, ultracentrifugation and chromatography.
用於分離重組因子VIII多肽之層析技術尤其包括逆相層析、高效液相層析、離子交換層析、疏水相互作用層析、凝膠電泳以及親和力層析。用於純化特定多肽的條件部分地視諸如淨電荷、疏水性、親水性、分子量、分子形狀等因素而定且為熟習此項技術者顯而易知。在一些實施例中,親和力技術可用於分離經改良之變異體因子VIII多肽。在利用親和力層析純化之一些實施例中,特異性結合變異體因子VIII多肽之任何抗體均可用。在利用親和力層析純化之一些實施例中,可使用結合至與因子VIII共價連接之聚醣的蛋白質。在利用親和層析純化之另其他實施例中,可使用結合至因子VIII活性位點的任何小分子。對於產生抗體,藉由注射因子VIII多肽(例如,因子VIII變異體)或其片段對各種宿主動物進行免疫接種,該等宿主動物包括(但不限於)兔、小鼠、大鼠等。在一些實施例中,因子VIII多肽或片段藉助於之側鏈官能基或附接至側鏈官能基連接子而附接至適合載劑,諸如BSA。Chromatography techniques for isolating recombinant Factor VIII polypeptides include, inter alia, reverse phase chromatography, high performance liquid chromatography, ion exchange chromatography, hydrophobic interaction chromatography, gel electrophoresis and affinity chromatography. The conditions used to purify a particular polypeptide depend in part on factors such as net charge, hydrophobicity, hydrophilicity, molecular weight, molecular shape, etc. and will be apparent to those skilled in the art. In some embodiments, affinity technology can be used to isolate modified variant Factor VIII polypeptides. In some embodiments utilizing affinity chromatography for purification, any antibody that specifically binds a variant Factor VIII polypeptide may be used. In some embodiments utilizing affinity chromatography for purification, proteins that bind to glycans covalently linked to Factor VIII may be used. In still other embodiments utilizing affinity chromatography for purification, any small molecule that binds to the Factor VIII active site may be used. For the generation of antibodies, various host animals including, but not limited to, rabbits, mice, rats, etc. are immunized by injecting Factor VIII polypeptides (eg, Factor VIII variants) or fragments thereof. In some embodiments, a Factor VIII polypeptide or fragment is attached to a suitable carrier, such as BSA, via a side chain functionality or a linker attached to a side chain functionality.
在一些實施例中,重組因子VIII多肽自重組宿主細胞或細胞培養基回收或分離後,其藉由此項技術中已知之任何適合方法進一步純化。在一些其他實施例中,經純化之因子VIII多肽與其他成分及化合物組合以提供包含視需要用於不同應用及用途之重組因子VIII多肽的組成物及調配物(例如,醫藥組成物)。In some embodiments, after the recombinant Factor VIII polypeptide is recovered or isolated from the recombinant host cell or cell culture medium, it is further purified by any suitable method known in the art. In some other embodiments, purified Factor VIII polypeptides are combined with other ingredients and compounds to provide compositions and formulations (eg, pharmaceutical compositions) including recombinant Factor VIII polypeptides, if desired for different applications and uses.
在一些其他實施例中,凍乾經純化之重組因子VIII多肽或經調配之重組因子VIII多肽。在一些實施例中,重組因子VIII多肽直接在身體內產生(亦即,身體內之細胞,諸如人類或另一動物)且不經純化。然而,在一些替代實施例中,重組因子VIII多肽在身體(亦即身體內之細胞,諸如人類或另一動物)內產生且使用此項技術中已知之方法自身體收集。在一些其他實施例中,純化此等所收集之重組因子VIII多肽。 醫藥組成物 In some other embodiments, the purified recombinant Factor VIII polypeptide or the formulated recombinant Factor VIII polypeptide is lyophilized. In some embodiments, recombinant Factor VIII polypeptides are produced directly in the body (ie, cells in the body, such as humans or another animal) without purification. However, in some alternative embodiments, the recombinant Factor VIII polypeptide is produced within the body (ie, cells within the body, such as a human or another animal) and collected from the body using methods known in the art. In some other embodiments, the collected recombinant Factor VIII polypeptides are purified. pharmaceutical composition
在另一態樣中,本揭露內容提供包含重組因子VIII多肽之各種組成物及型式,包括(但不限於)下文所描述之彼等。在一些實施例中,本揭露內容提供適用於醫藥組成物及其他組成物中之重組多肽或重組聚核苷酸。In another aspect, the present disclosure provides various compositions and forms comprising recombinant Factor VIII polypeptides, including (but not limited to) those described below. In some embodiments, the present disclosure provides recombinant polypeptides or recombinant polynucleotides suitable for use in pharmaceutical compositions and other compositions.
視投予模式而定,包含治療有效量之本文中所描述之重組因子VIII的組成物呈固體、半固體或液體形式。在一些實施例中,組成物包括諸如稀釋劑、緩衝劑、賦形劑、鹽、乳化劑、防腐劑、穩定劑、填充劑以及其他成分之其他醫藥學上可接受之組分。關於調配及投予的技術細節在此項技術中已熟知且描述於文獻中。在一些實施例中,此等組成物在作為基因療法引入之後直接在人體中產生。Depending on the mode of administration, compositions comprising a therapeutically effective amount of recombinant Factor VIII described herein are in solid, semi-solid, or liquid form. In some embodiments, the compositions include other pharmaceutically acceptable components such as diluents, buffers, excipients, salts, emulsifiers, preservatives, stabilizers, fillers, and other ingredients. Technical details regarding formulation and administration are well known in the art and described in the literature. In some embodiments, these compositions are produced directly in humans after being introduced as gene therapy.
在一些實施例中,本揭露內容提供一種包含本文所描述之重組因子VIII多肽之醫藥組成物。在一些實施例中,醫藥組成物進一步包含醫藥學上可接受之載劑或賦形劑。用於遞送重組因子VIII多肽之任何合適格式可用於本揭露內容中,其包括但不限於丸劑、錠劑、凝膠錠、膠囊、口含錠、糖衣藥丸、散劑、軟凝膠、溶膠-凝膠、凝膠、乳液、植入物、貼片、噴霧劑、軟膏、擦劑、乳膏、糊劑、凍膠、塗料、氣霧劑、口香糖、緩和劑、棒、溶液、懸浮液(包括但不限於以油為主之懸浮液、水中油型乳液等)、漿液、糖漿、受控釋放型調配物等。In some embodiments, the present disclosure provides a pharmaceutical composition comprising a recombinant Factor VIII polypeptide described herein. In some embodiments, the pharmaceutical composition further includes a pharmaceutically acceptable carrier or excipient. Any suitable format for delivering recombinant Factor VIII polypeptides may be used in the present disclosure, including, but not limited to, pills, lozenges, gel lozenges, capsules, lozenges, dragees, powders, soft gels, sol-gels. Gums, gels, lotions, implants, patches, sprays, ointments, liniments, creams, pastes, jelly, paints, aerosols, gums, emollients, sticks, solutions, suspensions (including But not limited to oil-based suspensions, oil-in-water emulsions, etc.), slurries, syrups, controlled release formulations, etc.
在一些實施例中,重組因子VIII多肽以適用於注射或輸注之形式(亦即,以可注射調配物形式)提供。在一些實施例中,重組因子VIII多肽之聚核苷酸序列以適用於注射或輸注之形式提供。In some embodiments, the recombinant Factor VIII polypeptide is provided in a form suitable for injection or infusion (i.e., in an injectable formulation). In some embodiments, the polynucleotide sequence of the recombinant Factor VIII polypeptide is provided in a form suitable for injection or infusion.
在一些實施例中,重組因子VIII多肽係在諸如溶膠-凝膠(包括以二氧化矽為主之(例如氧矽烷)溶膠-凝膠)之生物相容性基質中提供。在一些實施例中,重組因子VIII多肽經囊封。在一些替代實施例中,重組因子VIII多肽經囊封於奈米結構(例如奈米管、奈米小管、奈米膠囊或微膠囊、微球、脂質體等)中。In some embodiments, recombinant Factor VIII polypeptides are provided in a biocompatible matrix such as a sol-gel, including silica-based (eg, oxysilane) sol-gels. In some embodiments, the recombinant Factor VIII polypeptide is encapsulated. In some alternative embodiments, the recombinant Factor VIII polypeptide is encapsulated in nanostructures (eg, nanotubes, nanotubules, nanocapsules or microcapsules, microspheres, liposomes, etc.).
在一些實施例中,包含本揭露內容之重組因子VIII多肽之組成物可包括一或多種常用載劑化合物,包括(但不限於)糖(例如乳糖、蔗糖、甘露醇及/或山梨醇)、澱粉、纖維素(例如甲基纖維素、羥丙基甲基纖維素、羧基甲基纖維素鈉)、樹膠(例如阿拉伯膠、黃蓍、瓜爾膠等)及/或蛋白質(例如明膠、膠原蛋白等)。In some embodiments, compositions comprising recombinant Factor VIII polypeptides of the present disclosure may include one or more commonly used carrier compounds, including, but not limited to, sugars (e.g., lactose, sucrose, mannitol, and/or sorbitol), Starch, cellulose (such as methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose), gum (such as acacia, tragacanth, guar gum, etc.) and/or protein (such as gelatin, collagen protein, etc.).
在一些實施例中,重組因子VIII多肽藉由醣基化、化學交聯試劑、聚乙二醇化(亦即經聚乙二醇(PEG)或活化PEG等修飾)或其他化合物化學修飾(參見例如Ikeda, Amino Acids, 2005, 29:283-287;美國專利第7,531,341號、第7,534,595號及第7,560,263號;美國專利公開案第2013/0039898號、第2012/0177722號等)。In some embodiments, recombinant Factor VIII polypeptides are chemically modified by glycosylation, chemical cross-linking reagents, pegylation (i.e., modified with polyethylene glycol (PEG) or activated PEG, etc.), or other compounds (see, e.g., Ikeda, Amino Acids, 2005, 29:283-287; U.S. Patent Nos. 7,531,341, 7,534,595, and 7,560,263; U.S. Patent Publication Nos. 2013/0039898, 2012/0177722, etc.).
希望重組因子VIII多肽藉由此項技術中已知之任何適合方式投予,包括(但不限於)非經腸、經口、局部、經皮、鼻內、眼內、鞘內、經由植入物等。不希望本發明限於任何特定遞送方法及/或機制。It is contemplated that the recombinant Factor VIII polypeptide is administered by any suitable means known in the art, including, but not limited to, parenterally, orally, topically, transdermally, intranasally, intraocularly, intrathecally, via an implant wait. The present invention is not intended to be limited to any particular delivery method and/or mechanism.
在一些實施例中,醫藥組成物包含編碼本文所描述之重組因子VIII聚核苷酸之重組聚核苷酸,諸如用於基因療法。在一些實施例中,基因療法組成物包含編碼本文所描述之重組因子VIII多肽中之任一者的重組聚核苷酸。在一些實施例中,基因療法組成物包含病毒載體,該病毒載體包含編碼重組因子VIII多肽之重組聚核苷酸。在一些實施例中,病毒遞送載體包括(但不限於)腺病毒(AV)、腺相關病毒(AAV)、慢病毒(LV)、反轉錄病毒或疱疹病毒載體。在一些實施例中,基因療法組成物包含非病毒遞送組成物,其中重組聚核苷酸用脂質體、陽離子聚合物、樹枝狀聚合物調配或與細胞穿透肽結合。在一些實施例中,提供重組因子VIII多肽以經由mRNA療法遞送至細胞或組織,諸如藉由在囊封遞送載劑(例如脂質體)中調配聚核糖核苷酸(例如mRNA)。In some embodiments, pharmaceutical compositions comprise recombinant polynucleotides encoding recombinant Factor VIII polynucleotides described herein, such as for use in gene therapy. In some embodiments, a gene therapy composition comprises a recombinant polynucleotide encoding any of the recombinant Factor VIII polypeptides described herein. In some embodiments, the gene therapy composition comprises a viral vector comprising a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide. In some embodiments, viral delivery vectors include, but are not limited to, adenovirus (AV), adeno-associated virus (AAV), lentivirus (LV), retrovirus, or herpesvirus vectors. In some embodiments, gene therapy compositions comprise non-viral delivery compositions in which the recombinant polynucleotide is formulated with liposomes, cationic polymers, dendrimers or conjugated to cell-penetrating peptides. In some embodiments, recombinant Factor VIII polypeptides are provided for delivery to cells or tissues via mRNA therapy, such as by formulating polyribonucleotides (eg, mRNA) in an encapsulated delivery vehicle (eg, liposomes).
在一些其他實施例中,提供重組因子VIII多肽以經由細胞療法遞送至細胞或組織,其中編碼重組因子VIII多肽之聚核苷酸序列經引入至外源性細胞中且細胞(或多個細胞)經引入至受體或個體(例如展現因子VIII缺乏症之患者)中。在一些實施例中,細胞為幹細胞,尤其為人類幹細胞。 用途及方法 In some other embodiments, recombinant Factor VIII polypeptides are provided for delivery to cells or tissues via cell therapy, wherein a polynucleotide sequence encoding a recombinant Factor VIII polypeptide is introduced into an exogenous cell and the cell (or cells) Upon introduction into a recipient or individual (eg, a patient exhibiting Factor VIII deficiency). In some embodiments, the cells are stem cells, particularly human stem cells. Usage and method
在另一態樣中,本文所揭示之重組因子VIII多肽用於治療目的。在一些實施例中,重組因子VIII多肽及/或編碼重組因子VIII多肽之重組聚核苷酸用於治療與因子VIII缺乏症相關之病狀或疾病。In another aspect, the recombinant Factor VIII polypeptides disclosed herein are used for therapeutic purposes. In some embodiments, recombinant Factor VIII polypeptides and/or recombinant polynucleotides encoding recombinant Factor VIII polypeptides are used to treat conditions or diseases associated with Factor VIII deficiency.
在一些實施例中,用於治療及/或預防個體之因子VIII缺乏症之症狀的方法包含向患有因子VIII缺乏症之個體投予有效量之本文所描述之重組因子VIII多肽或其醫藥組成物。在一些實施例中,重組因子VIII之投予以酶替代療法形式提供。In some embodiments, methods for treating and/or preventing symptoms of Factor VIII deficiency in an individual comprise administering to an individual suffering from Factor VIII deficiency an effective amount of a recombinant Factor VIII polypeptide described herein, or a pharmaceutical composition thereof things. In some embodiments, administration of recombinant Factor VIII is provided as enzyme replacement therapy.
在一些實施例中,用於治療及/或預防個體之因子VIII缺乏症之症狀的方法包含向患有因子VIII缺乏症之個體提供編碼重組因子VIII多肽之重組聚核苷酸,諸如包含上述之重組多肽的基因療法組成物。在一些實施例中,重組聚核苷酸於病毒載體中提供。在一些實施例中,病毒載體為表現載體,其當向患者投予載體或插入哺乳動物細胞中時提供經編碼之重組因子VIII多肽的表現。在一些實施例中,病毒載體係以腺病毒、腺相關病毒、慢病毒、反轉錄病毒或疱疹病毒載體為主。在一些實施例中,重組聚核苷酸調配於如上文所描述之非病毒遞送組成物中。在一些實施例中,重組聚核苷酸例如使用CRISPR技術作為基因替代療法提供。In some embodiments, methods for treating and/or preventing symptoms of Factor VIII deficiency in an individual comprise providing to an individual suffering from Factor VIII deficiency a recombinant polynucleotide encoding a recombinant Factor VIII polypeptide, such as comprising the above Recombinant peptide gene therapy compositions. In some embodiments, the recombinant polynucleotide is provided in a viral vector. In some embodiments, the viral vector is an expression vector that provides expression of an encoded recombinant Factor VIII polypeptide when the vector is administered to a patient or inserted into a mammalian cell. In some embodiments, the viral vector system is based on adenovirus, adeno-associated virus, lentivirus, retrovirus or herpesvirus vectors. In some embodiments, recombinant polynucleotides are formulated in non-viral delivery compositions as described above. In some embodiments, recombinant polynucleotides are provided as gene replacement therapies, eg, using CRISPR technology.
在一些實施例中,與因子VIII缺乏症相關且用重組因子VIII多肽或編碼重組因子VIII多肽之聚核苷酸治療的病狀或疾病為A型血友病。在一些實施例中,血友病為後天性A型血友病。在一些實施例中,A型血友病係來自基因編碼因子VIII中之遺傳缺陷。在一些實施例中,因子VIII缺乏症之症狀藉由治療改善。 實例 In some embodiments, the condition or disease associated with Factor VIII deficiency and treated with a recombinant Factor VIII polypeptide or a polynucleotide encoding a recombinant Factor VIII polypeptide is hemophilia A. In some embodiments, the hemophilia is acquired hemophilia A. In some embodiments, hemophilia A results from a genetic defect in the gene encoding Factor VIII. In some embodiments, symptoms of Factor VIII deficiency improve with treatment. Example
以下實例,包括實驗及所達成的結果,僅為了說明目的而提供,而非理解為限制本發明。The following examples, including experiments and results achieved, are provided for illustrative purposes only and are not to be construed as limiting the invention.
在以下實驗揭示內容中,在適用時應用以下縮寫:ppm (百萬分之一);M (莫耳);mM (毫莫耳)、uM及µM (微莫耳);nM (奈莫耳);mol (莫耳);gm及g (公克);mg (毫克);ug及µg (微克);L及l (公升);ml及mL (毫升);cm (公分);mm (毫米);um及µm (微米);sec. (秒);min (分鐘);h及hr (小時);U (單元);MW (分子量);rpm (旋轉/分鐘);℃(攝氏度);CDS (編碼序列);DNA (去氧核糖核酸);RNA (核糖核酸);FIOPC (相較於陽性對照之倍數改良)。 實例 1 FVIII 基因獲得及構築表現載體 In the following experimental disclosures, the following abbreviations shall be used where applicable: ppm (parts per million); M (molar); mM (millimole), uM and µM (micromolar); nM (nanomolar) ); mol (mol); gm and g (gram); mg (milligram); ug and µg (microgram); L and l (liter); ml and mL (millilitre); cm (centimeter); mm (millimetre) ;um and µm (micron); sec. (second); min (minute); h and hr (hour); U (unit); MW (molecular weight); rpm (rotation/minute); ℃ (degrees Celsius); CDS ( Coding sequence); DNA (deoxyribonucleic acid); RNA (ribonucleic acid); FIOPC (fold improvement compared to positive control). Example 1 Obtaining FVIII gene and constructing expression vector
編碼具有B區域缺失之WT人類FVIII序列(SEQ ID NO: 2)之合成基因(SEQ ID NO: 1)如先前描述構築(參見例如美國專利公開案第2017/0360900號)。寡核苷酸BamHI-pcDNA-FVIII-F及XhoI-pcDNA-FVIII-R用於擴增FVIII變異體之編碼序列的片段。PCR產物接合至BamHI/XhoI線性化哺乳動物表現載體pcDNA3.1(+) (Invitrogen)或含有CMV啟動子及BGH-pA (牛生長激素聚腺苷酸化)序列之載體。熟習此項技術者通常已知之定向進化技術用於在此質體構築體內產生衍生自SEQ ID NO: 2之基因變異體(參見例如美國專利第8,383,346號及國際專利公開案WO2010/144103)。The synthetic gene (SEQ ID NO: 1) encoding the WT human FVIII sequence with a deletion of the B region (SEQ ID NO: 2) was constructed as previously described (see, eg, US Patent Publication No. 2017/0360900). The oligonucleotides BamHI-pcDNA-FVIII-F and XhoI-pcDNA-FVIII-R were used to amplify fragments of the coding sequence of FVIII variants. The PCR products were ligated into the BamHI/XhoI linearized mammalian expression vector pcDNA3.1(+) (Invitrogen) or a vector containing the CMV promoter and BGH-pA (bovine growth hormone polyadenylation) sequence. Directed evolution techniques, generally known to those skilled in the art, were used to generate genetic variants derived from SEQ ID NO: 2 in this plastid construct (see, eg, US Patent No. 8,383,346 and International Patent Publication WO2010/144103).
哺乳動物細胞密碼子最佳化之人類FVIII之分泌表現使用天然FVIII信號肽來實現。純系主要表現自HEK293T細胞、Expi293F™ (ThermoFisher Scientific)細胞及HepG2細胞中之pDH.1(+)載體。此方法使用來自A型血友病患者之血漿,在顯色分析(參見例如Aniara Diagnostica BIOPHEN™ FVIII:C)及活化部分凝血激酶時間(APTT)分析中提供具有可量測活性之上清液。 Codon-optimized secretory expression of human FVIII in mammalian cells is achieved using the native FVIII signal peptide. The pure line mainly expresses the pDH.1(+) vector in HEK293T cells, Expi293F™ (ThermoFisher Scientific) cells and HepG2 cells. This method uses plasma from hemophilia A patients to provide supernatants with measurable activity in chromogenic assays (see, e.g., Aniara Diagnostica BIOPHEN™ FVIII:C) and activated partial thromboplastin time (APTT) assays.
在一些實施例中,為識別與SEQ ID NO: 2相比具有類似穩定性及改良血液凝血功能之突變多樣性,構築組合庫產生衍生自SEQ ID NO: 2之FVIII變異體。在未經攻擊(unchallenged)條件(未培育,pH 7.4)中或在37℃至55℃下於人類血漿(生理pH 7.1-8.2)環境中培育一小時至十七小時之後篩選等效體積之上清液。歸因於增加之FVIII表現或FVIII比活性而具有改良之活性的FVIII變異體係以其相較於親代FVIII之倍數改良為主來識別的。具有增加之穩定性之FVIII變異體係藉由將在經攻擊(challenged)條件下觀測到之倍數改良除以在未經攻擊條件下觀測到之倍數改良來加以識別。此途徑以經增加之表現為主減少針對選擇變異體之偏好,但不改變穩定性。綜合活性分數(所有三個條件之倍數改良之乘積)及穩定性(穩定性分數之乘積)係用於對經改良之變異體中的突變進行分級以包括於後續FVIII庫中。在額外實施例中,使用實例中所描述之額外方法及序列。 實例 2 高通量生長FVIII及FVIII變異體之高通量(HTP)生長 In some embodiments, combinatorial libraries are constructed to generate FVIII variants derived from SEQ ID NO: 2 in order to identify mutational diversity with similar stability and improved blood coagulation function compared to SEQ ID NO: 2. Screening above equivalent volumes in unchallenged conditions (unincubated, pH 7.4) or after incubation in human plasma (physiological pH 7.1-8.2) for one to seventeen hours at 37°C to 55°C Clear liquid. FVIII variant systems with improved activity due to increased FVIII performance or FVIII specific activity are primarily identified by their fold improvement compared to the parent FVIII. FVIII mutant systems with increased stability are identified by dividing the fold improvement observed under challenged conditions by the fold improvement observed under unchallenged conditions. This approach reduces the preference for selected variants based on increased performance but does not alter stability. The combined activity score (the product of fold improvements across all three conditions) and stability (the product of stability scores) were used to rank mutations in improved variants for inclusion in subsequent FVIII libraries. In additional embodiments, additional methods and sequences described in the Examples are used. Example 2 High-Throughput Growth High-Throughput (HTP) Growth of FVIII and FVIII Variants
使用具有ExpiFectamine™ 293轉染套組(ThermoFisher Scientific)或LIPOFECTAMINE ®3000試劑(ThermoFisher Scientific)進行脂質體轉染方法,用具有CMV啟動子及含有編碼具有B區域缺失之野生型FVIII或變異體之載體的BGH-pA的pcDNA 3.1(+)轉染Expi293F™ (ThermoFisher Scientific)細胞或HepG2細胞。Expi293F™ (ThermoFisher Scientific)細胞在生長培養基(Expi293™表現培養基,ThermoFisher Scientific)中培養。在轉染之前立即將細胞以10 8個細胞/孔/400 µL之生長培養基中之密度轉移至NUNC™96孔DeepWell™培養盤(ThermoFisher Scientific),且在培育箱中於37℃、8% CO 2下培育。在生長培養基(EMEM與10%胎牛血清,二者均來自Corning)中培養HepG2細胞。在轉染之前24小時,將細胞以10 4個細胞/孔/250 µL之生長培養基中之密度接種至NUNC ®Edge 2.0 96孔培養盤(ThermoFisher Scientific),且在培育箱中於37℃、5% CO 2下培育。將細胞在特定條件下培育24-96小時,以允許FVIII變異體之表現以及分泌。將來自轉染之條件培養基(50-100 µL)轉移至Corning 96孔固體黑色培養盤(Corning)中以進行活性及/或穩定性分析。 實例 3 HTP 中變異體之活體外表徵上清液之HTP分析(顯色分析) Lipofectamine transfection was performed using ExpiFectamine™ 293 Transfection Kit (ThermoFisher Scientific) or LIPOFECTAMINE ® 3000 Reagent (ThermoFisher Scientific), using a CMV promoter and a vector encoding wild-type FVIII or a variant with a deletion of the B region. BGH-pA pcDNA 3.1(+) was transfected into Expi293F™ (ThermoFisher Scientific) cells or HepG2 cells. Expi293F™ (ThermoFisher Scientific) cells were cultured in growth medium (Expi293™ Expression Medium, ThermoFisher Scientific). Immediately before transfection, cells were transferred to NUNC™ 96-well DeepWell™ plates (ThermoFisher Scientific) at a density of 10 8 cells/well/400 µL of growth medium and incubated in an incubator at 37°C, 8% CO 2 times to cultivate. HepG2 cells were cultured in growth medium (EMEM with 10% fetal calf serum, both from Corning). 24 hours before transfection, cells were seeded into NUNC ® Edge 2.0 96-well culture plates (ThermoFisher Scientific) at a density of 10 4 cells/well/250 µL of growth medium and incubated in an incubator at 37°C, 5 Cultivated under % CO 2 . Cells are incubated for 24-96 hours under specific conditions to allow expression and secretion of FVIII variants. Conditioned medium (50-100 µL) from transfection was transferred to Corning 96-well solid black culture plates (Corning) for activity and/or stability analysis. Example 3 In vitro characterization of variants in HTP HTP analysis of supernatant (chromogenic analysis)
FVIII變異體活性藉由量測來自合成肽受質之對硝基苯胺(pNa)的釋放來測定。對於未經攻擊之分析,使如上文所描述產生之25 µL Expi293F或HepG2條件培養基升溫至37℃且與25 µL「試劑1」(BIOPHEN™ FVIII:C, Aniara)及25 µL「試劑2」(BIOPHEN™ FVIII:C, Aniara)在96孔黑色不透明底部微量滴定盤中混合。將反應物短暫地混合且在37℃下培育5分鐘。隨後添加25 µL「試劑3」(BIOPHEN™ FVIII:C, Aniara),且將反應短暫混合且在37℃下培育5分鐘,隨後用25 µL pf 2%檸檬酸淬滅。使用EnVision® 2105多模式盤讀取器(PerkinElmer)監測405 nm處之吸光度來分析pNA之釋放。「試劑1」、「試劑2」及「試劑3」為由Aniara供應之顯色分析(BIOPHEN™ FVIII:C)的組分且如供應商所推薦使用。 上清液之HTP分析(凝血分析) FVIII variant activity was determined by measuring the release of p-nitroaniline (pNa) from synthetic peptide substrates. For unchallenged analysis, 25 µL of Expi293F or HepG2 conditioned medium generated as described above was warmed to 37°C and mixed with 25 µL of "Reagent 1" (BIOPHEN™ FVIII:C, Aniara) and 25 µL of "Reagent 2" ( BIOPHEN™ FVIII:C, Aniara) was mixed in a 96-well black opaque bottom microtiter plate. The reaction was mixed briefly and incubated at 37°C for 5 minutes. 25 µL of "Reagent 3" (BIOPHEN™ FVIII:C, Aniara) was then added and the reaction was mixed briefly and incubated at 37°C for 5 minutes before being quenched with 25 µL pf 2% citric acid. The release of pNA was analyzed using an EnVision® 2105 multi-mode disk reader (PerkinElmer) monitoring absorbance at 405 nm. "Reagent 1", "Reagent 2" and "Reagent 3" are components of the chromogenic assay (BIOPHEN™ FVIII:C) supplied by Aniara and were used as recommended by the supplier. HTP analysis of supernatant (coagulation analysis)
FVIII變異體活性藉由使用活化部分凝血激酶時間分析量測A型血友病患者血漿(George King Bio-Medical, Inc.)之凝血速率來測定。對於未經攻擊之分析,使如上文所描述產生之25 µL Expi293F或HepG2條件培養基升溫至37℃且與30 µL A型血友病患者血漿(George King Bio-Medical, Inc.)及50 µL aPTT-XL試劑(Pacific Hemostasis)在96孔黑色不透明底部微量滴定盤中混合。將反應物短暫地混合且在37℃下培育3分鐘。隨後添加10 µL之200 µM氯化鈣(Sigma Aldrich),且短暫混合反應物。使用EnVision® 2105多模式盤讀取器(PerkinElmer)監測405 nm處之吸光度歷經5-10分鐘之時間來分析凝血。 用血漿預處理之上清液之HTP分析 FVIII variant activity was determined by measuring the coagulation rate of hemophilia A patient plasma (George King Bio-Medical, Inc.) using activated partial thromboplastin time analysis. For unchallenged analysis, 25 µL of Expi293F or HepG2 conditioned media generated as described above was warmed to 37°C and mixed with 30 µL of hemophilia A patient plasma (George King Bio-Medical, Inc.) and 50 µL of aPTT -XL reagent (Pacific Hemostasis) was mixed in a 96-well black opaque bottom microtiter plate. The reaction was mixed briefly and incubated at 37°C for 3 minutes. Then 10 µL of 200 µM calcium chloride (Sigma Aldrich) was added and the reaction was mixed briefly. Coagulation was analyzed using an EnVision® 2105 multimode disk reader (PerkinElmer) monitoring absorbance at 405 nm over a period of 5-10 minutes. HTP analysis of supernatants pretreated with plasma
FVIII變異體用A型血友病患者血漿(George King Bio-Medical, Inc.)攻擊以模擬變異體可在血流內遇到的條件。首先,將如上文所描述產生之50 µL Expi293F或HepG2條件培養基及50 µL A型血友病患者血漿(George King Bio-Medical, Inc.)添加至96孔圓底微量滴定盤中。用PlateLoc ®熱微量培養盤密封機(Agilent)密封培養盤,且在37-55℃下培育1-24小時。隨後藉由上述之顯色或凝血分析來分析樣品。 實例 4 衍生自 SEQ ID NO: 2 之 FVIII 變異體 FVIII variants were challenged with hemophilia A patient plasma (George King Bio-Medical, Inc.) to simulate conditions that the variants may encounter within the bloodstream. First, 50 µL of Expi293F or HepG2 conditioned medium and 50 µL of hemophilia A patient plasma (George King Bio-Medical, Inc.) generated as described above were added to a 96-well round-bottom microtiter plate. The plates were sealed with a PlateLoc® Thermal Microplate Sealer (Agilent) and incubated at 37-55°C for 1-24 hours. The sample is then analyzed by chromogenic or coagulation assays as described above. Example 4 FVIII variants derived from SEQ ID NO: 2
在此實例中,描述了為測定FVIII變異體活性而進行的實驗。此等變異體使用顯色分析來測試,如實例3中所描述。
表 4.1及
表 4.2中顯示使用Expi293F細胞表現之變異體的結果。
在此實例中,描述了為測定FVIII變異體活性而進行的實驗。此等變異體使用顯色分析來測試,如實例3中所描述。
表 5.1及
表 5.2中顯示使用Expi293F細胞表現之變異體的結果。
在此實例中,描述了為測定FVIII變異體活性而進行的實驗。此等變異體使用顯色及凝血分析來測試,如實例3中所描述。
表 6.1及
表 6.2中顯示使用Expi293F細胞或HepG2細胞表現之變異體的結果。
在此實例中,描述了為測定FVIII變異體活性而進行的實驗。此等變異體使用顯色及凝血分析來測試,如實例3中所描述。
表 7.1及
表 7.2中顯示使用Expi293F細胞或HepG2細胞表現之變異體的結果。
在此實例中,描述了在攻擊之後藉由分析蛋白質活性來進行以測定FVIII變異體活性之實驗。在未培育之後及在A型血友病患者血漿(George King Bio-Medical, Inc.)中培育之後測試此等變異體的FVIII活性,如實例3中所描述。變異體使用顯色及凝血分析來測試,如實例3中所描述。
表 8.1及
表 8.2中顯示使用Expi293F細胞或HepG2細胞表現之變異體的結果。
在此實例中,描述了在攻擊之後藉由分析蛋白質活性來進行以測定FVIII變異體活性之實驗。在未培育之後及在A型血友病患者血漿(George King Bio-Medical, Inc.)中培育之後測試此等變異體的FVIII活性,如實例3中所描述。變異體使用顯色及凝血分析來測試,如實例3中所描述。
表 9.1及
表 9.2中顯示使用Expi293F細胞或HepG2細胞表現之變異體的結果。
在此實例中,描述了在攻擊之後藉由分析蛋白質活性來進行以測定FVIII變異體活性之實驗。在未培育之後及在A型血友病患者血漿(George King Bio-Medical, Inc.)中培育之後測試此等變異體的FVIII活性,如實例3中所描述。變異體使用顯色及凝血分析來測試,如實例3中所描述。
表 10.1及
表 10.2中顯示使用Expi293F細胞或HepG2細胞表現之變異體的結果。
在此實例中,描述了在攻擊之後藉由分析蛋白質活性來進行以測定FVIII變異體活性之實驗。在未培育之後及在A型血友病患者血漿(George King Bio-Medical, Inc.)中培育之後測試此等變異體的FVIII活性,如實例3中所描述。變異體使用顯色及凝血分析來測試,如實例3中所描述。
表11.1中顯示使用Expi293F細胞或HepG2細胞表現之變異體的結果。
野生型人類FVIII之B區域缺失形式中之推定T細胞抗原決定基係使用如此項技術中已知之免疫抗原決定基資料庫(IEDB;免疫抗原決定基資料庫以及分析資源網站)工具以及專有統計分析工具來識別(參見例如iedb.org及Vita等人,Nucl. Acids Res., 2010, 38 (資料庫期): D854-62, 電子版2009年11月11日)。野生型人類FVIII之B區域缺失形式(SEQ ID NO: 2)經解析為所有可能的15-聚體分析框架,其中各框架與最後一個重疊14個胺基酸。使用IEDB網站上推薦之方法,藉由對與八個常見II類HLA-DR對偶基因(DRB1*0101、DRB1*0301、DRB1*0401、DRB1*0701、DRB1*0801、DRB1*1101、DRB1*1301及DRB1*1501)之預測結合進行評分,評估15-聚體分析框架的免疫原性潛能。多肽內所含之潛在T細胞抗原決定基簇(亦即人類FVIII內所含之子區域,其具有針對免疫原性之異常高潛能)使用統計分析工具識別,如此項技術中已知。針對已知抗原決定基之IEDB資料庫篩選所識別之T細胞抗原決定基簇。Putative T cell epitopes in the B-region deleted form of wild-type human FVIII were determined using tools as known in the art as the Immune Epitope Database (IEDB; Immune Epitope Database and Analysis Resource Website) and proprietary statistics. Analysis tools to identify (see, for example, iedb.org and Vita et al., Nucl. Acids Res., 2010, 38 (Database Issue): D854-62, electronic version November 11, 2009). The B-region deleted form of wild-type human FVIII (SEQ ID NO: 2) was resolved into all possible 15-mer analytical frames, where each frame overlapped the last one by 14 amino acids. Using the method recommended on the IEDB website, by matching eight common class II HLA-DR allele genes (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301 and DRB1*1501) were combined to perform scoring to evaluate the immunogenic potential of the 15-mer analysis framework. Potential T cell epitope clusters contained within the polypeptide (ie, subregions contained within human FVIII that have an unusually high potential for immunogenicity) were identified using statistical analysis tools, as are known in the art. The identified T cell epitope clusters were screened against the IEDB database of known epitopes.
藉由評估在實例3之篩選中識別的活性FVIII變異體與八個常見II類HLA-DR對偶基因之結合,來識別其預測免疫原性位準。各變異體之總免疫原性分數以及免疫原性命中計數經計算。總免疫原性分數(TIS)反映變異體之總體經預測免疫原性(亦即較高分數指示較高經預測免疫原性位準)。免疫原性「命中計數」(IHC)指示具有不尋常地高之免疫原性潛在性之15-聚體分析框架數目(亦即較高分數指示較高免疫原性潛在性)。相較於參考序列而言引起總免疫原性分數降低及/或免疫原性命中計數減少之突變被視為潛在「去免疫突變」且示於
表 12.1、
12.2、
12.3、
12.4、
12.5、
12.6、
12.7、
12.8以及
15.2中。將大部分去免疫突變之集合重組以產生多種具有活性之變異體,且預測與WT人類FVIII之B區域缺失形式(SEQ ID NO: 2)相比具有顯著較低免疫原性。
在此實例中,肽係以野生型B區域缺失之人類因子VIII為主設計的,具有或不具有突變被認為會改變蛋白質的免疫原性。特定言之,二種多肽(SEQ ID NO: 2347及SEQ ID NO: 2348)係藉由Abzena Ltd. (Cambridge, United Kingdom)製備。SEQ ID NO: 2347之肽的序列與SEQ ID NO: 2中之序列相比不具有胺基酸變化,而SEQ ID NO: 2348之肽的序列在肽之胺基酸位置12處含有L→G取代,其相當於相對於SEQ ID NO: 2之L318G取代。使用EpiScreen TMT細胞抗原決定基匹配技術,使用50個健康人類供體之外周血液單核細胞(PBMC)分析此等肽之CD4 +T細胞抗原決定基之存在。使用AIM V ©培養基(Invitrogen, Paisley, UK)將PBMC調節至2.5-3.0E6個細胞/毫升之細胞密度。將5 µM肽或對照培養基添加至平底96孔培養盤中之PBMC中。對於各肽供體對,進行6次反應。培育培養物6天,隨後添加0.75 µCi氚標記之胸苷(Perkin Elmer ©, Beaconsfield, UK)至各孔中。培養物再培育18小時,隨後使用TomTec Mach III細胞收集器(Receptor Tech. Ltd., Warwick, UK)將細胞收集至過濾器墊上。各孔之每分鐘計數(CPM)在微量培養盤β計數器(Perkin Elmer®, Beaconsfield, UK)上以平行、低背景計數模式測定Meltilex™ (Perkin Elmer®, Beaconsfield, UK)閃爍計數。學生t檢驗比較接受肽之孔與接受培養基之孔的反應,以確定反應之顯著性(p<0.05)。陽性反應為個別肽-供體對之平均CPM值除以培養基對照之平均CPM值大於1.90的反應。此實驗之結果顯示於 圖 1中。 In this example, the peptide was designed based on wild-type human Factor VIII with a deletion of the B region, with or without mutations thought to alter the immunogenicity of the protein. Specifically, two polypeptides (SEQ ID NO: 2347 and SEQ ID NO: 2348) were prepared by Abzena Ltd. (Cambridge, United Kingdom). The sequence of the peptide of SEQ ID NO: 2347 has no amino acid changes compared with the sequence of SEQ ID NO: 2, while the sequence of the peptide of SEQ ID NO: 2348 contains L→G at amino acid position 12 of the peptide. Substitution, which is equivalent to the L318G substitution relative to SEQ ID NO: 2. Peripheral blood mononuclear cells (PBMC) from 50 healthy human donors were analyzed for the presence of CD4 + T cell epitopes of these peptides using EpiScreen ™ T cell epitope matching technology. PBMC were adjusted to a cell density of 2.5-3.0E6 cells/ml using AIM V © medium (Invitrogen, Paisley, UK). Add 5 µM peptide or control medium to PBMC in flat-bottom 96-well plates. For each peptide donor pair, 6 reactions were performed. Cultures were grown for 6 days before 0.75 µCi of tritium-labeled thymidine (Perkin Elmer © , Beaconsfield, UK) was added to each well. Cultures were incubated for a further 18 hours before cells were harvested onto filter pads using a TomTec Mach III cell harvester (Receptor Tech. Ltd., Warwick, UK). Counts per minute (CPM) for each well were determined by Meltilex™ (Perkin Elmer®, Beaconsfield, UK) scintillation counting in parallel, low background counting mode on a microplate beta counter (Perkin Elmer®, Beaconsfield, UK). Student's t test compares the response of wells receiving peptide to wells receiving medium to determine the significance of the response (p<0.05). A positive reaction is a reaction in which the average CPM value of the individual peptide-donor pairs divided by the average CPM value of the medium control is greater than 1.90. The results of this experiment are shown in Figure 1 .
與實例1類似,使用定向進化技術產生含有使用Abzena, Ltd.肽T細胞分析(SEQ ID NO: 2069 (核苷酸序列);SEQ ID NO: 2070 (胺基酸序列))測試之突變的基因變異體(衍生自相同質體構築體內的SEQ ID NO: 1514) (參見例如美國專利編號8,383,346及WO2010/144103)。此變異體(SEQ ID NO: 2070)使用實例2中所描述之方法產生且在未培育之後及在A型血友病患者血漿(George King Bio-Medical, Inc.)中培育之後測試其FVIII活性,如實例3中所描述。變異體使用顯色分析來測試,如實例3中所描述。結果顯示於 圖 2中。 實例 14 衍生自 SEQ ID NO: 2 之截短 FVIII 變異體之活性 Similar to Example 1, directed evolution techniques were used to generate genes containing mutations tested using the Abzena, Ltd. Peptide T Cell Assay (SEQ ID NO: 2069 (nucleotide sequence); SEQ ID NO: 2070 (amino acid sequence)) Variant (SEQ ID NO: 1514 derived from the same plasmid construct) (see, eg, US Patent No. 8,383,346 and WO2010/144103). This variant (SEQ ID NO: 2070) was generated using the method described in Example 2 and tested for FVIII activity after no incubation and after incubation in hemophilia A patient plasma (George King Bio-Medical, Inc.) , as described in Example 3. Variants were tested using chromogenic analysis as described in Example 3. The results are shown in Figure 2 . Example 14 Activity of Truncated FVIII Variants Derived from SEQ ID NO: 2
類似於實例1,熟習此項技術者通常已知之定向進化技術用於產生衍生自含有相同質體構築體內因子VIII截斷形式之SEQ ID NO: 2的基因變異體(參見例如美國專利編號8,383,346及WO2010/144103)。此等變異體使用實例2中所描述之方法產生且使用顯色分析測試,如實例3中所描述。結果顯示於 圖 3中。 實例 15 衍生自 SEQ ID NO: 2 之截短 FVIII 變異體 Similar to Example 1, directed evolution techniques commonly known to those skilled in the art were used to generate genetic variants derived from SEQ ID NO: 2 containing a truncated form of Factor VIII within the same plastid construct (see, e.g., U.S. Patent No. 8,383,346 and WO2010 /144103). These variants were generated using the method described in Example 2 and tested using chromogenic analysis, as described in Example 3. The results are shown in Figure 3 . Example 15 Truncated FVIII variants derived from SEQ ID NO: 2
在此實例中,描述了藉由分析蛋白質活性來進行以測定FVIII變異體活性之實驗。此等變異體使用顯色分析來測試FVIII活性,如實例3中所描述。
表15.1中顯示使用Expi293F細胞表現之變異體的結果。
藉由評估在此實例之篩選中識別的活性FVIII變異體與八個常見II類HLA-DR對偶基因之結合,來評估其預測免疫原性位準,如同實例12。各變異體之總免疫原性分數以及免疫原性命中計數經計算。總免疫原性分數(TIS)反映變異體之總體經預測免疫原性(亦即較高分數指示較高經預測免疫原性位準)。免疫原性「命中計數」(IHC)指示具有不尋常地高之免疫原性潛在性之15-聚體分析框架數目(亦即較高分數指示較高免疫原性潛在性)。相較於參考序列而言引起總免疫原性分數降低及/或免疫原性命中計數減少之突變被視為潛在「去免疫突變」且示於
表 15.2中。
在此實例中,描述了為表徵如本文所指示產生之FVIII變異體而進行之實驗。 在Expi293F™細胞或HepG2細胞中產生因子VIII In this example, experiments performed to characterize FVIII variants generated as indicated herein are described. Production of Factor VIII in Expi293F™ cells or HepG2 cells
使用具有ExpiFectamine™ 293轉染套組(ThermoFisher Scientific)或LIPOFECTAMINE ®3000試劑(ThermoFisher Scientific)進行脂質體轉染方法,用pcDNA 3.1(+)或CMV啟動子及含有編碼具有B區域缺失之野生型FVIII或變異體之載體的BGH-pA轉染Expi293F™ (ThermoFisher Scientific)細胞或HepG2細胞。Expi293F™ (ThermoFisher Scientific)細胞在生長培養基(Expi293™表現培養基;ThermoFisher Scientific)中培養。在生長培養基(EMEM與10%胎牛血清,二者均來自Corning)中培養HepG2細胞。Expi293F™細胞或HepG2細胞經質體DNA轉染且在懸浮液中生長3-7天。隨後收集條件培養基,藉由離心澄清且過濾,且儲存於-80℃下直至表徵。 來自Expi293F™細胞或HepG2細胞之FVIII變異體表現之分析(ELISA) Lipofectamine transfection was performed using the ExpiFectamine™ 293 Transfection Kit (ThermoFisher Scientific) or LIPOFECTAMINE ® 3000 reagent (ThermoFisher Scientific) using the pcDNA 3.1(+) or CMV promoter and a protein encoding wild-type FVIII with a deletion of the B region. or variant vector BGH-pA to transfect Expi293F™ (ThermoFisher Scientific) cells or HepG2 cells. Expi293F™ (ThermoFisher Scientific) cells were cultured in growth medium (Expi293™ Expression Medium; ThermoFisher Scientific). HepG2 cells were cultured in growth medium (EMEM with 10% fetal calf serum, both from Corning). Expi293F™ cells or HepG2 cells are transfected with plastid DNA and grown in suspension for 3-7 days. The conditioned medium was then collected, clarified by centrifugation and filtered, and stored at -80°C until characterization. Analysis of expression of FVIII variants from Expi293F™ cells or HepG2 cells (ELISA)
條件培養基中之FVIII變異體表現使用人類因子VIII ELISA套組(Ab272771, Abcam)根據公司標準操作方案進行分析。比色分析量測0.0002 IU/ml至0.84 IU/ml範圍內之總人類FVIII。在96孔微量滴定盤中,將大於0.84 IU/ml之FVIII變異體在tris-BSA緩衝液(A221406-RUO, Aniara Diagnostica)中稀釋。使用EnVision多模式盤讀取器量測450 nm下之所有孔的吸光度。來自此分析之結果呈現於 圖 4及 圖 5中,繪製一式三份之平均值±標凖偏差。 FVIII變異體活性之分析(顯色分析) The expression of FVIII variants in conditioned media was analyzed using human factor VIII ELISA kit (Ab272771, Abcam) according to the company's standard protocol. The colorimetric assay measures total human FVIII in the range of 0.0002 IU/ml to 0.84 IU/ml. FVIII variants greater than 0.84 IU/ml were diluted in tris-BSA buffer (A221406-RUO, Aniara Diagnostica) in 96-well microtiter plates. The absorbance of all wells was measured at 450 nm using an EnVision multi-mode disk reader. Results from this analysis are presented in Figures 4 and 5 , plotting the mean ± standard deviation of triplicates. Analysis of FVIII variant activity (chromogenic analysis)
FVIII變異體活性藉由量測來自合成肽受質之對硝基苯胺(pNa)的釋放來測定。對於未經攻擊之分析,使如上文所描述產生之25 µL經稀釋或未經稀釋之Expi293F或HepG2條件培養基升溫至37℃且與25 µL「試劑1」(BIOPHEN™ FVIII:C, Aniara)及25 µL「試劑2」(BIOPHEN™ FVIII:C, Aniara)在96孔黑色不透明底部微量滴定盤中混合。將反應物短暫地混合且在37℃下培育5分鐘。隨後添加25 µL「試劑3」(BIOPHEN™ FVIII:C, Aniara),且將反應短暫混合且在37℃下培育5分鐘,隨後用25 µL pf 2%檸檬酸淬滅。使用EnVision® 2105多模式盤讀取器(PerkinElmer)監測405 nm處之吸光度來分析pNA之釋放。「試劑1」、「試劑2」及「試劑3」為由Aniara供應之顯色分析(BIOPHEN™ FVIII:C)的組分且如供應商所推薦使用。來自此分析之結果呈現於 圖 6及 圖 7(正規化之前)中以及 圖 8及 圖9(使用由上述ELISA測定的蛋白質濃度正規化之後)中,繪製一式三份之平均值±標凖偏差。 FVIII變異體活性之分析(凝血分析) FVIII variant activity was determined by measuring the release of p-nitroaniline (pNa) from synthetic peptide substrates. For unchallenged assays, 25 µL of diluted or undiluted Expi293F or HepG2 conditioned medium generated as described above was warmed to 37°C and mixed with 25 µL of "Reagent 1" (BIOPHEN™ FVIII:C, Aniara) and 25 µL of "Reagent 2" (BIOPHEN™ FVIII:C, Aniara) was mixed in a 96-well black opaque bottom microtiter plate. The reaction was mixed briefly and incubated at 37°C for 5 minutes. 25 µL of "Reagent 3" (BIOPHEN™ FVIII:C, Aniara) was then added and the reaction was mixed briefly and incubated at 37°C for 5 minutes before being quenched with 25 µL pf 2% citric acid. The release of pNA was analyzed using an EnVision® 2105 multi-mode disk reader (PerkinElmer) monitoring absorbance at 405 nm. "Reagent 1", "Reagent 2" and "Reagent 3" are components of the chromogenic assay (BIOPHEN™ FVIII:C) supplied by Aniara and were used as recommended by the supplier. Results from this analysis are presented in Figures 6 and 7 ( before normalization) and in Figures 8 and 9 (after normalization using protein concentrations determined by the ELISA described above), plotting the mean ± standard deviation of triplicates . Analysis of FVIII variant activity (coagulation analysis)
FVIII變異體活性藉由使用活化部分凝血激酶時間分析量測A型血友病患者血漿(George King Bio-Medical, Inc.)之凝血速率來測定。對於未經攻擊之分析,使如上文所描述產生之25 µL經稀釋或未經稀釋之Expi293F或HepG2條件培養基升溫至37℃且與30 µL A型血友病患者血漿(George King Bio-Medical, Inc.)及50 µL aPTT-XL試劑(Pacific Hemostasis)在96孔黑色不透明底部微量滴定盤中混合。將反應物短暫地混合且在37℃下培育3分鐘。隨後添加10 µL之200 µM氯化鈣(Sigma Aldrich),且短暫混合反應物。使用EnVision® 2105多模式盤讀取器(PerkinElmer)監測405 nm處之吸光度歷經5-10分鐘之時間來分析凝血。使用R指令碼自所收集之資料點外推凝血起始時間來執行分析。來自此分析之結果呈現於 圖 10中,繪製一式三份之平均值±標凖偏差。 A型血友病患者血漿中之FVIII變異體穩定性之分析 FVIII variant activity was determined by measuring the coagulation rate of hemophilia A patient plasma (George King Bio-Medical, Inc.) using activated partial thromboplastin time analysis. For unchallenged analysis, 25 µL of diluted or undiluted Expi293F or HepG2 conditioned media generated as described above was warmed to 37°C and mixed with 30 µL of hemophilia A patient plasma (George King Bio-Medical, Inc.) and 50 µL aPTT-XL reagent (Pacific Hemostasis) were mixed in a 96-well black opaque bottom microtiter plate. The reaction was mixed briefly and incubated at 37°C for 3 minutes. Then 10 µL of 200 µM calcium chloride (Sigma Aldrich) was added and the reaction was mixed briefly. Coagulation was analyzed using an EnVision® 2105 multimode disk reader (PerkinElmer) monitoring absorbance at 405 nm over a period of 5-10 minutes. The analysis was performed using R scripts to extrapolate the clotting onset time from the collected data points. Results from this analysis are presented in Figure 10 , plotting the mean ± standard deviation of triplicates. Analysis of the stability of FVIII variants in plasma of patients with hemophilia A
FVIII變異體用A型血友病患者血漿(George King Bio-Medical, Inc.)攻擊以模擬變異體可在血流內遇到的條件。首先,將如上文所描述產生之50 µL Expi293F或HepG2條件培養基及50 µL A型血友病患者血漿(George King Bio-Medical, Inc.)添加至96孔圓底微量滴定盤中。用PlateLoc ®熱微量培養盤密封機(Agilent)密封培養盤,且在37-55℃下培育1-96小時。隨後藉由上述之顯色分析來分析樣品。來自此分析之結果呈現於 圖 11中,繪製一式三份之平均值±標凖偏差。 FVIII variants were challenged with hemophilia A patient plasma (George King Bio-Medical, Inc.) to simulate conditions that the variants may encounter within the bloodstream. First, 50 µL of Expi293F or HepG2 conditioned medium and 50 µL of hemophilia A patient plasma (George King Bio-Medical, Inc.) generated as described above were added to a 96-well round-bottom microtiter plate. The plates were sealed with a PlateLoc® Thermal Microplate Sealer (Agilent) and incubated at 37-55°C for 1-96 hours. The samples were then analyzed by chromogenic analysis as described above. Results from this analysis are presented in Figure 11 , plotting the mean ± standard deviation of triplicates.
儘管本發明已參考特定實施例加以描述,但各種改變可被作出且等效方案可經取代以適應特定情形、材料、物質組成、方法、一或多個方法步驟,藉此在不脫離所主張內容之範疇之情況下達成本發明的效益。 Although the invention has been described with reference to specific embodiments, various changes may be made and equivalents may be substituted to adapt the particular situation, materials, compositions of matter, method, method step or steps without departing from what is claimed. The benefits of the present invention are achieved within the scope of the content.
出於所有目的,本揭露內容中所引用之每一個公開案以及專利文獻均以引用之方式併入本文中,如同各該公開案或文獻經特定地且個別地指示以引用之方式併入本文中一般。公開案以及專利文獻之引用意欲為以下指示:任何該文獻不為相關先前技術,且不構成承認該文獻之內容或日期。Each publication and patent document cited in this disclosure is hereby incorporated by reference for all purposes as if each such publication or document was specifically and individually indicated to be incorporated by reference. Average. Citation of publications and patent documents is intended to be an indication that any such document is not relevant prior art and does not constitute an admission of the contents or date of the document.
(無)(without)
圖1顯示50個供體的百分比,當在用於檢查免疫原性之T細胞分析中與重組因子VIII之肽一起培育時,其外周血液單核細胞(PBMC)產生CD4 T細胞反應。 Figure 1 shows the percentage of 50 donors whose peripheral blood mononuclear cells (PBMC) generated a CD4 T cell response when incubated with peptides of recombinant Factor VIII in a T cell assay used to examine immunogenicity.
圖2顯示研究之結果,其中重組因子VIII多肽使用Expi293F或HepG2培養物表現且在與A型血友病患者血漿(George King Bio-Medical, Inc.)一起培育之前或之後使用顯色分析(BIOPHEN™ FVIII:C, Aniara)評估活性。活性相對於SEQ ID NO: 1514顯示。 Figure 2 shows the results of studies in which recombinant Factor VIII polypeptides were expressed using Expi293F or HepG2 cultures and before or after incubation with hemophilia A patient plasma (George King Bio-Medical, Inc.) using a chromogenic assay (BIOPHEN ™ FVIII:C, Aniara) to assess activity. Activity is shown relative to SEQ ID NO: 1514.
圖3顯示研究之結果,其中經截短之重組因子VIII多肽使用Expi293F培養物表現且使用顯色分析(BIOPHEN™ FVIII:C, Aniara)評估活性。活性相對於SEQ ID NO: 2顯示在左軸線上。相對於SEQ ID NO: 2移除之胺基酸的數目顯示在右軸線上。 Figure 3 shows the results of studies in which truncated recombinant Factor VIII polypeptides were expressed using Expi293F cultures and activity assessed using a chromogenic assay (BIOPHEN™ FVIII:C, Aniara). Activity is shown on the left axis relative to SEQ ID NO:2. The number of amino acids removed relative to SEQ ID NO: 2 is shown on the right axis.
圖4顯示藉由ELISA所量測,重組因子VIII多肽變異體在Expi293F細胞中之表現。 Figure 4 shows the performance of recombinant Factor VIII polypeptide variants in Expi293F cells as measured by ELISA.
圖5顯示藉由ELISA所量測,重組因子VIII多肽變異體在HepG2細胞中之表現。 Figure 5 shows the performance of recombinant Factor VIII polypeptide variants in HepG2 cells as measured by ELISA.
圖6顯示在用藉由ELISA測定之蛋白質濃度正規化之前,藉由條件培養基之顯色分析所量測,表現於Expi293F細胞中之重組因子VIII多肽變異體之活性。 Figure 6 shows the activity of recombinant Factor VIII polypeptide variants expressed in Expi293F cells as measured by chromogenic analysis of conditioned media before normalization with protein concentrations determined by ELISA.
圖7顯示在用藉由ELISA測定之蛋白質濃度正規化之前,藉由條件培養基之顯色分析所量測,表現於HepG2細胞中之重組因子VIII多肽變異體之活性。 Figure 7 shows the activity of recombinant Factor VIII polypeptide variants expressed in HepG2 cells as measured by chromogenic analysis of conditioned media before normalization with protein concentrations determined by ELISA.
圖8顯示在用藉由ELISA測定之蛋白質濃度正規化之後,藉由條件培養基之顯色分析所量測,表現於Expi293F細胞中之重組因子VIII多肽變異體之活性。 Figure 8 shows the activity of recombinant Factor VIII polypeptide variants expressed in Expi293F cells as measured by chromogenic analysis of conditioned media after normalization with protein concentrations determined by ELISA.
圖9顯示在用藉由ELISA測定之蛋白質濃度正規化之後,藉由條件培養基之顯色分析所量測,表現於HepG2細胞中之重組因子VIII多肽變異體之活性。 Figure 9 shows the activity of recombinant Factor VIII polypeptide variants expressed in HepG2 cells as measured by chromogenic analysis of conditioned media after normalization with protein concentrations determined by ELISA.
圖10顯示使用表現重組因子VIII多肽變異體之Expi293F細胞之條件培養基的活化部分凝血激酶時間分析量測之凝血活性。 Figure 10 shows coagulation activity measured by activated partial thromboplastin time analysis using conditioned media of Expi293F cells expressing recombinant Factor VIII polypeptide variants.
圖11顯示殘餘活性,如在重組因子VIII多肽變異體暴露於自A型血友病患者獲得之血漿中不同時段之後使用重組因子VIII多肽變異體之顯色分析所量測。 Figure 11 shows residual activity as measured using a chromogenic assay of recombinant Factor VIII polypeptide variants after exposure to plasma obtained from hemophilia A patients for various periods of time.
TW202334195A_112100265_SEQL.xmlTW202334195A_112100265_SEQL.xml
(無)(without)
Claims (82)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263297690P | 2022-01-07 | 2022-01-07 | |
US63/297,690 | 2022-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202334195A true TW202334195A (en) | 2023-09-01 |
Family
ID=88927465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112100265A TW202334195A (en) | 2022-01-07 | 2023-01-04 | Recombinant factor viii variants |
Country Status (1)
Country | Link |
---|---|
TW (1) | TW202334195A (en) |
-
2023
- 2023-01-04 TW TW112100265A patent/TW202334195A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11497798B2 (en) | Human alpha-galactosidase variants | |
JP6230158B2 (en) | A novel high-functional enzyme that converts the substrate specificity of human β-hexosaminidase B and imparts protease resistance | |
US20220356458A1 (en) | Human alpha-galactosidase variants | |
US20210269787A1 (en) | Human alpha-galactosidase variants | |
US20240026326A1 (en) | Engineered amylase variants | |
KR20190117577A (en) | Engineered Phenylalanine Ammonia Lyase Polypeptide | |
TW202334195A (en) | Recombinant factor viii variants | |
US20230340073A1 (en) | Recombinant factor viii variants | |
US11987823B2 (en) | Engineered lipase variants | |
US20230279404A1 (en) | Engineered oxalate decarboxylases | |
TW202313969A (en) | Engineered methionine gamma lyase variants |